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Abstract
A novel class of lipid formulation was investigated comprising GRAS (generally 
regarded as safe) materials. The formulations were all ‘surfactant-free’ (S-F) 
formulations, and also referred to as ‘Type IV’ lipid formulations. These 
formulations were isotropic, transparent, thermodynamically stable at room 
temperature and typically composed of > 50 % of mixed mono-, di- and tri­
glycerides, > 30 % medium chain fatty acids oil and < 20 % hydrophilic co-solvent.
At equilibrium, S-F formulations enhanced the solvent capacity of corticosteroids 
(log P > 3) and hydroxy benzoate derivatives over type II SEDDS and type III 
SEDDS, but generally were not superior solvents to mixtures of mono-, di- and tri­
glycerides (Imwitor 988® and or Capmul MCM®) alone, for lipophilic steroids (log 
P < 3). In general, type III SEDDS which were composed of high hydrophilic 
content (hydrophilic surfactant, HLB > 1 2 , and hydrophilic co-solvent), were also 
better solvents for most steroidal compounds and hydroxy benzoate derivatives than 
type II SEDDS and type I SEDDS formulations.
Surfactant with HLB > 12 inhibited lipolysis of MCT and mixed glycerides when the 
concentration of surfactant exceeded 40 % w/w. Hydrophobic surfactants (HLB < 10) 
did not inhibit lipolysis. Thus, the digestibility of dispersions formed by self- 
emulsifying systems would be dependent on the surfactants used and the quantity of 
TG available for lipolysis. Co-solvents did not appear to influence lipolysis, once the 
formulations had dispersed.
Phase separation of lipid formulations following their dispersion in simulated 
intestinal fluid was studied. The lipid formulation behaviour was dependent on 
monoglyceride content. When sufficient monoglyceride (> 60 %w/v) was present 
demulsification and phase separation was noticed and was found to be dependent on 
the presence of phospholipid. This resulted in sedimentation of the phase rich
V
monoglyceride and water. The presence of triglyceride stabilised the formation of 
mixed micelles, which remained in a finely dispersed state. This unexpected phase 
separation is likely to have a considerable effect on the fate of drug dissolved in 
SEDDS formulations. The high concentrations of monoglyceride may be 
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Origins
In recent years much attention has been focused on lipid formulations, with particular 
emphasis on self-emulsifying drug delivery systems (SEDDS) to improve oral 
bioavailability df lipophilic drugs (Constantinides, 1995; Pouton, 1997). Poor oral 
bioavailability of lipophilic drugs may be due to a combination of factors including; 
poor solubility / dissolution, degradation in the gut lumen, poor membrane 
permeability or presystemic elimination (O’Driscoll, 1996). The balance between 
considerations pertinent to dissolution and membrane permeability has led to the 
development of recent biopharmaceutical drug classification system proposed by 
Amidon et al, (1995) where by drugs are considered to belong to one of four 
categories depending on their dissolution and membrane permeability characteristics. 
There is now general agreement that lipid formulations can enhance the oral 
bioavailability of a range of class II or class IV drugs, particularly those with a 
solubility of less than 100 pg / ml (Craig et al, 2000).
From a practical and aesthetic standpoint, lipid based formulation are ideally prepared 
as a unit dose form which could be filled into either a sealed hard or soft gelatin 
capsule (Pouton, 1997). Consequently, much attention has focused on the use of 
SEDDS, which can be prepared as isotropic mixtures of oil, surfactant, co-surfactant 
and drug. They form fine oil-in-water emulsions when introduced into aqueous 
media under mild agitation. The digestive motility of the stomach and intestine 
provide the agitation necessary for self-emulsification in vivo (Shah et al, 1994). 
Factors controlling the in vivo performance of SEDDS include digestibility, particle 
size of the droplet, and the influence of polarity of the oil droplets on drug release 
into the aqueous phase. Through the normal process of fat digestion (lipolysis), 
mixed bile salt and lecithin micelles are secreted from the gall bladder and solubilize 
the breakdown products arising from lipolysis, such as monoglycerides and fatty 
acids. Small oil droplets provide a large interfacial area for pancreatic lipase to 
hydrolyse triglycerides and the mixed micelles formed can act as a reservoir of 
breakdown products by maintaining them in solution in the lumen. When fatty acids
l
or monoglycerides are absorbed from the aqueous contents of the gut, dissolved 
material can be more freely made available by partitioning from the mixed micelle 
(Solomon et al, 1997).
The maximum oral bioavailability of a drug from a lipid-based dose form will depend 
on the composition of the formulation and is likely to involve the following 
processes: (i) digestion of the medium or long-chain triglyceride lipid, (ii) drug 
solubilization either within the bile salt micellar milieu of the pre- or post-prandial 
intestinal tract, or other formulation-derived colloidal structures, (iii) dissociation of 
solubilized drug from either bile salt or formulation-derived micelles to support 
absorption, and (iiii) a potential effect of either formulation excipients, or drug, on 
enterocyte-based metabolism and/or efflux pumps (Charman, 2000).
The ability of lipids and/or food to enhance the bioavailability of poorly water- 
soluble drugs has been well reviewed recently by Porter and Charman (1997, 2001). 
In concert with the recent increase in lipidic formulations, there has been an increase 
in the number of attentive mechanisms proposed by which absorption of lipophilic 
drugs can be enhanced, namely:
■ Increase in effective lumenal drug solubility (Porter and Charman, 2001).
■ Improved drug dissolution by reducing the gastrointestinal transit, thereby 
slowing delivery of the lipophilic drug to . the absorptive site 
(Constantinides et al, 1996).
■ Increased intestinal epithelial permeability (i.e. changes to the physical 
barrier function of the GI) due to the presence of various combinations of 
lipids, lipid digestion products, and surfactants (Swenson and Curartolo, 
1992).
■ Increased tight junction permeability and decreased/inhibited p- 
glycoprotein drug efflux (i.e. changes to biochemical barrier function)
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(Nerurkar et al, 1996; Yu et al, 1999).
■ Enhanced intestinal lymphatic transport resulting in a reduction in first 
pass metabolism of highly lipophilic drugs (Porter et al, 1997, 2001).
The conversion of this scientific potential into commercial products, however, has 
only recently been developed from simple lipid solution formulations, such as those 
commonly used to deliver fat soluble vitamins, towards effective self - emulsifying or 
self - microemulsifying lipid formulations for cyclosporin (Neoral®), and 
subsequently ritonavir (Novir®) and saquinavir (Fortovase®).
Though the type of lipid formulation and the properties of the excipients used will 
have a critical influence on the fate of the drug in the gut, there is insufficient data in 
the literature to allow formulators to make appropriate choices. The aim of lipid 
formulations is to ensure that the drug remains in solution throughout gastrointestinal 
transit.
More information is needed on:
■ The solvent capacity of formulations and how each excipient influence 
solvent capacity.
■ The influence of excipients on the changes in solvent capacity after dispersion 
of the formulation.
■ The interaction between dispersed formulation and the digestive system, and 
the fate of drugs after digestion of oily components.
3
Introduction
1.1 Introduction to lipid formulations
In recent years there has been a considerable increase in the number of drugs that are 
pharmacologically active but poorly absorbed from the intestine, and it would be 
valuable to find ways of overcoming the in poor bioavailability (Charman et al, 
1997). The Biopharmaceutics Classification System (BCS) (Amidonef al, 1995) 
categorized drugs into four classes as shown in Table 1.1, depending on their 
solubility and permeability characteristics, which are the underlying parameters 
controlling drug absorption. According to this classification, Class I (High Solubility- 
High Permeability) drugs should be more than 90 % absorbed and the rate-limiting 
step to drug absorption is the drug dissolution and/or gastric emptying e.g. 
paracetamol, where the dissolution step is rapid. Class II {Low Solubility -  High 
Permeability) drugs are those with low solubilities but have the potential to be 
completely absorbed due to high low membrane permeability. Examples include 
steroids and cyclosporin A. Class III (High Solubility -  Low Permeability) drugs are 
the mirror image of Class II drugs (Dressman et al, 2000). They have good solubility 
but low permeability through the gut wall makes the absorption incomplete. 
Examples include a  - methyldopa and atenolol. Both the rate and the extent of 
absorption of class II drugs may be highly variable; this variation will usually be due 
to the variables of gastrointestinal transit, luminal contents, and membrane 
permeability rather than dosage form factors. Class IV {Low Solubility -Low 
Permeability) drugs have poor solubility, permeability and often have poor 
bioavailability like (furosemide, griseofulvin and hydrochlorothiazide) (Lobenberg et 
al, 2000). This classification scheme provides a basis for establishing in vitro-in vivo 
correlations and for estimating the absorption of drugs based on the fundamental 
dissolution and permeability properties of physiologic importance. It has been 
reported that oral bioavailability of poorly-water soluble drugs (Class II) may be 
improved due to the presence of lipid after a high fat meal (Crounse, 1961, Crounse, 
1963) or by reformulating in oily vehicles such as digestible triglycerides or a
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mixture of oils and surfactant (MacGregor et al, 1997).
Drug dissolution is a prerequisite to drug absorption for almost all drugs given orally 
(Amidon et al, 1995). The hydrophobic drug is presented in a crystalline state within 
the dosage form leading to a slow dissolution within the lumen of the gastrointestinal 
tract and perhaps insufficient time to allow complete absorption. Formulation of 
hydrophobic drugs in a lipid-based product can avoid the dissolution step which leads 
to improved bioavailability or gives rise to a more consistent profile of drug 
absorption with time. With all these formulations, the precise mechanism of 
enhancement of bioavailability is poorly understood. Various physiological 
mechanisms have been proposed to explain the beneficial effect of co-ingested lipid 
on the absorption of water insoluble compounds including: altered gastrointestinal 
motility, increased bile flow and drug solubilization (Bates and Sequeria, 1975), 
increased mucosal permeability (Muranushi et al, 1980) and increased lymphatic 
absorption (Palin et al, 1982). The role of the lipid digestion process will depend on 
whether the drug is administered with a dietary source of lipid or by presentation of 
the drug within a lipid-based formulation. Also, some of the components of lipid 
formulation, such as co-solvents and surfactants, may influence the lipid digestion 
process abrogating the advantage to drug bioavailability which is dependent on 
digestion of lipid (Pouton, 1985).
5






I High High IVI VC if the dissolution rate is 
slower than the gastric emptying 
rate , otherwise limited or no correlation
w/o
stabilization and protection against 
chemical and enzymatic hydrolysis
II Low High IVIVC expected if the in vitro dissolution 
rate is similar to the in vivo dissolution 
rate, unless the dose is very high
SEDDS, O/W
improved solubilization and 
dissolution increased bioavailability
III High Low Absorption (permeability) is rate determining 
and limited or no IVIV with dissolution rate
W/O stabilization and protection against 
chemical and enzymatic hydrolysis 
increased bioavailability
IV Low Low Limited or no IVIVC expected SEDDS, O/W improved solubilization and 
dissolution increased bioavailability
Table 1.1 The BCS for oral drug delivery and the potential microemulsion systems based on the aqueous solubility and 
membrane permeability considerations (1Amidon et al, 1995,2Constantinides et al, 1995)
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1.2 Types of dietary lipids
In the Western diet, dietary fat constitutes a significant source of calories, 
approximating 30% of total caloric intake. Therefore, dietary intake of fat has 
received considerable attention in the last few decades since lipid food enhances the 
absorption of some hydrophobic drugs, such as cyclosporin A (Gupta et al, 1990). 
Carey et al (1970) has classified lipids into two main groups illustrated in Figure 1.1. 
Lipids were classified according to their interaction with water as either polar or non­
polar lipid. Non-polar lipids are insoluble in the water phase e.g. cholesteryl esters 
(CE), hydrocarbons, and carotene (Figure 1.1 A). The polar lipids are sub-classified 
further (Figure 1 .IB): (I) insoluble non-swelling amphiphiles (vegetable oils, 
triacylglycerol, diacylglycerol, non-ionised long chain fatty acids and fat soluble 
vitamins); (II) insoluble swelling amphiphiles like (phospholipids); and (III) soluble 
amphiphiles like (detergents). For class I lipids, the addition to water form a thin film 
of lipid molecules, termed a monolayer. However, Class II lipids form a monolayer 
on the surface of water. They have a unique ability to interact with water to form 
laminated lipid-water structures referred to as lamellar liquid crystals. In the liquid 
crystal phase, non-polar groups of lipid molecules face one another sandwiching 
water between the polar groups, referred to as ‘swelling’. Class III lipids can be 
further classified into soluble amphiphiles with lyotropic mesomorphism, like the 
sodium salt of long chain FAs and those without. When soluble amphiphiles with 
lyotropic mesomorphism exceeds their CMC, monomers aggregate to form micelles. 
In aqueous solution, the polar group of the monomers face outside, and the non-polar 
groups face inside. Lyotropic mesomorphism refers to when materials such as 
sodium oleate forms an intermediate liquid crystal phase before forming micelles 
(Nordskog et al, 2001). However, soluble amphiphiles such as bile salt will go 
through the intermediate liquid crystal phase (Carey, 1970).
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1.3 Luminal digestion of dietary lipid
The majority of dietary lipid is ingested in the form of triglycerides, which are long 
chain length, C 16-C 18 (Tso, 1985). Lipolysis is the result of three sequential steps 
which involve (I) dispersion of fat globules into a coarse emulsion of high surface 
area, (II) enzymatic hydrolysis of fatty acid esters (primarily triglycerides) at the 
oil/water interface and (III) dispersion of the products of lipid digestion by bile into 
an absorbable form allowing absorption into the portal vein or the lymph (Charman et 
al, 1996). Lipid digestion and absorption, including all the previous steps, is required 
for the conversion of triglycerides into a useful energy source (Carey et al, 1983).
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Figure 1.1 Classification of dietary lipids based on their interaction with water (Carey 
et al, 1970; Nordskog et al, 2001).
1.3.1 Digestion o f lipids in the stomach
Primary lipid emulsification occurs in the stomach where human gastric lipase (hGL) 
has been proposed to be responsible for between 10-30% of total gastrointestinal 
lipolytic activity. Human gastric lipase has been found to be located inside granules 
in the apical region of chief cells and is mainly active in the fundic portion of the 
stomach (Moreau et al, 1989). Bodmer et al (1987) has cloned hGL and reported that 
it is a terminal glycoprotein of 379 amino acids with a predicted molecular weight of 
43162. A 96 molecule region around Ser 152, includes the active site of pancreatic 
lipase (Gargouri et al, 1989;Winkler et al, 1990). Human gastric lipase was cloned 
from a partial N-terminal sequence obtained using a sample purified by gel filtration 
from human gastric juice. It has the ability to cleave the ester bond at the sn-1 and 
sn-3 positions of the TG, although the gastric lipase preferentially cleaves the sn-3 
position relative to the sn-1 regardless of the FA. The activity of hGL is dependent 
upon triglycerides chain length (Gargouri et al, 1986b) and pH, the maximum activity 
reported to be at pH value 5.4 (Hamosh, 1984). Milk fat, the primary dietary source 
for neonates, contains considerable amount of SC and MC-TG. Both lingual lipase 
and gastric lipase play a major role in lipid digestion, particularly in neonates (Tso et 
al, 1982). Furthermore, the pancreatic lipase system is not fully developed in 
neonates.
In the normal diet, triglycerides and lecithin proportions (50:1 to 20:1) tend to form 
an emulsion system consisting of triglyceride droplets surrounded by an outer closed 
packed monolayer of lecithin (Carey et al, 1983) The lecithin monolayer decreases 
interfacial tension, so helping to stabilize the emulsion by preventing droplet 
coalescence and increasing the hGL activity. In addition, partially digested protein, 
complex polysaccharide and membrane-derived phospholipids present in the 
stomach, aid emulsification properties and can decrease surface tension further thus 
enhancing hGL activity (Carey et al, 1983). In vitro studies have shown a correlation 
between hGL activity and interfacial tension at the triglyceride - water interface
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(Gargouri et al, 1984,1986a).
Inclusion of amphiphiles such as salts and some protein enhanced hGL activity by 
reducing interfacial tension. This was thought to be the result of protein unfolding 
due to different of the enzyme structure to denaturation (Solomon, 1998).
Products of lipolysis, which are diglycerides and fatty acids, have advantages in 
further enhancing emulsification by either lowering surface tension of triglyceride 
droplets (Hamsh et al, 1984) or by promoting immediate pancreatic lipase activity 
upon release of the emulsion into the duodenum (Gargouri et al, 1986). However, the 
mechanical forces of the stomach antrum (Armand et al, 1994) are thought to be 
important factor. Contractions increase intraluminal pressure so that the stomach 
contents are pushed towards the closed pylorus and then retropelled back to the 
stomach body, providing mixing followed by applied shear force, which tear the 
liquid interface apart when chyme is released through the pylorus (Solomon, 1998).
Short-and medium chain fatty acids in water exhibit pK^ values in the range of 4.8. 
However, because they are hydrophilic they are soluble in both ionised and unionised 
forms. Both are released as a result of hGL in the stomach and these fatty acids leave 
the surface of the fat droplets and are absorbed passively by the stomach mucosa. 
These are transported to the liver bound to albumin via the portal vein. Since the 
aqueous pK^ values of long chain fatty acids released by lingual as well as gastric 
lipases are at or above neutrality, they will be protonated at stomach pH values and 
form liquid fatty acid oils (Carey, 1983a). The squirting of antral contents back to the 
corpus provides most of the mechanical action involved in the initial emulsification 
of dietary TG. The DG and FA resulting from the action of acid lipases in the 
stomach, and the PL that is normally present in the diet, further aid the emulsification 
of dietary fat (Nordskog et al, 2001).
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1.3.2 Duodenal digestion
In the duodenum, the enzyme responsible for the majority of triglyceride hydrolysis 
is pancreatic lipase, representing 2-3% of the total protein present. Some hGL 
activity will remain whilst the pH of the chyme is between 5 and 7 (Dutta et al, 
1982). The lipid emulsion (chyme) enters the small intestine as fine lipid droplets 
(<0.5 pm) that are extremely stable (Carey, 1983; Tso, 1985).
Pancreatic lipase activity is optimal in the presence of a sufficient concentration of 
colipase, a non - enzymatic protein cofactor, (Borgstrom et al, 1984). Pancreatic 
lipase enzyme has a pH -activity profile opposite to the site of action in the gut. I t . 
has maximum catalytic activity in the pH range of 6.5-9.0 [cf. the duodenal pH range 
of 6.2-8.1 reported by Hemell et al, 1990] (MacGregor et al, 1997). Pancreatic lipase 
(L) binds to the substrate (S) from the hydrophobic site, but is rapidly inactivated by 
conformational changes in the absence of bile salt, as shown in Figure 1.2A. In 
addition, colipase binds to the interface and to lipase. The binding of colipase to 
lipase increases its activity by a factor 1.4-1.5, and stabilizes the enzyme (Figure 
1.2A).
In contrast to hGL, the presence of amphiphiles such as bile salts or phospholipid at 
the surface of the emulsion droplet prevents binding of pancreatic lipase to the 
triglyceride surface (Carey et al, 1970) as demonstrated in Figure 1.2B. The 
mechanism is not yet well defined, but is most probably a surface effect and pH 
dependent (Borgstrom, 1975). Colipase acts in conjunction with the enzyme (in a 
molar ratio of 1:1) in order to protect pancreatic lipase from desorption induced by 
physiological concentration of bile salts, (reviewed by Pouton & Embleton et al,
1997) when bile salts are present above their critical micellar concentration. The 
presence of long chain fatty acids already in the core of the emulsion droplet from the 
previous hGL activity enhances binding affinity of colipase and thus pancreatic lipase 
to the lipid interface (Patton et al, 1978). Adsorption of the complex at the site of the 
triglyceride-water interface and the subsequent hydrolytic activity of pancreatic lipase
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releases the lipolytic products, Sn-2 monoglycerides and fatty acids (Stadler et al, 
1995). Diglycerides located at the lipid interface from previous hGL activity are also 
subject to further hydrolysis by pancreatic lipase. Positional specificity is an 
important factor. The enzyme shows a preference for Sn-1 and Sn-3 ester bonds. It 
is proposed that hGL has limited Sn-2 activity (Tiruppathi et al, 1982) and so can be 
differentiated from colipase- dependent pancreatic lipase. Pancreatic lipase acts more 
efficiently with 1-MG than with 2-MG. However, since the absorptive rate is 
comparatively fast, most of the 2-MG is absorbed before degradation or isomerization 
to form 1-MG (Nordskog et al, 2001).
Pancreatic lipase is secreted together with a proenzyme of colipase (procolipase) from ' 
acinar cells in the pancreas. Procolipase is activated to form colipase (Larsson et al, 
1981) by trypsin cleavage, resulting in removal of the 5 amino acids from the N- 
terminus. The function of procolipase cleavage is unclear, as both procolipase and 
colipase are capable of promoting lipase-mediated hydrolysis of triglycerides 
(Larrson et al, 1991), though colipase was found to be more efficient than procolipase 
under certain reaction conditions.
Crystallography has been used to study the binding and activation sites of human 
pancreatic lipase at a lipid interface. It is defined that hPL is a single chain 
glycoprotein of 449 amino acids arranged as two domains connected by a hinge 
region (Winkler, 1990). According to the resolution of 3-D structure of hPL by X - 
ray crystallography, residues 337-449 form a carboxy terminal domain, which 
contains a binding site for the procolipase.
Normally a 1:1 stiochiometric complex forms between enzyme and cofactor. 
Procolipase has three finger shaped-regions with non-polar amino acids concentrated 
in each fingertip. These were thought to provide a means of binding between 
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Figure 1.2 Representative model for the function of the lipase-colipase-bile salt 
system (Borgstrom, 1977b).
Residues 1-336 of hPL form the amino terminal domain (Winkler et al, 1990) typical 
of a a-hydrolyase fold (Olli et al, 1992) with a dominant central parallel sheet that 
contains the active site. The catalytic site is amino acids residues [Ser 152, Asp 176, 
and His 263 (Winkler et al, 1990)] with Ser 152 being the nucleophilic residue
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essential for catalysis (Luthi-Peng et al, 1992). Conformational change of the 
enzyme is assumed to be necessary to allow contact with the active site, which is 
otherwise protected by an amphipathic helix acting as a lid (Luthi-Peng et al, 1992). 
The hydrophobic catalytic centre is uncovered due to rolling back of the lid, which is 
modulated by the hydrophobicity of the surface surrounding the active site 
(Brozowski et al, 1991).
The active site bound by phospholipid is apparently not changed, although the 3-D 
structure a hPL-procolipase complex, co-crystallized with mixed micelles of 
phosphatidylcholine and bile salts, indicates conformation changes in the enzyme 
cofactor complex (van Tilburghef al, 1993). When the enzyme is in the closed 
conformation, van der Waals bonds exist between a surface loop (a-loop) over the 
active site and the lid. When the lid rolls back, the a-5 loop folds into the core of the 
protein rendering the active site serine, in the base of a hydrophobic canyon, 
accessible to the solvent ideal for lipid substrate binding.
The same study (van Tilburgh et al, 1993) reported that repositioning of the lid and 
a-5 loop in hPL also results in creation of an electrophilic region. This is an 
oxyanion hole around the active site, which acts to stabilize the negative charge 
generated during ester hydrolysis of the substrate. An interaction occurs between the 
N-terminal region of procolipase and the open conformation of the lipase lid via 
direct H-bonds, giving increased stability to the hydrophobic surface around the 
active site in preparation for interaction with the lipid interface. The importance of 
lid binding for function of the complex was illustrated by the chemical modification 
of procolipase residues involved in these H-bonds, which resulted in loss of 
procolipase activity (Larsson et al, 1991).
The bending angle between the C and N terminal domains of hPL has also been 
suggested to be important for positioning of the lid and subsequent catalytic activity 
(Aoubala et al, 1995). There is information regarding the possible interactions 
between substrate and enzyme made possible by crystallisation of hPL colipase
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complex with an inhibitor of lipase (a Cn alkyl phosphate).
1.4 The physico-chemical state of lipids during digestion
The physicochemical behaviour of lipids and their hydrolytic products in the 
gastrointestinal tract is an area of interest that has attracted attention over many years 
(Hoffman et al, 1964). Major studies of fat digestion in humans were reported by 
Borgstrom (1974); Carey e/ al (1983); and Hemell et al, (1990). These workers 
reported in vitro studies of the equilibrium phase behaviour of relevant materials over 
a range of physiological relevant conditions. The emulsification of dietary fat is. 
thought to occur mostly in the stomach, because no further marked emulsification has 
been observed in the duodenum, despite the presence of excess amphiphiles 
(Armand et al, 1999).
According to in vivo data, partially emulsified droplets in the stomach are between 1 
to 100 pm diameter in the stomach, with the largest fraction in the range of 20 to 
40 pm, while in the duodenum the emulsified droplets between 1 to 50 pm in size 
(Armand et al, 1994). Although studies of droplet size revealed the same size in the 
stomach and duodenum, droplets differed in lipid composition owing to the higher 
lipolytic activity in the duodenum. This was reflected in neutral lipid depletion and 
duodenal droplet enrichment with the lipolytic products, cholesterol and 
phospholipids (Armand et al, 1999).
1.4.1 The role o f  biliary lipids in drug dissolution and solubilization
Biliary lipids (bile salts and lecithin mixed micelles and cholesterol) are released as 
bile from the gall bladder and adsorb onto the surface of the crude emulsion, leading 
to the production of a more stable emulsion, with a smaller particle size. The 
reduction in droplet size provides an increase in surface area available for binding of 
the pancreatic lipase/co-lipase complex an interfacial enzyme system that acts at the 
surface of the emulsified TG droplets, leading to the quantitative production of one
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molecule of 2-monoglycerides (MG) and two FA molecules for each TG (Shiau, 
1981).
During digestion, a multilamellar liquid crystalline bilayer is formed at the oil water 
interface comprised mainly of monoglycerides and fatty acids, with phospholipid, 
cholesterol and bile salt (Charman et al, 1997). Parts of the liquid crystalline bilayer 
are released as a multilamellar vesicle due to the high surface pressure that results 
from the continued lipolytic activity. By the action of unsaturated bile salt micelles, 
layers from the multilamellar vesicles bud off and become solubilized to form 
unilamellar vesicles with hydrodynamic radii of between 400 to 600 A. These 
represent the initial phase in the process of lipolytic product dispersal, being 
composed of aqueous mixed lipids saturated with bile salts. The formation of smaller 
intestinal mixed micelles (hydrodynamic radii of 80 A) depends on the mixed lipid to 
bile salts ratio. The components of intestinal mixed micelles are bile salts, long chain 
fatty acids, monoglycerides, cholesterol and phospholipids. They act as a sink for 
lipolytic products under normal conditions in vivo (Semeriva et al, 1971).
1.5 Absorption of lipids
The absorption of lipophilic products (monoglycerides, medium and long chain fatty 
acids) usually occurs by passive diffusion through the brush border membrane 
(BBM) of the intestinal mucosa into the enterocytes. The BBM of the enterocytes 
lining the small intestine is separated from the bulk aqueous phase of intestinal 
contents by a poorly mixed unstirred water layer (UWL) that constitutes a major 
barrier to absorption of poorly water-soluble lipid digestion products. 
(Westergaard et al, 1974). The UWL is a near stagnant layer of water, mucus, and 
glycocalyx adjacent to the intestinal wall that is created by incomplete mixing of the 
luminal contents near the intestinal mucosal surface (Thomson et al, 1993).
Some evidence suggests that a certain amount of absorption is also possible directly 
from the unilamellar vesicular phases (Narayanan et al, 1996). This is a controversial
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hypothesis which needs some examination. There is other evidence suggesting that 
absorption may be enhanced by the presence of a BBM fatty acid - binding protein 
(FABPm) in the cytoplasm of the epithelial cells (Stermmel et al, 1985). FABPm has 
been located on the outer surface of the enterocyte membrane and is thought to act as 
a medium and long chain fatty acid receptor (Clark et al, 1989), possibly helping lipid 
transport into the cell by acting as translocase (Nunn et al, 1986).
In this model, dissociation of the lipolytic product from the vesicles or micelles is 
necessary before absorption can occur (Westgaard et al, 1974). The mechanism of 
transfer of lipolytic products from the micellar phase to the BBM is thought to occur 
by one of three mechanisms (reviewed by Thomson et al, 1993). The collision model 
describes partitioning of the fatty acid directly from the micelle into the BBM of the 
enterocytes (Westgaard et al, 1974).
In the second model, the fatty acids first partition into an intermediate aqueous phase, 
UWL which is rich in solublizing materials and in which fatty acids are sufficiently 
soluble to promote diffusion and absorption by passive transport. This is referred to 
as "the aqueous" model (Thomson et al, 1993). An acid microclimate may be present 
within the UWL adjacent to the BBM (Levitte et al, 1992). Such a microclimate can 
be formed by mucus entrapment of hydrogen ions transported into the intestinal 
lumen by various types of antiporters (Blair et al, 1975, Lucas, 1984).
Fatty acid uptake may occur via the "dissociation" model, which depends on an acid 
microclimate (reviewed by Thomson et al, 1993). The unionised form of fatty acid is 
ensured by the low pH of this environment, leading to decreasing solubility in 
micelles and enhancing partitioning into BBM (Shaiu, 1990). These results increased 
critical micelle concentration (CMC), enhancing dissociation of micelles and 
promoting fatty acid release (Shaiu, 1981). Bile salts can act repeatedly until lipid 
absorption is complete, because upon dissociation of the intestinal mixed micelles the 
bile salt diffuses back to the intestinal lumen where once again it can form micelles, 
which take up further lipolytic product (Solomon, 1998). Most bile salts are actively
17
absorbed in the terminal ileum, then transported to the liver and enter the 
enterohepatic circulation (Lewis et al, 1990).
1.6 Lipid metabolism within enterocytes and lymphatic transport.
There does not appear to be a clear explanation in the literature regarding the 
mechanism by which the lipoidal products move across enterocyte cell membrane 
(Embleton et al, 1997). Once in the enterocyte, long-chain fatty acids and 
monoglycerides are assumed to diffuse through the cell cytoplasm to the endoplasmic 
reticulum, and intracellular fatty acid-binding proteins detected in enterocytes may be 
involved (Cistola et al, 1989). Lipolytic products are then reassembled into- 
triglyceride.
Two pathways of triglycerides synthesis have been identified (reviewed by Tso, 
1985). The extent to which each pathway is utilized depends upon the lipid mixture 
absorbed. The quantitatively important or default pathway is the monoglyceride path, 
illustrated in Figure 1.3, and which accounts for 85% of intestinal triacyglyceride 
synthesis. This involves the direct acylation of absorbed, exogenous 2- 
monoacylglycerol with activated fatty aids via MG acyl transferase (MGAT) to form 
corresponding diglycerides and subsequently via diacylglycerol acyltransferase 
(DGAT) to form TG (reviewed by Porter et al, 2001). If the monoglyceride supply is 
low, the a-glycerophosphate (the phosphatidic acid) pathway converts three 
molecules of absorbed fatty acids and endogenous glycerol into triglycerides within 
microsomes (Thomson et al, 1993). The phosphatidic acid pathway appears to be 
more important in the re-esterification of endogenous fatty acids because it uses the 
endogenous glycerol-3-phosphate and therefore is not dependent on the absorbed 
monoglycerides (Tso et al, 1987).
The source of the lipid core for assembly of lipoprotein (Thomson et al, 1993), 
namely chylomicrons (CM) (through the monoacylglycerol pathway) and very low- 
density lipoprotein (VLDL) (through the phosphatidic acid pathway), are the re-
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esterified triglycerides with acyl chains of more than 12 carbon atoms (Morre, 1977). 
The chylomicrons and very low-density lipoprotein particles are spherical complexes 
consisting of a triglyceride core surrounded by a coat of cholesterol, phospholipid and 
apoprotein. Both are the primary lipoproteins secreted by the intestine. Under fasting 
conditions where intestinal lipid concentration is low, VLDL appears to be dominant, 
whereas CM production increases at higher lipids intake (Tso et al, 1987). These 
complexes stabilize lipid in the aqueous medium of the cytoplasm and lower the 
cellular concentration, promoting passive absorption. Complexes migrate toward the 
basolateral membrane and are released by exocytosis into the intercellular space 
(Nunn et al, 1986). This directs them to the lymphatic system via the lacteal ducts- 
and they then pass through the thoracic duct into the left subclavian veins. 
Subsequently they are taken up by the liver and adipose tissue (reviewed by 
Couvreur et al, 1996).
The short or medium chain triglycerides (less than 12 carbon atoms) do not take part 
in re-esterfication of triglycerides; rather, they partition into the continuous phase of 
the gut lumen and are absorbed passively. They are formed in the stomach mucosa, 
conjugated with albumin in the portal vein and transported to the liver (Staggers et al, 
1981).
In summary, the intestinal bilayer is one of the least permeable membranes in the 
body and is known to contain FA transporter proteins (Cortot et al, 1978). Both 
cytosolic fatty acid binding proteins, I-FABP and L-FAB.P play an important role in 
the intracellular transport of absorbed FA. FABP exhibits a degree of specificity in 
lipid migration to the endoplasmic reticulum and the subsequent re - esterfication 
process, since FABP prefers binding to long-chain fatty acids. The absorption of 
lipophilic molecules from the intestinal lumen is considerably more complicated than 
was first thought.
Recent data suggest that I-FABP can directly extract fatty acid from membranes 
(Thumserer al, 2000) and bind fatty acids presented to the apical side of the
19
enterocyte more than those presented basolaterally, indicating that I-FABP may be 
more important in the delivery of fatty acid from the brush border membrane to 
specific intracellular sites. Another hypothesis indicated that more fatty acid appears 
to be bound to L-FABP in the enterocytes (Alpers et al, 2000) and studies in mice 
and Caco-2 cells suggest that I-FABP is not necessary in the intracellular processing 
of fatty acids. An open mind needs to be kept on the mechanisms by which drugs can 
be absorbed from solubilized systems.
Figure 1.3 Schematic representation of the a - Monoacylglycerol pathway.
1.7 Role of the lipid digestion process in drug absorption from lipid based 
formulation
Assuming that absorption of a poorly-water soluble drug can be enhanced by lipid 
processing, it is possible to speculate about the formulation factors which will affect 
absorption. Different mechanisms by which stimulation of the lipid digestion cascade
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may enhance drug bioavailability are discussed below.
1.7.1 Gastric emptying
The bioavailability of formulations of poorly soluble drugs could be improved by 
lengthening the residence time in the gastrointestinal tract allowing complete 
dissolution (reviewed by Couvreur et al, 1996). Recent research has revealed 
mechanisms by which contact time can be extended by careful adjustment of the 
timing of dosing, taking into consideration normal physiological activities, like 
gastric emptying.
The stomach functions as a mixer and grinder, regulating the rate of delivery of 
gastric contents into the intestine. Wall tone following a fatty meal is affected by 
some of the lipolytic products released by hGL activity. These are emptied from the 
stomach as spurts of 1-5 ml into the duodenum, reducing the rate of gastric emptying 
(Cortot et al, 1982).
Cholecystokinin, a polypeptide hormone, is involved in slowing gastric emptying 
(Schwizer et al, 1997). The presence of fat in the terminal ileum slows the rate of 
gastric emptying and therefore co-administration with a fatty meal or postprandial 
administration may enhance the absorption of poorly soluble drugs, by increasing the 
residence in the stomach and upper intestine (reviewed by Couvreur et al, 1996).
There is extra literature describing the possible benefits of reducing gastric emptying 
time, which can prolong the drug absorption phase and, hence, improve drug 
bioavailability. Recent work reported a 95% increase in bioavailability of ontazolast 
when administered as a 20% soybean oil-in-water emulsion over that obtained from 
an aqueous suspension. The improved bioavailability was due to prolonged 
absorption of ontazolast from the emulsion formulation resulting from slower gastric 
emptying. With ontazolast there was a need for pre-absorptive lipolysis of 
triglycerides (Soybean oil) prior to release and subsequent gastrointestinal absorption 
of ontazolast (Hauss et al, 1998). The oral absorption of cefoxitin from arachis oil
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and Miglyol 812 has been investigated in rats. In this case, pre-dosing the animals 
with Miglyol 812 before administration of Cefoxitin in an aqueous suspension did not 
enhance absorption, suggesting that increased drug absorption may not be due to 
slowing gastric emptying. Enhanced absorption with Miglyol emulsion, compared 
with the arachis oil emulsion, was still obtained following intraduodenal 
administration, which also indicating that gastric emptying was unimportant (Palin et 
al, 1986).
Griseofulvin (Crounse, 1961), phenytoin (Hamaguchi et al, 1993), and danazol 
(Charman et al, 1993) have a greater bioavailability in the presence of food. One 
possible explanation is that delayed gastric emptying caused by the presence of food 
in the stomach allows more time for disintegration and dissolution of these 
formulations before they enter to the small intestine (Mithani et al, 1996). It is, 
however, difficult to isolate this as the causative mechanism.
1.7.2 Emulsification
The physiological emulsification process, which occurs in the stomach and continues 
during lipolysis, may have a beneficial effect on the dispersion of lipid formulations, 
resulting in formation of a larger surface area available for drug release and 
enzymatic activity. In general, dispersion of lipid droplets to form an emulsion of 
high surface area is an essential step in the efficient intestinal absorption of lipids. 
Ontazolast, as discussed before, was investigated using four different formulae, an 
intravenous solution, aqueous suspension, emulsion (a 20% soybean oil in water 
emulsion with Tween 80®), and a SEDDS composed of Gelucire 44/14® and Peceol®.
The SEDDS forms a very fine emulsion on contact with the GI fluid in vivo. Peceol® 
is a readily dispersible lymphotropic solubilizing agent comprised mainly of a 
mixture of a mono-and di-glycerides of oleic acid. Peceol® has chemistry similar to 
the end - products of intestinal lipid digestion. In this study the SEDDS was chosen 
with reference to previous studies and showed a significant increase in the absorption
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of the hydrophobic drug, cyclosporin A, from "pre-digested" olive oil, when 
compared with non-digested oil.
It was proposed that lymphatic transport of many lipophilic drugs occurs in 
association with triglyceride absorption from the gastrointestinal tract. Thus, it was 
hypothesized that Peceol® would provide an efficiently absorbed source of lipid for 
promoting lymphatic drug transport. In fact, the relative ontazolast bioavailability 
determined from the AUC(o-8%) calculated from plasma profiles, did not differ 
significantly for any lipid-based formulation. Compared with the emulsion, 
variability was somewhat less for the SEDDS 20/80 and Peceol solution, suggesting 
that the variable cause of lipid digestion may have reduced gastrointestinal absorption 
of Ontazolast from the emulsion. The values of Cmax were variable and did not differ 
significantly between any of the lipid-containing formulation but followed the rank 
order of SEDDS 20/80> emulsion > SEDDS 50/50> Peceol® solution. However, the 
values of Tmax were reduced and similar for both SEDDS formulation in comparison 
to Peceol® solution and the emulsion formulation, for which T max values were over 
2-fold greater.
From this study, it can be concluded that, although Peceol® represented more closely 
the end-stage of lipid digestion, the Ontazolast absorption from Peceol® solution 
represented by the Tmax was identical with that of the emulsion. This suggests that the 
absorption of Ontazolast from Peceol® is dependent on factors other than a reduced 
need for absorptive lipolysis. The addition of Gelucire 44/14® (HLB=14) to Peceol® 
(HLB=3) increased the HLB of the final SEDD formulation. This has been reported 
to facilitate the release of hydrophobic drugs from lipophilic vesicles and to facilitate 
more efficient formation of a fine dispersion of the solubilized drug in the GI fluids.
1.7.3 Digestion
Perhaps a better strategy for the formulator is to design the lipid formulation to act as 
a suitable substrate for lipolytic enzymes. The production of a colloidal solution by
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the lipid digestion process has already been discussed. Another factor in favour of 
digestible lipids is the stimulatory effect the lipolytic product would have on gall 
bladder evacuation, enhancing bile salt and phospholipid secretion in high 
concentration with cholesterol (Carey, 1983).
Bile salts and lecithin possess surfactant properties summarized in Table 1.2, which 
enhance the dissolution rate of crystalline drugs by reduction in surface tension and 
increased wettability of the surface of the drug. The contact angle between solid 
surface and a liquid can used to express the wetting properties of bile salts 
(Florence et al, 1986). The closer the contact angle of the liquid to zero, the greater 
the wetting of the solid, whereas values 90° or above are known prevent liquid 
penetration into capillary pores of a powder and inhibit wetting (Saunders, 1971).
Particle size reduction of the drug enhances dissolution. However, hydrophobic 
drugs may agglomerate upon fine particle reduction depending on the shape of the 
resultant powder aggregates. The pore size and contact angle will influence the 
ability of liquid to penetrate the powder capillary and wet the solid surface (Bates et 
al, 1966).
Bile salts can increase the rate of dissolution via enhanced wetting in a drug-specific 
manner. Miyazaki et al. (1979,1981) suggested that the enhanced dissolution of 
phenylbutazone in simple bile salt solutions was mediated via increased wetting, 
whereas micellar solubilization was responsible for improved dissolution of 
indomethacin. Similarly, Weintraub et al (1969) found that the effects of 
physiological bile salt concentrations could not be explained by solubility results 
alone.
Solubilization of hydrophobic drugs is defined as passage into solution of substances 
that are hydrophobic in a given medium of bile salts, involving the previous presence 
of a colloidal solution whose particles take up and incorporate within or upon 
themselves (McBain et al, 1955). Micelles are aggregates of surfactant monomers
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(when present above the CMC), which are capable of rapid breakdown and 
reformation. Solubilization of insoluble materials may occur upon partitioning within 
micellar structures. There is sufficient evidence in the literature to support the view 
that bile salt-lecithin mixed micelles are usually a good solvent, for lipophilic drugs 
(reviewed by MacGregor et al, 1997). However, the mechanism by which the 
dissolution rate is enhanced may vary (Baskatselou et al 1991, Naylor 1993) in vitro, 
bile salts enhanced dissolution for hydrophobic compounds that exhibit food related 
increase in absorption such as griseofulvin (Crounse, 1961), danazol (Martha et al 
1982, Miyazaki et al 1979) and phenytoin (Miyazaki et al 1981). However, BS do 
not enhance dissolution in all cases, such as with large molecular weight antibiotics • 
pafenolol, neomycin, and kanamycin, penicillamine and tetracycline (reviewed by 
Charman et al, 1997).
Mechanisms
1 Solubilization/Wetting
2 Prolonging GI residence time (decreases
gastric emptying, decreased GI motility.
3 Protection from luminal degradation
4 Protection form brush border or luminal metabolism.
5 Enhanced membrane permeability
6 Increased membrane contact/absorption by lipid
adsorption mechanism
7 Absorption via lymphatics
8 Decreased hepatic secretion.
Table 1.2 The mechanisms by which lipids and surfactant increase oral 
bioavailability.
Dissolution is usually described by the Noyes-Witney equation (Weintraubs et al, 
1969)
DR = dc/dt= (AcsD)(Vh) eq 1.1
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DR, the dissolution rate, is a function of the surface area available for dissolution, A, 
the saturation solubility of the compound, D, the volume of the dissolution medium, 
V, and the boundary layer thickness, h.
As well as the physical features of the drug, many physiological parameters can also 
play a role in determining the dissolution rate (Dressman et al, 2000). The physical 
and physiological parameters relevant to drug dissolution are tabulated in Table 1.3, 
along with their corresponding parameters in Eq. (1.1)













pH, buffer capacity 
Bile, food components
Concentration o f drug 
in solution
Permeability
Volume of GI contents Secretions, Administered fluids
Table 1.3 Physical and physiological parameters affecting class II drugs dissolution
The dissolution rate of hydrophobic drugs is often increased by the action of bile 
salts. Bile salts may decrease interfacial energy between the drug and the dissolution 
medium, thereby increasing the effective surface area (A) available for dissolution 
(O’Driscoll, 1996). They may also increase the solubility of the drug (Cs) via 
micellar solubilization. Typically, wetting effects predominate at bile salt 
concentrations below the CMC and solubility effects tend to prevail above the CMC 
(Heertjes et al, 1969/1970).
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However, in vivo results using bile duct-cannulated rats indicated that the presence of 
endogenous bile the enhanced absorption rate of ethyinylestradiol-3-cyclopentylether 
from the small intestine. In summary, the mechanisms by which bile salts enhance 
dissolution rate and solubility of poorly soluble drugs has been shown to be a 
combination of wetting, solubilisation and the physico-chemical properties of the 
drug (Couvreur et al, 1996). For a series of structurally-related steroid compounds, 
the wetting effect was reported to be predominant over solubilisation effect of bile 
salts. However, for danazol, the most lipophilic compound studied, the increase in 
solubility was the most important factor (Couvreur et al, 1996).
Several workers have taken the step of using lecithin and bile salts in a micellar 
system. A further consideration is that lecithin is converted by phospholipase A l  into 
lysolecithin in the duodenum. Lysolecithin enhanced dissolution rates and 
solubilisation of hexestrol, dienestrol, and griseofiilvin in in vitro systems (Bates et 
al, 1967). Hydrophobic bile salts form aggregates or micelles when their 
concentration exceeds the critical micellar concentration (CMC). Different bile salts 
form different types of micelles and the structure depends on the concentration of bile 
salts (Schwartz et al, 1996). The CMC of different bile salts can change as a function 
of the pH and is influenced by the concentration of lipids and cations. For example, 
trihydroxy bile salts have a higher CMC than dihydroxy bile salts. At physiological 
pH, the CMC of most bile salts varies between 2 and 5mM (Schwartz et al, 1996). 
Concentrated bile exists as mixed aggregates in the form of vesicles or micelles when 
stored in the gall bladder.
Originally, Small (1967) described the structure of bile salt/lecithin mixed micelles as 
disc-shaped, bimolecular leaflets of lecithin surrounded on their hydrophobic parts by 
bile salts molecules, as shown in Figure 1.4A (Carey, 1983). Later, Mazer et al 
(1980) proposed the mixed disc model in which the disc-shaped micelle was 
proposed to comprise a lecithin bilayer (possibly with cholesterol and/or cholesterol 
ester incorporated) interspersed at constant ratio with hydrogen bonded bile salt
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dimers. Some bile salts molecules were arranged as a layer on the outer micelle 
surface, where they prevented contact between the lecithin hydrocarbon chain and 
water, as presented in Figure 1.4B.
Early studies, suggested that, at physiological bile saltdecithin ratios (< 2:1), the 
structure of the micelle is “an isometrical particle of globular shape, having a 
centrosymmetric arrangement” i.e. lecithin molecules are sandwiched between a half 
circle of bile salt dimers (reviewed by Naylor, 1993), as shown in Figure 1.4C. 
Recently, studies reported by Walter et al (1991) and Kozlov e/ al (1997), the 
vesicle - micelle transition of PC-NaTDC was assessed by comparing cryo- 
transmissoin electron microscopic (Cryo-TEM) images of the structures formed with 
the associated turbidity changes. They identified an intermediate stage between 
vesicles and small spheroidal mixed micelles, and showed that, at the upper 
boundary, all the structures are spheroidal mixed micelles, as shown in Figure 1.4D.
The initial step in vesicle solubilization at low cholate concentration is associated 
with pore formation and recognition of the bilayer lipid. The region of transient pore 
formation is followed by the formation of larger sheets (twenty to several hundred nm 
in diameter), where their hydrophobic edges are stabilized by cholate molecules. The 
high edge activity of cholate induces the formation of cylindrical mixed, flexible 
micelles that appear to peel from the bilayer sheet. These structures are similar to the 
so-called ‘rod-like’ structures proposed by Hjelm et a l (1988,1990) and are not like 
the mixed disc model previously described by Small (1970). Commonly, cylindrical 
micelles are expected to form close to the micellar phase, which is close to a phase 
boundary with pre-micellar bile salt/lecithin vesicles (Pedersen et al, 1995).
1.7.4 Assessment o f  drug and lipid absorption
Enhancing absorption of hydrophobic drugs by alteration in membrane permeability 
in the presence of lipolytic product, has become a wide area for discussion 
(Muranishi, 1985) (Table 1.2). Mixed micelles could enhance intestinal permeability
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Figure 1.4 Proposed molecular models for the structure of bile salt-lecithin mixed 
micelles. (A) disc-shaped model, (B) mixed disc shaped model, (C) “an isometrical 
particle of globular shape, having a centrosymmetric arrangement” i.e. lecithin 
molecules are sandwiched between a half circle of bile salt dimers, (D) spheroidal 
mixed micelles (Carey, 1983; Naylor et al, 1993).
by three different processes:
Firstly, lipolytic product and BS may alter the intrinsic solvent properties of the 
intestinal membrane leading to increased penetration via paracellular or transcellular 
routes (Muranishi et al, 1994).
Secondly, solubilization of poorly water-soluble drugs within bile salt micelles may
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facilitate diffusion through the UWL, leading to increased absorption. Mixed 
micelles, which facilitate solubilization of high quantities of lipophilic drug and 
enhance drug diffusion across the UWL, may release high concentrations into the 
aqueous fluid surrounding the microvilli ready for absorption across BBM. The UWL 
has been suggested to be the main barrier to intestinal absorption of lipophilic drugs. 
Components of mixed micelles and lipid-based formulations, i.e. bile salts 
amphiphiles, non-ionic surfactants and fatty acids, have been reported to increase 
membrane permeability (Curatolo et al, 1994) by altering the configuration of the 
membrane in such way that it becomes easier for drugs to permeate (Muranishi,
1985). Increasing the bioavailability of the drug in the presence of lipid digestion 
products depends on the nature of the drug absorption. Highly polar and/or high 
molecular weight drugs may be improved by bile salts or other amphiphiles.
Thirdly, in spite of all the efforts to increase the absorption of hydrophobic drugs by 
different mechanisms, there are some reported disadvantages, which may affect 
intestinal absorption. Some fatty acids increase the thickness of UWL and reduce the 
intestinal blood flow. Micellar solubilization of drugs may result in reduction in the 
rate of diffusion of free drug whilst retention of drug within micellar structures may 
reduce free drug available for absorption (Poelma et al, 1991, del Estate et al, 1993). 
However, the ability of single, specific lipid components to enhance lymphatic 
transport, namely, degree of saturation, fatty acid chain length and lipid class, have 
the predominant effect on the bioavailability of lipophilic drugs.
1.7.4.1 Degree o f unsaturation o f lipid
In general, the degree of fatty acid unsaturation has been shown to have a large effect 
on the rate of absorption and partitioning of lipids between portal blood and intestinal 
lymphatics. Lipids with increasing degrees of unsaturation appear to produce larger 
lymph lipoprotein particles and preferentially promote lymphatic lipid transport 
(Cheema et al, 1987, Okner et al, 1972). These early in vivo studies suggested that 
the improved absorption and intracellular transport of unsaturated lipids resulted from
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both improved digestion and a more significant increase in lipid fluidity and 
corresponding decrease in lipid hydrophobicity at body temperature for unsaturated 
rather than saturated lipids (Cheema et al, 1987, Bergstedt et a l, 1990).
In vivo examination of the lymphatic transport of palmitic acid, oleic acid and the 
trans-isomer of oleic acid, elaidic acid, found that administration of oleic acid led to 
re-esterification via the monoglyceride pathway and secretion of chylomicrons. In 
contrast, the fully saturated palmitic acid and elaidic acid resulted in higher 
phospholipid output, in the form of smaller lipoproteins, possibly via stimulation of 
the a-glycerophosphate pathway (Bernard et al, 1987). In support of these general 
trends, Noguchi et al (1985) reported a doubling of the lymphatic transport of 
testosterone undecanoate after administration in a polyunsaturated (MaxEPA) lipid 
vehicle when compared with monounsaturated oleic acid, in spite of subsequent 
studies showing that the extent of lymphatic transport of MaxEPA oil (C20:s) and 
olive oil (primarily Ci8:i) were similar (Chernenko et al, 1989).
1.7.4.2 Chain length o f the administeredfatty acids
The partitioning of absorbed (and potentially resynthesised) lipids between the portal 
blood and the intestinal lymph was first described in the 1950s. In these studies, the 
majority of fatty acids with chain lengths of Cm and above were found to be 
recovered in thoracic lymph, whereas a larger proportion of the shorter chain lipids 
were absorbed directly into the blood (Bloom et al, 1951a, 1951b).
Sylven and Borgstrom (1969) demonstrated that the lymphatic transport of 
exogenously administered cholesterol increased in a linear fashion after co­
administration with triglycerides of increasing fatty acid chain length. Vahouny and 
Treadwell (1958) described similar trends such that the lymphatic transport of 
cholesterol was increased by co-administration with oleic acid, linoleic acid and 
stearic acid, although, in these studies, no increase in cholesterol transport with 
butyric, lauric or palmitic acid was seen. Furthermore, of all the respective
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triglycerides, only trilinolein improved the lymphatic transport of cholesterol above 
that seen with a control (lipid free) vehicle.
Similar fatty acid chain length effects have been observed in the absorption and 
lymphatic transport of co-administered drugs. For example, in fasting human 
volunteers, vitamin D3 was more efficiently absorbed after administration in peanut 
oil® (a long-chain triglyceride containing primarily oleic acid) than in Miglyol 812® 
(a medium-chain triglyceride containing primarily C g-C io saturated fatty acids). 
Since vitamin D3 is almost exclusively absorbed by the lymphatic route, the low 
absorption observed when administered with the medium-chain triglyceride probably 
represents a reduction in lymphatic transport, secondary to insufficient chylomicron 
formation (Holmberg et al, 1990). The effect of saturated fatty acids was dependent 
on the carbon chain length; the Cg caprylic acid had less effect than the C n  lauric acid 
and Ci6 palmitic acids. Cefoxitin absorption was enhanced in the presence of lauric 
acid as a result of a reversible transient effect on the membrane fluidity and not by 
complex formation between cefoxitin and the fatty acid. Medium chain fatty acid 
could also increase permeability of cefoxitin by fluidity the membrane (Palin et al,
1986).
A recent study was done by Caliph et al (2000) using Hf in cannulated, consicous, 
unrestrained rats after administration in lipidic vehicles with different fatty acid chain 
lengths. Both lymphatic transport (Cjg-based vehicle, 1 5 .8 %  of dose> Cg-io, 5 .5 % >  
C 4 , 2 .2 2 % > C o , 0.34%) and total systemic exposure (Cjg, 2 2 .7 %  of dose> Cg.10, 
1 9 .2 % >  C 4 , 15 .2% > C o, 6.4%) of Hf were enhanced by the presence of lipids in the 
formulation specifically by an increase in the fatty acid chain length of the co­
administered lipid. Increase in lymphatic drug transport appeared to correlate with 
increases in lymphatic lipid transport (Caliph et al, 2000).
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1.7.4.3 Glycerides structure o f administered lipid
The absorption of structured lipids has also been well studied (reviewed by Tso et al, 
1999; Porter et al, 2001) and it is clear that the variability in the structure inherent in 
the design of these systems may improve drug delivery systems. Charman and Stella 
(1986) examined the lymphatic transport of DDT in anaesthetized rats and reported a 
2-fold increase in the cumulative extent of lymphatic transport of DDT after 
administration in a formulation comprising long-chain (Cis) fatty acid compared with 
the equivalent triglyceride-based lipid vehicle. A shorter lag time was also associated 
with administration in the fatty acid vehicle when compared with the triglyceride 
(TG) vehicle. They thought that this was a result of the shorter time required for the 
synthesis of chylomicrons from the fatty acid vehicle when compared with the TG 
vehicle that required additional pre-absorptive digestion.
In contrast, Charman and his colleagues (2000) recently examined the lymphatic 
transport of halofantrine (Hf), after administration to conscious rats in simple 
solutions comprising either oleic acid/glyceryl monoolein (FA / MG) or peanut oil 
(TG) and no significant differences in the extent of lymphatic transport of Hf were 
evident (Porter et al, 1996). This may due to a compound specific difference, but 
also represent the potential differences in processing power of the GIT between the 
two studies.
In the DDT study, the lipid solutions were administered intraduodenally to 
anaesthetised rats, whereas the Hf formulations were administered orally to conscious 
rats. It is possible; therefore, that the increased luminal processing (and, specifically, 
pre-duodenal, gastric processing) improved oral dosing in combination with the 
possible suppression of intestinal mixing in anaesthetised animals. This led to a more 
complete processing of the TG formulation in the Hf study, circumventing the 
advantages seen previously with the pre-digested FA/MG formulation in the DDT 
experiments. However, the impact of various structured lipids on the absorption of 
co-administered compounds such as cholesterol is much less clear (Tso, 1985;
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Porter et al, 1996) and their application as pharmaceutical excipients has not been 
widely addressed.
1.7.5 Intestinal lymphatic absorption o f hydrophilic drugs
Co-administration of lipids (or food) has been shown to increase the bioavailability of 
poorly water-soluble drugs (Winstanely et al, 1989, Toothacker et al, 1980, and 
Armstrong et al, 1980). The lymphatic system present throughout the gastrointestinal 
tract varies in terms density, absorptive capacity and functional characteristics. The 
major physiological role of the intestinal lymphatics is in the transport of fats, lipid 
soluble vitamins and to aid in the maintenance of the body's water balance. The- 
intestinal lymph, along with hepatic and regional lumbar lymph, drain via cystemi 
chyli into the thoracic lymph duct which empties into the general circulation at the 
junction of the left internal jugular and left subclavian veins (Charman et al, 1991). 
Hydrophobic compounds transported by the intestinal lymphatics are almost 
exclusively associated with the triglyceride cores of chylomicrons synthesised by the 
enterocytes (Hauss et al, 1998).
The major factor contributing to significant lymphatic drug transport is the co­
administration of a suitable lipid source to " drive " chylomicron synthesis (Hauss et 
al, 1998). Chylomicrons are triglyceride-rich lipoprotein particles and range in size 
between 50 and 500 nm. A typical composition is 86-92% triglycerides, 6-8% 
phospholipid, 2-4% sterol (free and esterified) and about 1-2% protein (Charman and 
Stella, 1991). Chylomicrons are present in lymph at concentration of nearly 1-2% 
during periods of peak lipid transport (Tso et al, 1982, Shiau et al, 1985).
In 1951, Bloom et al, found that the factors which determined transport of fatty acids 
were either the free form through the portal blood of intestinal lymphatics or re- 
esterified to a triglyceride (reviewed by Charman & Stella, 1991). The portal blood 
transport of orally administered fatty acids appears to increase as the chain length of 
the fatty acid decreases (as mentioned before).
34
Long-chain fatty acids are re-esterified to corresponding triglycerides that are then 
incorporated into, and transported by chylomicrons. Medium or short- chain fatty 
acids are poorly transported by the lymphatic system, as they are not incorporated to 
any extent in chylomicrons (Noguchi et al, 1985). Biochemical findings support this 
hypothesis because of the specificity of the fatty acid binding protein for long-chain 
fatty acids (Ockner et al, 1974), and the inactivity of acyl: Co A synthase towards fatty 
acids of chain length less than 12 carbons (Dawson et a/,1960).
While the lipid-based formulation significantly increased the amount of ontazolast 
(discussed earlier) transported by lymph, the total amount was insufficient to account 
for the improvement in bioavailability. Ontazolast had maximum lymphatic transport 
from the emulsion and Peceol® formulations, which are the highest rates of 
concurrent triglyceride transport. However, the SEDDS formulations, which 
enhanced absorption of ontazolast from the gastrointestinal tract, resulted in the 
highest concentration of ontazolast in the chylomicron triglycerides.
Based on to this study, the authors suggested that the fraction of absorbed drug 
transported via lymphatics is influenced by (I) the rate of drug absorption from the 
gastrointestinal tract and (II) the rate of concurrent triglyceride transport (Hauss et al,
1998). The intestinal lymphatic route is a specialised absorption and transport 
pathway for highly lipophilic drugs, lipidic derivatives and lipophilic xenobiotics.
Kwei et al (1998) studied the lymphatic transport of a poorly water-soluble (<1 g/ml) 
and highly lipid-soluble (>80 mg/ml in soybean oil®) compound: 5 - reductase 
enzyme inhibitor, MK-386, from three oral formulations: an aqueous suspension, a 
mixed lipid/surfactant (Imwitor®, mono- and di-glycerides of capric and caprylic 
acids/polysorbate 80) formulation and a long-chain lipid (soybean oil) solution 
formulation after oral administration of radiolabelled MK-386 to rats. Interestingly, 
the rank order of the total amount of MK-386 transported into the mesenteric lymph 
over a six hour post-dosing period was: aqueous suspension>mixed lipid/surfactant 
system>soybean oil, i.e. greatest for the lipid-free formulation. Furthermore, the
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mixed lipid/surfactant formulation contained a relatively large amount of surfactant, 
notably in excess of the critical micelle concentration and this may have affected the 
rate and extent of dissolution and subsequently the absorption profile of the poorly 
water-soluble MK-386. Nevertheless, MK-386 was primarily transported to the 
systemic circulation by the intestinal lymph (after administration of all three 
formulations), with up to 80-fold higher levels seen in the lymph compared with the 
portal blood.
One strategy for drug delivery, associated with intestinal lymphatic transport of 
lipophilic drugs is the potential for by-passing hepatic first pass metabolism after oral 
dosing and/or targeting drugs to regions of the lymphatic system. Applications of 
monoglycerides appear to hold promise for selective lymphatic delivery. These 
prodrugs are designed to avoid pre-systemic clearance, reduce gastrointestinal 
intolerance, and for targeting various disease states resident within the intestinal 
lymphatics (Charman et al, 1996).
Recently a triple-cannulated conscious dog model, which allows sampling of thoracic 
duct lymph, portal and systemic blood, has been described (Khoo et al, 2001). In 
contrast to the rat model, the dog model allows administration of dosage forms that 
are of a size relevant for human administration, and facilitates study of the effects of 
fed versus fasted states in drug absorption. In rat this is not possible as, due to the 
lack of a gallbladder, bile flow is continuous and the pulsatile response to food which 
occurs in dogs and man is absent (reviewed by O'Driscoll, 2002).
Postprandial administration of halofantrine (Hf), an important antimalarial, leads to 3- 
and 12-fold increases in oral bioavailability in humans and beagles, respectively, and 
corresponding 2.4-fold and 6.8-fold decreases in metabolic conversion to 
desbutylhalofantrine (Hfm). Factors contributing to the decreased postprandial 
metabolism of Hf could include inhibition of presystemic CYP3A metabolism by 
food components and/or recruitment of the intestinal lymphatics as an absorption 
pathway. Although previous rat studies confirmed Hf base is a substrate for
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lymphatic transport, it is difficult to extrapolate such data to higher species, as the 
largely constant bile flow in a rat precludes attainment of representative pre- and 
postprandial states, and formulations administered to rats are often not relevant to 
higher species. These limitations have now been addressed by development of a 
conscious dog model that allows simultaneous study of intestinal lymphatic and non­
lymphatic drug absorption and aspects of enterocyte-based drug metabolism. After 
oral administration of 100 mg Hf base, the mean fasted and postprandial lymphatic 
transport was 1.3% and 54% of the administered dose, respectively. Comparison of 
portal and systemic plasma Hfin concentration profiles suggested enterocyte-based 
conversion of Hf to Hfm; however, the proportion of Hf metabolized to Hfm was 
similar after fasted or postprandial administration. Hence, it appears that the 
previously observed decrease in the postprandial metabolism of H f is largely a 
consequence of significant postprandial intestinal lymphatic transport (which 
bypasses first pass hepatic metabolism). This new dog model will facilitate 
identification of the key factors that impact bioavailability, lymphatic transport, and 
metabolic profiles of highly lipophilic drugs (Khoo et al, 2001).
1.8 Drug Delivery systems f or poorlv-water soluble Drugs
Although lipids have been used in galenicals for over 100 years (Groves et al, 1976), 
the commercial success and clinical acceptance of lipid-based formulations for 
significant drugs with large market values has only occurred within the last two 
decades (Pouton, 1982; Wakerly et al, 1986).
As the commercial introduction of new lipid-based formulation is expected to 
increase, the question which arises is what is driving the growing interest in lipid- 
based formulations? Some of the reasons for the increasing interest in lipid-based 
systems include the following: (i) an improved understanding of the manner in which 
lipids enhance oral bioavailability and reduce plasma profile variability, (ii) new drug 
candidates being less water soluble and more potent (thereby allowing for lower unit 
doses), (iii) the higher purity and better characterisation of lipidic excipients, (iv)
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formulation versatility, (v) possible metabolic and biopharmaceutic advantages 
(Charman, 1999).
Lipid systems offer great potential in the design and fabrication of new carrier 
systems. Not only do lipids form a wide variety of physical structures, as seen in 
Table 1.4, but also each has the potential to solubilize varying quantities of poorly 
water-soluble drugs, hence achieving molecular dispersion of many drugs whose 
bioavailability might be comprised by poor dispersion characteristics (Florence, 
1997).
Micelles







Table 1.4 Varieties of lipidic systems.
1.8.1 Classification o f lipid delivery systems
A key strategy to better utilization of lipid-based formulations is to consider their 
performance from both formulation and physiological standpoints (Charman, 1999). 
The physico-chemical factors determining the absorption potential of an individual 
drug molecule are well known, and are shown in Table 1.2.
“Lipid formulations” have evolved from simple water-immiscible solvents to 
important microemulsions, that may potentially improve the bioavailability of poorly 
water - soluble drugs through induced changes in the absorptive environment of the 
small intestine. Hoar and Schulman introduced microemulsion as early as the
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1940s.by generating a clear single-phase solution by titrating a milky emulsion with 
hexanol.
Microemulsions are ‘thermodynamically stable, isotropically clear dispersions of two 
immiscible liquids, such as water and oil, stabilized by an interfacial film of 
surfactant molecules’ (Ccnstantinides et al, 1994). The surfactant may be pure, a 
mixture, or combined with other additives. Ordinary emulsions differ from 
microemulsions in that they require a large energy input, are thermodynamically 
unstable and will eventually separate.
In 1982, Pouton proposed a new type of lipid formulation termed ‘self-emulsifying 
drug delivery system’ (SEDDS), typically composed of 30% of Tween 85® and 70% 
of Miglyol 812® (saturated medium and long chain fatty acids). In 1986, Wakerly 
produced a similar formulation consisting of 30% Tagat TO® (polyoxyethylene-(25)- 
glycerol trioleate) and 70% Miglyol 812®. The self-emulsifying behaviour of the 
Tween 85® was found to be sensitive to acidic conditions; therefore, the Tagat TO® 
system is considered more useful.
Self-emulsification is a phenomenon which has been used commercially for many 
years in formulations of herbicides and pesticides (Groves, 1978). In early decades, 
these formulations were diluted to produce concentrates of crop-sprays allowing very 
hydrophobic compounds to be transported. On the other hand, self-emulsifying drug 
delivery systems (SEDDS) using safe excipients and delivered via the oral route have 
recently been used to improve the lipophilic drug dissolution and absorption of 
compounds such as cyclosporin A, ritnovair, saquinvair (Charman et al, 1997).
SEDDS are isotropic mixtures of natural or synthetic oil, solid or liquid non-ionic 
surfactant, and/or co-surfactant (Charman et al, 1992). They form fine oil-in-water 
emulsions when introduced into aqueous media with mild agitation (Kommur et al, 
2001). It is useful to note that under the definition given, SEDDS are not 
microemulsions, although they may be considered to be very close to
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microemulsifying systems when added to aqueous systems (Lawrence et al, 2000). 
SEDDS formulation offers many promising features for hydrophobic drugs; 
therefore, there is a need for sub-classification to aid the interpretation of comparative 
bioavailability studies.
Pouton (1999) classified SEDDS using three main criteria by which lipid formulation 
can be distinguished: 1) Does the formulation self-emulsify or remain poorly 
dispersed in water? 2) Is the dispersed formulation digestible by lipases? 3) When the 
formulations make contact with water are some of the components lost by dissolving 
in the aqueous phase? There are three useful types of formulations which typically 
have such properties and are shown in Table 1.5.
The simplest of these, non-emulsifying systems Type 1, contain a drug dissolved in 
an easily digestible oil usually made up of vegetable oil or medium chain-length 
triglycerides (fractionated coconut oil). These are safe food substances, categorized 
as GRAS (generally regarded as safe) by regulatory agencies and do not present a 
toxicological risk to the formulator. These preparations work well, as glycerides are 
rapidly digested via lipolysis into 2-monoglycerides, and free fatty acids, which are 
then solubilized within bile salt-lecithin mixed micelles to form a colloidal solution.
A reservoir of drug is likely to be formed in the colloidal dispersion, as the 
hydrophobic drug should solubilize in the mixed micelles, from where the drug can 
partition to be absorbed effectively by the passive (transcellular) route (MacGregor et 
al, 1997). Oily formulations may be an option for potent compounds with log P >4 
and their simplicity is appealing to formulators. For example, the bioavailability and 
the plasma profile of 5 a-reductase inhibitor from an oil solution were equivalent to 
these achieved using a self-emulsifying system (Loper et al, 1996). When an 
appropriate dose of the drug can be dissolved, a Type I formulation may well be the 
system of choice, in view of its simplicity and biocompatibility. However, the low 
drug solvent capacity of most oils, combined with their poor miscibility with the 
aqueous environment of the GIT leading to variable drug absorption, limits their use 
(Amemiya et al, 1998; Pouton, 2000).
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Type II, self-emulsifying formulations contain water-insoluble components including 
triglycerides, mixed mono- and di-glycerides and lipophilic surfactants (HLB < 12). 
The addition of a lipophilic surfactant may improve the solvent capacity of the 
formulation. Surfactants act to reduce the tension at the oil/water interface promoting 
micellar formation. As a result, these vehicles produce very fine dispersions in the 
GIT, with particle sizes ranging between 100-250 nm in systems consisting of 
polyoxyethylene-(25)-glyceryl trioleate (Tagat TO®) and medium chain triglycerides 
(Wakerley et a/,1986). This is a large surface area for drug partitioning which leads 
to improved drug absorption, independent of digestion, increasing bioavailability 
(Charman et al, 1992, Lawrence et al, 2000).
The main feature of Type II is (a) efficient self-emulsification and (b) absence of 
water-soluble components. Typically, Type II systems are best formulated with 
medium chain triglycerides and/or mono- or di-glycerides, mixed with ethoxylated 
oleate esters with HLB values of approximately 11 (water-dispersible surfactant) 
(Table 1.5) (Pouton, 1999). The minimum concentration of surfactant needed to form 
a self-emulsifying formulation is between 25%-40% with particle size 200-250 nm. 
In the presence of surfactant at 50%, the particle size will be approximately 100 nm. 
The efficiency of the emulsification is slower and contributed a viscous liquid 
crystalline gels, which form at the oil-water interface, when the concentration of the 
surfactant more than 65%. In such a case, very high energy is required to break up 
the particles to produce a stable emulsion. However, are no longer considered a self- 
emulsifying system.
The mechanism of interaction the Type II with the aqueous phase could be explained 
by the “diffusion and stranding”. These water-dispersible surfactants (upon mixing 
with aqueous phase), strongly interact with water, and form a variety of structured 
liquid crystal phases, and tend to form W/O/W emulsions spontaneously. Pouton 
(1999) proposed that self-emulsification is closely linked to the formation of 
dispersed lamellar liquid crystal formation allowing penetration of water into 
formulation, resulting in interfacial disruption, which is sufficient enough to peel
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emulsion particles from the surface of the bulk oil-surfactant interface. Type II 
systems will be digestible unless the surfactant concentration is too high. Solomon 
(1998) investigated the presence of the surfactant on the lipolysis process. It was 
reported that the surfactant are very slowly digested, and their presence at the oil- 
water interface can inhibit the digestion of glycerides present in the formulation. 
Surfactants with HLB >12 will inhibit the lipolysis of the glycerides.
Type IE systems are similar to Type II but include hydrophilic surfactants (HLB > 
12) and may include co-solvents, such as propylene glycol and ethanol. Co-solvents 
aid emulsification by diffusion and stranding, where they cause a disruption at the 
o/w interface by penetrating into the surfactant monolayer. This increases the 
distribution of lipophilic components in the aqueous phase. During mixing with 
excess water, the bulk of the hydrophilic, micelle-forming surfactant may also be 
transferred to the aqueous phase to form a micellar solution. The fate of the drug and 
lipid components after mixing with water could be solubilization in a swollen 
micellar solution, dispersion as a fine emulsion, or isolation and precipitation 
(Pouton, 1999; 2000).
These formulations generally have a greater drug solubilising capacity, although this 
may be reduced upon dilution in water (Constantinides et al, 1994). It is difficult to 
predict the phase changes that may occur on dilution and in practice these will occur 
dynamically, in a non-equilibrium manner, making it difficult to predict drug 
solubility and fate from the corresponding equilibrium phase-behaviour. Type IE can 
be sub-classified into Type DIA and Type EUB according to the proportion of water 
soluble surfactants or co-solvents.
Type IDA (Table 1.5) is typically mixtures of medium chain fatty acids oils, mixtures 
of mono-, di- and tri-glycerides and hydrophilic surfactant. Type IIIB, are similar to 
Type IEA, with the addition of a water-soluble cosolvent. Because of the greater 
hydrophilic content in Type IIIB, these are likely to result in a colloidal solution of 
drug and oil in aqueous micelles. The motivation for using hydrophilic surfactants or
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water-soluble co-solvents may be to increase the solvent capacity for drugs with 
intermediate logP (2<logP<4). This approach was used for reformulating 
cyclosporin A as ‘Neoral’ (Vonderscher and Meinzer, 1994). Type DIB formulations 
present the highest risk of precipitation. The extent of precipitation will depend on 
the physical chemistry of the drug and how hydrophilic is the formulation. Type DI 
can be referred to “self-microemulsifying systems” due to the optical clarity upon 
addition to the aqueous phase. Recently, Gershanik and Benita (2000) proposed a 
new type of SEDDS termed “lipid self-dispersing pharmaceutical vehicles” capable 
of forming drug-loaded fine lipid particles in the gastrointestinal (GI) lumen. These 
include self-microemulsion formulation, surfactant dispersions, pre-formulated 
freeze-dried, or microencapsulated emulsion and lipid/cross-linked polymeric 
matrices (reviewed by Gershanik et al, 2000). All these formulations can be 
administered in soft or hard gelatin capsules; and will produce fine oil 
droplets/micelles dispersion upon capsule disintegration and contact with aqueous 
solution. However, water-containing vehicles cannot be filled into soft gelatin 
capsules due to the hydrophilic nature of the gelatin shell, which absorbs water thus 
dehydrating and eventually disrupting the emulsion structure (Wakerly et al, 1986).
1.8.2 Biopharmaceutical issues
The choice of the formulation for each drug will depend on a number of factors; the 
required dose, on which types of formulation have sufficient solvent capacity to allow 
formulation of a unit dose, and in particular to the fate of the drug after the 
formulation has been administered to the gut. Most hydrophobic drugs will have low 
solubility in the lumen, so the target is to keep the drug in ‘reservoir’ form for 
absorption (Pouton, 1999).
Using the principle when simple monobasic electrolyte drugs are absorbed, the lumen 
becomes temporarily depleted of ionized drug and then a supply of free ionized drug 
(reservoir) available rapidly. If the base is strong enough such that the drug is
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predominantly ionized in the small intestine, then dissolution of the solid drug in the 
intestine will be rapid and its overall solubility in the lumen will be high.
In the case of weak bases, (pKu < 7), they will not be highly soluble in the small 
intestine, may dissolve in the stomach, with a possibility of precipitation after gastric 
emptying into the small intestine. Therefore, weak bases will not get the benefit of a 
drug reservoir if they administered in solid dosage form, due the dissolution rate- 
limiting step. Consequently, weak bases may benefit from reformulation in lipids 
which can provide a reservoir of drug dissolved in either lipid or micellar solution. 
The drug will stay in solution through its passage into the gut.
At this stage, the formulator should balance the physico-chemical properties of the 
drug with the lipid formulation i.e. a balance is required to produce a low-volume unit 
dose formulation while avoiding precipitation of the drug in the gut.
In practice, some solvents could solubilize the drug e.g. co-solvents (PEG), which 
may satisfy the need to increase the drug content in each capsule but would lead to 
unwanted precipitation. The use of co-solvents is often said to result in an acceptable 
precipitation in the form of ‘nanocrystalline ’suspensions, which would provide high 
surface area for dissolution (Liversidge et al, 1995). Whether precipitation can be 
controlled to form a nanocrystalline suspension from type IIIB products is unclear. 
To avoid drug precipitation, Type I and Type II formulations would be preferred to 
keep the drug stable until digested. However, this is not possible for all drugs (such 
as cyclosporin A) because of their limited solvent capacity. This limitation has 
initiated the use of Type III.
Generally, the most difficult drugs are those which have limited solubility in both 
water and lipids (typically with log P  approximately 2). The rate of absorption is 
another issue that should be taken into consideration. Self-emulsifying systems are 
known to disperse rapidly within the contents of the stomach, so the formulation will 
empty into the intestine as the aqueous solution. As expected, the rate of absorption
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of Type II and Type Dl systems are likely to be rapid, especially when given to a 
fasted stomach. Hypnotics or analgesics may benefit from this kind of formulation 
because they require a very rapid onset of action. However, such a formulation could 
be a disadvantage for a drug which has a low therapeutic index. Type I formulations 
could be safer for drugs that are intended for chronic use, both in view of the 
pharmacokinetic profile produced and also since they avoid the chronic 
administration of surfactant.
In contrast, Type II and Type HI could be used for drugs that are to be administered 
for patients who have a compromised lipid digestion. The ‘Sandimmune Neoral’ 
formulation has the advantage over the early Sandimmune formulation because of the 
small particle size after dispersion facilitates rapid absorption. This is a significant 
advantage in the treatment of patients who lack full bile function, such as liver 
transplant patients (Amante et al, 1997). Small particle size is not crucial for good 
bioavailability in all cases.
The content of the capsule will be emptied into the digestive environment of the 
upper small intestine, so the most important factor may not be the size of the particles 
in the initial dispersion, but rather their susceptibility to digestion and/or 
solubilization by mixed micelles of bile salt and phospholipids. Therefore, reducing 
the oil content and including a surfactant and water-soluble co-solvent as in Type DIB 
will decrease the possibility of droplets being digested. This suggests that self- 
emulsifying systems are dependent on the initial emulsification process to produce a 
colloidal dispersion (Pouton, 2000).
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Increasine Hydrophilic Contents
Type I Type II Type IIlA Type IIIB
Typical composition
Triglycerides or mixed glycerides 100% 40-80% 40-80% <20%
Surfactant 0 20-60% 20-40% 20-50%
(HLB<12) (HLB>11 HLB>11
Hydrophilic co-solvents 0 0 0-40% 20-50%
Particle size o f dispersion Coarse 100-250nm 100-250nm 50-100nm
Significance o f aqueous dilution Limited Solvent capacity Some loss of Significant phase
Importance unaffected solvent capacity changes & potential
loss o f solvent capacity
Significance o f aqueous digestibility Crucial Not crucial but Not crucial Not required
requirement likely to occur may be inhibited not likely
Table 1.5 Classification of SEDDS formulations (Pouton, 1999).
1.9 Scope of the research
The scope of the present study can be summarized as follows:
(1) Investigation of a novel ‘surfactant-free’ lipid formulations containing oils, mixed 
glycerides and water-miscible co-solvents. These types of formulations use 
excipients which have GRAS status, which offers toxicological advantage. The 
solvent capacities of surfactant-free formulations have been compared with other 
lipid formulations.
(2) To study the effect of the physico-chemical properties of hydrophobic drugs and 
the fate of the drug after dispersion of the formulation in water or simulated intestinal 
fluids. New methods have been developed to determine the equilibrium solvent 
capacity of dispersed formulation.
(3) To examine the digestion of lipid formulations, in the presence of pancreatic 
lipase. A general method, which uses a pH-stat to determine liberation of free fatty 
acid, has been available for some time but, given the complexity of the gut lumen, 
there is still much to learn about the use of in vitro models of lipolysis. This study 
included a further examination of the variables which can affect lipolysis, and the 
significance of these variables on hydrolysis of long-chain triglycerides (LTG), 
medium-chain triglycerides (MCT), tributyrin (SCT) and mixed mono-and- 
diglycerides (MG).
(4) To explore the digestion of individual excipients and representative lipid 
formulations from each class.
(5) To investigate the influence of lipid excipients on phase separation following 
dispersion in simulated intestinal fluid, in the absence and/or the presence of 
pancreatic lipase and bile salts.
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Chapter 2
An investigation o f the potential o f  “Surfactant-Free lipid Drug Delivery Systems
2.1 Introduction
There are some concerns regarding the use of surfactants in formulations, particularly 
for chronic administration. With an increasing number of lipid excipients available 
for use, there is a need for more information to allow the optimal choice of excipients. 
More knowledge is needed regarding surfactants, in particular of their toxicity and 
how important they are to the performance of a formulation.
One motivation for the formulator is to find an alternative formulation using lipid 
excipients which have GRAS (generally regarded as a safe) status. A study using rat 
intestinal preparations showed that 0.1% w/v aqueous solutions of both polysorbate 
and block copolymer non-ionic surfactants caused damage to the epithelial border 
(Walters et al, 1981). Upon removal of the non-ionic surfactant, the damaged 
epithelial border was readily repaired by the physiological regeneration of the 
gastrointestinal membrane, suggesting that the acute use of surfactant is likely to be 
tolerated.
This study addresses the short-term effects of absorption of a lipid formulation but, in 
many instances, chronic administration is required. Metabolism of ester ethoxylate 
type non-ionic surfactants in the gastrointestinal tract initially results in hydrolysis to 
release free polyoxyethylene glycol, fatty acids and the sorbitan or glycerol moiety 
from the backbone (Swenson et al, 1992). Due to their hydrophilicity and high 
molecular weight, polyoxyethylene glycols are not absorbed and are mainly excreted 
in the faeces. Such materials could solubilize cell membrane lipids, which may be a 
contributory factor to the observed membrane disruption.
The limited solubility of some drugs in lipidic solvents, uncertainties about what 
occurs to co-administered drugs/lipid in the gastro-intestinal tract and a lack of
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predictive testing procedures, both in-vitro and in commercial production, goes hand- 
in-hand with the safety issues of lipid excipients (Pouton, 1997).
For this reason, formulations containing oils, mixed glycerides and water-miscible 
co-solvents, most of which have GRAS status, were investigated in this study. The 
conditions under which isotropic solutions are formed with oil, mixed glycerides and 
co-solvent, was investigated using a series of steroidal drugs and hydroxy benzoate 
derivatives (log P  1.3-4).
The objective was to investigate whether these formulations offer any extra solvent 
capacity over (Type I) oil and mixed glyceride blends. Steroidal and hydroxy 
benzoate derivatives were considered to be models of typical hydrophobic drugs. 
Solvent capacity of surfactant-free formulations were compared with other SEDDSs 
formulations. In order to determine the equilibrium solubility accurately, samples 
were pre-heated and left to equilibrate before determining their solubility. The data 
of these tests are shown in Appendix 1, and summarized in this chapter.
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2.2 Materials
Co-surfactant (mixture of mono-, di-, and tri-glycerides)





Imwitor 988 Mixture o f caprylic C8:0 > 50% 300 4-6 Condea Chemie,
glycerides Ci0:0 > 40 % GMBH 
Hiils , INC
Capmul MCM Mixture o f caprylic C8;0 > 75% 343 5-6
and capric Cl0:0 > 10 % Abitec Corp.
fatty acids (Coloumbus, OH)
Imwitor 988®
Structure is: R-O-CH2-CH-OH-CH2 -O-R







































2- (or, P) Monoglycerides
R1 = C7H15; R2 = c 9H j 9
The RCO2 moiety is predominately caprylate and caprate with trace amounts of 
caproate, laurate and higher molecular weight fatty acids.
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Hydrophilic surfactant
Cremophor RH 40®: (TJSP name Polyoxyl 40 hydrogenated Castor oil).
Cremophor RH 40® is made by reacting 45 moles of ethylene oxide with one mole of 
hydrogenated castor oil (with HLB value = 14-6). It consists of hydrophobic and 
hydrophilic regions. A hydrophobic part is formed by glycerol polyethylene 
oxystearate with fatty acids glycerol polyglycol esters. The hydrophilic region is 
formed by polyethylene glycols and ethoxylated glycerol.
O |— O (CH2CH20 )xH
C H p — & — ( C H 2) ^ - C = C — C H j C H — ( C H 2)g -C H 3
O  i— O  ( C H 2C H 20 ) y H
6H 0 ^ -< C H 2)7-C==C--CH^H-(CH2)rCH3
O I O (CH2CH20 )z H
C H p -i i—(CH2)7-*C=C-CH2CH-(CH2)5-CH3
The number of moles of ethylene oxide reacting per mole of castor oil is the sum of x, 
y and z, which in turn is expressed as the ethoxylation number. Cremophor RH 40 
was obtained from BASF, Inc.
Tagat TO®:
Tagat TO® (polyoxyethylene- (25) -glycerol trioleate) is produced by the 
esterification of ethoxylated glycerol with oleic acid. A known weight of ethylene 
glycol oxide is treated with glycerol to produce polyethylene glycol glyceryl ether. 
The esterification is then continued using a commercial grade of oleic acid, obtained 
from hydrolysis and fractionation of olive oil. Tagat TO® contains an average of 25 
ethoxy residues per molecule with HLB value of 11.3 and Mwt of 3400. It was 
supplied by Goldschmidt Chemical, Germany.
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CH2  O (CH2  CH2  D)a H CH2 0(C H 2 CH2 0 )a R
CH 0(C H 2 CH2 0 )b H +  3 RCOOH — ► CH 0(C H 2 CH2 0 ) b R
Where a+b+c=25 for Tagat To 
R is principally CH3(CH2)7CH=CH (CH2)7 COOH
Tween 80® : polvoxythvlene-fSVsorbitan monoleate
Tween 80® is non-ionic surfactant belonging to a class known as polysorbate 
surfactants. It is manufactured from a nucleus with six hydroxyl groups. The 
hydrophilic character of Tween 80 is produced by introducing polyoxyethylene 
chains at hydroxyl sites. The molecular weight is 1310 and HLB value is 15. It was 
purchased from Sigma, UK.
Medium chain Oils
Miglvol 812®: Fractionated vegetable fatty acids of mixture of decanoyl (C8;0) and 
octanoyl (C,o.o) glycerides with a molecular weight of 550. It was provided from 
Condea Chemie. Gmbh, (Hills, Inc).
CH2 0(C H 2  c h 2  o )c h c h 2  O (CH2  c h 2  Q)c r
Fatty Acid POE-(XX)-GTO Surfactant .
R — O —(C H 2 CH2O j  - C H
R - 0 - ( C H 2CH20 ) y ( 0 C H 2CH2) z O R
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The fatty acid content is shown below:
FA C6 <0.1 





FA Ci2 < 0.7
Water-soluble co-solvents:
Transcutol P®: Ethoxydiglycol (INC)
Purified diethylene glycol monoethyl ether (EP). It is manufactured from raw' 
materials of petrochemical origin, with Mwt of 134.17. It was supplied by Alfa 
Chemical Ltd, (Gattefosse, France)
Chemical formula: C2H5-0-CH2-CH2-0-CH2-CH2-0H
PEG 400:
Poly(oxy-l,2-ethandiyl), Mwt = 400, Aldrich, UK.
Propylene glycol:
Propane-,1,2,3-triol, Mwt = 76.9, Sigma, UK.
Glycerine:
l,2,3,propanetriol, Mwt = 92.09, Sigma, UK.
Solvents.:
Ethanol 96% v/v GPR.
Methanol 96% v/v GPR






formula Log P Mwt Cas. # Supplier
Testosterone C19 H28 O2 3.3 288.4 T 1500 Sigma
Progesterone C21 H30 O2 3.8 314.7 P 0130 Sigma
Hydrocortisone C21 H30 O5 1.53 362.47 H 4001 Sigma
Testosterone Acetate C21 H30 O3 4.7 330.5 T 1625 Sigma
Hydrocortisone Acetate C23 H32O6 2.48 392.49 H 4126 Sigma
Table 2.2 Hydroxy benzoate
Name
Chemical
formula Log P Mwt Cas. # Supplier
Butyl paraben Cn H 14O3 3.24 194.2 H 9503 Sigma
Methyl paraben C8 H803 1 . 6 6 152.1 H 6654 Sigma
Ethyl paraben C9 H 10O3 2.19 166.18 11,198-8 Aldrich































2.3.1 Surfactant-free formulations / Phase behavior
Formulations were classified into two main categories, as shown in Table 2.3. Those 
which included surfactant and those which are surfactant-free. The focus of the 
initial part of this investigation was surfactant-free formulations prepared from tri-, 
di- and mono-glycerides with water-soluble co-solvents. The initial objective was to 
determine regions of mutual solubility using phase diagrams. Each of the axes on the 
diagram represented the percentage contributed to the formulation by each of the 
three constituents. For phase studies, 5 g mixtures of the medium chain triglyceride 
of fractionated coconut oil (Miglyol 812®) plus the co-surfactant (mixture of mono-, 
di-, and tri-glycerides; Capmul MCM® or Imwitor 988®) were mixed with water- 
soluble co-solvent in 20 g screw-capped vials using a 1 ml Gilson pipette. The three 
components of the system were thoroughly mixed by using a vortex mixer 
(Whirlimix, Fisons Ltd), placed in water bath at 50°C for 2 mins, then kept for 24 - 
48 hour at room temperature at 25°C before being visually assessed for phase 
behaviour. Six combinations of triglyceride, medium chain fatty acid oil and water- 
soluble co-solvent were selected to provide a range of possible formulations. If the 
mixture of constituents formed a continuous phase throughout the vial, the 
formulation was classified as miscible, whereas vials which displayed two or more 
phases were described as immiscible. For systems comprising four components, the 
weight ratio of a pair of hydrophilic co-solvents was kept constant so that there were 
only three variables, each of which can be presented by one side of the triangular 
phase diagram.
2.3.2 Equilibrium solubility studies
2.3.2.1 Determination o f equilibrium solubility at 50°C and 25°C
The equilibrium solubility was determined by pre-heating samples at 25°C and 50°C. 
The samples were composed of steroids dissolved in surfactant-free formulae
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comprising mixtures of tri-, di- and mono-glycerides and water-soluble co-solvents. 
Once the miscible surfactant-free formulations have been identified, bulk mixtures as 
shown in Table 2.4 were prepared by ad-mixing appropriate quantities of various 
components and mixing with a vortex mixer (Whirlimix) or stirring if necessary to 
ensure thorough mixing. Once a stable, clear, formulation had been prepared, the 
drug of interest was added with vortexing for 4 minutes to ensure mixing, with three 
replicates prepared for each sample. The samples were heated for 1.5 hour at 50°C 
then equilibrated at 25°C with continuous shaking. The samples were analyzed using 
UV spectrophotometer analysis method at 0, 6, 12, 24, 36, 48 hours, 4, 6 days and 2, 
3, 4 weeks to ensure that the solubility at equilibrium had been determined.
23.2.2 Determination o f the equilibrium solubility o f testosterone at different
temperatures.
Solubility studies in viscous oils present two problems. At 25°C, the dissolution may 
be slow so that equilibrium is not reached. If the oils are heated to get the drug into 
solution, then excess drug may not re-crystallize. Testosterone was used as a model 
drug to examine the effect of several temperature of initial solubilization on the 
apparent solubility after equilibration at 25°C. This was a further check that the 
solubility at equilibrium was being accurately estimated. Samples were prepared as 
in section 2.3.2.1, heated at different temperatures (30, 40, 50, 60, 70 and 80°C) then 
stored at room temperature with continuous shaking. The pre-heated samples were 
then analyzed after intervals of time of 0, 6, 12, 36, 48 hours and 4 days at 25 °C.
2.3.3 Solubility studies of dmgs in lipid formulations
Once the miscible surfactant-free formulations have been identified, bulk mixtures 
were prepared admixing appropriate quantities of various components and mixing 
with a vortex mixer (Whirlimix) or stirring if necessary to ensure thorough mixing. 





1 PG FCO Imwitor 988®
2 PEG400 FCO Imwitor 988®
3 Transcutol P FCO Imwitor 988®
4 Gly.+PG FCO Imwitor 988®
5 Gly.+Trans.P FCO Imwitor 988®
6 Glycerine FCO Imwitor 988®
Table 2.3 Combinations of triglyceride, hydrophilic co-solvent and lipophilic co-surfactant selected as possible formulations
Increasing Hydrophilic content ------------
Type I Type II Type m  A Type HI B Surfactant-Free
Composition
*Triglycerides or 100% 40-80% 40-80% < 20% 50-80%
mixed glycerides
* Surfactant HLB <12 0 20-60% 0 0 0
HLB >11 0 0 20-40% 20-50% 0
*Hydrophilic cosolvents 0 0 0-40% 20%-50% 20%
*Particle size of coarse 100-250nm 100-250nm 50-100nm < 200nm
dispersion
*Significance of limited solvent capacity some loss of significant phase solvent capacity
aqueous dilution mportance unaffected solvent capacity changes potential affected
*Significance of crucial not crucial but more not crucial but may not required not likely more likely
digestibility requirement likely to occur be inhibited to occur to occur
Table 2.4 Surfactant -  free formulations compared to SEDDS formulations (Modified from Pouton, 1999).
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added, vortexing for 4 minutes to ensure mixing. The three replicates were prepared 
for each sample. The formulas were subsequently stored at room temperature for 48 
hours for equilibration before assay.
2.3.3.1 Solubility o f steroids and hydroxy benzoate derivatives in lipid 
excipients.
In order to understand more clearly the solubility of steroids and hydroxy benzoate 
derivatives in lipid formulations, the solubilities in each lipid excipient were 
determined. The drug was added in excess to lipid excipient, vortexed for 4 minutes- 
and then stored for 48 hours (for equilibration) at room temperature with shaking. 
Mixtures were then centrifuged at 2000g for 25 min using a Beckman centrifuge 
before a sample of the supernatant was taken, diluted with a suitable solvent, usually 
methanol 96%w/w for (hydrocortisone, testosterone and progesterone); ethanol (96% 
w/w) for (testosterone acetate and hydrocortisone acetate) and acetonitrile (99%w/w) 
for hydroxy benzoate derivatives; to be analysed by UV spectrophotometry. 
Cremophor RH 40® is solid material at room temperature; therefore, it was melted at 
30°C before starting the experiment. The drug added to the melted surfactant and the 
mixture kept at 30°C for analysis.
2.3.3.2 Solubility o f Steroids and hydroxy benzoate in lipid formulations
The solubility of each of the steroids and hydroxy benzoate derivatives were 
measured for each formulation and are shown in Table 2.3 using the above methods.
2.3.3.3 UV Assay
Quantitative determination of the concentration of steroid dissolved in the supernatant 
was achieved using an ultraviolet spectroscopic method. Each steroid and hydroxy 
benzoate derivative was analysed by scanning over a range of wavelengths (200 to
60
320 nm) using a double beam instrument (Perkin-Elmer Lambda7, UV / VIS 
Spectrophotometer). Standard curves for each of the drugs in the appropriate solvent 
were constructed and the peak wavelength determined. The Beer-Lambert law was 
closely obeyed for each drug (r2 values of 0.99 were typical). The solubility of each 
drug was calculated using Beer's Law:
El% = A/Cg% .B eq 2.1
l cm
A stands for the absorbance of the solution, Cg% is the concentration absorbing 
substance in g / ml, and B is the path length (constants).
For the assay of drugs dissolved in excipients or formulations, the absorbance was 
determined against a blank of formulation diluted appropriately.
2.3.4 Particle size analysis of dispersion formed by surfactant-free formulation 
using the Malvern Mastersizer
Emulsions formed by surfactant-free (S-F) formulations were prepared by adding 
1 ml of formulation to 100 ml of distilled water in a 250 ml conical flask using a 1 ml 
Gilson pipette. After mixing in a water bath shaker at 50 r.p.m, emulsions were 
visually grouped into 1 of 4 systems; 1) crude dispersion {Co}- indicating a 
formulation which showed poor or minimal emulsification with large oil droplets 
present on the surface; 2) coarse emulsion {Cr}- indicating a dull greyish white 
emulsion possibly with a slightly oily appearance; 3) self-emulsifying system {S}- 
indicating a bright white, milk like, emulsion; 4) microemulsion {M}- indicating a 
rapidly forming clear or slightly hazy bluish emulsion. The particle size analysis of 
S-F formulations was determined using an optical configuration represented by the 
Malvern Mastersizer presentation model 0807. Conventional Fourier optics were 
used with 100 nm and 300 nm lenses for particle sizes in the range of 0.3 to 600 pm. 
The emulsion was transferred from a conical flask to the mastersizer cell by means of
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a glass pipette. Each dilution was performed in triplicate and the size distributions of 
the resultant emulsions compared using the apparent normal distribution of the 
diameter at 50 and 90 %, D (u, 0.5) and D (u, 0.9) respectively (Charman et al, 1992; 
Shah etal, 1994).
2.4 Results and discussion
2.4.1 Phase diagrams
Several SEDDSs formulations containing surfactants have been described previously 
(Constantinides et al, 1995; 1996). It was decided to investigate the formulation of a 
new type of ‘Surfactant-Free’ formulations, assessed drug solubility and investigate 
whether these formulations self-emulsify.
The ternary phase diagrams of systems containing oils with medium chain fatty acids, 
mixtures of mono-, di-, and tri-glycerides and water-soluble co-solvent, were studied 
and used to identify areas of mutual solubility and are shown in Figures 2.1-2.5. 
Miscibility depended on the nature of the oils, the hydrophilic co-solvent and their 
mixing ratios. Figures 2.1 and 2.2 showed phase diagrams of mixtures of mono-, di-, 
and tri-glycerides (Imwitor 988®), medium chain fatty acids (Miglyol 812®) and 
hydrophilic co-solvent PG and PEG 400 respectively. The phase diagrams showed 
that these components were able to form miscible areas as long as they contained at 
least 40% of mixture of glycerides, beyond which the systems become immiscible, 
and also a maximum 50% of medium chain glycerides. The PEG 400 systems 
(Figure 2.2) produced a much larger area of miscibility than those produced with PG 
(Figure 2.1). The larger miscibility region can be accounted for differences in the 
interaction of the medium chain fatty oil (Miglyol 812®) with the water-soluble co­
solvents. The hydroxyl content of PG is also greater than PEG 400. Figure 2.3 
represents that Transcutol P® produced large areas of miscibility in the presence of
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MCT and mixtures of mono-, di-, and glycerides due to its lower hydrogen bonding 
capacity, whereas with glycerine there were no miscible mixtures.
To accommodate glycerine, four component mixtures were prepared, the hydrophilic 
component containing Glycerine/ PG (1:1) and/or Glycerine/ Transcutol P® (1:1). 
These are shown in Figures 2.4 and 2.5, respectively. This approach produced a 
miscible area provided at least 60%-70% of the mixture included glycerides (Imwitor 
988®) and the formulation contained <30% medium chain oil (Miglyol 812®). As can 
be seen, the area of mutual solubility produced by the S-F systems is extended over a 
wide range of compositions controlled by both the polarity of the co-solvent and the' 
mono-, di-, and tri-glyceride content of the oil. Long chain triglycerides produce very 
few miscible S-F formulations even with PEG 400 or Transcutol P®. This is because 
the co-solvents are too hydrophilic to mix with the hydrophobic long chain 
triglycerides.
It is clear from the phase diagrams that the S-F formulations are clear, transparent, 
isotropic and thermodynamically stable. They are typically isotropic mixtures of 
medium chain oils <40% (Miglyol 812®), mixtures of mono-, di-, and tri-glycerides 
>40% (Imwitor 988®) and water soluble co-solvent <30% (Transcutol P®, PG, PEG 
400). Since the formation of the S-F formulation is thought to be thermodynamically 
stable, the order of the addition of the components should not have any effect on the 
formulations.
2.4.2 Drug incorporation into lipid excipients of SEDDSs formulations
In properly selecting a suitable lipid system for drug solubilization and delivery, it 
would be useful to have pre-formulation data particularly on aqueous solubility, 
and/or lipid excipients formulations or binary mixtures of lipid excipients. This 
should allow the formulator to make an early choice between the types of SEDDSs
63
formulations and to predict for which drugs the solvent capacity can be improved by 
the use of co-solvents (Constantinides, 1995).
Steroids and hydroxy benzoate derivatives were used as models of BCS class II 
drugs, being poorly water-soluble, highly membrane permeable drugs. Solubility 
studies were carried out for steroids in lipid excipients and SEDDS formulations. 
Drugs were assayed by UV spectrophotometry. Each experiment was repeated under 
the same conditions three times. Statistical analysis was not undertaken for each 
experiment due to complexity of the systems studied.
The steroids were selected as poorly water-soluble drugs, with log P (1-4). Their oil 
solubility was limited. Hydroxy benzoate derivatives with log P  (1-4) were used with 
high oil solubility. Therefore, control experiments were done to ensure that the 
equilibrium solubility is estimated accurately.
2.4.2.1 Determination o f the equilibrium solubility o f steroids
Formulations of SEDDSs and their individual excipients are of a viscous nature; 
therefore, it was not easy to predict the length of time required to reach equilibrium. 
It was convenient to use gentle heating to speed dissolution, but it was important to 
make sure that the solubility measurements after re-equilibration at room temperature 
were true values rather than measurements of the supersaturated state.
Increasing the temperature resulted in a decrease in the surface tension of the solvent 
and a decrease in the viscosity of the formula, thus increasing the dissolution rate and 
solubility of the solute in the formula. The solubility of steroids was studied in 
surfactant-free formulations by either shaking at 25°C or mixing at 50°C followed by 
re-equilibration at 25°C for different time intervals. Figures 2.6-2.9 show the effect 
of pre-heating on the apparent solubility of steroids at 25°C in S-F formulations. At 
the first time point, there was 2-fold more drug in solution for samples pre-heated at
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50°C than at 25°C. At 25°C, the solubility of steroids exhibits nearly the same 
solubility at 50°C after approximately 96 hours. Figure 2.6 showed that progesterone 
exhibited 2.744 g % w/v ± 0.7 %, after 96 hours at 25°C, and at 50°C 2.298 g % w/v 
± 0.6 %. Figure 2.7 indicated that testosterone required 96 hours to reach 
equilibrium. The amount of testosterone solubility at 25°C was 2.603 g % w/v, ± 
0.3% was very close to the amount dissolved in the pre-heated samples 2.815 g% 
w/v, ± 0.4%. The solubility of testosterone acetate at 25°C after 96 hours was 
2.07g%w/v ± 0.4% whereas at 50°C after 96 hours was 2.394 g %w/v ± 4%. Figure
2.8 showed that at 25°C, the solubility of hydrocortisone 21-acetate slightly increased 
up to 12 hours then decreased until it reached equilibrium after 192 hours.
Figure 2.9 showed that increased sharply the initial solubility of pre-heated 
testosterone samples, which indicated that the drug reached a supersaturated state 
when pre- heating was used. The samples took at least 96 hours to reach equilibrium. 
Nearly all the pre-heated samples exhibited the same % w/v solubility 3.0% w/v, 
± 0.4 % at the end of four days.
Therefore, the protocol used for determining a single point of solubility was to mix 
lipid excipients in the presence of the drug for 2-3 minutes then left for equilibration 
for at least 48-96 hours before further analysis was undertaken.
2.4.2.2 Determination o f the intrinsic solubility o f steroids and hydroxy 
benzoate derivatives in lipid excipients.
The partition coefficient of the drug (Log P  octanol/water) is an important indicator 
of the likely solubility properties of a drug. For example, the solubility of 
hydrocortisone with a log P  value of 1.53 in lipid excipients can be ranked for their 
solvent capacity: Imwitor 988® (1.55 g % w/v) > Capmul MCM® (1.002 g % w/v) > 
Cremophor RH40® (0.733 g % w/v) > Miglyol 812® (0.1 g%  w/v) « Tagat To®
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(0.1 g%  w/v). However, for hydrocortisone acetate (Log P  2.7) the rank was 
Miglyol 812® (0.386 g % w/v) > Imwitor 988® (0.22 g % w/v) > Cremophor RH 40® 
(0.147 g% w/v) > Capmul MCM® (0.1224 g% w/v) > Tagat To® (0.025 g % w/v). 
Both hydrocortisone and the acetate form produce a significant solvent capacity in the 
hydrophilic co-solvent. For example, the intrinsic solubility of hydrocortisone can be 
ranked in the following order: PEG 400 (1.228 g%  w/v) > Transcutol P® (1.077 
g% w /v) > PG (1.0 g% w/v). The acetate form can be ranked in the following 
manner: Transcutol P® (0.78 g % w/v) > PG (0.367 g % w/v) > PEG 400 (0.333 
g % w/v). Therefore, the intrinsic solubility of hydrocortisone and the acetate form 
would be highly sensitive to the formulation contents.
As the partition coefficient increased as in case of testosterone (Log P  3.3) the rank 
was: Cremophor RH 40® (0.975 g % w/v)> Miglyol 812 ® (0.847 g % w/v) Imwitor 
988® (0.816 g % w/v) >Capmul MCM® (0.79 g % w/v)> Tagat To® (0.301g % w/v). 
While, the acetate form (LogP 4.7) the rank was: Tagat TO® (1.274 g% w /v) > 
Imwitor 988® (1.10 g % w/v) > Cremophor RH 40® (1.60 g % w/v) > Capmul MCM® 
(1.04 g% w /v) Miglyol 812® (1.035 g% w/v). Both testosterone and the acetate 
form are exhibited better solvent capacity in hydrophilic co-solvents. Testosterone 
was ranked in the following manner: Transcutol P® (1.11 g % w/v) > PEG 400 (0.95 
g % w/v) > PG (0.822 g % w/v).
Testosterone acetate, also, exhibited the same order of the solvent capacity in the 
hydrophilic co-solvent: Transcutol P® (1.142 g % w/v) > PEG 400 (0.92 g % w/v) > 
PG (0.87 g % w/v). Therefore, testosterone may produce better solvent capacity in a 
mixture of hydrophilic surfactant (HLB >12) mixed with mono-, di-, and tri­
glycerides in the presence of hydrophilic co-solvent i.e. Type HI. On the other hand, 
the acetate form may produce better solvent capacity in a mixture of hydrophilic 
surfactant (HLB<12) and mixed mono-, di and tri- glycerides (Imwitor 988® and 
Capmul MCM®) i.e. Type n. Progesterone (log/* 3.8) exhibited the following rank: 
Imwitor 988® (1.6 g % w/v) > Cremophor RH 40® (1.21 g % w/v) Capmul MCM®
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(1.2 g% w /v) > Miglyol 812® (1.147 g% w /v) > Tagat TO® (0.83 g% w /v). 
Therefore, progesterone intrinsic solubility could be much better in mixed glycerides, 
mono-, di-, and tri-glycerides with or without hydrophilic surfactant (HLB > 12) in 
the presence or absence of hydrophilic co-solvents.
However, in the case of hydroxy benzoate derivatives all the derivatives exhibited a 
much higher g % w/v solubility in Imwitor 988® (9.0 g % w/v - 27.0 g % w/v), 
Miglyol 812® (7.0 g % w/v-12 g % w/v) compared with the steroid derivatives (0.2 g 
% w/v-1.5 g % w/v and 0.03 g % w/v-1.1 g % w/v) respectively. This is most likely 
to the molecular volume; the parabens have lower molecular weight than the steroids ’ 
and their lower melting points which indicates lower crystal lattice energy.
In general, the co-solvent can be a good solvent for hydrophobic drugs when the 
polarity is intermediate, as seen with Transcutol P®. For example, hydrophobic drugs 
like hydrocortisone acetate, testosterone, and testosterone acetate was observed a 
higher solubility in Transcutol P® 0.779 g %w/v, 1.11 g % w/v and 1.14 g %w/v 
respectively.
Mixed glycerides, mono-, di-, and tri- glycerides (Imwitor 988® or Capmul MCM®) 
could be very much better solvent than in lipid formulations for most of hydrophobic 
drugs.
2.4.2.3 Determination o f the intrinsic solubility o f steroids and hydroxy 
benzoate derivatives in SEDDS formulations
The solubility of hydrophobic drugs in lipid excipients gives an early indication of 
the solubility in the SEDDSs formulations. The solubility of steroids in an S-F 
formulation was greater than in the lipid excipients and/or SEDDS formulations. The 
greatest solubility was measured in a S-F formulation with PG as a water-soluble co­
solvent. In the case of testosterone, the solubility was 2.568 %w/v and the acetate
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form was 2.06 g%w/v. Hydrocortisone exhibited the highest solubility in the 
presence of PG in surfactant- free formulations 1.203 g%w/v. While progesterone 
and the hydrocortisone acetate exhibited better solvent capacity in the presence of 
Transcutol P® in the S-F formulations 2.598 g%w/v and 0.178 g%w/v, respectively.
Steroids with a high log P>3 showed the highest solvent capacity in mixtures of 
mono-, di-, and tri-glycerides, hydrophilic co-solvents and medium chain 
triglycerides oil. On the other hand, the solvent of mixture of mono-, di- and tri­
glycerides could be the best solvent for steroids with low log P<3.
Pouton (1999) classification of SEDDS formulations into three categories based on 
their hydrophilic content is shown in Table 2.4. The solubility of steroids studied in 
the SEDDS formulations was compared to his classification system.
Figures 2.10-2.12 show the effect of different ratios of Miglyol 812®: Tagat To® on 
solubility. From the data showed, type II formulations are drug dependent. For 
example, Figure 2.10 indicated that as the percentage of TTO® increased from 20 % 
to 80%, the solubility of hydrocortisone increased from 0.105 g % w/v to 0.418 g % 
w/v. However, the acetate form showed a better solubility when the percentage of 
Miglyol 812® was increased from 20% to 80% in the formulation, 0.01 g % w/v to 
0.069 g % w/v respectively. This result was expected because the solubility of 
hydrocortisone acetate in the M 812® was 0.386 g%w/v higher than in TTO® 0.025 g 
% w/v. Although, the value was lower than expected. This means that the drug is 
more sensitive to the formulation and a type I (Miglyol 812®) could be the best 
solvent. Figure 2.11 showed that testosterone and its acetate form followed the same 
order of solubility as hydrocortisone acetate. As the percentage of medium chain 
triglycerides oil increased from 20% to 80%, the solubility of testosterone and its 
acetate form increased from 0.504 g % w/v to 0.82 g % w/v and from 0.459 g % w/v 
to 0.69 g % w/v respectively. Both drugs exhibited better solvent capacity in the 
presence of medium chain triglycerides (Miglyol 812®) than mixed with a hydrophilic
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surfactant. The solubility of testosterone in M 812® was 0.874 g % w/v and the 
acetate form was 1.035 g % w/v respectively. Figure 2.12 illustrated that 
progesterone followed the order of hydrocortisone, as the percentage of TTO® 
increased from 20 % to 80 % the solubility increased from 0.81 g % w/v to 1.507 g % 
w/v. Type II formulations have the advantage that they are less likely than type HI 
formulations to lose their solvent capacity after emulsification, but will have lower 
solvent capacities than type DI systems for drugs with intermediate log P and high 
molecular weight as for steroids.
Moving from Type II system to Type III, the solubility was enhanced due to an’ 
increase the hydrophilic content. In Type HI A, the experiment indicated that the 
solubility of hydrocortisone and its acetate ester would be at a maximum of 
0.77 g % w/v and 0.206 g % w/v respectively when the concentration of the 
surfactant and water-soluble co-solvent was used at a ratio of 1:1. Progesterone, 
testosterone and its acetate ester exhibited maximum solubility, 1.364 g%  w/v, 
1.034 g % w/v and 1.104 g % w/v respectively when the ratio of surfactant to water- 
soluble co-solvent was 3:2.
As the hydrophilic content (Cremophor RH40®, 40 %) was increased the solubility of 
steroids increased as shown in type III B. In general, type m  are suitable for drugs 
with an intermediate LogP (1-4) as in the case of steroids and hydroxy benzoate 
derivatives. Hydroxy benzoate derivatives exhibited a higher % w/v solubility in 
SEDDS formulations compared to the steroids. For the hydroxy benzoate 
derivatives, the more hydrophilic the drug, the more soluble in high-content 
hydrophilic SEDDS formulation e.g. methyl paraben log/* (1.6) indicated higher % 
w/v solubility 50.0 g % w/v 7 4 % in type in  B. Typically, hydroxy benzoate 
derivatives (log P >2) are soluble in the following order: S-F>Type III B > Type EH A 
> Type II, related to their solvent capacity in the SEDDs formulation.
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Further studies were done to investigate whether a linear relationship exists between 
the content of glycerides and the solubility of the steroids. These are shown in 
Figures 2.13-2.14. In general, as the weight fraction of mono-, di-, and tri-glycerides 
(Imwitor 988®) increased the % w/v solubility increased. It can be seen in Figure 
2.13 that as the weight fraction of glycerides to medium chain oil increased the 
solubility of hydrocortisone and acetate ester increased. The solubility of mixtures 
went hand-in-hand with the solubility of the excipients; e.g. the % w/v solubility of 
hydrocortisone acetate in ratio (3:7) Miglyol 812®: Imwitor 988® was 0.117 g % w/v, 
whereas the intrinsic solubility in Imwitor 988® was 0.22g % w/v. The same order 
can be applied in Figure 2.14, where the solubility of testosterone and its acetate ester' 
increased when the ratio of Imwitor 988®: Miglyol 812® increased 7:3.
Figures 2.15-2.17 showed that water-soluble binary mixture of mono-, di-, and tri­
glycerides and hydrophilic co-solvent (Imwitor 988® with PG and/or PEG 400) were 
tested for their solvent capacity using steroids. All the steroids, exhibited greater 
solvent capacity (% w/v) in these binaries than in SEDDS formulations. The type of 
water-soluble co-solvent affects the solvent capacity. The optimum ratio of mixtures 
of mono-, di and tri-glycerides and hydrophilic co-solvent is drug dependent. Figure 
2.15 showed that progesterone exhibited the maximum solubility at ratio (3:7) 
Imwitor 988®:PG and/or PEG 40. The solvent capacity was 1.68 g%  w/v and 
1.90 g%  w/v, respectively. The same order can be seen in Figure 2.16, where 
hydrocortisone exhibited the maximum solvent capacity at a ratio 3:7 Imwitor 988®: 
PG and/or PEG 400. The solubility was 1.871 g % w/v and 1.631 g%w/v, 
respectively. Whereas hydrocortisone acetate exhibited the maximum solvent 
capacity at a ratio of 5:5 where the solvent capacity was 0.251 g % w/v. Figure 2.17 
showed that in the presence of PEG 400 as hydrophilic co-solvent the maximum 
solvent capacity of testosterone was at ratio of 3:7 Imwitor 988®: PEG 400 0.897 g 
% w/v. However, in the presence of PG as a hydrophilic co-solvent the maximum 
solvent capacity was at a ratio 5:5, 2.39 g%w/v. Testosterone acetate exhibited that 
maximum solvent capacity in the presence of PEG 400 at a ratio 3:7 Imwitor 988®:
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PEG 400, 1.19 g%w/v and in the presence of PG the ratio was 8:2 Imwitor 988®: PG, 
0.965 g%w/v. In general, binary mixtures of PEG 400 and Imwitor 988® produced 
better solvent capacity for all of steroids except for testosterone.
2.4.3 Particle size analysis of surfactant-free formulations
Surfactant-free formulations, which exhibited miscibility are indicated in the phase 
diagrams Figures 2.1 —2.5. The characterization of the dispersion were performed 
using the water dispersion model. From inspection of the phase diagrams, most of 
the formulations exhibit crude to coarse emulsions upon dispersion into water. The- 
effect of co-solvent concentration, in mixtures of glycerides, on droplet size 
distribution is presented in Figures 2.18 and 2.19. Figure 2.18 represented that S-F 
formulation containing mixtures of mono-, di- and tri-glycerides <50%, and 
increasing the co-solvent concentration (from 10% to 30%) decreased the mean 
droplet size. A smaller droplet size was observed when the co-solvent concentration 
was in the range <15% Transcutol P® and the co-surfactant was in the range 50-90 % 
mixture of glycerides. Such decrease in droplet size may reflect the formation of a 
better close packed film of the cosurfactant at the oil-water interface, thereby 
stabilizing the oil droplet (Kommuru et al, 2001).
The type of co-solvent affects particle size, as shown in Figure 2.19. This indicated 
the effect of increasing the concentration of different co-solvent on a fixed ratio of 
Imwitor 988®: Miglyol 812® (6:4). Transcutol P® indicates the smallest particle size 
among the other hydrophilic co-solvents. Although, the addition of co-surfactant 
(Imwitor 988®) to the co-solvent lowered the interfacial tension, fluidised the 
hydrocarbon region of the interfacial region of the interfacial film, and decreased the 
bending stress of the interface, the decrease in droplet size was not significant. 
Kommuru et al (2001) has reported that the presence of co-solvent in microemulsion 
formulation increased the droplet size.
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2.5 Summary of results and conclusions
The mixed glyceride (mono-, di-, tri-glycerides) excipients, Imwitor 988® and 
Capmul MCM®, were particularly good solvents for all o f the corticosteroids 
particularly steroids with log P<2. There was a marked difference in solubility of 
steroids in MCT oil and, consequently, it was considered that the addition of co­
solvent might improve the solvent capacity of triglyceride-based systems. Surfactant- 
free formulation are typically composed of mixtures of Transcutol P® < 30 %, 
Imwitor 988® >50% and Miglyol 812® >30%. Surfactant-free (type IV)- 
formulations were generally better solvents than SEDDS type II formulations but 
were generally not superior solvents to mixed glycerides of mono-, di-, and tri­
glycerides (Imwitor 988 ®) and (Capmul MCM®) alone. Type IH SEDDS, which are 
hydrophilic, were also better solvents for most of the steroidal compounds than type 
II SEDDS. Although the homologous series of steroids span a considerable range of 
log P, their solubilities across a range of excipients and formulations were 
surprisingly similar, generally ranging from 0.2-2.1 g % w/v. Hydrocortisone acetate 
had a lower solubility in most systems than the other steroids, and generally, 
progesterone showed the highest solubility. On the contrary, for hydroxy benzoate 
derivatives, as the log P increased the solubility decreased, in most systems.
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Figure 2.1 Phase diagram of mono-, di-, and tri- glycerides, medium
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F igure 2.2 Phase diagram  of mono-, di-, and tri-glycerides and 
m edium  chain fatty acids oil and polyethylene glycol (PEG  400) 
as hydrophilic co-solvent
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Figure 2.3 Phase diagram of mixture of mono-, di-, and tri-glycerides
and medium chain oil, and Transcutol P as hydrophilic co-solvent




Figure 2.4 Phase diagram of mixture of mono-, di-, and tri-glycerides, 
medium chain oil and mixture of hydrophilic co-solvent
0
100 90 70 60 50 40
Miglyol 812
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Figure 2.5 Phase diagram of mixture of mono-, di-, and tri- glycerides
and medium chain oil and mixture o f hydrophilic co-solvents
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Figure 2.6 Solubility profile o f progesterone in surfactant-free
formulations at 25°C and 50°C, respectively at different time intervals
( the error bars represent the standard deviation o f three experiments)
Prog, at 25°C 






Figure 2.7 Solubility profile o f testosterone and its acetate ester in 
surfactant-free form ulations at 25°C and 50°C, respectively at d ifferent time
intervals ( the error bars represent the standard deviation o f three experim ents)
T.A. at 25°C 
T.A. at 50°C 






Figure 2.8 Solubility  profile o f  hydrocortisone and its acetate form  
in surfactant-free form ulations at 25°C and 50°C, respectively  
at different tim e intervals( the error bars represent the standard  
deviation o f three experim ent)
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Figure 2.9 Solubility  profile o f  testosterone in surfactant-free form ulations 
at d ifferent tem peratures vs tim e intervals( the error bars represent the 












Figure 2.10 Solubility profile o f  hydrocortisone and its acetate form  
in different ratios of type II formulations o f M CT and glyceryl 
trioleate surfactant (M iglyol 812: Tagato TO) at 25°C  
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Figure 2.11 Solubility profile o f testosterone and its acetate fonn  in 
different ratios o f type II formulations o f M C T  and glyceryl 
trioleate surfactant (M iglyol 812: Tagat T O ) at 25°C  
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F igure 2.12 Solubility  profile o f  progesterone in type II form ulations 
in d ifferent ratios o f  M CT and glyceryl trioleate (M iglyol 812 : T agat TO) 
and m ixed m ono-, di- and tri-glycerides and M CT ( Im w itor 988 : M iglyol 812) 
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Figure 2.13 Solubility  profile o f hydrocortisone and its acetate form  in m ixture 
o f  m ono-, di- and tri-glycerides and M C T (Im w itor 988 : M iglyol 812)
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Figure 2.14 Solubility profile o f testosterone and its acetate form in mixtures
of mono-, di-, and tri-glycerides MCT (Imwitor 988 : Miglyol 812)
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Figure 2.15 Solubility profile o f progesterone in mixtures o f mono-, 
di-, and tri-glycerides and hydrophilic co-solvents at 25°C  
( the error bars represent the standard deviation o f the three experiments)
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Figure 2.16 Solubility profile of hydrocortisone and its acetate form in mixtures
of mono-, di-, and tri-glycerides and hydrophilic co-solvent at 25°C
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Figure 2.17 Solubility profile o f testosterone and its acetate form in mixtures 
of mono-, di-, and tri-glycerides and hydrophilic co-solvent at 25°C  
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Figure 2.18 Effect of adding hydrophilic co-solvent (Transcutol P)on 
mixtures of mono-, di-, and tri-glycerides and medium chain fatty acids 
oil (Imwitor 988 : Miglyol 812) on the particle size distribution 
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Figure 2.19 Effect o f  adding different hydrophilic co-solvent on a m ixture o f m ono-, di-, and 
tri-glycerides and m edium  chain fatty acids oil (Im w itor 988 : M iglyol 812) (6:4) on particle  
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Assessing the fate o f  hydrophobic dru2S after dispersion o f  lipid formulations in 
aqueous media
3.1 Introduction
Lipid systems for oral administration can include triglycerides, diglycerides, 
monoglycerides, lipophilic surfactants, hydrophilic surfactants, and water-miscible 
co-solvents. The fate of lipid formulations, and the drug, after oral administration 
will depend on the aqueous solubility of the individual components, and the phase 
changes that occurs on dilution into an aqueous medium. Phase changes and 
dissolution of water-miscible components could lead to loss of overall solvent 
capacity and precipitation of the drug. This is undesirable because the 
biopharmaceutical advantage of a lipid formulation is the possibility that the drug can 
remain in solution in the gut, thereby avoiding the slow dissolution step, which can 
cause low and variable bioavailability from solid dosage forms. Aqueous solubility 
plays an important role in the determination of a drug bioavailability (Morelock et al, 
1994). Since a drug must be soluble in the gastrointestinal fluid to be orally active, 
the rate and extent of dissolution depend critically upon water solubility (Yalkowsky 
et al, 1980). Despite the potential of lipid formulation vehicles, very few studies to 
date have systematically examined the fate of the hydrophobic drugs in aqueous 
solution of lipid excipient and/or lipid formulation. The solubility of the drug is 
determined by the interaction of solute with solvents and the crystallinity of the solute 
(Ran et al, 2001). Solvent alteration is the most effective means to produce a 
thermodynamically stable increase in solubility. Yalkowsky et al, (1981) discussed 
the most commonly used approaches for solubilizing nonionizable drugs, such as 
steroids; namely cosolvency and micellization.
Co-solvency, the addition of water miscible solvents, such as ethanol, propylene 
glycol, polyethylene glycol and glycerine, to aqueous systems is routinely used as an
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aid to the solubilization of drugs in aqueous vehicles. In some other cases, the use of 
appropriate co-solvents can increase the aqueous solubility of a drug considerably. In 
other cases, the solubilizing effect is much less significant and may even lead to drug 
precipitation (Yalkowsky et al, 1981). Despite their popularity and utility in 
pharmacy, there are few systematic approaches for selecting co-solvents and 
predicting their solubilization effects on drugs. The selection of the appropriate co­
solvent system can ensure the solubility of all formulation components and minimize 
the potential for precipitation, which may result from cooling or from dilution with 
body fluids. A straightforward and reliable approach that requires little or no 
experimental and thus minimal time and drug, is the log-linear model proposed by 
Yalkowsky and co-workers (1972, 1976, 1981). The log-linear model describes an 
exponential increase in nonpolar drug solubility with a linear increase in co-solvent 
concentration, and can be used to estimate drug solubility at high co-solvent 
concentrations. This relationship is described by:
Log Stot = log Sw + <r * fc eq3.1
Where Stot is the total solute solubility in the co-solvent-water mixture, Sw is its water 
solubility, o is the co-solvent solubilization power for the particular co-solvent-solute 
system, and fc is the volume fraction of the co-solvent in the aqueous mixture. The a  
term can be obtained from the slope of the log (Stot/ Sw) versus co-solvent volume 
fraction (fc) profile of selected drug and co-solvent.
These co-solvents have hydrogen bond donor and/or acceptor groups as well as small 
hydrocarbon regions. Their hydrogen bonding groups ensure water miscibility while 
their nonpolar hydrocarbon regions interfere with water’s hydrogen bonding network. 
By disrupting self-association, they reduce water’s ability to “squeeze out" nonpolar 
compounds and thus increase solubility.
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Co-solvents can interact with water via two mechanisms. The organic nature of 
water-miscible co-solvents would lead to one type of interaction with water, which 
has been described, by the terms “iceberg” formation or “hydrophobic hydration” 
(Franks et al, 1966). Since this phenomenon depends on the ability of water to form 
cohesive bonds with other water molecules, it would be expected to be prevalent at 
relatively low concentrations of co-solvent, where an excess of water molecules exist. 
This phenomena has been reported in a number of investigators in aprotic co­
solvents: water mixtures and in short-chain alcohol: water mixtures (Kimura et al, 
1975). In addition to hydrophobic effects, the polar groups of co-solvent molecules 
lead to interactions with water of the hydrogen-bonding type. It has been suggested 
that low concentrations of relatively polar co-solvents, such as short-chain alcohols, 
may enhance water structuring through hydrogen bonding interactions in addition to 
the hydrophobic effect. Interactions between water and co-solvent which result in an 
increase in solvent structuring have been shown to reduce solvent-solute interactions. 
When the fraction of co-solvent is high relative to water, hydrogen bonding between 
water and co-solvent should also occur, but the significant structuring of water would 
be lost (Rubino et al, 1991).
Micellization and solubilization
Surfactant molecules consist of two moieties, one with affinity to water and the other 
to oil. When added to a mixture of oil and water, they self-assemble at the oil-water 
interface, so that the hydrophilic block stays in water and the hydrophobic one 
remains in oil. As the surfactant concentration increases, the monolayer at the oil- 
water interface becomes more densely populated and the interfacial tension decreases. 
At a certain concentration of surfactant, molecules start to self-associate in the bulk of 
one of the phases, forming supramolecular aggregates, (i.e. often spherical micelle in 
water) after reaching the critical micellar concentration (CMC). Above the CMC the 
concentration of free surfactant is not high regardless of the amount added because 
the surfactant molecules are aggregated into micelles (Kabalnov et al, 1996).
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Nonionic surfactants can be prepared for example by reacting ethylene oxide with 
long chain hydrocarbons with terminal polar groups e.g. -OH, -COOH. This 
procedure introduces ethoxy groups, which are polar in nature and form hydrogen 
bonds with water. It increases the solubility of nonionic surfactants in water. The 
resulting molecules still have amphipathtic character and micelle formation takes 
place. In the micelle, the hydrophilic groups are orientated outwards and the 
lipophilic groups are inwards in aqueous solution. The CMC for non-ionic 
surfactants is, in general, low because of the absence of the electrical repulsive forces 
which are expected to oppose the micellization of ionic surfactants. Therefore, most 
of the surfactant is in the micellar state even in dilute aqueous solution. Surfactants 
in solution tend to form micelles, aggregates of colloidal dimensions existing in 
equilibrium with molecules or ions from which they are formed. One of the most 
important properties of micellar systems is their ability to solubilize hydrophobic 
drugs. For aqueous micelles, solubilization is closely related to the hydrophobic and 
amphithatic properties of solubilizate. One of the important roles for micelles is their 
use as reservoirs of monomers (Mittal, 1977a). Solubilization in micellar systems 
offers an attractive way of formulating poorly soluble drugs. For conventional 
polyoxyethylenated non-ionic surfactants maximal solubilization generally occurs at 
a hydrocarbon chain length of Ci6 atoms. An increase in chain length and decrease in 
the number of polyoxyethylene units indicate no increase in solubility, because when 
the alkyl chain length exceeds Ci6, the chain is no longer liquid at 298 K and some of 
the polyoxyethylene glycol in order to depress its melting point and maintain a liquid 
micellar core (Lawrence, 1996).
Solubilization in the presence of surfactant (micellization) was defined by McBain et 
al, (1955) ‘as spontaneous passage of insoluble molecules in water into an aqueous 
solution of a surface active agents in which thermodynamically stable solution is 
formed into fine particle’ (reviewed by Elworthy, Florence and Macfarlane, 1975). 
Organic solutes can be solubilized by incorporation into surfactant micelles. The 
more non-polar the solute, the more likely it is to be incorporated near the core of the
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micelle. The relationship between drug solubility in a micellar solution and 
surfactant concentration is described by the following equation:
f^micStot = Sw + k(Csurf - CMC) eq. 3.2
Where Csurf is the concentration of micellar surfactant (i.e. the total concentration 
minus the critical micellar concentration), Sw is the concentration of solute in pure 
aqueous solution, CMC is the critical micellar concentration of surfactant, and k is 
the molar solubilization capacity, the number of moles of solute that can be 
solubilized by 1 mole of micellar surfactant (Yalkowsky, 1999).
The exact location in the micelle at which solubilization occurs (the centre of 
solubilization) varies with the nature of the drug solubilized which reflects the 
interaction between the drug and the surfactant. Large polar drugs are believed to be 
solubilized in the aqueous medium between the individual molecules of surfactant in 
the palisade layer with the polar groups of the solubilizate oriented toward the polar 
groups of the surfactants and the nonpolar portions oriented toward the interior of the 
micelle. Interaction is predominantly by H-bonding or dipole-dipole attraction 
between the polar groups of solubilizate and surfactant. The extent of penetration in 
the palisade layer depends on the polar to nonpolar structures in the solubilizate 
molecules; longer-chain and less polar compounds penetrating more deeply than 
shorter-chain and more polar materials.
Several parameters could affect micelle formation and consequently solubilization, 
e.g. addition of salts, co-surfactant and changing pH. The addition of salts, in 
general, increased the solubilization but decrease the CMC, depending on the amount 
of the salt added. Addition of salt decreased the concentration of monomers present, 
thereby increasing the concentration of surfactant present as micelles, with a 
concomitant increase in the solubilizing power (McBain et al, 1941). The change in 
the CMC of non-ionic surfactants on the addition of electrolyte has been attributed
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mainly to “salting out” or “salting in” of the hydrophobic groups in the aqueous 
solvent by the electrolyte, rather than to the effect of the latter on the hydrophilic 
groups of the surfactant (Elworthy, Florence and Macfarlane, 1975). When the 
monomeric form of a surfactant is salted out by the presence of an electrolyte, 
micellization is favoured and the CMC of the surfactant is decreased; when the 
monomeric is form is salted in, the CMC is increased. The hydrophobic group in the 
monomer phase is most likely affected by the addition of the electrolyte to the 
aqueous phase since the hydrophilic groups of the surfactant are in contact with the 
aqueous phase in both monomeric and micellar forms of the surfactant, while the 
hydrophobic groups are in contact with the aqueous phase only in the monomeric 
form. Therefore, the effect of the electrolyte on the hydrophilic groups in the 
monomeric and in the micellar forms may cancel each other (Elworthy, Florence and 
Macfarlane, 1975). Florence (1981) stated that the addition of sodium chloride to a 
mixture of surfactant and water alters the boundaries of the phases, possibly by 
altering the degree of hydration of the polyoxyethylene head groups of the nonionic 
surfactant. Interaction of solubilizate with the micelle may lead to changes in the 
packing of the monomer. There would be a shift in the phase boundaries not only of 
the isotropic micellar solution but also of the boundaries of mesomorphic phases, 
some of which disappear when disrupted by added solute because of the more 
delicate balance of forces in these systems.
Adding co-surfactant may alter the size and shape of micelles, and may increase the 
amount of solubilized oil in the system. Addition of a surfactant with low HLB limits 
the total surfactant solubility and thus the usefulness of the system, but small amounts 
of a hydrophobic detergent will sufficiently alter the micellar properties to result in 
changes in solubilization (Florence, 1981).
The solubilities of hydrophobic drugs in aqueous dispersions of SEDDS formulations 
are poorly understood and documented. Hydrophobic drugs are absorbed by 
transmembrane diffusion from the aqueous lumen of the gut. Most of the
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hydrophobic drugs will have low solubility in the lumen, so the aim in practice 
should be to provide a reservoir of drug in a readily available form. Consequently, 
hydrophobic drugs may benefit from reformulation in lipids, which can provide a 
reservoir of drug dissolved in either lipid or micellar solution. Type I or type II lipid 
formulations are good candidates to avoid precipitation of hydrophobic drugs. 
However, these systems have limited solvent capacity for drugs such as cyclosporin 
A, which has encouraged the use of type in systems (Pouton, 1999). Type IQ 
systems upon dilution will form supersaturated solutions, but this need not 
necessarily lead to a rapid precipitation. The key issue is that if the drug precipitates 
on dilution of the formulation in the gut, then any advantage is likely to be lost.
It will be important for future formulations to establish methods for assessment of 
precipitation and predictive methods to prevent problems associated with solubility 
experiments. It is appropriate to consider the likely fate of each type of lipid 
formulation at this stage. Self-emulsifying systems are expected to disperse rapidly 
within the contents of the stomach, which indicates that the formulation will empty 
into the intestine in a manner similar to the emptying of aqueous solutions. 
Consequently, the rate of absorption from a type II and a type in system is likely to 
be rapid, particularly when administered to a fasted stomach. Hypnotics and 
analgesics are ideal to be formulated in these formulations because they require rapid 
onset of action. On the contrary, these formulations may be disadvantageous for a 
drug with low therapeutic index. Type I formulations are ]ikely to be dependent on 
digestion by lipolysis, is a process which takes place in the small intestine. The drug 
will be solubilized in mixed micelles of bile salts as long as the drug does not 
precipitate during digestion. Therefore, the drug will not have an unusually rapid 
onset of action. The most important factor is the digestibility of the formulation. If 
the formulation is non-digestible then a colloidal state must be provided by self- 
emulsiflcation, whereas if digestible oils are used, the colloidal state can be obtained 
by natural digestion. The overall bioavailability is equivalent to that achieved by type 
II or type III.
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In this work, the factors which affect the precipitation of drugs on dissolution of lipid 
formulations, are investigated. At one extreme, when a hydrophobic drug is 
formulated in an aqueous co-solvent (such as propylene glycol or PEG 400), there is 
usually a drastic loss of solvent capacity and consequent precipitation of drug. At the 
other (lipophilic) extreme, if a drug is formulated in a triglyceride (TG) oil there will 
be no dissolution of TG, and no precipitation of drug. It can be anticipated that self- 
emulsifying formulations may also lead to a loss of solvent capacity, depending on 
the extent to which water-soluble components are used. Thus, type II SEDDS and S- 
F formulation should be less susceptible to precipitation than type DI SEDDS.
The inclusion of hydrophilic surfactants and co-solvents could lead to precipitation 
depending on the proportion of water-soluble components used. If the formulation 
contains a high proportion (Type DI B) then precipitation is to be expected. Whether 
this becomes a problem will depend on the rate of crystallization in the gut. This 
aspect of lipid formulation has not been studied thus far. In this chapter the approach 
that has been taken is to determine the equilibrium solubility of model drugs in 
dispersed systems. This is intended to help predict the likelihood of precipitation 
after administration of lipid systems. Therefore, steroids were chosen to give a range 
of log P because we expected that some would precipitate but others would stay in 
solution on dilution.
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3.2 Materials and methods
3.2.1 Materials
In addition to the materials mentioned in chapter 2, the following materials used:
Trizma®-maleate (tris-maleate) C4H11NO3C4H4O4 50 mM Sigma
Sodium chloride NaCL 150 m Sigma
Calcium chloride dihydrate CaCi2.H20 5 mM Sigma
Sodium hydroxide NaOH qs Fisons
3.2.2 Methods
3.2.2.1 Solubility Measurements
An excess amount of steroid powder was added to 20 ml glass vials containing 
various percentages (0.1 % w/v-4.0 % w/v) of hydrophilic co-solvents, lipophilic 
surfactants and dispersed SEDDS formulation (Ch.2, [Table 2.4]). Triplicate sample 
vials prepared for each lipid excipients and/or SEDDS formulation in water or tris- 
maleate buffer (pH 6.5) and were placed on an end-over-end shaker water bath at 
room temperature for 48 hour. Samples with drug were considered to reached 
equilibrium after 2 days and removed from the shaker. The samples were then 
centrifuged using Jouan 3.11 centrifuge (Decon laboratories, Ltd, model # FS200B, 
UK) at 3230 g for 20 min. Supernatant was diluted using methanol 96%v/v before 
measured the absorbance using the UY Spectrophotometer. The concentration of the 
drug was calculated as mentioned in (Ch.2, [2.2.2.3 UV assay].














PEG400 s/ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
PG ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
CRH 40® ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Tween 80® ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Miglyol 812® ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ V
S-F (M812®+1988®+ PG) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
(30%+50%+20%)
Type II (M812®+TTO®) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
(40%+60%)
Type IIIA (M812®+I988®+CRH 40®) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
(30%+30%+40%)
Type IIIB (M812®+I988®+CRH40®+PG) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
(10%+10%+40%+40%)
Table 3.1 Lipid excipients and SEDDS formulation used to assess the fate of steroids in water and/or 
tris-maleate buffer (pH 6.5) at 25°C. The dilution was used lg excipients in 25 ml (4 %w/v) of water 
and/or tris- maleate buffer (pH 6.5) (* indicates that the experiment were done).
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3.3 Results and discussion
The solubility values of steroid derivatives (g%w/v) in diluted hydrophilic co-solvent, 
lipophilic surfactant and SEDDS formulations (% w/w) are presented in appendices 
2, Tables 2.1-2.9. Experiments were performed in triplicate (SD <2% of mean).
3.3.1 Cosolvencv
Yalkowsky et al, (1981) has shown that the solubilization capacity a  is dependent 
upon the molecular hydrophobic surface area of the solute and on the interfacial 
tension of the pure co-solvent. The solubilizing power (a) for the drug is dependent 
upon the drug polarity, measured by log P  Co/W, and can be calculated from equation
3.1 (by the linear regression of the log solubility (% w/v) plot of the data. The 
dependence of a  on log Pc on the solubilization for steroid derivatives is shown in 
Table 3.2. The more hydrophobic the drug (log P) the greater the solubilization 
capacity. Although some exceptions were observed in case of testosterone and its 
acetate ester. The solubilizing capacity increased from 0.284 for hydrocortisone (log 
P  1.61) to 0.4864 for testosterone acetate (log P  4.7) in aqueous solution of 4%w/v 
PG. The same trend was observed for aqueous solution of 4%w/v PEG 400. The 
solubilizing capacity increased from 0.247 for hydrocortisone to 0.264 for 
progesterone. Testosterone and its acetate ester produced a lower solubilizing 
capacity than expected in the aqueous solution of PEG 400 0.112 and 0.1306 
respectively due to an experimental error.
The solubilizing capacity of steroids in tris-maleate buffer (pH 6.5) of 4 %w/v PEG 
400 showed an increase from 0.260 for hydrocortisone to 0.466 for progesterone. 
The same trend was observed for tris-maleate buffer (pH 6.5) of 4 % w/v PEG 400 
for hydrocortisone and its acetate ester 0.381 and 0.155 respectively. In case of 
progesterone, testosterone and its acetate ester indicated a decrease in solution of PG
0.4579, 0.1453 and 0.235 respectively. These unexpected measurements as a result
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of the solubility of the drug in dispersed co-solvent did not reach saturation in some 
cases. Furthermore, there may have been problems associated with obtaining 
homogenous samples of the dispersion upon centrifugation.
Usually, co-solvents form a homogenous solution with water. These solutions act as 
modified solvents having a polarity between that of water and the pure co-solvent 
(Yalkowsky, 1999). In any co-solvent mixture, the concentration of the unionised 
species and the ionized species in equilibrium. The unionised species, in general, is 
often assumed to be primarily responsible for improvement in total drug solubility. 
Figures 3.1- 3.5 show the solubility measurements obtained for steroids in propylene 
glycol and/or polyethylene glycol 400 dispersed into water and/or tris-maleate buffer 
pH 6.5. These data indicate a general increase in solubility as the weight fraction of 
co-solvent in the mixture is increased. The solubility increases are greater for more 
hydrophobic drugs. Although the data indicated an increase in solubility when the 
weight fraction increased, it is apparent that plots are not linear. At low weight 
fraction of co-solvent, the solubility of steroids was low.
A possible explanation for the low solubility can be obtained from the work of 
Kimura et al. who observed similar patterns of deviations in heat of solutions data of 
lipophilic solutes in alkanol: water mixtures (Kimura et al, 1975). At low 
concentrations of co-solvent water retains its ability to form highly ordered structures. 
Co-solvents possess both polar and nonpolar groups and it is expected that 
hydrophobic hydration occurs around nonpolar portions of the molecule, while 
hydrogen bonds are formed between polar groups and water. Such interactions 
between water and co-solvent reduce the interaction between water and the solute 
molecules, resulting in a solubility that is lower than is expected (Rubino et al, 1991). 
The interaction between water and a more lipophilic drug would be more highly 
dependent on the availability of water molecules in order to maintain the solute in 
solution due to the lower density of hydrogen bonding groups on the solute as seen in 
case of hydrocortisone and its salt. Thus, the more lipophilic species of the drug
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series might more sensitive to the co-solvent-water interactions and this could 
explain the apparent correlation between observed solubility and steroids series. In 
addition, Arnett and McKelvey (1965) reported that endothermic shifts due to 
hydrophobic hydration are dependent on the size of the solute. In other calorimetric 
studies systems, in which a single solute is examined in binary mixtures of various 
short chain alkanols and water, the magnitude of the co-solvent is similarly related to 
the alkyl chain length of alkanol. At high concentrations of co-solvent, the three- 
dimensional structure of water is lost and water molecules would be more available to 
interact with solute molecules; this leads to greater solubilites.
Log solubilization curves of a series of steroids in PG and PEG 400 in H2O and/or 
tris-maleate buffer pH 6.5 at 25 °C are shown in Figures 3.1-3.5. The solubilization 
curves show similar pattern for all steroids but a different patterns in the quantity 
dissolved.
The intrinsic solubility (S j) of testosterone and its acetate ester in pure PG was 0.828g 
% w/v and 0.876 g % w/v, respectively then the maximum dose, which can be 
administered in solution, is approximately 8.28 mg / ml and 8.76 mg/ ml, respectively
i.e. 8.28mg in 1 ml capsule and 8.76 mg in 1 ml capsule, respectively. This means 
that a hydrophilic co-solvent of 1 g diluted in 100ml must be able to dissolve the drug 
at 8.28 mg / 100ml (0.0828 g % w/v). The solubility of testosterone and its acetate 
ester at 1 g % w/w aqueous solution of PG was 0.0113 g % w/v and 0.109 g % w/v, 
respectively. This indicates that there would be loss of the original quantity <40% of 
testosterone leading to precipitation but still the co-solvent can keep some of the drug 
in solution. Progesterone has similar trend, the intrinsic solubility is 1.071g%w/v, so 
the maximum dose is approximately 10.071 mg/ml, this mean a 1 g of hydrophilic co­
solvent diluted to 100 ml must be able to dissolve the drug at 10.071 mg/100 ml i.e. 
0.01 g%w/v and at l%w/v aqueous solution of PG was 0.0063g% w/v. However, 
hydrocortisone acetate exhibited a significant loss in aqueous solution of PG 0.0068 
g%w/v given the intrinsic solubility is 0.337g%w/v i.e the maximum dose is
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approximately is 3.37mg/ml, this means lg of hydrophilic co-solvent diluted to 100 
ml must be able to produce the drug at 3.37mg/100 ml (0.0337g%w/v). The intrinsic 
solubility of hydrocortisone is l%w/v i.e. the maximum dose which can be 
administered in solution, is approximately 10 mg/ml, this means that lg of 
hydrophilic co-solvent diluted to 100 ml must be able to dissolve the drug at 10 
mg/100 ml i.e. 0.01%w/v, the results shows that the aqueous solubility of lg  of PG 
diluted in 100 ml water was able to dissolve 0.0113%w/v i.e. 11.4 mg/100 ml, this 
results indicated that co-solvent can keep hydrocortisone into solution higher than 
expected.
Based on the data shown, PEG 400 indicated better ability to keep the drug in 
solution than PG. Figures 3.1 and 3.2 showed that testosterone and its acetate ester 
exhibited better solubility at 1 %w/v of aqueous solution of PEG 400 or in tris- 
maleate buffer pH 6.5 0.0328 g%w/v, 0.054 g%w/v; 0.1075 g %w/v and 0.1280g% 
w/v respectively, than at 1% w/v aqueous solution of PG or in tris-maleate buffer (pH 
6.5) 0.0113 g%w/v, 0.0715g% w/v; 0.109 g%w/v, and 0.095g% w/v respectively. 
Figure 3.3 showed that progesterone followed the same trend; in the presence of 
l%w/v of aqueous solution and/or of PEG 400 or tris-maleate was 0.0141 g % w/v 
and 0.0940 g % w/v, respectively, while in the presence of PG the solubility was 
0.0063 g % w/v and 0.0225 g % w/v respectively. Figure 3.4 showed that 
hydrocortisone acetate follow similar pattern to the other steroids. However, in 
Figure 3.5 showed that hydrocortisone exhibited higher solubility in the presence of 
PG in water and/or tris-maleate buffer 0.0103 g%w/v andO.0153 g%w/v respectively 
than in the presence of PEG 400 either in water or in tris-maleate buffer (pH 6.5) 
0.0113g%w/v and 0.0109g%w/v respectively.
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Solubilization power a
PG PG PEG 400 PEG 400
H 20 Tris-maleate H 20 Tris-maleate
Hydrocortisone 0.284 0.381 0.247 0.260
Hydrocortisone acetate 0.127 0.155 0.288 0.298
Testosterone 0.394 0.145 0.112 0.262
Testosterone acetate 0.486 0.235 0.131 0.193
Progesterone 0.465 0.458 0.264 0.466
Table 3.2 The solubilization power of steroids either in water or in tris-maleate buffer 
(pH 6.5) at 25 °C of 4 % w/v PG and/or PEG 400 solution (a is the linear regression 
of the log plot of the data).
3.3.2 Micellization and solubilization
Solubilization by surfactant is generally believed to be via uptake of solute molecules 
into isotropic solutions of surfactants (Florence, 1986). Two surfactants, Cremophor 
RH 40® (CRH 40®) and Tween 80® (T 80®), were used as representative non-ionic 
surfactants. They were chosen on the basis of their polyoxyethylene chain length. 
Tween 80 (polyoxyethylene-20-sorbitan monooleate) is a clear, yellow liquid at room 
temperature with HLB = 15. Cremophor RH 40® (polyoxyl-40-hydrogenated castor 
oil) is white solid material at room temperature with HLB = 14-16.
Surfactant CMC
Cremophor RH 40 0.0039
Tween 80® 0.000021
Table 3.3 The critical micellar concentration of non-ionic surfactant used in the 
research (Samah et al, 1989).
In general, both CRH 40® and T 80® produce similar effect on steroids solubility. 
These effects for all surfactant-steroid systems are given in Figures 3.6-3.11. The 
amount of drug solubilized (g/100ml) was linearly related to surfactant concentration 
(% w/v) (r2 = 0.98 ± 0.5), either in water or in tris-maleate buffer pH 6.5 at 25°C. The
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y-x intercept equated to steroid's aqueous solubility indicating that its solubility at the 
CMC was very close to that in water. This is expected since the CMCs of surfactant 
were very low when compared with the surfactant concentration used (Barry et al,
1976). In Figure 3.9, the aqueous solubility of hydrocortisone at 0.1 % w/w CRH 40® 
in water is 0.2 g /ml and this is very close to its solubility in water (0.25 g/ml). When 
surfactant concentrations were compared on a weight basis, the solubilizing efficiency 
of the surfactants, decreased with increasing polyoxyethylene chain length. The 
aqueous solubility of steroids increased in water in the presence of CRH 40® or T 80® 
as the polarity of the steroids increased i.e. increased log P.
In the presence of tris-maleate buffer pH 6.5, the aqueous solubility of steroids 
increased more in the presence of T80® than in the presence of CRH 40®. 
Ethoxylated surfactant owing to the absence of electric charges, are insensitive to pH 
and practically unaffected by salt concentration (Becher, 1983a). Nevertheless, the 
addition of some electrolytes will change the orientation of the water molecules on 
the surface giving a positive surface potential. With increasing salts concentration, 
non-ionic surfactant lose part of the water of hydration. This is a salting out effect 
and will lead to a decrease in the CMC of the surfactant. The salting out of neutral 
molecules depends on the concentration and the ionic radius of the added electrolytes. 
The smaller the hydrated ions the bigger the salting out effect because of the stronger 
polarizing effect. Addition of electrolytes decreases hydration of the ether linka 96 
non-ionic surfactant and shifts the hydrophilic-lipophilic balance to the lipophilic site 
(Lissant, 1974).
Steroids are non-electrolytes at neutral pH (6.5); the drug is primarily uncharged and 
the solubilization by both surfactants is approximately similar. Tween 80® solutions 
exhibited higher solubility in tris-maleate buffer pH (6.5) than in the presence CRH 
40®. Figures 3.6 and 3.7 showed that testosterone and its acetate ester exhibit better 
solubility in the presence of l%w/v T80® in tris-maleate buffer 0.3781 %w/v and
0.3375 %w/v) than in the presence of CRH 40® 0.3425 %w/v and 0.3075%w/v
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respectively. Figure 3.8 showed that hydrocortisone acetate followed the same order, 
better solubility in the presence of l%w/v T 80® in tris-maleate buffer pH (6.5) 0.211 
%w/v than in the presence of CRH 40® 0.200%w/v respectively. On the contrary, 
Figures 3.9 and 3.10 showed that hydrocortisone and progesterone had better 
solubility in the presence of 1 % w/w CRH 40® of tris-maleate buffer pH (6.5) 0.1695 
% w/v and 0.2085 % w/v, respectively than in the presence of T 80® 0.1400 %w/v 
and 0.1778 % w/v respectively. Results revealed that the micellar sizes of surfactants 
decrease while hydration increases as polyoxyethylene chain increases and so, 
inclusion of non-polar, non-electrolyte steroids into the increasingly polar micellar 
environment decreased (Barry et al, 1976).
The intrinsic solubility of hydrocortisone in CRH 40® was 0.73 %w/v, then the 
maximum dose which can be administered in solution is approximately 7.3 mg/ml;
i.e. 7.3 mg in 1 ml capsule. This means that a lg of CRH 40® diluted in 100 ml water 
must be able to dissolve that hydrocortisone at 7.3 mg/100 ml (0.073 %w/v). The 
aqueous experiments revealed that both surfactants could keep drug into solution 
higher than expected. The same trend happened with testosterone and its acetate 
ester, the aqueous solubility was much higher than expected. The intrinsic solubility 
in CRH 40® was 0.97 %w/v and 1.06 %w/v, respectively. The maximum dose which 
can be administered in solution is approximately 9.7mg/ml, 10.6mg/ml, respectively. 
This means that a 1 g of CRH 40® diluted in 100 ml water must be able to dissolve 
that testosterone and its acetate ester at 9.7mg/100ml (0.097%w/v), 10.6 mg/100ml 
(0.106%w/v), respectively. Progesterone has similar behaviour; the intrinsic 
solubility in CRH 40® was 1.21%w/v. This means that the maximum which can be 
administered in solution is approximately 12.1 mg/ml (12.1 mg in 1 ml capsule) i.e. 
1 g of CRH 40® diluted in 100 ml water must be able to dissolve that progesterone at 
12.1mg/100 ml (0.121%w/v). The data indicated that a saturated solution in pure 
T80® or CRH 40® would stay in solution on dilution.
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Different opinions were describing the hydrated polyoxyethylene chain. Schick 
(1963) has been proposed that polyoxyethylene chain is an expanding spiral i.e. a 
cone shape, with the narrower end at the surface of hydrocarbon core. Later, other 
researchers mentioned that the micellar structures of these surfactants were nearly 
spherical and extensively hydrated (reviewed by Elworthy et al, 1975). Although 
there is space for hydrating water in the outer parts of the micelles, there is virtually 
none close to the hydrocarbon core due to crowding of the polyoxyethylene chains 
(Elworthy et al, 1975). This produces a region which is largely purely 
polyoxyethylene, rather than polyoxyethylene-water, which may act as a site of 
solubilization of semi-polar drugs. A cross section of a polyoxyethylene surfactant 
micelle therefore offers a complete range of polarity. The non-polar hydrocarbon 
core will be, via the semi-polar polyoxyethylene portion, to pure water on the 
micellar surface. For semi-polar steroid drugs, it would be likely that the unhydrated 
polyoxyethylene portion close to the hydrocarbon core, so that the least polar 
steroids, testosterone acetate>progesterone> testosterone, would be closest to the core 
and the polar ones, hydrocortisone and hydrocortisone acetate, furthest from the core 
and closer to the hydrated polyoxyethylene portion (Barry et al, 1976).
3.3.3 The fate of SEDDS formulation upon dilution
Lipid formulations are considered when the poor aqueous solubility of a drug 
candidate is attributed to its hydrophobicity (Anderson et al, 1999). For lipid 
formulations it is necessary to understand how solubility is affected by mixing 
different components, such as medium chain oils, hydrophilic co-solvents and non­
ionic surfactants and how solubility is related to the molecular weight, melting point 
and log P of the drug. It is useful to be able to anticipate whether precipitation of the 
drug is likely to occur after dispersion of the formulation in gut. The solubility of 
each steroid was determined in aqueous dispersions of SEDDS formulations either in 
water or in tris-maleate buffer (S) pH 6.5. This data was used to predict whether a 
saturated solution of drug in the undiluted formulation would remain in solution (at
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equilibrium) in dilutions of 1 in 25 ml. The mass (mg) of each steroid dissolved in 
the aqueous dispersion (4 % w/v) was estimated from experimental data and tabulated 
in Tables 3.4 and 3.5.
The mass of steroid in 1 g pure formulation was calculated from the data described 
previously on intrinsic solubility (Si), as shown in Table 3.4.
Type I formulations show, in general, the extent of solubility of aqueous dispersions 
of the SEDDS formulations increased with the hydrophobic character of steroids. 
Type I systems are represented by using Miglyol 812® as medium chain fatty acid oil. 
The date in Table 3.5 showed that the intrinsic solubility of steroids in Miglyol 812® 
is limited. The intrinsic solubility of progesterone, testosterone, and its acetate ester 
are 1.147 % w/v, 0.847 % w/v and 1.035 % w/v respectively. The data in Table 3.4 
showed that 1 g of pure M 812® diluted to 100 ml water and/or tris-maleate buffer 
(pH 6.5) must be able to dissolve 11.47 mg, 8.470 mg, and 10.35 mg per 100 ml, 
respectively. However, in fact the data showed that the mass recovered was much 
less than expected 6.91 mg, 3.49 mg, and 4.67 mg respectively when diluted into 
water and 3.99 mg, 2.86 mg and 3.81 mg respectively when diluted into tris-maleate 
buffer. The same trend was observed for hydrocortisone and its acetate ester form. 
The hydrocortisone formulation was soluble at 0.37 mg and 0.271 mg respectively 
after dilution in either water or tris-maleate buffer respectively. The corresponding 
figures for hydrocortisone acetate were 2.2 mg and 1.41 mg respectively. The 
experimental data indicated an unexpected result that precipitation of the drugs may 
occur after dilution of type I formulations in water or tris-maleate buffer. Normally, 
type I (MCT) would be expected to keep the drug in solution upon digestion, since 
medium chain glycerides will undergo lipolysis, which facilitates dispersion of the 
drug into colloidal solution. However, if the dose of the drug is low, as in steroids, 
the formulator may be uncertain of the fate of the drug.
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H 1.000 0.370 0.271 1.760 0.290 0.310 7.770 2.680 2.590 10.890 2.100 2.310 12.030 4.900 4.560
H.A 3.860 2.211 1.020 0.480 0.141 0.123 2.060 0.520 0.630 3.000 0.430 0.449 1.632 0.651 0.563
T 8.470 3.490 2.860 7.600 3.010 3.750 10.340 3.600 2.790 11.300 2.000 2.270 25.660 12.300 9.190
T.A 10.350 4.760 3.810 6.690 3.300 3.560 11.040 3.560 2.990 8.400 1.990 1.870 20.600 8.630 9.210
P 11.470 6.910 3.990 6.100 2.420 2.420 13.640 4.250 4.310 14.890 2.890 2.789 22.150 8.470 9.170
Table 3.4 The mass (mg) of steroids in 4 g formulation either diluted in 100 ml of water or in tris-maleate buffer (pH 6.5) and the 
mass of steroids in pure formulations (1 g).































H. 1.53 0.100 0.037 0.027 0.176 0.029 0.031 0.777 0.268 0.259 1.089 0.210 0.231 1.203 0.490 0.456
H.A. 2.48 0.386 0.022 0.102 0.048 0.014 0.112 0.206 0.052 0.063 0.300 0.043 0.045 0.163 0.651 0.560
T. 3.30 0.847 0.349 0.286 0.760 0.301 0.283 1.034 0.375 0.279 1.130 0.020 0.227 2.566 1.230 0.919
T.A 4.70 1.035 0.476 0.381 0.669 0.330 0.301 1.104 0.356 0.299 0.840 0.199 0.187 2.060 0.863 0.921
P. 3.80 1.147 0.691 0.399 0.610 0.246 0.242 1.364 0.425 0.431 1.489 0.289 0.279 2.215 0.847 0.917
Table 3.5  The aqueous solubility of steroids at 4 % w/w S E D D S  formulation in water and/or tris-maleate buffer pH 6 .5  
(S  % w/v) and their intrinsic solubility (Si g % w/v) at 2 5 °C .
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These unexpected measurements could be as a result of the solubility of drug in the 
dispersed formulations did not reach saturation in some cases. Furthermore, there 
may have been problems associated with obtaining homogenous samples of the 
dispersion upon centrifugation.
In type II system, the magnitude of the observed aqueous solubility of steroids in the 
dispersion of type LI diluted either in water or in tris-maleate, can be ranked in the 
following order: testosterone acetate>testosterone > progesterone> hydrocortisone > 
hydrocortisone acetate. The expected mass of progesterone, testosterone, and 
testosterone acetate from dissolving 1 g of pure type II formulation to 100 ml was 
6.10 mg, 7.6 mg and 6.69 mg respectively. The amount of mass recovered from 
progesterone, testosterone, and testosterone acetate was 2.46 mg, 3.01 mg, and
3.3 mg respectively when diluted into water. The amount of hydrocortisone and its 
acetate form mass recovered was 0.29 mg and 0.141 mg, respectively, which less than 
expected 1.76 mg and 0.48 mg respectively. The data indicated that at least 50% of 
the drug would be precipitated on dilution of a Type II system.
Type II systems are defined as self-emulsifying systems that are comprised of water- 
insoluble components. They are composed of non-ionic ester ethoxylated surfactant 
with an intermediate HLB 12 mixed with medium chain triglycerides. The type II 
mechanism could be described by the ‘interfacial turbulence’ mechanism. The 
process of emulsification is thought due to the occurrence of turbulence at the oil- 
water interface. The occurrence of turbulence is due to unequal adsorption and 
diffusion of surface-active materials at the interface. The unequal surfactant 
concentration leads to corresponding spreading of the interface, causing violent 
turbulence. This causes droplets of one phase to appear in the other along the oil- 
water interface. The surfactant forms a new oil-water interface around the droplets 
and emulsification occurs. They have the tendency to form lamellar liquid crystalline 
structures upon dilution, which facilitate penetration of water in formulation, 
resulting into interfacial disruption, which is strong enough to eject the emulsion
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particles from the surface of the bulk oil-surfactant interface. From the data shown in 
Tables 3.4 and 3.5, the molecular weight of testosterone (Mwt=288.4) and its acetate 
ester (Mwt = 330.5) are appropriate in size to be dissolved within the interface, unlike 
hydrocortisone acetate (Mwt=404.3). The melting point may play a role in 
solubilization; testosterone and its acetate ester 152° and 140° respectively is lower 
than hydrocortisone and its acetate form 217°-220° and 220° respectively.
Table 3.5 showed the ability of hydrophobic drugs to stay in solution should improve 
upon moving from type II to type m  systems. This is achieved by the inclusion of 
hydrophilic surfactants (such as Cremophor RH 40®). The intrinsic solubility of 
steroids in type HI systems is better than in type II formulations. Therefore, the 
amount of mass expected to be dissolved in 1 g pure type IE formulation diluted in 
100 ml solution must be more than in type E and type I (Table 3.4). Upon dilution of 
Type E SEDDS in water, the hydrophilic co-solvent diffuses away from the oil into 
the aqueous phase, thus the mechanism is ‘diffusion and stranding’. The hydrophilic 
surfactant may also transfer to the aqueous phase to form a micellar solution. The 
fate of hydrophobic drugs in type IE systems, upon mixing with water could be 
solubilization in a swollen micellar solution, dispersion as a fine emulsion, or 
isolation and precipitation. For steroids, most of them had a precipitation problem.
Due to this confusion, type IE system can be subdivided further into two types 
depending on the presence of surfactant. In type IE B tfie hydrophilic content is 
higher than in type IE A. Pouton (1999) mentioned that for drugs having an 
intermediate log P, the best formulation would be type E3 B, because the content of 
oil is less than 20 %. However, the results revealed that there was no specific 
relationship between aqueous solubility (4 % w/v) of the drug and its hydrophobic, 
molecular weight and melting point; rather it is drug dependent.
All steroids exhibit better solubility in dispersions of type IE A than dispersions of 
type IE B systems. The intrinsic solubility of testosterone and its acetate ester in type
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HI A was 1.034 %w/v and 1.1040 %w/v respectively and in type III B was 
1.130%w/v and 0.84% w/v respectively. This means 1 g of type III A would dissolve 
10.34 mg of testosterone and 11.04 mg for testosterone acetate. The mass recovered 
of testosterone either in aqueous dispersion of type HIA or in tris-maleate buffer was 
3.60 mg, and 2.79 mg respectively and 3.56 mg and 2.99 mg respectively for 
testosterone acetate. Either in the presence of type in  B dispersed in aqueous 
solution or in tris-maleate buffer, the mass recovered was 2.00 mg and 2.27 mg, 
respectively for testosterone and 1.99 mg and 1.87 mg respectively for its acetate 
ester. This represents a loss of up to 80% of the drug, in spite of the presence of 
hydrophilic surfactant CRH 40®, <40 % which would be expected to solubilize the 
drug through the micellization. The presence of hydrophilic co-solvent <35 % would 
be expected to lead to precipitation of the drug, so the amount of mass recovered after 
dilution of type LH B was less than in type El A.
The same basic observations applied to hydrocortisone and its acetate ester. The 
intrinsic solubility of hydrocortisone was 0.77 %w/v and 0.206 %w/v for 
hydrocortisone acetate. Therefore, 1 g of pure type HIA should be able to dissolve 
7.7 mg for hydrocortisone and 2.06 mg for the acetate ester. The mass recovered of 
hydrocortisone upon dilution type III A either in water or in tris-maleate buffer was 
2.68 mg and 2.59 mg, respectively, and 0.52 mg and 0.63 mg respectively for the 
acetate ester. The amount of drug recovered in the presence of type IHB was 2.10 mg, 
2.31 mg, respectively for hydrocortisone and 0.43 mg; 0.44 mg respectively for the 
acetate ester.
Progesterone formulations behaved in a similar manner. The mass recovered in the 
presence of type El A upon dilution either in water or in tris-maleate buffer was more 
4.25 mg and 4.310 mg respectively than in the presence of type El B 2.89 mg and 
2.79 mg respectively.
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The previous data was anticipated for the use of type III A and type El B 
formulations, however the mass recovered was much less than expected for the type I 
and type II formulations. This could have been due to experimental error, perhaps the 
time for equilibration was insufficient or the samples were not sufficiently 
homogeneous before and after centrifugation.
In S-F formulation, the presence of >20 % medium chain fatty acid oil and > 40 % of 
mono-, di-, and tri-glycerides may fulfil a valuable role in preventing precipitation of 
the drug on dilution in water. The presence of high oil content is usually desirable 
because it will be digested rapidly following its entry into the duodenum. In this way 
the increased concentration of drug in solution within mixed micelles enables rapid 
absorption in the upper small intestine (Hutchison et al, 1996). The data showed that 
in comparison with pure co-solvent formulations, S-F formulations helped to keep the 
drug in solution upon dilution either in water and/or in tris-maleate buffer. However, 
again, the amount of mass recovered was much less than expected due to the previous 
reasons mentioned. For example, the intrinsic solubility of hydrocortisone and its 
acetate ester in the formulation was 1.203 %w/v and 0.1632 %w/v respectively. 
Therefore, 1 g of pure S-F must be able to dissolve 12.03 mg in 100 ml for 
hydrocortisone and 1.632 mg in 100 ml for hydrocortisone acetate. The mass 
recovered for hydrocortisone upon dispersion of S-F either in water and/or tris- 
maleate was 4.90 mg and 4.56 mg respectively, and 0.651 mg and 0.563 mg 
respectively, for its acetate ester. The same followed for progesterone; the recovered 
mass was much less 8.47 mg in water and 9.17 mg in tris-maleate than the expected 
mass upon dilution S-F either in water and/or in tris-maleate buffer 22.15 mg. The 
expected mass of testosterone and its acetate ester upon dilution S-F was more 25.66 
mg and 20.6 mg; respectively than the recovered upon dilution either in water and/or 
in tris-maleate buffer 12.3 mg and 9.21 mg respectively for testosterone 8.630 mg and 
9.21 mg respectively for testosterone acetate.
106
3.4 Conclusion
Formulations selection is important in relation to the objective of keeping the drug in 
solution throughout its passage in the gut. The first estimation to make from the 
equilibrium solubilities is what happens in the expected worst case represented by 
formulation as a simple co-solvent solution. The average solubility of steroids in co­
solvent is l%w/v; therefore, the maximum dose that can be administered in solution 
is approximately 10 mg/ml, i.e. lOmg in a 1ml capsule. This means that a 
formulation of lg  diluted to 100ml must be able to dissolve the drug at lOmg/100ml 
(0.01% w/v; 0.1 mg/ml). The data indicated that at least 60% of the drug would be 
precipitated on dilution of a co-solvent.
Since the steroids are only soluble at approximately 1.1 %w/v in each formulation, 
then the maximum dose, which can be administered in solution, is approximately 
11 mg/ ml, i.e. 1 lmg in a 1ml capsule. This means that a formulation of lg  diluted to 
100ml must be able to dissolve the drug at llmg/lOOml (0.011% w/v; O.llmg/ml). 
Type I formulation (Miglyol 812®) would be expected to keep the drug in solution 
upon dispersion and digestion better than type in  A and Ed B. Surfactant-free 
formulations could be used to administer a higher dose of steroids since the steroids 
are soluble at approximately 2 %w/v. Then the maximum dose, which can be 
administered in solution, is approximately 20 mg/ml, i.e. 20mg in a 1ml capsule. 
This means that a formulation of lg diluted to 100ml must be able to dissolve the 
drug at 20mg/l 00ml (0.02% w/w; 0.2mg/ml).
The aqueous solubility of drugs in dispersions of SEDDS formulations was not as 
high as expected but gave an idea of the minimum solubility of the drug after 
dispersion. Steroids were not very successful model drugs to examine the fate of 
drugs after dispersion, because of their low solubility in the formulations. Steroids 
are non-electrolytes that are poorly soluble in the lumen of the small intestine. 
Therefore, they may benefit from reformulation into lipid systems, which can give a
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reservoir of drug dissolved in either lipid or micellar solution. The key issue is the 
hydrophilic content (surfactant and co-solvent) that is required to keep the drug in 
solution. In practice, the presence of co-solvent and surfactant can improve the 
solvent capacity of the formulation, but the instant they are diluted the fates of co­
solvent systems will differ from surfactant systems. For co-solvent dispersions large 
amounts of the drug may precipitate whereas surfactants are capable of forming 
micellar solutions, which may be provide better solvents. The results presented here 
indicated that even in the presence of surfactant there is a possibility of loss of the 
drug from type III B formulations.
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Figure 3.1 The fate of testosterone in water and/or tris-maleate 
buffer (pH 6.5) of hydrophilic co-solvent at 25°C represented by log
solubility Vs hydrophilic co-solvent concentration (% w/v)
Z 3 &A o
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Hydrophilic co-solvent concentration (% w/v)
•  PEG 400/ H20
■ PG/ H20
A PEG 400 / Tris-maleate
T PG/ T ris-maleate
O PEG 400/ H20  (0.1-0.9 % w/v)
□ PG/ H20  (0.1-0.9 w/v%)
A PEG 400 / Tris-maleate (0.1-0.9 % w/v)
V PG/ Tris-maleate (0.1 -0.9 % w/v)
Figure 3.2 The fate of testosterone acetate in water and/or tris-maleate 
buffer (pH 6.5) of hydrophilic co-solvent at 25°C represented by log 







5.04.50.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
Hydrophilic co-solvent concentration (% w/v)
•  PEG 400/ H20
■  PG/ H20
A PEG 400/ Tris-maleate
▼ PG/Tris-maleate
O PEG 400/ H20  (0.1-0.9 % w/v)
□ PG/ H20  (0.1 -0.9 % w/v)
A PEG 400/ Tris-maleate (0.1 -0.9 % w/v)
V PG/ Tris-maleate (0.1-0.9 % w/v)
F igure 3.3 T he fate o f  p rogesteron e in w ater an d /or tris-m aleate
b uffer (pH 6.5) o f  h ydroph ilic  co-so lvent at 25°C represented  by log
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Figure 3.4 The fate of hydrocortisone acetate in water and/or tris-maleate 
buffer (pH 6.5) of hydrophilic co-solvent at 25°C represented by log solubility 
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Figure 3.5 The fate of hydrocortisone in water and/or tris-maleate 
buffer (pH 6.5) of hydrophilic co-solvent at 25°C represented by log 
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Figure 3.6 The fate of testosterone in aqueous solution of water and/or
tris-m aleate buffer pH 6. 5 o f  lipophilic surfactant at 25°C
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Figure 3.8 The fate of hydrocortisone acetate in water or/and tris-maleate
buffer solution pH 6.5 o f lipophilic surfactant at 25°C ( the error bars
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Figure 3.10 The fate of progesterone in aqueous solution of water
and/or tris-maleate buffer pH 6.5 of lipophilic surfactant at 25°C
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Chapter 4
In vitro method for simulation o f intestinal lipolysis o f lipid formulations: the 
effect o f experimental variables on hydrolysis o f glycerides using pH-stat 
method
4.1 Introduction
In order to obtain useful information from an in vitro lipolysis model, it is 
essential to undertake the experiments in a reaction medium that is 
physiologically representative (MacGregor et al, 1997). However, it is 
complicated by the fact that the GI environment is subject to inter- and intra­
individual variations, making it difficult to choose a single set of reaction 
conditions for in vitro model studies. It is therefore advantageous to determine 
the effects of key physiologically variables on the rate of lipolysis (Alvarez et al, 
1989).
A pH-stat is used to monitor the progress of enzymatic hydrolytic reactions where 
protons are liberated (Brocklehurst, 1992). The use of a pH-stat in many 
biochemical reactions has been practised for at least 100 years, (Verger et al,
1977). A major effort in lipolysis research is directed toward establishing the 
assay procedure using the pH-stat (Alvarez et al, 1989, Challis, 1991, Solomon, 
1998). Using the pH-stat method enabled the extent of digestion of a lipid -based 
formulation, in a physiologically representative reaction medium, to be predicted 
with respect to time.
The primary objective was to determine the pancreatic lipase-colipase activity 
present in a crude extract from porcine pancreas [termed “Pancreatin”] and to 
validate the experimental method. The influence of various physiological factors 
[e.g. variations in lipase, BS concentrations, BS: LC ratio and variation in pH] on 
the rate of lipolysis were investigated. A study was also performed to establish 
the importance of triglyceride chemical structure on the rate of lipolysis via 
digestion of four different triglyceride oils. Several control experiments were 
performed to ensure validity of the results obtained using the pH-stat method. 
The set up, calibration, operation and maintenance of the pH-stat are discussed,
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followed by the methodology chosen for the in vitro model of lipolysis. This 
assay procedure was used for all lipolysis experiments described in chapters 5 and 
6 .
4.2 Principles and theoretical basis of pH-stat assay of lipolysis
4.2.1 Basic principles o f the assay
The use of the radiometer pH-stat allows continuous titration, in which the pH is 
kept approximately constant by frequent addition of an alkali or acid (Dixon et al, 
1979). The pH-stat operates by monitoring the electrode potential (expressed as 
pH), during a chemical reaction (Solomon, 1998). The instrument is pre-set to an 
end-point pH value, which corresponds to the constant pH at which the reaction is 
required to take place. When the chemical reaction is started, protons are 
liberated or taken up, with a resultant change in the potential, the autotitration 
process start, which keeps the pH constant by continuous addition of acid or base. 
The lipolysis kinetic analysis can be expressed by drawing a progress curve, 
during the course of a reaction by plotting the volume of titrant as function of 
time.
4.2.2 The relation o f  lipase activity to lipolysis assay
Pancreatic lipase-colipase catalyses the lipolysis of the triglycerides by splitting 
the ester linkages resulting in with one monoglyceride and two fatty acids. The 
fatty acids release protons with a resultant drop in pH. The pH-stat senses the 
increased proton activity and titrates a measured volume of NaOH to maintain the 
initial pH. The number of moles of sodium hydroxide used can be then be equated 
with moles of fatty acids to calculate the percentage of triglycerides digested 
through the course of the reaction.
4.2.3 Sources o f errors in the lipolysis process
The main difficulty in measuring lipolysis of slowly digesting oils over long 
periods of time (e.g. 1 hour) is that the pH of the reaction medium can fall due to 
factors other than lipolysis of triglycerides. The liberation of amino acids from
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protein degradation (pancreatin is an impure extract and may contain proteolytic 
enzymes capable of digesting insoluble fragments) and the lipolysis of lecithin are 
important factors affecting measurement of the lipolysis process. Other problems 
are the presence of unknown liquid junction potential between saturated KC1 and 
the reaction mixture, and the ability of the liquid from the calomel electrode 
(situated below the surface of the reaction solution) to leak. The effect of any 
diffusion potential upon the potential measured by the pH-stat was considered to 
be minimal and was therefore disregarded.
In the current state of pH-stat measurement, it is necessary to obtain reliable 
constant stirring (ensuring a reproducible surface interface), and an effective 
system to prevent absorption of atmospheric carbon dioxide. The control 
functions that determine the rate of addition of titrant, therefore, are of 
considerable importance. If settings are too slow, delays may occur in titrant 
addition whereas rapid addition of titrant can result in overshooting the required 
end-point pH value. The concentration of titrant, buffer capacity and size of the 
sample are the factors, which affect selection of an appropriate titration rate. The 
proportional band selector determines the volume of titrant added and the pause 
between additions. This selector is set to a pH span prior to the end-point pH 
value. Titrant delivery is gradually reduced as the end-point pH is approached. 
The setting of the proportional band selector is normally chosen so that a 
reduction in titrant delivery starts when nearly 90% of titrant needed.
To compensate for possible interference due to these factors, blank or control 
experiments were performed to determine the proportional band and titration 
speed settings. Initial lipolysis experiments were performed in tris-maleate buffer, 
which has the advantage of avoiding problems caused by other buffers of calcium 
salt precipitation and absorbance of carbon dioxide. Also, tris-maleate buffer can 
be used over a wide range (pH 5.5-8.6), which covers the physiological pH range 
between (4.8-8.2) found in the duodenum (Bowman et al, 1967). The appropriate 
concentration of titrant (sodium hydroxide) was 1 M, ensuring addition of a low 
volume to the reaction mixture, therefore minimising dilution effects and possible 
reduction in reaction temperature.
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4.2.3.1 Investigation o f blank rate.
A blank rate is defined as the existence of an apparent reaction within an assay 
system without one of the reaction component (Tipton et al, 1992). If the blank 
rate is significant, its source needs to be understood and the rate be quantified so 
that appropriate corrections can be made. In the standard pH-stat assay, the 
volume of titrant added should be directly related to release of fatty acid from 
triglyceride with no interference from a blank rate. A series of control 
experiments as performed with various components eliminated in turn. A blank 
rate occurred only when enzyme was present in the system. Adding pancreatin to 
tris-maleate buffer caused an immediate drop in pH followed by no further release 
of titrant over 60 min. A 0.02 ml volume of sodium hydroxide (1 M) corrected 
the drop in pH within 2 sec; this volume was constant for all experiments 
performed. The drop in pH could be due to acidity of the enzyme suspension or 
endogenous substrate material contained within it. However, adding pancreatin to 
simulated bile solution consumed 0.05 ml of sodium hydroxide (1 M) during 60 
min, which was slightly higher than the amount added in case of tris-maleate 
buffer. Verger et al (1984) suggested that the presence of lecithin could be 
responsible for the increase of the amount of sodium hydroxide, because addition 
of pure pancreatin porcine lipase in the presence bile salt is able to hydrolyse the 
sn-l ester bond of egg lecithin. It was found that subtraction of the blank rate in 
the case of kinetic studies is not appropriate because the blank rate obtained is part 
of integral enzyme activity. Thus to discount it would result in an 
underestimation of the enzyme activity. In the case of kinetic reactions, 
subtraction was also considered unnecessary due to minimal and constant nature 
with the blank rate compared to the overall titrant volume recorded.
4.3 Materials
4.3.1 Tris®-maleate buffer
Trizma®-maleate (tris-maleate) C4H11NO3C 4H4O4 50 mM Sigma T3128
Sodium chloride NaCL 150 mM Sigma S9625
Calcium chloride dihydrate CaCi2.H 20 5 mM Sigma C3881
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Sodium hydroxide NaOH qs Fisons S/4880/60
4.3.2 Pancreatin Lipase -  colipase
Pancreatin (a crude extract from porcine pancreas) was used as a source of 
pancreatin lipase-colipase activity. This material was supplied by Sigma USP 
specifications (PI500).
4.3.3 Simulated bile solution
Taurodeoxycholic acid sodium salt 3.0-30mM Sigma T0875
L-a-phosphatidylcholine 0.7-3mM Sigma P9671
( 6 0 %  pure from fresh frozen egg yolk)
4.3.4 Glycerides
Tributyrin C 1 5 H 2 6 O 6  










Anti-foam A (100 active silicone Polymer) 
Normadose sodium hydroxide solution 1 M 
Standard pH 4 phthalate buffer 
Standard pH 7 phosphate buffer 






4.4.1 The pH-stat equipment
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• Radiometer pH-state system ETS822 was comprised of the following 
parts:
PHM82 pH meter
TTT80 Titration assembly with stirrer (No.847-714)
ABU 80 Autoburette.
Glass indicating electrode (No.GG2040C)
Calomel pH reference electrode (No. K4040C)
*A11 from Radiometer Analytical A/S, Copenhagen, Denmark.
• Gallenkamp water bath
• B&T Circon pump
• Water-jacketed titration vessel (250ml capacity)
• Magnetic stirrer
The pH-stat was assembled as a single unit. However, the reaction vessel was 
connected via tubing to a pump unit and a heated water bath which circulated the 
temperature controlled water to the reaction vessel. An integral thermoregulator 
on the water-bath maintained temperature with a separate thermometer suspended 
in the water bath to act as an external check (Solomon 1998).
4.4.2 Preparation o f buffer solutions
Buffer solutions with pH values in the range 5.0 to 8.5 were prepared by 
dissolving appropriate quantities of tris-maleate, sodium chloride and calcium 
chloride dihydrate in distilled water followed by addition of sodium hydroxide 
pellets to adjust to the required pH at the experimental temperature 
Standard buffer is 1 L solution composed of
• 11.86g of tris-maleate
• 0.74g of CaCk. 2H2O
• 8.77g of NaCl
• 1.59g of NaOH for pH 6.5 or 3.24g of NaOH for pH 8.5 or any other
quantity according to the pH required.
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4.4.3 Preparation o f  simulated bile solution (SBS)
The simulated bile solution was prepared daily to minimise degradation of the 
components. Sodium taurodeoxycholate and phosphatidylcholine (lecithin) were 
dissolved in tris-maleate buffer of the specified pH (detailed in section 4.4.2) with 
the aid of heated magnetic stirrer. The heat and agitation were maintained for 
approximately 30 min at 35 °C, until the lecithin was in solution. The solution 
had an optically turbid or opalescent appearance. The solution was stored at 4°C 
until required.
4.4.4 Preparation o f pancreatin solutions
The crude extract of pancreatin with distilled water was prepared in an appropriate 
ratio {e.g. 500 mg of pancreatin + 2 ml distilled water for a 250 mg/ml lipase 
solution) in polyethylene glycol 10 ml tube, followed by mixing for 3 min (using 
a Whirlimixer from Fisons, Loughborough, UK) to ensure thorough mixing. The 
lipase solutions, containing insoluble materials, were equilibrated at the required 
temperature for 20 min prior to use. At this point, the solution was mixed and 
centrifuged using a Jouan B 3.11 bench top centrifuge (model No. FS200B, 
Decon laboratories; UK) for 30 min at 3226 g. Then supernatant solution was 
kept at 4°C. The pancreatin solution was warmed up to 37°C before addition to 
the reaction. The lipolysis process started the moment the pancreatin solution was 
added.
4.4.5 Preparation o f emulsions
An appropriate amount of triglycerides or SEDDS samples were weighed in a vial 
and added to reaction medium (100 ml) i.e. pH 5.0-8.5 tris-maleate buffer, which 
was placed in the reaction vessel. The vial used to weigh sample was rinsed three 
times using remaining simulated bile solution. During the emulsification process 
foam is formed due to the presence of bile salts and lecithin, and so 10pl 
Antifoam agent (Sigma, UK) was added. At this point the stirrer was switched on 
and the medium was left to equilibrate to 37°C (±0.5°C) for 10 min. When a 
stable pH reading was obtained for 10 min, the pH of the emulsion was raised to
121
the exact reaction pH {i.e. 5.0- 8.5) by addition of sodium hydroxide from the 
autoburette with a record made of the initial pH and volume of titrant used. The 
emulsion was left for another 30 min to stabilise at the required pH before starting 
lipolysis. When a stable pH reading was obtained, the pancreatin solution (section 
4.4.4) was added to the reaction medium, which initiated the assay. An electronic 
timer and the titration were started simultaneously at this stage. The volume of 
titrant was recorded manually using the timer at intervals of every lOsec for the 
first twenty min followed by readings every 5 min for a further 40 min
4.4.6 pH-stat conditions
4.4.6.1 Parameters o f  pH-stat 
The following parameters were determined before establishing the assay method: 
PHM82
Sensitivity left as set after calibration (±1% absolute)
Temperature 37°C or 25 °C















imprecision display 0.05 ml
titrant volume ±7 pi ± 0.15%
0.05 pH units (accuracy ± 5%) 
pH-stat
depressed (when end-point pH >
reaction medium p H ) 
± 0.02 pH units
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4.4.6.2 PHM82 standard pH  meter calibration procedure
A daily calibration procedure was necessary to check electrode function and 
response of the pH meter. The standard buffer solutions used to calibrate the pH 
meter were chosen according to the end point pH of the assay. Buffer solutions of 
pH 4 and 7 were used for an end point below 7.0. When the end points above 7 
the buffer solutions pH 7 and 9 were used. All calibration procedures were 
performed at 37°C.
4.4.6.3 Calibration Procedure.
Electrodes were removed from storage solutions, rinsed with distilled water and 
located in the electrode head. The pH meter sensitivity dial was set at 100 % and 
the temperature dial to 37°C. The standard pH 7 buffer was left in the reaction 
vessel until a stable pH reading (± 0.01 pH units) had been displayed for 30 min. 
Using the buffer dial to alter parallel displacement, the pH reading was adjusted to 
the manufacturers specified pH value at 37°C unless the correct reading was 
already shown. The pH was monitored for a further 15 minutes to ensure the 
reading remained stable. The second buffer solution (pH 4 or 9.2, as appropriate) 
was placed in the vessel and left until a stable pH reading had been displayed for 
15 min. If adjustment to the manufacturers specified value was necessary this was 
performed using the sensitivity dial, which alters slope. A check was made to 
ensure the reading remained stable for 15 min. If the pH reading was within ± 
0.01 pH units of the manufacturers specified value then calibration was complete. 
If the pH reading fell outside of these limits the whole procedure was repeated 
until results were within the specification.
4.4.6.4 Method for standard pH-stat assay
The standard pH-stat assay discussed here was used for all lipolysis experiments; 
any further modifications made to the assay for a particular investigation are 
described under the corresponding experiments.
123
4.4.6.4.1 Preliminary assay procedure
Pancreatin (250mg/ml) was prepared by weighing powder into a 25ml disposable 
polyethylene glycol plastic tube, and making up to volume. The required amount 
of triglycerides was weighed into an amber glass vial. If lipolysis of a pure 
surfactant was under investigation, and the surfactant was solid at room 
temperature, liquefaction (by heating) was necessary to ease handling and ensure 
dispersion into the reaction mixture.
4.4.6.4.2 Assay method.
Simulated bile solution (100 ml) was required for each assay; 90% of the solution 
was placed in the reaction vessel. The previously weighed sample of triglycerides 
or mixture of triglycerides and surfactant was added. The vial was rinsed using 
the remaining SBS, followed by 10pl of anti-foam A. The stirrer unit was 
activated immediately; the reaction medium was left to equilibrate to 37°C 
(+0.5°C) for 10 min. Then the mixture was titrated up to the required pH end­
point, with a record made of the initial pH and titrant volume used. This step 
allowed adjustment for slight variations in starting pH values of the reaction 
mixture caused by different batches of simulated bile solution and properties of 
the triglyceride and surfactants (Solomon, 1998). While the reaction medium was 
reaching equilibrium temperature, a vial of pancreatin solution was heated at 37°C 
for a pre-incubation period of 20 min. Addition of 1ml stock pancreatin solution 
initiated the reaction. The titrator and the electronic timer were switched on at 
this stage. The volume of titrant used was recorded manually using the timer at 
intervals of 10 sec for the first 20 min followed readings every 5 min for a further 
40 min.
4.4.6.4.3 Clean up and switch o ff procedure
After each experiment, the vessel was washed using thoroughly soap and distilled 
water, followed using ethanol 99%v/v to ensure no contamination occurred 
between assays. Electrodes were cleaned by wiping that with clinical tissues, 
followed by distilled water rinse, and a final wipe with absolute ethanol 99 %v/v.
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The calomel pH reference electrode was placed in a solution of saturated 
potassium chloride while the glass electrode was placed in standard pH 4 buffer 
solutions.
4.4.6.4.4 Assessment o f the pH-stat results
The assay gave readings of the volume of titrant used per unit time, which 
corresponded to protons released from fatty acid on a one-to-one molar basis. In 
the literature, the workers assume each triglyceride molecule underwent 
hydrolysis to form two fatty acids and a monoglyceride molecule. All free fatty 
acids were ionised; therefore, it was possible to determine the percentage of 
triglyceride digested. For tributyrin, the calculation was based on complete 
hydrolysis to three fatty acids and glycerol. Hydrolysis of short-chain fatty acids 
(SCT) (tributyrin) to completion was assumed to be rapidly cleaved, especially in 
vitro in the presence of bile salts (Gurr et al, 1971). The percentage of triglyceride 
digested out of the total initially present was then determined from the 
concentration of free fatty acids. The percentage of triglyceride digested or 
amount of fatty acid neutralised was plotted against time to produce a progress 
curve of lipase activity referred to in future text as a digestion profile.
4.5 Expression of lipase activity of pancreatin enzyme.
Pancreatin was used a source of pancreatin lipase-colipase activity. It is of 
interest that the relative amounts of hydrophobic amino acids in the pancreatic 
lipases from human sources do not differ from those found for other pancreatic 
enzymes (Verger et al, 1973; Borgstrom et al, 1977b). Porcine pancreatin 
enzyme contains a single peptide chain with an NH2-terminal serine and COOH- 
terminal cystine, and has a high degree of sequence similarity to human derived 
source with a similar pH-activity profile (Vandermeers et al, 1974; Breg et al,
1995). Lipase has been defined as an interfacial enzyme that specifically interacts 
with water-insoluble substrate (Borgstrom et al, 1977b). Bile salts inhibit lipase 
by preventing the binding of the enzyme to its substrate; colipase binds a bile-salt 
covered triglycerides-water interface and provides a high affinity “anchor” site for 
lipase (Borgstrom et al, 1977).
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Tributyrin is the substrate preferred over long chain triglycerides to determine the 
activity of pancreatin for three reasons (I) the product formed, butanoic acid, is 
completely ionised to water-soluble product under alkaline conditions (pH 8 to 
pH 9), (II) there is no need to add any emulsifier because it emulsifies 
spontaneously in dilute sodium chloride solution (Borgstrom et al, 1984), (III) 
tributyrin is hydrolysed between two and ten times faster than long chain 
triglycerides. This results in a linear reaction rate, which is normally maintained 
for a sufficient time period to assess maximum activity.
Two batches of crude pancreatin were used in this project; the supplier specified a 
minimum lipase activity corresponding to the United States Pharmacopoeia (USP) 
specification. Since pancreatin lipase was prepared as a crude extract, lipase 
activity was determined to ensure reproducibility between batches I and II of 
pancreatin used throughout this study.
4.5.1 Method
Pancreatic lipase activity was measured with a pH-stat titrator by continuously 
titrating the released free fatty acids with 1 M NaOH at pH 8.5 at 25°C. The 
tributyrin emulsion was prepared from mixing tributyrin 2.4 g in 100 ml buffer 
containing 50 mM tris-maleate pH 8.5, 5 mM calcium chloride dihydrate and 
150 mM sodium chloride. The pancreatin suspension was prepared in distilled 
water (150 mg/3 ml), mixed by vortexing and incubated at 25°C followed by one 
minute thorough mixing before use. For each assay, tributyrin emulsion 100 ml 
and 25 mg of pancreatin (0.5 ml of suspension) (section 4.4.4) were used. The 
emulsion was left to equilibrate in the reaction vessel for 30 min with continuous 
stirring before the addition of enzyme. Lipolysis was initiated by the addition of 
pancreatin solution to triglycerides. An electronic timer and the pH-stat were 
activated immediately. The initial pH, pH 8.5, was maintained by continuously 
titrating the liberated fatty acids with 1.0 M NaOH. The amount of lipolysis was 
noted every 10 sec for 20 min. The highest volume of titrant used, over six 
consecutive readings, corresponded to the maximum catalytic potential of the 
enzyme per min under assay conditions.
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4.5.2 Results
The activity of pancreatic lipase is normally expressed in terms of tributyrin units 
or TBUs (Borgstrom et al, 1984). One TBU is the enzyme activity that can 
liberate 1 mmole of fatty acid per minute from tributyrin at 25°C and pH 8.5 in the 
presence of 5 mM CaCl2 and 150 mM NaCl. Normal human duodenal contents 
are reported to contain 1000 TBU of colipase-lipase per ml. The enzyme activity 
of pancreatin (TBU per mg of pancreatin) was used to express the activity of the 
enzyme, as shown in Table 4.1.
Pancreatin Specific activity of
pancreatin
Batch (Maximum No. of TBU
No. Supplier Batch No. per mg per minute).
I Sigma 28H0518 6.0
II Sigma 99H11617 5.6
Table 4.1 Lipase activities determined for each batch of pancreatin used in the 
standard pH-stat assay.
From Table 4.1, it can be seen that there is a minimal difference between batches 
in terms of TBU per mg of pancreatin. To assess the reproducibility of kinetics 
results generated from the experimental model, the activities of pancreatin from 
three separated lipolysis experiments for each pancreatin batch performed under 
identical reaction conditions were compared. The mean values of TBU mg min 
were obtained for each batch represented in the Table 4.1. The coefficient 
variation of batches, I and II was 4.3% and 3.9% respectively. The experimental 
model indicated highly reproducible results.
4.6 Enzyme concentration
For most enzymes acting independently in solution, the initial velocity (V) of the 
reaction would be expected to be directly proportional to the concentration (E) of 
the enzyme {i.e. zero activity at zero enzyme concentration).
V=K(E)
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This is the normal case, but deviations can occur, either due to an artefact of assay 
system or of the enzyme itself (Dixon et al, 1979). The initial velocity 
relationship to enzyme concentration was measured to ensure that no interference 
was present from the standard pH-stat assay system. Further, experiments were 
performed to determine the initial velocity of enzyme after centrifugation. This 
approach enabled determination of the enzyme concentration (250 mg of crude 
pancreatin) selected for use in the standard pH-stat assay throughout this work.
4.6.1 Method
The digestion profiles of SCT (TBU), MCT( Miglyol 812®) and LCT ( Com oil®) 
were assessed over a 1 hour period using three different enzyme concentration 
(500 mg/ml, 250 mg/ml, 50 mg/ml), prepared as described in section 4.4.4. As a 
quantity of 250 mg/ml pancreatin had been proposed for use in the rest of 
experiments, a series of lipase solutions were prepared (250mg/ml) from 
pancreatin by mixing the crude extract with distilled water and/or with tri-maleate 
buffer, as mentioned in section 4.4.4. The resulting solutions, which contained 
insoluble material, were then held for different times of centrifugation 
(10, 20, 30, 60, 120) minutes. A series of digestion profiles were performed for 
both pancreatin batches I and II.
4.6.2 Results
The lipolysis of SCT, MCT, and LCT was assessed over a 1 hour period using
three different concentrations of enzyme. A linear relationship between initial
velocity and pancreatin concentration (r2=0.9876) was obtained, if data 500 mg
for pancreatin were omitted. Frequently, the linear portion of an assay is
sufficiently prolonged to the initial rate. It can be estimated accurately simply by
drawing a tangent or by calculating taking first derivatives of the early part of the
progress curve, where loss of linearity occur relatively rapidly due to depletion of
substrate or reading equilibrium. Decreasing the enzyme concentration to slow
down the rate of product formation, and increasing the sensitivity of the assay
method, may prolong the linearity. It has been commonly assumed that
measurement of reaction rates should be restricted to a period in which 5 % or less
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of the substrate has been utilised (Segel, 1975). The rate of lipase activity follows 
a direct but non-linear, correlation. For example, Figure 4.1 showed that 
increasing the concentration of pancreatin from 50 mg/ml to 250 mg/ml promoted 
the percentage lipolysis of TBU after 20 min by a approximately 3.2 fold. In 
contrast, when the concentration of pancreatin lipase increased from 250 mg/ml to 
500 mg/ml, the rate of lipolysis after 20 min was raised by 1.2 fold, as shown in 
Figure 4.1. The previous observation was observed to MCT (Miglyol 812®) and 
LCT (Com oil®) as shown in Figures 4.2 and 4.3 respectively.
When considering the suitability of using 250 mg/ml of pancreatin in the standard 
pH-stat assay, different samples from batch II and I were centrifuged for (10, 20, 
30, 60 & 120 min) at the same speed 3226 g. The initial velocities decreased with 
increasing time of centrifugation until a plateau was recorded at 3226 g for 30 min 
as presented in Figure 4.4. Therefore, 250 mg/ml of pancreatin centrifuged for 
30 min was concluded to be appropriate for use in the standard pH-stat assay. The 
digestion profile of SCT produced maximum extent of digestion possible at 
pH 8.5 at 25°C as shown in Figure 4.5. Figures 4.5 and 4.6 showed that the effect 
of reconstitution of pancreatin batch I with tris- maleate buffer and/or water. The 
resulting initial velocity of the enzyme suggests a higher activity towards the 
substrate of SCT in tris-maleate buffer than in water. Therefore, following to this 
result, the enzyme was reconstituted using the tris-maleate buffer throughout this 
research.
4.7 Selection of the triglyceride substrate
The method of choice for selection of the appropriate triglycerides suitable for use 
in the standard pH-stat assay was susceptibility to the hydrolytic activity of 
pancreatin. Five triglyceride substrates were analysed under conditions of the 
standard pH-stat assay for of 60 min (section 4.4.5), to ensure that any inhibition 




The percentage of total triglyceride after 60 min is summarized in Table 4.2 for 
each triglyceride. The various triglycerides were analysed at equal weight (mass) 
approximately lg under the same condition of the standard pH-stat (pH 7.0, 37°C) 
assay, therefore use of a percentage calculation eliminated errors introduced by 
their different molecular weight values and hence molar concentration. Each 
sample was reanalysed three times taking the average and the coefficient of 
variation. They calculated based 2FA released from TG and 1FA from DG. From 
the data shown in Table 4.2, although MCT, fractionated coconut oil was chosen 
for further investigation because of the high total percentage of digestion in the 
assay system. It is pharmaceutically acceptable, has a high standard of purity, low 
cost and availability with specified proportions of fatty acids. Other glycerides 
were used for further investigation that helps to clarify the effect of different 
parameters of the pH-stat assay system.
4.8 Effect of pH on enzyme activity
In general, enzymes are only active over a limited range of pH and in most cases, 
an optimum pH is observed (Dixon et al, 1979). The pH optimum for porcine 
lipase with tributyrin as substrate is in the range 8-9 (Borgstrom et al, 1973). The 
optimum pH for lipase activity will depend upon conditions of the assay medium, 
such as the concentration of bile salt, the ionic strength of the buffer and 
temperature (Borgstrom, 1954). The fasting duodenal pH in healthy subjects is
6.5, so the standard pH-stat assay was run at pH 6.5 in all-previous work 
(Borgstrom et al, 1984). Therefore, the standard pH used through the research is 
pH 7.0. The maximum velocity of pancreatin activity towards different type of 
substrates was therefore assessed over a pH range of 5 to 8.5.
4.8.1 Method
All lipolysis profiles were performed under standard pH-stat assay conditions, 
using five different substrates (section 4.7) at approximately 1 g. End-point pH 
values were used between 5.0 and 8.5 at increments of 0.5. Simulated bile
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solution for each experiment was prepared using tris-maleate of an apparent pH 
value. A concentrated solution of tris-maleate buffer was prepared without 
sodium hydroxide. The buffer solution was then adjusted to the required pH by 
adding solid sodium hydroxide and was made up to the volume required. 
Simulated bile solution was equilibrated at 37°C and the pH was adjusted with 
1 M sodium hydroxide, if required.
4.8.2 Results
A series of digestion profiles SCT, LCT and MCT (expressed as millimoles of 
fatty acids liberated with time using a range of pH between 5-8.5), in triplicate for 
each end-point pH are shown in Figures 4.7-4.9. The initial velocity of the 
reaction was determined after ensuring no lag phase was present at the start of the 
reaction. In Figures 4.7-4.9 showed that a'lag phase occurred at high pH 8 and
8.5, while at pH 7.5-6.5 typical hyperbolic curve was obtained. The percentage 
digestion of different SCT, LCT, mixed mono-, di- and tri-glycerides and MCT 
after 20 min and 60 min varies with pH as shown in Figures 4.1-4.14 respectively. 
For tributyrin at pH 7.5, 60.8% of the total triglycerides had been digested after 
60 min. Some triglycerides appear to have undergone hydrolysis approximately 
half the amount of fatty acids and glycerol present, e.g. MCT (Miglyol 812®) the 
percentage of digested triglycerides was 49.05% at pH 7.5. For LCT (Com oil®) 
at pH 6.5, 10.5% of the total triglycerides present had been digested, whereas at 
pH 7.5 this figure increased to 29.67 %. This may be due to a high rate of enzyme 
activity coupled with a high degree of emulsification conferred by the presence of 
bile salt. The bell-shaped graph of the pH-rate profile as shown in Figures 4.10- 
4.14 could be considered as the composite of two sigmoidal titration curves. The 
ionisation status of the ionic groups present in the enzyme or substrate may 
explain the observed decrease in enzyme activity away from the optimum pH 7.5 
(Segel, 1975). The free enzyme, the enzyme-substrate complex or the substrate 
may undergo such catalytic changes. It is known that the N-terminal domain of 
the pancreatic lipase contains the catalytic triad Ser, His, Asp and is responsible 
for triglyceride hydrolysis (Hermoso et al, 1996).
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% purity % of TG 
digested
Manufacture
Tributyrin Tributyrin(SCT) Q :0 302.4 99% 65%
(CV=0.807%)
Sigma, UK
Imwitor 988® Mixture of caprylic 
glycerides





Capmul MCM® Mixture of caprylic 
and capric 
fatty acids
TG = 15% 






















c 16:, (0.3%) 
Ci6:0 (14%) 
C14:0 (0 .6%)
866.6 99% 23.5% 
(CV= 0.912)
Sigma, UK
Table 4.2 Percentage of digestion of triglycerides under standard pH- stat conditions
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Semeriva et al (1971) suggested that the histidine of pancreatic lipase needs to be 
ionised to achieve the maximal rate of hydrolysis of tributyrin. Early work used a 
pKa value for histidine in their system of 5.8 although the environment of the 
enzyme can influence the exact pKa values (Borgstrom, 1958). An effect of pH 
on the stability of the enzyme, which may become irreversibly inactivated, is 
known to occur with porcine pancreatin lipase at pH values lower than 5 
(Verger et al, 1984). Borgstrom et al (1977b) indicated that the rate-limiting step 
of lipolysis at alkaline pH is the slow formation of ternary lipase-colipase-bile salt 
complex and its adsorption to the substrate interface. The effect may occur in 
combination; for instance, the fall on both sides from the optimum may be due 
either to a fall in affinity due to a decreased saturation of the enzyme with 
substrate and /or to instability of the enzyme. This could be confirmed by further 
experimentation involving pre-incubation of the enzyme for a period equal to the 
length of the assay at various pH values before commencing digestion at pH 7.5. 
If the reaction rate was decreased, this would indicate pH-related enzyme 
inactivation. The emphasis in this work is characteristics assay conditions rather 
than the enzyme activity. The choice of the buffer and the ionic strength of the 
simulated bile solution are important factors and need further consideration. 
When making up a buffer with a given molarity at different pH values, the ionic 
strength will vary with pH. Tris-maleate has been used to cover a wide range of 
pH from 5.8-8.6 and exhibits the smallest changes in ionic strength, because the 
conjugate base has a charge (Z)=0 (Stevens et al, 1972). If necessary, solutions 
could have been brought to constant ionic strength by adding the appropriate 
quantity of a neutral non-inhibitory salt.
4.9 Effect of bile components
The two major solutes of bile are bile salts and lecithin. Bile salts are not only 
water-soluble end products of cholesterol metabolism, but are also amphipathic 
molecules with multiple physiological functions (Hofmann et al, 1992). Bile salts 
are important surfactants in the biological systems; they solubilize lecithin and 
cholesterol to form mixed micelles. Bile regulates a number of cholesterol
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metabolising enzymes in the liver and intestine and facilitates absorption of 
dietary fats by emulsifying large droplets, making them more accessible to 
pancreatic lipase. Further, bile salts remove the products of pancreatic hydrolysis, 
e.g. fatty acids, through micelle formation (O'Connor et al, 1984). Bile salts and 
lecithin are the two major components in bile and the molar ratio is approximately 
2:1 to 5:1. Together they are essential to the formation of mixed micelles (Naylor, 
1993). As an amphiphilic compound, lecithin exerts a synergistic effect with bile 
salts via the formation of mixed micelles. The final effect on lipolysis depends on 
the ratio of lecithin to bile salts. Low ratios enhance enzyme activity, whereas 
high ratios lead to inhibition (Lykidis et al, 1997).
Small (1967) demonstrated that the micelle actually expands or swells with an 
increase in lecithin content. This facilitates the uptake of biological lipids such as 
cholesterol, fatty acids, steroids, and fat-soluble vitamins that have very poor 
solubility when only bile salts are present. In accordance with Brockerhoff 
(1971), the presence of bile salts keeps the reaction rate constant for a longer 
period. He interrupted this effect as a protection of the lipase from inactivation by 
unfolding at the hydrophobic surface of the substrate by increasing the substrate 
surface area, either by increasing the amount of the substrate or its degree of 
dispersion; higher bile salts concentrations are needed to prevent inhibition 
(Borgstrom, 1993). However, it is difficult to establish from the literature exactly 
what is the typical level of BS in the human small intestine. Hemell et al (1990) 
has reported that BS concentration is ranging from 5.8-37 mM with an average 
value of 14.5 mM, ±8.8  mM. The purpose of the work described in this section 
was two fold. The initial objective was to determine the ratio of BS to LC and 
their impact on the lipolysis profile for different substrates. The other objective 
was centred on determining the effect of bile salt concentration on the rate of 
lipolysis for different triglycerides.
4.9.1 Method
A series of lipolysis experiments was carried out at 37°C using 250 mg/ml
pancreatin lipase (section 4.4.4) and 100 ml of 1% w/v emulsion in standard
buffer pH 7.0, prepared using different concentrations of Ox-bile (0, 4, 15, 30, 60,
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90, 120, 150, 200, and 250 mM) without using lecithin. In other experiments, 
three ratios of BS to LC (2:1, 4:1, and 5:1) were added to the standard buffer at a 
different pH range between 6.0 - 7.5 in 0.5 increments. The ratio of 2:1 and 4:1 
were chosen according to Dressman et al (1998) fast state simulated intestinal 
fluid (FaSSIF) and fed state simulated intestinal fluid (FeSSIF) state. 5:1 ratio 
normally used by the early workers (Challis, 1990; Solomon, 1998).
4.9.2 Results
It has been common practice to use single synthetic BS NaTDC, rather than any 
natural BS or a physiologically representative mixture of synthetic BS (Alvarez et 
al, 1989). It has been found that the identity of BS had no appreciable impact on 
the rate of lipolysis; therefore, Ox-bile has been used instead of NaTDC to 
determine the effect of bile salt concentration. Moreover, the cost of Ox-bile is 
less than NaTDC. It was evident that the increase of BS concentration increases 
the lipolysis rate up to its CMC. The percentages digestion of five different 
substrate of SCT, MCT, LCT and mixed glycerides are shown in Figures 4.15, 
4.16, 4.17, 4.18 and 4.19 respectively. MCT and SCT (Miglyol 812® and 
Tributyrin) as shown in Figures 4.15 and 4.16 respectively the highest percentage 
of digestion for the first 20 min was 43.69 % and 70.83 % respectively at 30 mM 
Ox-bile. In contrast, increasing the Ox-bile to 260 mM followed a decrease after 
the first 20 min up to 35.23 % and 56.52 % respectively. Figure 4.17 represented 
that LCT (Com oil®), when the bile salt concentration increased from 30 mM to 
260 mM the extent of lipolysis increased in absolute terms from 36.96 % to 
41.96%. Figures 4.18 and 4.19 showed that mixtures of mono-, di- and tri­
glycerides (Capmul MCM®, and Imwitor 988®) followed the same trend as MCT 
and SCT. When experiments are performed in vitro under conditions in which the 
molar ratio of lipolytic products to BS exceeds 1:1 the rate of lipolysis may be 
impeded. The experimental system contained 1 g of either SCT (Tributyrin) or 
MCT (Miglyol 812®) and LCT (Com oil®). Complete lipolysis of these oils to 
MG+2FA respectively, yields 5.7 and 3.4 mmole of lipolytic product, given that 
the reactions were carried out in a volume of 100 ml. These quantities correspond 
to concentrations of 57 mM and 34 mM.
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Clearly, these levels are within the solubilized capacity of BS when the latter are 
present at 60 mM. As a result, the lipolysis of both MCT and SCT progressed 
rapidly when BS concentration was 26 mM. Thus, in the case of MCT, a plateau 
was reached after 20 min, which is approximately 45.78%. It is interesting to 
speculate why some approximately <4% additional lipolysis was observed in the 
subsequent 40 min. One possible reason for this was that the amount of BS 
decreased which facilitated solubilization of more diglycerides. Since pancreatic 
lipase must bind to an interface to adopt its most catalytically active 
confirmations; the latter (diglyceride) would there be a less effective substrate for 
further digestion. Lipase is thus protected from irreversible inactivation, whilst its 
catalytic activity against the substrate is lost although colipase has a negative 
charge in the pH range of lipase activity. The effect of bile salts in displacing 
lipase from the substrate interface parallels the loss of lipase catalytic activity. 
The inactivation of lipase by bile salt is related to its critical micellar 
concentration (CMC) and is due to the accumulation of bile salts at the interface, 
thus giving it a negative charge. Colipase binding is decreased by an increase by 
bile salt concentration and the extent of binding of colipase to the substrate 
interface (Borgstrom et al, 1984).
Clearly, experiments in vitro with high concentrations of BS will not provide a 
‘sink’ for which lipolytic products can be discharged. The relationship between 
bile salt concentration and substrate surface area is directly proportional. 
Lipolytic product removal is a rate-limiting factor for the progress of lipolysis as 
shown in Figures 4.15 and 4.16. In general, increasing bile salt concentration is 
dependent on the substrate concentration i.e. increasing BS concentration does not 
necessarily increase the rate of lipolysis because removal of the lipolytic product, 
is the rate-limiting step.
The ratio of BS:LC was chosen according to Dressman et al (1998). The FeSSIF 
(fed) state contained NaTDC to LC 15 mM: 3.75 mM respectively, while the 
FaSSIF (fast) state was 3.0 mM:0.75 mM (2:1). A series of lipolysis experiments 
were run using these ratios and those represented by Solomon (1998) (4:1) 8 mM: 
1.5 mM as shown in Figures 4.20-4.24. Figures 4.20 and 4.21 respectively
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showed that altering the concentration of bile salts and lecithin present in 
simulated bile solution at pH 7.0 does not alter the extent of SCT and MCT 
triglycerides for the first 20 min. However, there is an increase in the percentage 
of digestion of total diglycerides after 60 min. Similar conditions were applied for 
a mixture of glycerides as shown in Figures 4.23 and 4.24. While for LCT (com 
oil) there is a sharp increase in the total digestion of triglycerides after 20 min and 
60 min accompanied with increasing of BS to LC 5: 1 as shown in Figure 4.22. 
Changing the ratio of BS to LC was studied at different pH. The greatest change 
in the percentage digestion of triglycerides in SCT, MCT and LCT occurred at 
pH 7.0 as shown in Figures 4.20-4.22 respectively.
4.10 Effect of calcium concentration
Alavrez and Stella (1989) reported that calcium ions play a major role on the rate 
of triglycerides hydrolysis. Although it has been reported that lipase cofactor 
does not need ions. Calcium ions have been shown to be involved in the 
mechanism of action of pancreatic lipase (Borgstrom, 1980; Armand et al, 1992). 
Calcium ions can modulate either lipase velocity or the lag phase until the 
maximal enzyme activity is reached. Calcium ions may decrease the electrostatic 
repulsion occurring at the emulsion-water interface. Excess calcium can induce 
coalescence of emulsified particles. The calcium concentration required to 
activate lipase is somewhat higher than that expected to be found in the intestinal 
contents. The average of calcium concentration in the lumen appears to be diet- 
dependent and is proposed to be approximates 7 mM (Mansbach et al, 1975). 
However, if the diet does not provide the calcium concentration required to 
activate lipase, the bile particularly in the gallbladder, is rich in calcium (about 
ll-38m M ) and can provide a microenvironment necessary for lipase activity. 
The role of calcium ions is still unclear and hence the effect of calcium ion 




Lipolysis experiments were carried out at 37°C using 250 mg/ml pancreatin lipase 
(6 TBU /mg) (section 4.4.4) and 100 ml of 1% w/v emulsion (SCT, MCT, LCT 
and mixed mono-,di-, and tri-glycerides) in standard buffer pH 7.0, with BS:LC 
ratio 4:1 (15mM: 3.75mM) and the calcium concentration was 0 mM, 5 mM and 
40 mM respectively.
4.10.2 Results and Discussion
Calcium concentration had a significant effect on the rate of lipolysis 
approximately 2 fold increase of LCTs (Com oil®) as shown in Figures 4.25 and 
4.26. Based on Borgstrom (1980) results, in the absence of Ca the lag phase 
was indefinitely long; increases in Ca2+ concentration decreased the lag time, but 
not in the final steady-state rate, as seen with LCT (Com oil®) as shown in Figure 
4.25. The aqueous solubility of the lipolytic product of MCT and LCT is low 10‘4 
and 10'7M, respectively. The lag phase is believed to be measure of the ease of 
penetration of the lipase-colipase complex into the interface of the TG. The 
presence of calcium is proposed to be more important for the lag phase than the 
presence of phospholipids and bile salts. In the presence of calcium, a lipase 
complex formed with the TDC-phospholipid mixed micelle appears to be the 
catalytically most effective enzyme complex (Alvarez et al, 1989). Such 
complexation forms a liquid crystalline phase (Patton et al, 1979), in which FA 
are soluble and probably transported to the gastrointestinal membrane to facilitate 
absorption. Figure 4.26 showed that SCT (TB) was insensitive to calcium 
concentration, and MCT (Miglyol 812®) were much less dependent than LCT. 
Mixed glycerides (Capmul MCM® and Imwitor 988®) showed slight increases in 




In the previous studies, an in-vitro lipid digestion model has been established to 
provide, a detailed and quantity map of the chemical kinetics and phase behaviour 
of common lipid excipients during digestion, under simulated physiological 
conditions. Standard pH-stat conditions involve assembling 100ml of aqueous 
solution of electrolytes, bile salts, solubilized phospholipid, which includes 
approximately lg of pure lipid excipients, dispersed using stirring system. The 
standard pH-stat solution contained 50mM tris-maleate buffer [pH 7.0], 5mM 
CaCL2.2H20 , 150mM NaCl, 15mM Na TDC, 3.5mM LC [FeSSIF state]. This is 
maintained at the desired temperature using a water bath or jacketed vessel. 
Pancreatin (containing pancreatic lipase and colipase) is added as a concentrated 
solution (usually 250 mg in 1ml at 6 TBU/ mg). The data showed that the rate 
and extent of lipid excipients digestion profiles is markedly dependent on the fatty 
acid chain length. Thus, the rate and extent of medium chain lipid digestion and 
mixed mono-di-, and tri-glycerides was significantly higher than the 
corresponding long chain lipid, and the extent of medium chain lipid digestion 
was effectively independent of bile salt concentration and calcium concentration. 
Conversely, efficient digestion and dispersion of long chain lipids was much more 
dependent on bile salt concentration and calcium concentration.
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Figure 4.1 Dissociation profile of pancreatin using














Figure 4.2 Dissociation profile of pancreatin using
MCT (Miglyol 812) as a substrate using pH-stat method
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Figure 4.3 Dissociation profile of pancreatin using
















Figure 4.4 Effect o f  centrifugation tim e (3226g) on pancreatin  
activity (How m any TBUs per m in)using pH -stat method
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Pancreatin 250mg/ml, water (batch I) 
Pancreatin 250mg/ml, buffer (batch I) 
Pancreatin 250mg/ml, buffer (batch II)
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Time of centrifugation (min)
120 140
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Figure 4.5 Effect of centrifugation time on the dissociation 
profile of tributyrin in water using 250 mg/ml 




























Figure 4.6 Effect of centrifugation time on the dissociation 
profile of tributyrin in tris-maleate buffer (pH 7.0) using 


























Figure 4.7 Effect of pH on the digestion profile of SCT
























Figure 4.8 Effect of pH on digestion profile of LCT 
























Figure 4.9 Effect of pH range on the digestion profile 























Figure 4.10 The effect of pH on the total percentage of
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Figure 4.11 The effect of pH on the total percentage of 






Figure 4.12 The effect of pH on the total percentage of
digestion of mixed glycerides mono-, di-, and tri-glycerides
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Figure 4.13 The effect of pH on the total percentage of 
digestion of mixed glycerides mono-, di-, and tri-glycerides 




Figure 4.14 The effect of pH on the total percentage of




Figure 4.15 Effect of Ox- bile concentration on the total
digestion of SCT(Tributyrin) using pH- stat conditions
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Figure 4.16 Effect of Ox -bile concentration on the total digestion 
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Figure 4.17 Effect of Ox-bile concentration on the total digestion
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Figure 4.18 Effect of Ox-bile concentration on the total digestion 
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Figure 4.19 Effect o f Ox-bile concentration on the total digestion
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Figure 4 .20  E ffect o f  BS : L C  ratios on the total p ercentage
d igestion  o f  tributyrin  u n d er stan d ard  pH -stat conditions
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Figure 4.21 Effect of BS:LC ratios on the total digestion of
MCT (Miglyol 812) under standard pH-stat conditions
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Figure 4.22 Effect of BS:LC ratios on the total digestion 
of LCT (Corn oil) under standard pH-stat conditions
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Figure 4.23 Effect of BS:LC ratios at different pH on the 
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F igure 4 .24 E ffect o f  BS : LC ratios on the to ta l d igestion  o f
m ixed m ono-, di- and tr i-g lycerid es (Im w itor 988) under
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Figure 4.25 The effect of calcium concentration on the 
digestion profile of corn oil under standard pH-stat 
conditions
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Figure 4.26 Effect of calcium concentration on the rate of 
lipolysis of mixed mono-, di-, and tri-glycerides, SCT, MCT and 
LCT using pH-stat method (the error bars represent the 
standard deviation of three experiments)
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Chapter 5
Lipolysis o f co-surfactant, surfactants, and lipid formulations in vitro in simulated 
intestinal fluid.
5.1 Introduction
Fat digestion in the gastro-intestinal tract is likely to have a profound effect on the 
state of dispersion of lipid formulation and the fate of the drug (MacGregor et al, 
1997; Pouton, 2000). Lipid formulations for administration of drugs to the 
gastrointestinal tract generally consist of a drug dissolved in a blend of two or more 
excipients, which may be natural triglycerides, oils, partial glycerides, surfactants or 
co-surfactants and water-soluble co-solvents. There are a diverse of delivery systems, 
with different properties depending on the blend of excipients used. Some are self- 
emulsifying, some give rise to clear colloidal dispersions on dilution, others do not 
disperse until they are digested by pancreatic lipase. Whatever the formulation, the 
fate of the drug in vivo is likely to be influenced by whether any of the excipients are 
digestible, and whether digestion is able to proceed or instead is inhibited by the 
presence of surfactants.
Pancreatic lipase plays a major role in the lipolysis. The adsorption of pancreatin 
lipase colipase to the substrate is a fundamental process because the enzyme catalyzes 
a heterogeneous reaction that involves an interfacial activation step (Hermoso et al,
1996). Unlike enzymes acting on soluble substrates, lipolytic enzymes act at the 
interface between an aqueous medium containing the lipolytic enzyme and the water- 
immiscible substrates, generally TG (Alvarez et al, 1989). Therefore, any compound 
that can bind to or interact with the interface is able, to some extent, to modify and 
alter the activity of these enzymes. Because the substrate is generally much smaller 
than the enzyme, substrate diffusion is rate-limiting. For a water-soluble lipolytic 
enzyme, the substrate is generally part of an emulsion and/or micelle. These 
structures may be orders of magnitude larger than the enzyme. Thus, the maximum
155
rate attainable by a simple Michaelis-Menten mechanism is limited by diffusion of 
enzyme to the substrate, a process considerably slower than diffusion of monomeric 
substrate in solution (Brockman et al, 1984).
Bile salts, above the range of their critical micellar concentration, inhibit pancreatic 
lipase activity toward its substrate; this inactivation is reversed by colipase 
(Borgstrom, 1975). The inactivation is due to the accumulation of bile salt in the 
interface, giving it a negative charge and hindering the binding of similar negatively 
charged lipase to the supersubstrate, thereby also preventing the formation of an 
enzyme-substrate complex at the catalytic site by increasing the electrostatic, 
repulsion between the substrate and the enzyme (Wickham et al, 1998). The addition 
of colipase to the bile salt-lipase substrate system has, however, a dramatic effect on 
the binding of lipase to the substrate interface that is parallel to a reversal of the 
inhibition of the catalytic activity (Borgstrom et al, 1975). The lipase-colipase 
complex is composed of two more-or-less rigid regions connected by a hinge: one of 
the regions is formed by the N-terminal domain excluding the flap, and the other is 
formed by C-terminal domain, colipase, and the flap (Hermoso et al, 1996). The 
pancreatin enzyme adopts an inactive, closed conformation with a surface loop from 
N-terminal domain (the flap) covering the active site and the colipase has an open 
conformation resulting from the repositioning of the flap. The motion of the flap 
makes the active site accessible to the substrate, simultaneously forming a functional 
oxyanion hole and generating the lipase interfacial binding site. Therefore, once the 
flap is opened, either by the water-substrate interface or by detergent micelles in the 
presence of colipase, monomers of nonionic surfactants may behave as inhibitors by 
binding to the active site. The open conformation has only been observed when 
lipase was co-crystallized with colipase and either bile salt or phospholipid (Hermoso 
et al, 1996). This, in turn, suggests that binding to the water-lipid interphase may 
require a certain degree of conformational flexibility. Kinetic data indicate that the 
binding between colipase and lipase in the presence of substrate is strong and occurs 
in an approximately stiochiometric relationship (Borgstrom, 1975). Colipase does
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not bind to a pure hydrocarbon interface nor does it affect the binding of lipase to 
such an interface. It appears that colipase structure provides a more specific binding 
to a substrate interface and thus directs lipase to its substrate superstructure.
It is well established that the kinetics of lipolysis are simply described by a reversible 
rate-limiting penetration step of the enzyme into the interface, characterized by a lag 
time before the steady state reaction is reached (Wieloch et al, 1982). Recently, the 
in vitro hydrolysis of phospholipid-emulsified triolein particles, intralipid, by 
pancreatic lipase in the presence of colipase has shown unusual biphasic kinetics. An 
initially slow accelerating phase (zero-order kinetics) preceded a sudden phase of 
high hydrolytic rate (Martigne et al, 1987). The lag time is not due to diffusional 
limitation but rather to slow interfacial penetration of the enzyme (Wickham et al, 
1998). The duration of the low activity phase was shown to be dependent, among 
other factors, on the orientation and the concentration of enzyme, and substrate in a 
surface phase by forces independent of their direct interaction (Brockman et al, 1984; 
Wieloch et al, 1982). Because this is a major function related to enzyme-substrate 
complex formation in homogenous catalysis, direct enzyme-substrate interaction 
characterized by an interfacial Km probably used mainly to regulate the specificity of 
catalysis. The action of a lipolytic enzyme at an interface generates products which 
can directly activate or inhibit adsorption or catalysis by binding to the enzyme. 
Nevertheless, the generation of surface-active products can change the interfacial 
tension, alter lipid packing, change substrate concentration and may even change the 
amount of surface in the system. The interfacial nature of lipolysis implies that it is 
the concentration of substrate molecules at the lipid-water interface, which is a direct 
determinant of rates of lipolysis. Accordingly, it is important, in studying the 
lipolysis reaction, to understand the physical behaviour of the enzyme-substrate 
complex. A more relevant consideration with respect to lipolysis is the concentration 
and the type of the glycerides at the lipid-water interface i.e. on the surface of 
triglycerides-rich fat emulsions.
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Diglycerides are more surface-active than triglycerides because of their free hydroxyl 
groups. Therefore, they can be expected to reside predominantly in surface phases. 
However, diglycerides do not normally accumulate but are hydrolyzed by most 
triglyceride lipases to monoglyceride or glycerol and fatty acids. The surface 
concentration (2-5% of the TG at the interface) of TG decreases with lipolysis of the 
particle. This indicates qualitatively that the interfacial availability of triglyceride for 
hydrolysis is a function of the surface composition of the particle, which changes as 
lipolysis proceeds (Brockman et al, 1984).
Therefore, the objectives of the present investigation are:
• To investigate the pancreatin enzyme kinetics acting upon SCT (tributyrin) 
under the standard pH-stat conditions. The lipolysis kinetics are described 
through the Michaelis-Menten equation parameters (Km and Vmax)-
• To study the fate of enzyme activity in the presence of non-ionic surfactant 
under standard pH-stat conditions.
• To conduct further experiments using SEDDS formulation as substrate under 
pH-stat conditions, based on the in-vitro kinetics studies.
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5.2 Materials
In addition to the materials mentioned in chapters, 2, 3, and 4, the following 
surfactants were used:
Trade name Scientific name Dominant Molecular HLB
fatty acids weight
Labrafil M Oleoyl Macrogol C ]6 4 -  9 % 440 3 - 4
1944 CS glycerides. Ci8 < 6 %
(Apricot kernel oil C,8:i 58 -  80 %
PEG-6 complex) Ci8:2 1 5 - 3 5 %
C20 < 2 %
C20:1 < 2 %
Labrafac CC Medium chain c 8 65% 327.6
triglycerides (EP) Qo 35%
Labrafil M Linoleoyl Macrogo- C ,6 4 - 2 0  % 779.2 3 - 4
2125 CS glycerides (EP). C]8 < 6 %
(Com oil PEG-6 Cl8:l 20 -  35 %
complex) Ci8: 2 50 -  65 %
C20 < 1 %
C20.I < 1 %
Labrasol Saturated C8 50 -  80 % 469.4 14
Macrogol glycerides C]o 2 0 - 5 0 %
EP
C 12 < 3 %
C14 < 1 %
Gelucire 44/14 Lauroyl Macrogol- 32 C8 < 15% 664.76
glyceride EP Cjo < 12 %
C 12 30 - 50 %
C | 4 5 - 2 5 %
C l 6 4 - 2 5  %
C i 8 5 - 3 5 %
Table 5.1 The polyglycolyzed glycerides surfactant used throughout the investigation. 
The surfactants were purchased from Gattefosse, s.a, France.
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5.3 Determination of the kinetic parameters, Km and Vmax for pancreatin acting
upon SCT under standard pH- stat conditions
Enzyme properties are determined mainly by means of kinetic studies. The total 
concentration of enzyme is a constant, which often imposes a great simplicity on the 
steady-state rate law relating velocity to substrate or to substrate and inhibitor. As a 
result, the enzymes manifest the well-known Michaelis-Menten behaviour with 
rectangular -  hyperbolic rate law:
T> =  (V m a x * S )/(K m + S) eq (5.1)
The Michaelis-Menten equation (eq 5.1) relates the rate of substrate consumption or 
product formation (u -  referred to intial velocity) of an enzyme reaction to the initial 
substrate concentration (S) present. The kinetics parameters (Km and Vmax) describe 
the shape of a rectangular hyperbola; therefore, Km and Vmax are constants. Vmax is 
the maximum velocity of the reaction when the substrate concentration is saturating 
the enzyme. Km is the Michaelis constant describing the substrate concentration at 
which the reaction proceeds at half its maximum initial velocity (Morris, 1974; 
Eisenthal et al, 1992).
The derivation of the equation 5.1 depends on three supposition (Eisenthal et al, 
1974):
• The rate of the reverse reaction is insignificant during the measurement time.
• The measurement is made in the steady state when the concentration of 
enzyme-substrate complex is unchanging.
• The formation of enzyme-substrate complex will not significantly deplete the 
concentration of free substrate.
If the previous assumptions are correct, then the intial part of the progress curve 
representing the enzyme reaction will exhibit linear behaviour. In general, the initial 
velocity plotted against the substrate concentration and the gradient of the linear 
portion is taken to the initial velocity as shown in Figure 5.1(Comish-Bowden,
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1996). The concentration of substrate was expressed as the total SCT present in the 
system. This resulted in a v against s hyperbola with s described as units of 
millimoles per unit volume. However, the actual concentration of lipid available to 
the enzyme may not directly relate to the total lipid present. The quantity of lipid 
partitioned from the bulk into the surface phase or the emulsion droplet size and, 
hence, interfacial area may vary, limiting availability of substrate for enzyme 
adsorption. If this is the case, the kinetic parameters may reflect primarily the 
properties of enzyme adsorption to the interface, not the interfacial interaction of 
enzyme and substrate. This concern arises because of the non-equilibrium nature of 
emulsion particles.
Differences in the particle distribution from one preparation to the next can change 
the value of Km expressed in molar units (Brockman et al, 1984). Under conditions 
of the pH-stat assay, it is difficult to know how relevant variations in emulsion 
droplet size would be once lipolysis commenced. The simulated bile solution, along 
with lipolytic products released, will aid triglyceride emulsification. This, combined 
with the mechanical stirring action of the pH-stat, could result in emulsion droplets of 
uniform size irrespective of substrate concentration, thus the effect on the kinetic 
parameters determined could be minimal.
The plot indicates that at very low concentrations of substrate, the reaction is first 
order with respect to substrate, and at high concentrations of substrate, u has a 
maximum value (Vmax) and the reaction is zero-order kinetically with respect to 
substrate (Morris, 1972). As substrate concentration is increased, the enzyme 
eventually becomes saturated with substrate. In practice, however, it is difficult to 
draw rectangular hyperbolae accurately, because it is difficult to locate the 
asymptotes correctly (because one is tempted to place them too close to the curve); it 
is difficult to perceive the relationship between groups of hyperbolic curves, and to 
detect deviations from the expected curve if they occur (Comish-Bowden, 1996). 
However, the Michaelis-Menten relationship is not directly related to the action of an 
enzyme upon an insoluble substrate. Therefore, for the kinetics of a lipolytic enzyme
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acting at an interface, a model of two separate stages has been proposed, resulting in a 
two-dimensional form of the Michaelis-Menten equation (Brockman et al, 1984). The 
first stage is an equilibrium to describe the reversible penetration of enzyme into the 
interface. Once penetration has occurred a second equilibrium exists for the catalytic 
interaction between a molecule of enzyme and a substrate molecule. These 
difficulties were recognized by Michaelis-Menten who instead plotted d  against log 
a.
5.3.1 Method
A series of fourteen digestion profiles of pancreatin acting upon SCT (tributyrin) 
under standard pH-stat conditions were tested. The substrate concentrations were 
chosen to span at least five times the Km value. The digestion profiles represented 
product formed, expressed in terms of fatty acid released in millimoles per unit 
volume, with respect to time or total percentage digested per volume with respect to 
time. Each digestion profile was tested to ensure that the initial portion was linear. 
The initial rate was then calculated from gradient of the initial linear portion that 
normally occurred during the first six minutes from the start of digestion. 
Computerized linear regression analysis was applied to calculate the gradient.
5.3.2 Calculation Michaelis - Menten parameters (Km and Vmax )
5.3.2.1 The Eadie -  Hofstee plot
Multiplying both sides of equation 5.1 by u and rearranging, we obtain the equation 
straight line plot for the Michaelis -  Menten equation
v  = Vmax -  (Km * d / s )  eq (5.2)
This shows that a plot the initial measurements ( d )  against d  / s should be straight line 
with slope -  Km (-1.9018) and intercepts Vmax (0.1856) on the d  axis and Vmax / Km on 
the u/s as illustrated in Figure 5.2 (Comish-Bowden, 1996). This linear arrangement 
reveals best fit upon visual inspection between the data and a straight line in order to
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2check if the equation applies. Figure 5.2 shows a linear relationship (r = 0.9904) 
between substrate concentration (TBU) and initial velocity indicating that the 
Michaelis-Menten relationship was applicable, despite the heterogeneity of the 
reaction mixture.
53.2.2 The direct linear plot
Eisenthal and Comish-Bowden (1974) have described a quite different way of 
plotting the Michaelis -  Menten equation, showing the dependence of Vmax and Km:
Vmax = u + (u / s) * Km eq (5.3)
Plotting the substrate concentration used, s, and the initial velocity value, u, obtained 
from each digestion profile as an individual pair, creates the direct linear plot. The 
initial velocity is plotted onto the vertical axis representing the Vmax and the 
corresponding substrate concentration s, onto a negative horizontal Km axis. A 
straight line is then drawn between the two points and extrapolated into Vmax and Km 
parameters. The resulting lines obtained from each digestion profile should all 
intersect at the coordinates of the best fit Km and Vmax values, if the data fit the 
Michaelis-Menten equation. In practical each intersection point provides one 
estimate of Km and Vmax, therefore the median of the intersection co-ordinates are 
taken to the best fit of Km and Vmax. The direct linear plot has some advantages over 
the other because the error in any reading is likely to be positive as negative, the 
weighting is not relevant, and the method is less sensitive to outliers then least- 
squares fit method (Eisenthal et al, 1992).
Results
A pair of s and u obtained from each digestion profile of pancreatin acting upon SCT 
was used to build a direct linear plot as illustrated in Figure. 5.3. A measurement 
error can be seen from different intersection points. A computer software package 
was used to calculate the coordinate of each intersection and determine best-fit
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median values of Km and V max. Km and V max values are summarized in Table 5.2. 
Clearly, visual inspection of the direct linear plot will not disclose if the data 
considerably deviate from equation 5.1.
5.3.2.2 Least -  squares f i t  to a hyperbola
A software package was used to calculate the least-square fit of the data points to an 
initial velocity against the substrate concentration. This method calculates best-fit 
values of Km and V max and their standard deviation (Eisenthal et al, 1992). The 
method requires initial estimates of Km and V max (provided by one of the linear 
transformation).
The following sequences are summarized when using least-squares fit method for the 
normal statistical analysis of enzyme kinetics data (Eisenthal et al, 1992):
• Random errors in replicate values of the measured velocity, v, follow a normal 
distribution.
• There is no error in the substrate concentration, s.
• The correct weightings are known.
• Fluctuations in the y  values must be independent of any fluctuations in the x.
Results
The experimental data from the digestion profile of pancreatin upon SCT (TBU) 
under standard pH-stat conditions were fitted by using a curve fitting programme. A 
hyperbolic curve is the result of drawing the initial velocity against the substrate 
concentration as shown in Figure 5.4. Both Km and Vmax values calculated by the 
least squares method (Table 5.2) are based on the presence of a constant absolute 
measurement error in the data. Usually, a homogenous error is an inherent 
assumption of the least squares fit method but it is not necessarily applies for these
data. The data exhibit systematic variation of standard deviation, which is dependent
on the value of v, known as constant relative error. The addition of the weighting
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factors would facilitate the use this heterogeneous error. Therefore, large number of 
data are required confirming the correct weighting scheme.
5.3.3 Comparison o f the analytical method used
The previous method used gave different estimates for Km and Vmax when calculated 
from the same experimental data, which use to within confidence intervals. 
Therefore, the difference was not significant. Further tests was done for the least- 
squares fit, with weighting applied to the data which assumed a constant relative 
error.





Direct linear 0.387 0.373 - 0.390 11.9 11.1 - 12.9
(68 % confidence (68 % confidence
limits) limits)
Least squares fit to 0.374 0.012 11.1 0.69
hyperbola (standard error) (standard error)




Table 5.2 The value of Vmax and Km for pancreatin acting upon SCT under standard 
pH -  stat conditions) calculated using different analytical methods.
Using a constant relative error gave for Vmax and Km close to those given by the more 
statistically robust direct linear method. As a result, the data exhibit a heterogeneous 
error. The increase in the measured error was proportional to the increase of the 
velocity values (Table 5.2). The most reliable was the direct linear plot because of 
the absence of the weighting scheme. On the other hand, many data points were 
necessary in case of the least-square fit method to confirm the correct weighting 
scheme. The precise estimates of Vmax and Km would have standard deviations of less
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than 10% of the mean Vmax and Km values, as mentioned by Cleland (reviewed by 
Eisenthal et al, 1992). As in the case of the direct linear plot, the standard deviation 
in terms of the percent of the mean is 7.7% for Km and 3.11% for Vmax, and the values 
from the least squares fit method are 6.51% for Km and 1.98% for Vmax. The good fit 
of the experimental data to equation 5.1 increased the similarity of Km and Vmax 
values derived from the two analytical methods. Therefore, the choice of analytical 
method would probably not alter conclusions drawn from the use of Km and Vmax 
values in subsequent experiments.
5.4 Lipolysis of lipid formulations
5.4.1 Kinetics
Preliminary studies used pure triglycerides and lipid excipients as substrates. In the 
subsequent investigations the substrates were lipid formulations; combinations of 
mixed glycerides (mono-, di-, and tri-glycerides), MCT and /or surfactant with high 
or low HLB value. The digestion profiles were followed by continuously titrating 
the liberated fatty acids over time under standard pH-stat conditions as explained in 
chapter 4.
Throughout the research, an assumption was used to calculate the number of fatty 
acids released in each lipid formulation. Table 5.3 explains the main criteria used to 
estimate the FA expected to be released from mixtures of mono-, di- and tri­
glycerides (Imwitor 988®) and MCT (Miglyol 812®). In the presence of the 
surfactant the assumption made was different. Release depended mainly on the HLB 
of the surfactant. To allow assessment of the extent of inhibition the maximum 
expected liberation of FA was estimated. Table 5.4 represents the expected FA 
release from Miglyol 812® blended with 100% TG and Tagat TO® as lipophilic 
surfactant (HLB= 11.3). For the purpose of estimation Tagat TO® was considered as 
45% TG.
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mass of MCT 
Miglyol 812®















1.0 0.0 0.00200 0.00000 0.00000 0.00400 0.00600
0.9 0.1 0.00180 0.00013 0.00027 0.00373 0.00593
0.8 0.2 0.00160 0.00026 0.00054 0.00346 0.00586
0.7 0.3 0.00140 0.00039 0.00081 0.00319 0.00579
0.6 0.4 0.00120 0.00052 0.00108 0.00292 0.00572
0.5 0.5 0.00100 0.00064 0.00135 0.00264 0.00563
0.4 0.6 0.00080 0.00077 0.00162 0.00237 0.00556
0.3 0.7 0.00060 0.00090 0.00189 0.00210 0.00549
0.2 0.8 0.00040 0.00103 0.00216 0.00183 0.00542
0.1 0.9 0.00020 0.00116 0.00243 0.00156 0.00535
0.0 1.0 0.00000 0.00129 0.00270 0.00129 0.00528
* RMM TG= 500 ‘‘expected “ * max.
RMM DG = 358 TG 2 FA 3 FA
RMM MG = 200 DG 1 FA 2 FA
MG 0FA 1 FA
Table 5.3 The assumption made to calculate the FA released from the lipolysis of 
lipid formulations.
mass o f MCT 
Miglyol 812®
mass o f lipophilic 
surfactant 
Tagat TO®
moles of  
TG
from M 812®









1.0 0.0 0.00200 0.00000 0.00400 0.00400
0.9 0.1 0.00180 0.00009 0.00360 0.00378
0.8 0.2 0.00160 0.00018 0.00320 0.00356
0.7 0.3 0.00140 0.00027 0.00280 0.00334
0.6 0.4 0.00120 0.00036 0.00240 0.00312
0.5 0.5 0.00100 0.00045 0.00200 0.00290
0.4 0.6 0.00080 0.00054 0.00160 0.00268
0.3 0.7 0.00060 0.00063 0.00120 0.00246
0.2 0.8 0.00040 0.00072 0.00080 0.00224
0.1 0.9 0.00020 0.00081 0.00040 0.00202
0.0 1.0 0.00000 0.00090 0.00000 0.00180
* TTO considered 45 % as TG 
“  TG = 2 FA (produced from M 812® only)
*“  TG = 2 FA( M 812®)+ 2 FA (TTO®)
Table 5.4 The assumption made to calculate the FA released from the lipolysis of 
type II formulations (Miglyol 812® and Tagat TO®).
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mass of mixture mass of lipophilic moles of moles of moles of moles of moles FA max moles
Miglyol 812 and surfactant TG DG MG TG* expected FA
Imwitor 988® (1:1) Labrafil M® 1944 Cs from M 812®from 1988® from I 988® from LM® 1944 **
1 0 0.00100 0.000645 0.00135 0.00000 0.00265 0.00564
1 0.2 0.00167 0.000536 0.00112 0.00043 0.00388 0.00806
1 0.4 0.00143 0.00046 0.00096 0.00073 0.00332 0.00763
1 0.6 0.00125 0.00040 0.00008 0.00096 0.00290 0.00655
1 0.8 0.00111 0.000357 0.000075 0.00114 0.00258 0.00640
1 1 0.00100 0.000246 0.000067 0.00128 0.00225 0.00612
* TG = 2 FA from Labrasol M® 1944 Cs
** expected *** max.
TG 2 FA 5 FA
DG 1 FA 2 FA
MG 0 FA 1 FA
Table 5.5 The assumption made to calculate the FA released from the lipolysis of type IIIA in the presence of 
Labrafil M® 1944 CS (HLB 4-6) as hydrophilic surfactant.
mass of mixture 
Miglyol 812® and
Imwitor 988® (1:1)











1 0 0.00100 0.000645 0.00265
1 0.2 0.00167 0.000536 0.00388
1 0.4 0.00143 0.00046 0.00332
1 0.6 0.00125 0.00040 0.00290
1 0.8 0.00111 0.000357 0.00258
1 1 0.00100 0.000246 0.00225
Table 5.6 The assumption is made to calculate the FA released from the lipolysis of type IIIA in the presence of 
Cremophor RH 40® (14-16) as hydrophilic surfactant.
Tables 5.5 and 5.6 represent the expected difference in the total fatty acids that could 
potentially be released from different groups of surfactant. For example, Table 5.5 
showed that the expected lipolysis in the presence of polyglycolized glycerides like 
Labrafil M® 1944 Cs was estimated for glycerides and MCT. Other experiments 
required estimation of available fatty acid esters in blends of Cremophor RH 40®, an 
example of hydrogenated castor oil ethoxylates as shown in Table 5.6.
In general, the fatty acids liberated were calculated on the basis of 2-FA from TG, 1- 
FA from DG and 1 FA from MG. Although there is another possibility that MG 
produced from TG give another 1-FA.
5.4.2 The fate of the lipid formulations upon lipolysis in the presence non -
ionic surfactants
Hydrolysis rates of SEDDS displayed saturation kinetics with respect to total oil 
(substrate) concentration. The results of the lipolysis of SEDDS formulations under 
standard pH-stat conditions are displayed in Figures 5.4-5.13. The saturation data did 
not obey the typical Michaelis-Menten equation. The increase in the rate with the 
lipolysis was faster than expected from a square hyperbola. Figure 5.5 represents the 
profile of digestion over 60 min of type II formulations (MCT (Miglyol 812®) and 
lipophilic surfactant (HLB<12) (Tagat TO®)} under standard pH -  stat conditions. 
Examination of the resulting profiles from increasing concentration of TTO® 
suggested some suppression of pancreatin activity. This was evident from the total 
TG digested upon completion of the assay. At 40% of MCT in the presence of TTO® 
(60%) the percentage digested was <30% as illustrated in Figure 5.6. Whereas at 
40% of MCT, alone, the percentage digested was <35%. This effect could be 
explained by the phase separation of the oil and the surfactant (alkylphenol) on 
mixing with water to form two populations of droplets (one rich in MCT oil and the 
other in alkylphenol) only one of which enables lipolysis to proceed.
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Figure 5.7 show the fate of digestion over time of a fixed ratio of MCT (Miglyol 
812®) and mixed mono-, di-, and tri-glycerides (Imwitor 988®)(1:1) when CRH 40® 
(HLB 14-16) was added gradually under the standard pH-stat conditions. The lag 
phase was more obvious in the presence of CRH 40® than in the presence of TTO® or 
Labrafil M l941® as shown in Figure 5.8. The surfactant would be expected to be 
anchored at the oil-water interface. Therefore, it is likely that the lipolysis was 
inhibited once the oxyethylene mantle generated by the surfactant exceeded a critical 
thickness, which prevented bonding of colipase-lipase complex to the surface of the 
oil droplet. Figure 5.9 illustrated that the total percentage of digestion was 
significantly affected by the addition of CRH 40®. At 20% of CRH 40® did not' 
reduce the lipolysis of the mixed glycerides and MCT. At 50% of CRH 40® the 
effect upon the pancreatin activity was more clear as shown in Figures 5.7 and 5.9.
Figure 5.9 shows the difference in the total of digestion fixed ratio of MCT (Miglyol 
812®) and mixed glycerides mono-, di-, tri-glycerides (Imwitor 988®)(1:1) upon 
addition of surfactant with different HLB. Polyglycolized glycerides like Labrasol 
M®1944 (HLB 3-4) produced a greater than expected increase in the total percentage 
of digestion over a longer period of time as shown in Figure 5.10. The long chain 
polyglycolized glycerides (6-PEG Ci8:i and Cis:2) depressed pancreatin activity at 
steady state with a decrease in total MCT digested upon completion of the assay 
compared to the control (Solomon, 1998). Solomon (1998) mentioned that the Cig:2 
8-PEG had similar behaviour with the short lag phase, probably due to higher 
hydrophilic character compared to the 6-PEG variant. The inhibition of pancreatin 
activity by the Cigii and C18.2 polyglycolized glycerides had a different behaviour of 
inhibition other than more hydrophilic surfactants. This may be due to the fact that 
the long-chain polyglycolized glycerides are composed of natural oil in a complex 
with PEG. On the other hand, the medium-chain polyglycolized glycerides (Csii) 
showed little inhibition relative to their HLB numbers of 10 and 14, values for which 
other surfactant classes resulted in extensive enzyme inhibition. This may be a result 
of the composite nature of these products.
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Mixed mono-, di- and tri-glycerides (Imwitor 988®) and MCT (Miglyol 812®) were 
studied as a control experiment as presented in Figure. 5.11. During product 
activation lipolysis, the enzyme initially partitions between the bulk water and lipid 
interface. Hydrolysis starts and products temporarily remain at the interface, forming 
clusters or microheterogeneities. At the boundaries of these clusters, the binding of 
the enzyme is enhanced with resultant increase in hydrolytic rate (Wieloch et al, 
1982).
The fate of lipid formulations under standard pH-stat conditions is characterized by 
three distinct phases. In the activation phase or lag phase, the rate of reaction 
increases continuously until a maximum rate is reached. At this point it has been 
suggested that lipase and colipase bind to LC-BS micelles in solution. In the zero- 
order or initial-rate phase, the rate of FA production is linear with time. Linear 
kinetics is explained by an increased binding of lipase and colipase to the substrate 
surface, induced by the free fatty acids formed. The final phase is characterized by a 
continuous decrease in rate until the reaction stops, when all possible FA has been 
released or when the rate of FA formation becomes negligible. The presence of an 
activator phase and a lag phase depended on the nature of TG present in lipid 
formulation. In general, LCT and hydrophilic surfactant with high HLB value had a 
more pronounced and longer lag phase than MGT, SCT, and hydrophilic surfactant 
with low HLB value. Figure 5.12 illustrates the fate of different lipid formulations 
under the same standard pH -  stat conditions. The three phases are characterized in 
each formulation.
The lag phase was more pronounced in type IIIA than in type II and S-F formulation 
(Figure 5.12). The lag phase is due to the presence of CRH 40® (<35%) in type III A 
that inhibits the lipolysis. A possible explanation for their higher inhibitory effect 
may be due to strong attractive forces between the substantial castor oil component 
and MCT. Resultant adsorption of the hydrophobic castor oil moiety of the surfactant 
to the lipid interface could restrict binding of enzyme to the substrate, if surfactant 
concentration was sufficient to cover the entire interface. The castor oil has three
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sites where ethoxylation is most likely to occur (on the hydroxyl groups), with a 
possibility of ethoxylation also at the site of the three carbonyl groups. In the case of 
alcohol ethoxylates all the ethoxy groups form a single chain upon one site. 
Therefore, if the inhibitory effect is due to a barrier formed by ethoxy groups at the 
lipid interface, the castor oil ethoxylates would require a higher degree of 
ethoxylation to build up the length of the ethoxy chains, and thus reach the same 
inhibitory effect as an alcohol ethoxylate with a lower ethoxylation number.
Figure 5.12 shows that surfactant-free formulations typically follow the hyperbolic 
curve with no lag phase. The presence and type of co-solvent has no effect on the 
rate of lipolysis as illustrated in Figure 5.13.
Some experiments were run using the non-ionic surfactant as substrate under the 
standard pH-stat conditions. Table 5.7 summarized the total amount of FA released 
from each surfactant varied in accordance with HLB value and their chemical 
structure. Therefore, the total digestion over time (60 min) was varied. 
Polyglycolized glycerides (like Labrafils and Labrafac) with low HLB underwent 
lipolysis as if mixed glycerides. Hydrogenated castor oil ethoxylated (like CRH 40® 
and TTO®) with high HLB did not undergo lipolysis. Labrasol® had a different 
behaviour from the other examples that undergo lipolysis with high HLB value. This 
may be explained by its synthesis by trans-esterfication, which results in the presence 
of free triglyceride (and free PEG).
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Surfactant HLB % of digestion 
60 min
Gelucire 44/ 14® 4.653
Labrafil M® 1944 3 - 4 26.550
Labrafil M® 2522 3 - 4 36.567
Labrafac CC® 10 5.574
Labrasol® 14 91.063
Tagat TO® 11.3 zero
Cremophor RH 40 14-16 zero
Table 5.7 The percentage of digestion of non-ionic surfactant under standard pH-stat 
conditions.
5.4.3 Discussion
When pancreatin acted on lipid formulations under conditions of the standard pH-stat 
assay, no lag phase was observed. The supramicellar bile salt concentrations in the 
simulated bile solution would be expected to inactivate lipase by causing enzyme 
displacement from the lipid interface (Borgstrom, 1976). However, colipase present 
in pancreatin may have been able to overcome any desorbing activity of bile salts 
resulting in immediate lipase activity, possibly by acting as an anchor for lipase to 
bind to the substrate (Borgstrom, 1977a).
The process of colipase binding to the lipid substrate has been suggested to occur via 
hydrogen bonding with ester linkages in the lipid substrate (Borgstrom et al, 1984). 
The hydrogen bonds have been reported to be easily disrupted by non-ionic 
surfactants and octylphenol ethoxylate has been demonstrated to displace colipase 
from the lipid substrate interface. Tensioactive agents, such as non-ionic surfactants, 
have also been stated to mediate inhibition of lipase by affecting the interfacial 
quality of the substrate (Pieroni et al, 1990).
In the work presented here, pancreatin has demonstrated the ability to overcome the 
initial lag phase caused by the presence of polyoxyethylene glycerol fatty acid ester
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(TTO®), although the times taken to reach steady state did vary. This initial 
inhibition of enzyme activity upon commencement of the assay may be a direct result 
of surfactant altering the quality of the substrate interface. Colipase, whilst able to 
overcome any desorption of lipase due to bile salts in the reaction milieu, may be 
unable to overcome immediately effects of surfactant molecules.
Surfactant molecules could initially be assumed to accumulate at the lipid interface 
blocking adsorption of colipase, possibly by steric hindrance or interference with 
hydrogen bonding between colipase and triglyceride substrate. Eventually, binding 
of some colipase would allow limited lipolysis to proceed. The resulting 
accumulation of lipolytic products at the interface would thus promote further 
colipase binding and increase enzymatic activity to steady state.
Studies by other workers suggested that colipase rather than lipase is responsible for 
overcoming inhibition from non-ionic surfactants. Colipase has been shown to 
activate lipase in the presence of substrate interfaces to which lipase cannot bind 
alone (Verger et al, 1977). The addition of colipase in increasing amounts to a 
detergent inhibited system has also been demonstrated to eventually abolish the lag 
phase (Borgstrom, 1977c).
If the ability of colipase to restore lipase activity is related to length of the lag phase, 
the duration of lag phase must reflect the effect of surfactants on the binding of 
colipase. Solomon (1998) suggested after an experiment using MCT / nonylphenol 
ethoxylated surfactant mixtures, that digestion profiles from one batch of pancreatin 
had a shorter lag phase compared to a second batch. This implies that batch I 
pancreatin contained colipase with higher activity than batch II.
The literature goes some way to supporting this assumption, as the structure of 
colipase has been found to be related to the duration of the lag phase. Colipase 
isolated from porcine pancreatic glands can vary in the number of amino-acid 
residues present in the peptide chain. Proteolysis at the N-terminus will result in 
conversion of procolipase (colipase-101) to the more active colipase-96 form
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(Borgstrom et al, 1984). When acting upon phosphatidylcholine-stabilized 
triglyceride emulsion, colipase-96 can overcome lag times at 100 times lower 
concentrations than procolipase (Borgstrom et al, 1979). In addition cleavage of 
colipase-96 at the C-terminal end to colipase-85 reduced lag time further by a factor 
of six (Larsson et al, 1981).
Hermoso and his co-workers (1996) reported extensive studies designed to 
investigate the structural behaviour of porcine pancreatin enzyme in the presence of 
the non-ionic surfactant tetraethylene glycol monooctyl ether (TGME) and 
diisopropyl 4-nitrophenyl phosphate (E600). The former surfactants were compared 
with NaTDC, and ionic surfactant. They clearly demonstrated that the presence of 
micelles of either ionic or non-ionic surfactant plus colipase induces the opening of 
the flap exposing the active site of the lipase. The presence of the TGME molecule in 
the active site provided a structural basis for the inhibitory effect of the surfactant. 
Therefore, once the flap is opened, either by water-substrate interface, or by detergent 
micelles in the presence of colipase, monomers of non-ionic surfactant may behave as 
inhibitors by binding to the active site. In contrast to the inhibition induced by bile 
salts, non-ionic surfactant inhibition cannot be reversed by colipase (Hermoso et al, 
1996).
Solomon (1998) reported an extensive study of pancreatin activity on MCT in 
presence different types of non-ionic surfactants. She mentioned that alteration in the 
activity of pancreatin by nonylphenol ethoxylated surfactants (NPEs) appeared to be 
related to the degree of ethoxylation of the surfactant and, hence, surfactant 
hydrophile-lipophile balance. This may perhaps be explained by consideration of the 
behaviour of NPEs at a lipid-water interface. The orientation of nonylphenol 
ethoxylated surfactant molecules at an oil-water interface has been suggested to vary 






Figure 5.1 The state of orientation of NPEs with different numbers of ethoxy groups 
at an oil-water interface (modified from Marszall, 1987).
For NPEs with high lipophilic character, the surfactant molecule is represented as 
completely partitioned into the oil phase as illustrated in Figure. 5.1. As the number 
of ethoxy groups in the chain is increased from 5 to 8, the hydrophilic ethoxy chain 
gradually penetrates into the aqueous phase until only the nonylphenol moiety 
remains in the oil. Additional ethoxylation after this point results in the ethoxy chain 
adopting a meander form in the water with the hydrocarbon group also penetrating 
further into the aqueous phase.
In the standard pH-stat assay, triglyceride droplets, probably with associated lecithin, 
are dispersed in an aqueous reaction mixture as oil-in-water emulsion. The 
nonylphenol ethoxylated surfactant molecules are assumed to be located mainly at the 
interface between the triglyceride droplet and the aqueous environment. If the 
surfactant molecules adopt a similar conformation to that illustrated in Figure 5.1 
according to the length of their ethoxy chain, a mechanism to explain the change in 
their inhibitory effects with HLB can be proposed (Solomon, 1998).
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Nonylphenol and NPEs with ethoxy chain lengths below 5 have dominant lipophilic 
character. From Figure 5.1, the highly lipophilic nature of these surfactants would 
result in the Complete molecule being partitioned into the triglyceride droplet. The 
lipase and colipase would still be able to bind and start digestion immediately as 
demonstrated by the lack of a lag phase at the beginning of the digestion profiles 
produced in the presence of these surfactants. Penetration of the surfactant 
completely into the oil may cause a substrate dilution effect by acting as inert spacers, 
resulting in less triglyceride available at the interface for lipase to act upon. This is 
analogous to the concept of substrate dilution used in lipolytic enzyme kinetic studies 
where a lipid or detergent molecule known not to be a substrate for the enzyme is- 
introduced into the system (Pieroni et al, 1990).
The digestion profiles support the substrate dilution theory by exhibiting decreased 
enzyme activity at steady state and a reduction in the extent of triglyceride digestion 
achieved within the assay period as in the presence of Tagat TO®.
For NPEs and ethoxylates of hydrogenated castor oil with chains containing from 5 to 
15 ethoxy groups, the potency of inhibition increases with the degree of ethoxylation 
of the surfactant. Chains composed of 6 to 8 ethoxy groups will start to form an 
oxyethylene mantle around the lipid droplet, restricting access of colipase to the 
interface and thus delaying enzyme adsorption (Solomon, 1998). As the ethoxy chain 
is increased to 9 groups and above, the mantle will become harder to penetrate as the 
ethoxy chain adopts a meander form. This accounts well for the increase in duration 
of the lag phase with the degree of ethoxylation of the surfactant as in the presence of 
CRH 40®, reflecting restricted colipase binding to substrate. It also illustrates the 
dependence of lipase activity on the ability of colipase to overcome the presence of 
surfactant, thus revealing the advantage of colipase with higher activity.
The potency of inhibition of NPEs with ethoxy chain lengths of above 15 starts to 
diminish as hydrophilic character of the surfactant is increased by lengthening of the 
ethoxy chain. Figure 5.1 illustrates how partitioning of the nonylphenol moiety
177
further into the aqueous reaction system is likely due to the dominant hydrophilic 
character of the molecule. These highly hydrophilic surfactants may show reduced 
inhibition due to preferential partitioning of the surfactant from the lipid interface into 
the aqueous reaction medium. This would result in enhanced colipase binding to the 
lipid interface and a subsequent increase in the rate and extent of MCT lipolysis.
The polyglycolized glyceride (Cg-Cio) Labrosol is present with free glycerides and 
probably free polyethylene glycol as well. As the surfactant is added to the assay by 
weight, the mixture of constituents will have reduced the concentration of inhibitory 
substance present within the reaction system. Free polyethylene glycol would be 
expected to partition into the aqueous phase. More importantly the free medium 
chain glycerides could be assumed to be available at the lipid interface for hydrolysis 
by pancreatin and to enhance binding of colipase according to the colipase 
partitioning theory. This may explain the short lag phase seen and a final extent of 
triglyceride digestion equivalent to that shown by the MCT control.
In general, the chemical structure of the surfactant, in addition to the HLB value, was 
related to the potency of inhibition of a surfactant. The pattern of inhibition shown 
across a digestion profile had a particular character depending upon whether the 
lipophilic or hydrophilic moiety of the surfactant was dominant. This, in turn, 
suggested inhibition to be mediated by different mechanisms.
The high potency of inhibition demonstrated by the castor oil ethoxylates is suggested 
to relate to the extensive hydrophobic castor oil component. In all cases digestion 
profiles from the castor oil ethoxylates (Cremophor RH 40®) displayed a lag phase, 
indicating an initial delay in enzyme activity. Suppression of enzyme activity across 
the whole profile has been proposed to be a result of incorporation of surfactant 
molecules into the interface, where they effectively dilute the concentration of 
substrate available at the interface. The large size of the castor oil component and the 
close proximity of the ethoxylation sites to the fatty acid chains may prevent 
integration of these surfactants into the triglyceride interface. Instead, a surfactant
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layer may be formed upon the MCT surface thus preventing initial enzyme / substrate 
binding resulting in a lag phase.
5.5 Conclusion
It is clear that, under conditions of the standard pH-stat assay, a relationship exists 
between the hydrophile-lipophile balance of a surfactant and the ability of the 
surfactant to inhibit pancreatin activity towards MCT and mixed glycerides. At low 
HLB values surfactants have been proposed to inhibit pancreatin via lipophilic effects 
whereas when HLB is increased by ethoxylation hydrophilic inhibitory mechanisms 
may come into play. However, the results suggest that HLB not be the only factor 
involved, as the structure of the hydrophobe also appears to have an influential effect 
on the potency of inhibition shown by a surfactant. In general, for surfactants with 
the same extent of ethoxylation, the inhibitory effect appears to increase with the size 
of the hydrophobic moiety.
It could be argued that the overall size of the surfactant molecule when present at the 
lipid-water interface may alone be sufficient to inhibit lipase purely by preventing 
access of colipase to the substrate. The altered nature of the digestion profiles 
according to HLB value of the surfactant, however, tends to suggest the situation is 
more complex. For surfactants with dominant hydrophilic character, the effect upon 
digestion of MCT and mixed glycerides is to delay initial enzyme activity as 
indicated by a lag phase on the digestion profile. The lag phase is subsequently 
overcome after a variable period of time, which tends to increase with the hydrophilic 
character of the surfactant.
Conversely, the lipophilic surfactants, except the castor oil ethoxylates, decreased 
enzyme activity at steady state without evidence of a lag phase. Inhibition in this 
case was proposed not to be mediated by surface activity but to relate to a substrate 
dilution effect with surfactant molecules acting as inert spacers, reducing triglyceride 
concentration available at the interface for hydrolysis.
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Lipophilic surfactants also tended to cause a reduction in the percentage of 
triglyceride digested upon completion of the assay compared to that shown by lipid 
formulation control. This may be result of low HLB surfactants forming two phases 
of droplets, one of which is rich in surfactant. Any formulation formed of mixed 
glycerides and MCT incorporated in this phase could be expected to be held in a form 
unavailable to pancreatin, thus explaining the reduced level of triglyceride digestion 
observed at the end of the profile.
Throughout this study the mechanism of inhibition has been related to surfactants 
altering the availability of the substrate to the enzyme. A further point to remember 
is that mono-, di-, and tri- glycerides / MCT / surfactant emulsion systems could be 
expected to have different interfacial areas depending upon the HLB value of the 
surfactant, which could also influence pancreatin activity to some extent. The 
possibility of surfactant monomers in solution having a direct influence on the 
catalytic properties of lipase also cannot be ignored; some detergent molecules have 
been observed in crystallographic studies to locate at the entrance of the active site of 
lipase, bound to the hydrophobic part of the lid (Egloff et al, 1995).
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Figure 5.2 Representative model of the Michaelis-Menten equation 
(Eadie-Hofstce plot v versus v/s)
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Figure 5.3 Direct linear plot for the digestion of SCT by pancreatin 
using pH-stat method (Vmax and Km are determined from the best fit 
median values of the intercepts)
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Figure 5.5 Profile lipolysis o f  type II form ulation (M iglyol 812 
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Figure 5.6 Total digestion of type II formulations (Miglyol 812:Tagat To)
under standard pH-stat conditions ( the error bars represent the
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Figure 5.7 The effect o f  adding C rem ophor RH 40 ( H LB = 14- 16) on the profile 
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Figure 5.8 R epresentative exam ples o f the fate o f  m ixtures o f  
m edium  chain triglycerides and m ono, di, and tri-glycerides 
( M iglyol 812 : Imvvitor 988) ( 1:1 )in the presence o f  surfactant 
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Figure 5.9 The effect o f surfactant with different HLB value on the total 
percentage digested o f mixture o f medium chain triglyceride and mono, 
di, and tri-glycerides ( M iglyol 812:Im witor 988) ( 1:1) under standard 
pH stat conditions ( the error bars represent the standard devaition  
of three experiments)
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Figure 5.10 The effect o f  adding Labrsol M 1940 ( HLB = 4-6) on the profile 
o f  lipolysis o f  m ixtues o f  m edium  chain triglycerides and m ono, di, tri-glycerides 






















Figure 5.11 Total digestion o f mixtures o f  medium chain triglycerides and 
mono-, di-, and tri-glycerides formulations (Imwitor 9 8 8 rMiglyol 812) 
under standard pH-stat conditions ( the error bars represent 
the standard deviation o f three experiments)
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Figure 5.13 Profile lipolysis of surfactant-free formulations 
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Phase separation of lipid formulations following their dispersion in simulated 
intestinal fluid.
6.1 Introduction
The fate of lipids in upper small intestine contents following a lipid-rich meal in 
humans has been studied extensively by Borgstrom and co-workers (1962) (reviewed 
by Staggers et al, 1990). Although much work has been done to explore the various 
biochemical steps in lipid digestion [reviewed by Borgstrom (1977b), Carey (1983); 
and Hemell et al (1990)], the nature of the physical-chemical events involved still not 
completely understood. Hofmann and Borgstrom (1963, 1964) reported a classical 
hypothesis that intestinal lipids, during fat digestion, are partitioned between two or 
three physical states in the duodenal contents: an oily rich or emulsion portion, rich in 
TGs and DGs; a dilute, aqueous mixed micellar phase composed of bile salts and 
lipolytic products, and a precipitated “pellet” (Borgstrom, 1985; Hemell et al, 1990). 
The absorption of dietary lipid takes place from a micellar solution containing chiefly 
fatty acid and 2-MG. Later, Patton and Carey (1979) examined fat digestion using 
triolein as the substrate, in vitro under the light microscope, in the presence of bile 
salts and pancreatic lipase and colipase. They saw the sequential formation of two 
visible lipolytic phases: a crystalline phase followed by a viscous isotropic phase. A 
crystalline phase was identified as containing birefringent calcium soaps and ionised 
fatty acid, whereas viscous isotropic phase was composed mainly of MGs and 
protonated fatty acids (1:1) (Patton et al, 1981). They suggested that the viscous 
isotropic phase formed myelin figures in unsaturated bile salts solution and 
eventually dissolved into a clear micellar solution. In bile saturated with lipids, 
neither phase disappeared completely. When centrifuged, the first crystalline phase 
sedimented as a pellet. The upper (floating) oil phase contained mostly unhydrolyzed 
TG and some DGs; the aqueous phase was turbid and contained mainly MG and fatty 
acids with small amounts of di- and tri-glycerides. The density of the viscous
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isotropic phase after centrifugation seen on the slide was similar to that of the 
micellar phase. Therefore, the micellar phase in most instances may be a two-phase 
system and the rate of formation relative to the rate of solubilization into the micellar 
phase will determine the phase relationships occurring during in vivo digestion 
(reviewed by Borgstrom, 1985).
In 1990, Staggers et al updated the intestinal hypothesis through the definition of the 
complete condensed phase diagram of one system for typical physiological 
conditions. They also have determined the influence of several physical-chemical 
variables upon the phase boundaries of physical-chemical compositions of a two- 
phase zone. In healthy adult humans, duodenal contents were collected and aspirated 
following the feeding of a triacylglycerol-rich meal. The aspirates were collected 
during established lipid digestion and absorption into a “cocktail” of chemical 
inhibitors that rapidly inhibited ex vivo lipolysis. Ultracentrifugation showed that the 
lipids separated into a floating oil layer, several oil layers, several interfacial layers, a 
“clear” or turbid “subphase” and a precipitated “pellet” (Hemell et al, 1990). They 
identified the floating layer as oil-in-water emulsion particles with cores of 
triacylglycerol (TG), diglycerols (DG) and choesteryl esters (CE) emulsified with a 
surface coat of partially ionised fatty acids (FA), MGs (MG), 
diacylphosphatidylcholine (PL), and bile salts (BS). The interfacial layers exhibited 
lamellar liquid crystalline structure with similar emulsion particles dispersed among 
emulsifier. The subphases were identified as saturated mixed micelles composed of 
BS, FA acid-soap, MG, PL, cholesterol (Ch), and traces of DG and TG coexisted 
with unilamellar liquid-crystalline vesicles composed of the same lipids. Precipitated 
pellets were composed principally of emulsifying lipids, with smaller amounts of 
crystalline calcium soaps and BS (Hemell et al, 1990).
In the work described in this chapter, the physical chemistry of lipid excipients, 
SEDDS formulations and mixtures of mono-, di-, and tri-glycerides in vitro under 
standard pH-stat condition has been studied systematically. In the model lipid system 
used, phases were identified after ultracentrifugation and compared with the model
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mentioned by Hemell and Staggers (1990). The fate of hydrophobic drugs was 
determined in each phase using HPLC method.
6.2 Materials and methods
6.2.1 Materials
In addition to the materials mentioned in chapters 2 and 4, the following materials 
were used:
• Methanolic cocktail solution:
Name Concentration Cas. # Manufacture
Diisopropylfluorophosphate 50 mM D 0879 Sigma
Diethyl (p-nitrophenyl) phosphate 50 mM D 9286 Sigma
Acetophenone 50 mM A l, 070-1 Aldrich
Phenyl-boronic acid 250 mM P2, 000-9 Aldrich
The previous materials were diluted in methanol (99% v/v) in concentration not more 
than 2% w/w (Hemell et al, 1990).
• Drugs:
• The same drugs used in Chap. 2
• Drugs used as internal standard for HPLC analysis are the following:
Name Concentration Cas. # Manufacture
Corticosterone 0.000682 g % C 2505 Sigma
Dexamethasone 0.000264 g % D 1756 Sigma
Testosterone 0.000792 g % T 1500 Sigma
Hydrocortisone 0.000653 g % H 4001 Sigma
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• Phosphate buffer pH 6.5
Mwt Cas. # Concentration Used * Manufacture
A Potassium phosphate 
Monobasic, KH2P 0 2
136.1 P 5379 9.079 g/ L 
i.e. 6.67ImM
778 ml Sigma
B Sodium phosphate 
Dibasic, Na2HP04






364.5 H 5882 1.68 g / L 
i.e. 0.461 mM
1.68 g / L Sigma
Phosphate buffer (pH 6.5) prepared by mixing 350ml of mixture of A and B 
solutions, used in proportions shown in the accompanying Table, made up to 1L with 
methanol (99 % v/v), followed by adding cetrimide.
• Composition of lipid tested:
Lipid excipients and formulations tested are summarized in Table 6.1.
6.2.2 Methods
6.2.2.1 Visual inspection
A visual test of mixtures of mono-di-, and tri-glycerides (Imwitor 988®) and medium 
chain fatty acid oil (Miglyol 812®) with various aqueous phases or simulated 
intestinal fluids was carried out as shown in Tables 6.2 and 6.3. The excipients or 
formulations were introduced into 100 ml volumetric flask of solutions shown in 
Tables 6.2 and 6.3 at 25°C and the content were mixed vigorously for 5 min with a 
magnetic stirrer. The tendency was for phases to separate spontaneously. The 
identification of phases present was easier when mixtures were left for at least one 
hour. Photographs were taken using a digital camera to help identify and compare the 
phases. All experiments were repeated twice, with similar observations being made 
between repeats (Kummuru et al, 2001).
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Butyl paraben Methyl paraben Hydrocortisone Testosterone
5min 30 min 5 min 30 min 5min 30 min 5min 30 min
MCT (Miglyol 812®) ✓ ✓ ✓ ✓ ✓ ✓ ✓
LCT (Com oil) ✓ «✓ ✓ ✓ ✓ ✓ ✓
MCT (Miglyol 812®) ✓ ✓ ✓ ✓
without Ca
LCT (Com oil) <✓ ✓ ✓ ✓
without Ca
Mixed glycerides ✓ ✓ ✓ ✓ ✓ «/
Imwitor 988®
Surfactant- Free <✓ ✓ ✓ ✓ «/ ✓
M 812®+I 988®+ PG
30% + 50 % + 20%
Surfactant- Free ✓ ✓ ✓ ✓
without Ca
Type II ✓ ✓ ✓ ✓ ✓ ✓
M 812® + TTO®
40 % + 60 %
Type III A ✓ ✓ ✓ ✓ ✓ ✓
I 988®+ M 812® + CRH 40®
35 % + 35 % + 30 %
Type III B <✓ «✓ ✓ ✓ */ ✓
I 988® + M 812® + CRH 40®
+ PG
(9 : 1)35% + 35% + 30%
I 988®+ M 812® ✓ ✓ ✓ ✓ ✓ ✓
50 % + 30 %
I 988®+ M 812® ✓ ✓ ✓ ✓ ✓ ✓
50 % + 50 %
I 988®+ M 812® ✓ ✓ ✓ >✓ ✓ ✓
30 % + 70 %
I 988®+ M 812® ✓ ✓ ✓ ✓ ✓ ✓
70 % + 30 %
Table 6.1 Lipid excipients and formulations containing lipophilic drugs used in the 
investigation (* indicates that the experiments were done in terms of lipolysis and 
analyzed using the HPLC).
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Solutions Imwitor 988® Miglyol 812®
h 2o ✓ ✓
Trizma-buffer® (pH 7.0) ✓ ✓
Trizma-buffer® (pH 7.0) + BS (15 mM) ✓ ✓
Standard pH-stat solution (non-pure LC) ✓ ✓
Standard pH-stat solution (pure LC) ✓ ✓
Table 6.2 Mixture of glycerides and medium chain oil in different solutions were 
examined for visual phase separation.
Imwitor 988® Miglyol 812®
Standard pH-stat 
solution
2 g + zero ✓
2 g + 0.4 g ✓
2 g + 0.8 g ✓
2 g + 1.2 g ✓
Table 6.3 Mixture of glycerides and medium chain oils were mixed in standard pH- 
stat solution for visual phase separation.
6.2.2.2 In vitro lipolysis
A series of lipid excipients and self-emulsifying systems (4 g in 100 ml) as shown in 
Table 6.1 were dispersed in standard pH-stat solution and subjected to lipolysis 
(Chapter 4, section 4.4.6.4.2) under standard pH-stat conditions for studies of phase 
behaviour after lipolysis. At 30 min, following the addition of the lipase to the 
simulated intestinal fluid, <2%v/v (1 ml by Gilson pipette) of methanolic solutions of 
a “cocktail” of lipase inhibitors was added to quench the reaction (material, 6.2.1).
6.2.2.3 Separation and collection o f phases
To evaluate the efficiency of speed and duration of centrifugation, different samples 
were run at the same speed, 104630g, for different times. Later, all mixtures were 
ultracentrifuged at 104630g for 30 min at 37°C by using ultra clear tubes
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(38><102 mm), capacity 94 ml, in a SW-70.1 swinging bucket rotor (Model L8 -  70M 
ultracentrifuge, Beckman Instruments, Palo ALTO, CA).
The separated layers were aspirated from the ultracentrifuge tube into snap-cap 
microtubes (1.5 ml, 40 H x ll mm OD, Sigma-Aldrich, UK) in the manner described 
by Hemell et al (1990). The oily layer was collected first with a MedSaver 
disposable syringe (1 ml with 25 gauge, 5/8 -  in needle, Sigma-Aldrich, UK). After 
the oily layer was removed from the top, portions of the interface were withdrawn 
using MedSaver disposable syringes, placing the syringes at the side of the tube so as 
to minimize the contamination between phases. Only very small volumes (5-25 pi) 
of interface could be withdrawn before being contaminated with the micellar phase. 
A syringe with a stainless steel syringe needle (2 in length, 14 gauge) was then used 
to puncture the side of the tube at the level of the subphase (micellar phase). 
Thereafter, sufficient amount was removed, another syringe inserted to a deeper level 
to withdraw what is referred to as the swollen micellar phase. Finally, the pelleted or 
precipitate fraction was obtained first by removing all the supernatant material from 
the tube and scraping a spatula (Hemell et al, 1990). All the snap-cap microtubes 
were kept in the fridge for HPLC analysis.
6.2.2.4 Assay methodfor lipophilic drugs
Table 6.4 summarized the assay parameters for hydrocortisone, testosterone, butyl 
paraben, and methyl paraben. They were essentially the same, except for minor 
variations in the mobile phases and internal standards used in the chromatographic 
analysis (Charman et al, 1986). A 200 pi sample of each was diluted in the presence 
of internal standard (IS) (material, 6.2.1) with the specified solvent (Table 6.4). A 
100 pi diluted sample preparation was subjected to HPLC analysis under the 
following conditions; pump model 110A, UV detector model 153 (Beckman, 
Berkeley, CA 94710, USA), 25cm x4.6mm Hichrom C l8 BDS and the guard column 
5 pm S50DS2- 10C5. The method of internal standards was used to convert
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Drugs Log P Mwt X max Mobile phase
Internal
standard RT of IS RT of drug
Injection
volume Solvent Flow rate
Hydrocortisone 1.53 362.5 242 MeoH: H20  
55%: 45%
Cotricosteroid 12 min 9.2 min 100 mM MeoH 99 % v/v 1 ml/min
Testosterone 3.3 288.4 240 ACE: H20  
55 %: 45%
Dexamethasone 4.19 min 8.83 min 100 mM MeoH 99 % v/v 1 ml/min
Butyl paraben 3.24 194.2 252 Phs buffer: MeoH 
35%: 65%
Testosterone 13 - 14 min 11 min 100 mM ACE 99 % v/v 1 ml/min
Methyl paraben 1.66 152.1 231 ACE: H20  
27.5%: 72.5%
Hydrocortisone 12.6 min 7.76 min 100 mM ACE 99 % v/v 1 ml/min
Table 6.4 Parameters used for the HPLC analysis.
the measured peak heights of the drug and the internal standard to concentration of 
the drug. Values are reported as mean ± SD and the data were considered statistically 
significant at p  < 0.05 (Kummuru et al, 2001). Calibration curves for standard 
solutions were done with a correlation coefficient in all cases (R2 values of 0.999 
were typical) and summarized in Appendix 3 (Bakatselou et al, 1991).
6.3 Results
6.3.1 Visual inspection o f  mono-, di- and tri-glycerides behaviour in water, tris-
maleate buffer (pH 7.0) and standard pH-stat solution at ambient temperature.
Any understanding of the complex process of fat absorption requires clarification of 
the physico-chemical state of lipids in intestinal contents before and/or after digestion 
(Hofmann, 1963). Naturally, ingested TGs are hydrolysed by pancreatic lipase 
mainly to fatty acids and MGs, and these polar lipids are solubilized in bile salt 
micelles to form an isotropic micellar solution. All formulations dispersed to form 
emulsions in pure water but their behaviour in standard pH-stat solution, was 
dependent on MGs (Dressman et al, 1998). Therefore, some experiments were 
performed by mixing different weights of mixed glycerides (Imwitor 988®) and 
medium chain oil (Miglyol 812®) as shown in Table 6.3 in standard pH-stat solution 
at ambient temperature and then left to equilibrate. The visual test provided a 
measure of the apparent spontaneity of phase separation of lipid excipients in 100 ml 
standard pH-stat solution. In the present study, when sufficient MG was present 
>60%, as in Imwitor 988® demulsification and phase separation was observed, which 
was dependent on the presence of phospholipid and resulted in sedimentation of what 
was believed to be a phase rich in MGs and water, the “swollen gel phase” as 
illustrated in Figure. 6.1. The addition of TGs >30%, as in Miglyol 812® stabilized 
the formation of “mixed micelles”, which remained in a finely dispersed state. The 
tendency of MG to sediment was spontaneous and the more the solution was allowed
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to stand, the more clearly the phases were distinguished (Figure. 6.1). The addition 
of the medium chain oil (mixture of C8~60%  and C)0~40%  of DGs) gradually 
increased the micellar phase, containing MGs and some DGs, and decreased the 
extent of sedimentation of MGs (C8 ~ 90 of mixture of MG and DG). At >30% 
medium chain oil and >50% mixture of mono-, di- and TGs, only two phases were 
seen; the oily phase at the top containing the TG and DG, and the micellar phase 
slightly turbid solution containing MGs and the free fatty acids. In other 
experiments, adding mixtures of glycerides (Imwitor 988®) either to water or tris- 
maleate buffer (pH 7.0), made no difference in terms of solubilization; both caused 
sedimentation of MG in a viscous gel like phase. Adding bile salt and phospholipid 
(lecithin either pure or non-pure) to tris-maleate buffer exhibited the same behaviour 
as when the tris-maleate buffer was used alone (Table 6.2). Adding medium chain oil 
(Miglyol 812®) to water, tris-maleate buffer (pH 7.0) and standard pH-stat solution 
gave two phases. The oily phase is at the top and the rest is clear micellar phase. 
This is explained by the presence of mixed micelles comprising lecithin and bile salt 
was capable of solubilizing TG and DG to an appreciable extent under similar 
conditions to that of the intestine (pH 7.0) (Smith et al, 1976).
In 1963, Hofmann studied the behaviour and solubility of MGs in dilute and micellar 
bile salts solution. He mentioned that 1-monolaurin (C12) behaves as an amphiphile 
in dilute bile solution at 37°C. Its saturation ratio {i.e. micellar MGs/ micellar bile 
salt) is considerably higher than that of l-monomyristin(Ci4). The excess forms a 
viscous, slightly turbid phase which slowly settles; the phase is not birefringent. 1- 
monodecanoin (C10) and 1-monooctanion (Cs) behave similarly to 1-monolaurin. But 
their micellar solubilities are much higher (Hofmann et al, 1963).
One early hypothesis suggested that solutions of amphiphilic MGs and non-polar 
MGs become clear when equilibrated simultaneously with bile salts solution. 
Initially, only the amphiphilic MG can be solubilized to any extent. As its 
concentration in the micelle is increased, the resulting micelle can dissolve 
progressively more of the high melting point MG and remain liquid. However, if the
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3Imwitor 988® (2g) + 
Miglyol 812® (0.8g) in 
simulated intestinal pH- 
stat fluid tlOOmh.
4Imwitor 988® (2g) +
M iglyol 812® (1.2g) in 
simulated intestinal pH- 
stat fluid t50mh.
im w ito r  988® (2g) in 2Imwitor 988® (2g) +
simulated intestinal pH- Miglyol 812® (0.4g) in
stat fluid (50ml). simulated intestinal pH-stat
f l u i d  n O O m h .
Figure 6.1 Represents the fate of MG in simulated intestinal pH-stat fluid. When sufficient monoglycerides were present 
(> 60 %, Imwitor 988®), we observed demulsification and phase separation1, which was dependent on the presence of 
phospholipid and resulted in sedimentation of what was believe to be a phase rich in monoglycerides and water “swollen 
micelle”. The addition of triglycerides (>30%, Miglyol 812®) stabilized the formation of mixed micelles, which remained 
in a finely dispersed state as seen in photographs 2, 3 and 4.
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micelle contains large quantities of low melting point MG, at that point the 
solubilization of a MG becomes competitive. As non-polar MG is added to an 
aqueous bile salt solution, there is usually a change from an isotropic micellar 
solution to a liquid crystalline state. When excess MG is added to bile salts solution, 
a turbid phase appears which contains bile salt, MG, and water, and may form 
birefringence (Lawrence, 1961). The MGs may behave as an amphiphilic or non­
polar solute in bile salts solution depending on the experimental temperature. Body 
temperature is constant 37°C. Therefore, the normal products of pancreatic lipolysis 
are mainly 2-monoglycerides and fatty acids. The 2-monoglycerides will generally 
be unsaturated and, therefore, amphiphilic. Amphiphilic MGs and fatty acids are 
competitively solubilized by bile-salt solutions. Therefore, the intestinal content after 
a meal may be considered as amphiphilic, if the MG and fatty acids are considered as 
a single phase. They will be partitioned between the bile salt micelles and the 
emulsified oil phase; the oil phase containing most of the DG and TGs present in the 
intestinal contents (Borgstrom, 1985).
6.3.2 Phases behaviour o f  lipid excipients and formulations under standard
pH-stat conditions
The physical and chemical nature of the dispersed hydrolytic products of lipid 
excipients and formulations were studied under standard pH-stat conditions in 100ml 
standard pH-stat solution. The following lipid excipients and formulations containing 
hydrophobic drugs (hydrocortisone, testosterone, butyl paraben, and methyl paraben) 
were studied after in vitro lipolysis under standard pH-stat conditions, as described in 
chapter 4. Because the hydrolysis of lipid involves several complex steps of phase 
behaviour, the lipolysis process was stopped after 30 min following addition of 
pancreatin lipase to the simulated intestinal fluid, by adding a methanolic solution of 
a cocktail of enzyme inhibitor, facilitating the possibility of identifying the phases by 
ultracentrifugation. Lipolysis was stopped at 30 min because at this stage at least 
50% of the lipid was digested (chapter 4) which helped the clear detection of the 
phases present.
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A cocktail of enzyme inhibitors was used because no single inhibitor was completely 
effective in inhibiting colipase-dependent pancreatic lipase; hence, a combination of 
diethyl (4-nitrophenyl) phosphate and phenylboronic to inhibit lipase, 
diisopropylfluorophosphate to inhibit carboxyl ester hydrolase Cholesteryl esterase, 
and acetophenone to inhibit pancreatic phospholipase A2, were employed (Hemell et 
al, 1990). Earlier studies by Hofmann and Borgstrom (1964) showed that heating 
intestinal content at 60°C for 10 min completely inhibited lipase activity. They did 
control experiments showing that such heat inactivation or subsequent maintenance at 
70°C for 1 hour did not alter the glyceride or fatty acid composition of intestinal 
content. Later, experiments were performed showing increased release of FA from 
heated intestinal contents. The source was predominantly TG (Porter et al, 1971). 
Heating would enhance lipase activity, and TG would be hydrolyzed rapidly.
Another source of fatty acid was lecithin. In human intestinal contents, there is a 
pancreatic phospholipase which hydrolyzes lecithin to 1-acyl lysolecithin. The 
lecithinase is stable at 70°C. Therefore, even if pancreatic lipase as instantaneously 
inactivated in a sample of intestinal contents, there would be perturbations in 
phospholipid composition which might affect micellar size and alter lipid 
solubilization (Porter et al, 1971).
Centrifugation time had some impact on the apparent phase behaviour but generally 
only led to differences in the relative phase volumes, especially of the subphases and 
the interfacial phases. The greater the centrifugal time, the closer was the micellar 
phase boundary to that of the subphase, indicating a relative increase in micelle-to- 
vesicle ratios (Staggers et al, 1990). Figure 6.2 shows that with increasing time of 
centrifugation the white layer increased and sedimented leading to interference with 
the viscous gel-like layer at the bottom of the tube.30min centrifugation at 104630
The centrifuged samples were distinguished into oils, interfaces, sub-phase, gel-like 
viscous layer and precipitates (pellets); these are arbitrary distinctions that follow 
literature usage (Carey et al, 1983). Although the phases were ultracentrifuged, they
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Surfactant- free formulation 
(4g) + 1%  w/v hydrocortisone 
digested for 20 min under 
standard pH-stat conditions.
Surfactant- free formulation 
(4g) + 1%  w/v hydrocortisone 
digested for 20 min under 
standard pH-stat conditions 
and centrifuged at 104630 g 
for 10 mins.
Surfactant- free formulation 
(4g) + 1%  w/v hydrocortisone 
digested for 20 min under 
standard pH-stat conditions 
and centrifuged at 104630 g 
for 20 mins.
Surfactant- free formulation 
(4g) + 1%  w/v hydrocortisone 
digested for 20 min under 
standard pH-stat conditions 
and centrifuged at 104630 g 
for 30 mins.
Figure 6.2 The effect of centrifugation time on the phase separation. There were generally difference on the relative phase 
volume especially the subphase and the interface. The greater the centrifugal time, the closer to the micellar phase (subphase) 
boundary to the interface, indicating a relative increase in micelle-to-vesicle ratios. Therefore, 30mins centrifugation at 104630 
g was chosen as a standard for most samples so that direct comparison could be made.
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were not true homogenous phases, due to collection difficulties as described in 
methods (6.2.2.3) (Hernell et al, 1990).
The phases of lipid excipients and formulations were described below under the 
conditions mentioned before (section 6.2.2.2 and 6.2.23):
• Long chain TG (Corn oil)
Oily layer at the top (6-8ml) followed by milky, thick solution, believed to be 
micellar phase (<88ml).
• Medium chain TG (Miglyol 812®)
Oily layer at the top (4-6ml) followed by clear to slightly turbid solution, 
(<80ml) with some precipitates at the bottom of the tube.
• Mixed mono-, di-, and tri-glycerides (Imwitor 988®)Oily layer at the top
(2^tml) followed by a clear micellar phase (<38ml) and then viscous gely 
structure at the bottom (<50ml).
• Type II (Miglyol 812®: Tagat TO®)
(40%: 60%)
Micellar phase (subphase), white to slightly turbid was identified (<55%) 
followed by condensed thick layer at the bottom full of some pellets (>35%). 
An interface can be identified.
• Type III A (Imwitor 988® + Miglyol 812® + CRH 40®)
(35%+ 35% + 30%)
The solution was a clear micellar solution (subphase) (<90%) with some 
pellet at the bottom of the tube. The top of the solution (interface) (5-8ml) 
was more transparent than the micellar phase.
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• Type III B ({Imwitor 988® + Miglyol 812® / 9:1}+ CRH 40® + PG)
(35%+ 35% + 30%)
The micellar solution (subphase) was clear (100ml).
• Surfactant-free formulation (Miglyol 812® + Imwitor 988® + PG)
(30%+50%+ 20%)
At the top, interface (2-3ml) was slightly clear than the rest of the micellar 
solution (<45%) followed with subphase (micellar phase) (>50%).
• Mixture of mono-, di-, and tri-glycerides (Imwitor 988®) and MCT 
(Miglyol 812®) (50% + 50%)
Slightly oily layer at the top (3-4 ml) followed by a slightly interface (1- 
2 ml). The micellar solution (subphase) was clear (>50ml) followed by a 
viscous gel- like phase (<30 %).
• Mixture of mono-, di-, and tri-glycerides (Imwitor 988®) and MCT 
(Miglyol 812®) (30% + 70%)
Oil layer was at the top (5-7 ml) followed by slightly turbid thick solution 
with pellet at the bottom (>90 ml).
• Mixture of mono-, di-, and tri-glycerides (Imwitor 988®) and MCT 
(Miglyol 812®) (70% + 30%)
Slightly oily layer at the top (1-2 ml) followed by interface (1-2 ml). 
Micellar solution (subphase) was clear transparent (<20ml) followed by 
viscous gel-like phase (swollen micellar) (>70 ml).
• Mixture of mono-, di-, and tri-glycerides (Imwitor 988®) and MCT 
(Miglyol 812®) (50% + 30%)
Slightly oily layer at the top (1-2 ml) followed by interface (8-12ml). 
Micellar solution (subphase) was clear transparent (<70ml).
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6.3.3 Phase analysis o f hydrophobic drugs in lipid excipients and
formulations under standard pH-stat conditions.
The drug uptake in each lipid excipient and/or SEDDS formulations and mixtures of 
glycerides was analysed by HPLC after ultracentrifugation at 106430 g for 30 min. 
The concentration g %w/v of each drug in each phase of lipid excipients, SEDDS 
formulations, and mixture of glycerides were summarized in Appendix 3. It can be 
seen from the data that there was no significant difference in the distribution of the 
drug in each phase after 5 min or 30 min ultracentrifugation as shown in Figures 6.6-
6.16. Therefore, the drug concentration distributed in the phases was discussed based 
on ultracentrifugation 106430g for 30 min.
• Lipid excipients
As mentioned earlier a series of in vitro lipolysis experiments using 4 g of LCT (Com 
oil®), MCT (Miglyol 812®), and mixture of mono-, di-, and tri-glycerides (Imwitor 
988®) under standard pH-stat conditions was performed and quenched 30min after 
addition of pancreatin enzyme by adding cocktail of pancreatin enzyme inhibitor.
Following ultracentrifugation of LCT, two phases were observed, an oily phase at the 
top, followed by milky turbid phase crude emulsion as shown in Figure 6.3. The 
presence of a similar white pasty phase has been noted previously in potassium oleate 
systems in the absence of bile salt over a pH range of approximately 7.0-8.0, which 
was thought to be a metastable cubic phase water in oil lattice (Cistola et al, 1988). 
The oily phase in these studies comprised primarily of triglycerides and diglycerides 
with small amounts of monoglyceride and fatty acid. The white precipitated pellet 
contained fatty acid. In the presence of fasted bile salt concentrations, a larger 
proportion of the fatty acid and monoglyceride was distributed into the aqueous 
phase, but the relatively high lipid/bile salt mole ratios resulted in the production of a 
turbid aqueous phase, presumably indicating the presence of incompletely micellar- 












Model A Model B
Oily phase
Interface
^  Upper subphase
^  Mid subphase
Lower subphase




Figure 6.3a Schematic model of a typical sample of distal duodenal contents 
following ultracentrifugation as described by Hemell et al (1990), model A. Model B 
a representative model of the in vitro lipolysis under standard pH-stat conditions 
following ultracentrifugation throughout the research.
LCT (Com oil) MCT (Miglyol 812®)
Figure 6.3b Representative example of the fate of LCT (Com oil) and MCT 
(Miglyol 812®) under standard pH-stat conditions after ultracentrifugation 
106430 g for 30 mins in simulated intestinal pH-stat solution.
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vesicular structures (Sek et al, 2002). At higher bile salt level i.e. fed state the 
aqueous phase become less turbid, reflecting improved micellar solubilization.
For LCT (Com oil®), the distribution of the drugs in each phase was similar. More 
than 80% of the drug was in the milky turbid phase. The reminder was in the oily 
phase. The mass balance where the concentration of the drug in 4 g of lipid 
excipients, SEDDS formulation and mixture of glycerides in 100ml standard pH-stat 
solution was different for each drug in each lipid excipients and/or lipid formulations. 
Therefore, the concentration of drug in each phase was different. In Figures 6.5 and 
6.6 respectively showed that the concentration of butyl paraben (BP) (Log P 3.3, 
Mwt = 194.2) in the milky turbid phase was 0.081 g%, while testosterone (Log P 3.7, 
Mwt = 288.4) was 0.007lg%. A similar order can be seen with dmgs with log P <2. 
For example, Figures 6.7 and 6.8 respectively showed that hydrocortisone 
concentration was 0.0261 g % and methyl paraben concentration was 0.0808 g%. 
The molecular weight of the drug and the partition coefficient play a major role in the 
distribution of the drug. The concentration of the BP in the oily layer was 0.079 g% 
and MP was 0.0425 g% w/v as shown in Figures 6.5 and 6.8 respectively. The 
solubility of steroids was lower than hydroxy benzoate derivative because of the high 
molecular weight 0.0005 g% for hydrocortisone and 0.004 g% for testosterone.
In the case of MCT (Miglyol 812®) the distribution of the dmg was different from the 
corresponding LCT system because of the presence of an oily phase at the top 
followed by slightly turbid phase micellar or subphase and some pelleted material at 
the bottom as shown in Figure 6.3. Recently, Sek et al (2002) mentioned that 
compared with long chain lipolytic products, a significantly higher proportion of the 
medium chain lipolytic products dispersed into the aqueous phase, approximately 
80%. The aqueous phase comprising approximately lOOmM fatty acid and 20 mM 
MG, obtained after MCT digestion in the absence of bile salt was turbid, suggesting 
the presence of larger colloidal structures, whereas, at increasing bile salt 
concentrations, the turbidity was reduced, indicating improved solubilization of the 
lipolytic products into mixed micelle (Sek et al, 2002). The concentration of BP in
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micellar phase was 0.096 g%, while the testosterone was 0.0164 g% as shown in 
Figures 6.5 and 6.6 respectively. A similar observation was noticed for 
hydrocortisone 0.0087 g% and MP 0.012 g%, as shown in Figures 6.7 and 6.8 
respectively. The percentage of drug dissolved in the oily phase of MCT was higher 
than in LCT. This could be explained by the volume of the oil phase which being 
higher in LCT than in MCT after ultracentrifugation; therefore, the drug would be 
more diluted. Besides, the original solubility of each drug in MCT was much higher 
than in LCT (Chap. 2). For example, the concentration of the BP in the oily phase of 
MCT was 0.093 g% while in the oily phase of LCT was 0.0791 g% as shown in 
Figure 6.5. MP concentration was 0.066g% in the oily phase of MCT and 0.0425 g% 
in the oily phase of LCT as shown in Figure. 6.8. In the presence of LCT (com oil), 
more than >65% w/v of the drug remained in the aqueous micellar phase. On the 
contrary, MCT (Miglyol 812®) was not capable of maintaining more than 30%w/v of 
the dmg in solution. After ultracentrifugation lumps was noticed on the wall of the 
centrifuge. The precipitate phase was thought to be calcium soaps. Therefore, 
experiments were done in the absence of calcium using MCT as a substrate. 
Surprisingly, the precipitate was still found after centrifugation as well as the lumps. 
As a result, these lumps were thought to be a mixture of undigested MG and DG 
precipitated due to an excess centrifugation.
In the case of mixtures of mono-, di-, and tri-glycerides (Imwitor 988®), four phases 
were distinguished; an oily phase at the top followed by the micellar phase, followed 
by the viscous gel-like structure believed to be monoglycerides and some pellet at the 
bottom. In contrast to MCT digests, the aqueous phase (comprising lOOmM Cs/Cio 
fatty acid only) obtained after Cg/Cio MG/DG digestion was clear even in the absence 
of bile salt (Sek et al, 2002). The turbidity present in the MCT digests results from 
the presence of MG and is consistent with the relatively low aqueous solubility of 
monodecanoin in the absence of bile salt (approximately 4mM in sodium phosphate 
buffer), but increased solubility in the presence of bile salt (1 ImM in 4mM NaTDC) 
(Hofmann, 1963). The clarity of the aqueous phase obtained after digestion mixed
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mono-, di-, and tri-glycerides suggested that substantial quantities of lamellar phase 
were not formed or were pelleted out during centrifugation under these 
circumstances. This may reflect the higher proportion of Cs fatty acid resulting from 
the digestion of Capmul MCM® or Imwitor 988® e.g. Capmul MCM glycerides 
contain 17% 80% Cg and 18.3% Cio fatty acids when compared with Miglyol 812®
comprising 0.23% C6,59.5% Cg, 39.8% Cio, 0.24% C 1 2 .
In comparison with long chain lipid digestion, the higher rate and extent of digestion 
and greater aqueous phase distribution of medium chain lipolytic products may be 
attributed to several factors including solubility, hydrophilicity and phase behaviour. 
Medium chain fatty acids are ionised to a greater extent (apparent pK* 6.8) than long 
chain fatty acids (pK^ 8-8.5) at physiological pH, therefore increasing solubility and 
amphilicity and enhancing the potential for formation into bile salt micellar system 
(Cistola et al, 1988). Furthermore, the aqueous solubility of medium chain digestion 
products is significantly higher than that of long chain digestion products. For 
example, the aqueous solubility of decanoic acid is approximately 25pM whereas the 
solubility of oleic acid is approximately 1 pM. Partial ionisation of medium chain 
fatty acids may also lead to the production of stable fatty acidI fatty acid soap 
lamellar phases (Cistola et al, 1988), the formation which may encourage aqueous 
dispersion of medium chain lipid digestion products even in the absence of bile salt. 
Medium chain lipolytic products therefore rapidly dissociate from the digesting 
interface forming either a simple solution or colloidal dispersion, or may precipitate 
as soaps. This is in contrast to long chain systems where removal of lipolytic 
products is limited by the concentration of the bile salt, and the solubilization 
capacity of the digestion media.
Surprisingly, at least 70% of the drug was dissolved in the viscous gel-like phase. 
The fate of the drug could be precipitation because MG and FA could be absorbed 
through passive diffusion leaving the drug to precipitate. Therefore, having more 
than 50% of MG in formulation is undesirable. Less than 20% of the drug was 
dissolved in micellar phase as shown in Figures 6.5-6.8. The solubility of BP in the
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viscous gel-like phase 0.151 g% and for MP was 0.362 g%. However, in the micellar 
phase of mixed mono-, di- and tri-glycerides, the solubility of BP was 0.016g% and 
for MP was 0.076g%. The same trend can be applied for hydrocortisone, in the 
viscous gel-like phase the solubility was 0.0238 g% i.e.% drug recovered >80% and 
in the micellar phase was 0.0075g%.
• Mixtures o f  mono-, di-, and tri-glycerides and medium chain fatty acids
Other experiments were performed using different mixtures of medium-chain fatty 
acids oil (Miglyol 812®) added to mixture of mono-, di- and tri-glycerides under the 
same conditions. At a ratio of 30:70/ M 812®: I 988®, the phases were identified as 
for the mixtures of mono-, di-, triglycerides only. At least 80% of the drug was in the 
viscous gel phase as shown in Figures 6.9-6.12. The viscous gel-like phase was not 
identified at a ratio of 30:70/ M 812®: I 988®. The volume of the viscous gel-like 
phase in 30:70 ratio of M 812®: I 988® would be higher than at the other ratio. 
Therefore, the concentration of the drug in the micellar and pelleted phase in 30:70 
ratio of M 812®: I 988® would not be more than 15% each. Figures 6.9 and 6.10 
showed that the concentration of BP in the micellar phase and in the precipitate was 
0.021 g% and 0.065g% and testosterone was 0.0026 g% and 0.0075 g%. The 
concentration of hydrocortisone is 0.02599 g% and 0.0649 g% and MP in the 
micellar and pelleted phase is 0.071 g% and 0.023 g% as shown in Figures 6.1 land 
6.12 respectively. The concentration of BP in viscous gel-like phase of 70:30/1988®: 
M812® ratio is 0.160g%, and for testosterone is 0.0401 g% respectively (Figures 6.9 
and 6.10). The same observation was made for hydrocortisone 0.1504 g% and for 
MP 0.302 g%.
On the contrary, the ratio 70:30/ M812®:1988® resulted in three phases oily phase at 
the top followed by mixtures of interface and subphase and pellet phase at the bottom. 
The distribution of the drug between the phases was drug dependent. The drug was 
concentrated in the interface. The concentration of hydrocortisone was 0.0599 g% 
and 0.316 g% for MP. Testosterone and BP were more concentrated in subphase
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0.0233 g% and 0.066g% respectively. On some occasions, it was difficult to extract 
the oily phase because of its small volume compared to the other phases.
Other ratios were tested 50:50/M 812®: 1988®. The phases observed after 
ultracentrifugation were an oily phase at the top followed micellar phase, and a 
viscous gel-like phase. The volume of the subphase was >40% of the total volume 
and the viscous gel phase was <20%. Although the volume of the micellar pha* 2 0 4  
higher than the viscous gely phase, the drug was highly concentrated in viscous gti 
phase. For example, the concentration of hydrocortisone in the micellar phase and 
viscous gel-like structure was 0.0287 g% and 0.215 g% respectively. The 
concentration of MP in interface and gel-like phase was 0.016 g% and 0.377 g% 
respectively. Similarly, for BP the solubility in interface and gel-like phase is 
0.0287 g% and 0.215 g% respectively and for testosterone is 0.0021 g% and 
0.0235 g% respectively (Figures. 6.9-6.12).
Another mixture was tested. The ratio of M 812®:I 988® was 62.5:37.5 (5:3), the 
same as in S-F formulations. Only two phases were observed; an interface phase and 
the rest was a clear micellar phase with some pellet. More than 80 % of the drug was 
concentrated in the micellar phase (subphase). Therefore, it can be concluded that for 
every 5 parts mixture of mono-, di- and tri-glycerides, 3 parts of medium chain fatty 
acid oils are needed to get the micellar solution (Figures. 6.9-6.12). For example, the 
concentration of BP was 0.229g% and for hydrocortisone was 0.0223 g%. The same 
trend observed for MP was 0.301 g% and for testosterone was 0.0365 g%.
• SEDDS formulations
The physico-chemical behaviour of the SEDDS formulation under standard pH-stat 
conditions was dependent on the contents of the formulations; therefore, the 
distribution of the drug would be expected to vary. As the hydrophilic content 
(surfactant, HLB >12 and co-solvent) increased, the micellar phase would be more
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prevalent for example after the dispersion and digestion of Type III B formulations. 
Type III B contained at least 40% hydrophilic surfactant (HLB>12) and >40% 
hydrophilic cosolvent. After ultracentrifugation only a clear micellar phase was 
apparent with 100% of the drug dissolved in this phase as shown in Figures.6.13-
6.16. For example, BP concentration was 0.459 g%, 0.0527 g% for testosterone, 
0.0372 g% for hydrocortisone, and 0.534 g% for MP (Figures 6.13-6.16 
respectively).
When type III A formulation was investigated where the concentration of the 
hydrophilic content was <45% (surfactant, HLB >12 and co-solvent), three phases 
can were apparent after ultracentrifugation. An interface phase at the top followed 
by a micellar phase and a pellet at the bottom. For almost all drugs, at least 50% of 
the drug dissolved in the subphase (micellar phase) and interface.
For example, the BP concentration was 0.213 g% in the micellar phase, 
hydrocortisone was 0.0193 g% and methyl paraben was 0.382 g% as shown in 
Figures 6.13, 6.15 and 6.16 respectively. Figure 6.14 showed that the concentration 
of testosterone was 0.0493g% in the interface. However in the case of type II where 
at least 40% medium chain fatty acids (M 812®) were mixed with hydrophilic 
surfactant (TTO®, HLB <12) <50%, four phases can be distinguished. At least 50% 
of the drug was dissolved in the micellar phase. For example, Figures 6.13 and 6.14 
showed that the concentration of BP was 0.189 g% and 0.0296 g% for testosterone 
respectively. On the other hand, hydrocortisone and MP were more concentrated in 
the interface 0.030lg% and 0.292 g% respectively as shown in Figures 6.15-6.16.
S-F formulation produced three layers after ultracentrifugation, interface at the top, 
followed by subphase and precipitate. More than 50% of the drug was dissolved in 
the subphase and less than 20% in the interface. For example, the concentration of 
BP in micellar and precipitate was 0.240 g % and 0.132 g % respectively and for 
testosterone was 0.042 g % in micellar phase and 0.0018% in precipitate. The same
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trend was observed for hydrocortisone 0.0194 g % and 0.0054 g % respectively. For 
MP the corresponding concentration was 0.396g% in the micellar phase.
6.4 Discussion
The above results indicate that the micellar hypothesis of fat absorption may not 
apply directly to all formulations. Its general principles are appropriate but the 
description which was presented 20 years ago was an oversimplification. The 
floating oil phase contained mostly unhydrolyzed TGs and DGs. The oil phase was a 
very small fraction of simulated intestinal contents with respect to volume in these 
experiments (Hofmann et al, 1964). Therefore, the concentration of the hydrophobic 
drugs was small compared with the other phases <10%. By chemical and phase 
analyses, Carey and his co-workers (1990) defined the floating phase (oil phase) that 
was comprised of oil-in-water emulsion particles with cores of TG, DG, and 
cholesteryl esters (CE) emulsified with a surface coat of partially ionised fatty acids 
(FA), MG, diacylphosphatidylcholine (PL) and bile salts. The turbid aqueous phase 
(micellar) contained mainly MGs and fatty acids with small amounts of TGs and 
DGs. The aqueous or ‘micellar’ phases can include at least two different aggregates: 
mixed disc-like micelles (multilamellar) saturated with lipolytic product and 
liposomes (unilamellar vesicles with hydrodynamic radii = 200-600 A). Usually, in a 
static system, these different phases are in equilibrium with the micellar phase and are 
interconvertible.
In the intestinal contents, mixed lipids are formed by lipolysis at the same time as 
they are mixed with bile. The physical condition of lipids of bile is therefore of 
interest for the interactions. Concentrated bile, as it exists in the gall bladder is in the 
form of mixed bile salt-lecithin micelles in isotropic solution with particle size 40 -  
60 A (Amsejoe/1 al, 1969; Borgstrom, 1985). On dilution, the micellar bile salt 
concentration decreases with spontaneous growth in micellar size until the phase limit 
is reached and liposomal aggregates are formed. Hepatic bile exhibited similar 
behaviour which also can be predicted to form large mixed-disc micelles folding into
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vesicles with particles of hydrodynamic radii of ~ 350 A (Arnsejo et al, 1969; 
Borgstrom, 1985). Hernell and co-workers showed by quasielastic light scattering 
(QLS) analysis of the components of subphases, that much larger proportions of 
lipids were solubilized by micelles than were dispersed as unilamellar vesicles. 
When followed as a function of time, vesicles frequently dissolved spontaneously 
into mixed micelles, indicating that, in the non-equilibrium in vivo conditions, the 
constituent’s micellar phase was often not saturated with lipids. In an environment 
rich in of bile salts, unilamellar vesicles probably represent the primary dispersed 
product of human fat digestion and facilitate the dissolution of lipolytic products into 
unsaturated mixed micelles (Hernell et al, 1990). In nature, human intestinal contents 
are in a metastable state so that unilamellar vesicles of the subphases are likely to be 
appreciably smaller than the sizes predicted by 5-7 day equilibrium of the model 
systems. These vesicles often spontaneously dissolved into mixed micelles over 
time, strongly suggesting that they did not originate from supersaturated mixed 
micelles, in which case they would have been expected to grow in size (Staggers et 
al, 1990).
The turbidity and heterogeneity of the micellar phase seen here may have been due to 
low total lipid concentration in relation to the bile salt concentration (Borgstrom, 
1985). Turbidity is known to occur when large liposomes are present and other 
aggregates form with a density close to that of the micellar solution. In the absence 
of sufficient bile salt and phospholipid, the micellar phase may contain liquid 
crystalline structures or other phases such as inversed L2 micelles containing fatty 
acids and MGs.
The present study shows the importance of MG, at low relative bile salt 
concentration, which may lead to the formation of liquid crystalline phases and 
optically isotropic L2 phase. The latter phase could be expected to be one of the 
major phases found in human intestinal content after administration of formulations 
rich in MGs. The presence of L2 is of interest because it is rich in hydrocarbon 
content and has properties resembling those of the oil phase. It may act to help
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disperse the oil phase, increasing the velocity of lipolysis. In other studies performed 
for the present study, the solubility of DG and TG in bile salt solution was found, by 
contrast, to be extremely low. Excess DG and TG separated as an emulsion, but the 
emulsion contained undissolved DG or TG and did not contain bile salt or water. If 
moderate concentrations of DG and TG were present in intestinal content, these lipids 
should exist in the form typical emulsion droplets. Therefore, all the lipids present in 
intestinal contents are present either as emulsified droplets and the liquid phase 
between the droplet is ionic and non-micellar, or as an emulsified oil phase coexisting 
with a micellar phase (Hofmann et al, 1964). In the presence of calcium and 
insufficient amount of bile salts, the ‘crusty’ crystalline phase (most likely 
comprising insoluble Ca2+-fatty acid soaps) may form pellets (precipitate). Pelleted 
lipids originated directly from the emulsifiers on the surface of the emulsion. Both 
unilamellar vesicle phase and a micellar subphase may be critically dependent upon a 
micellar bile salt concentration for both solubilization and multilamellar—►unilamellar 
vesicle transformation (Staggers et al, 1990).
In some of the model systems studies here, an unexpected phase sedimented to the 
bottom of the tube as demonstrated in Figure 6.3. This was a viscous gel, believed to 
contain MGs and fatty acids. This unexpected phase separation is likely to have a 
considerable effect on the fate of drug dissolved in such formulations. Mixed mono- 
and di-glycerides are often good solvents for hydrophobic drugs and are used to 
increase the solvent capacity of lipid formulations. Our results suggest that use of 
high concentrations of MGs may be disadvantageous and could result in precipitation 
of drug.
Clearly, in view of the experimental findings described in this section, these results 
are compatible with the proposed model of the physical-chemical steps in fat 
digestion as shown in Figure 6.4 (Hernell et al, 1990; Embleton et al, 1997). In many 
adult humans, biliary lipids are mixed with pancreatic lipase/colipase complex, and 
together adsorb to the crude DG and TG surfaces, entering from the stomach. Lipase 
and colipase are secreted in equimolar proportions, giving duodenal concentrations of
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~ 1-2 x 1 O'7 M. They can release 150-300 pmoles of Sn-1 and Sn-3 long-chain fatty 
acids/min/ml of intestinal fluid (Carey et al, 1983). Biliary lipids, which may be a 
two-phase micelle-plus-vesicle system, stabilize the emulsion particles and reduce the 
emulsions sizes (Carey, 1983). The partially ionized FA normally enhances 
emulsification, these promoting binding of colipase-lipase complex to the emulsion 
surface and MG (Borgstrom, 1980). During lipolysis, lipids products, which may 
enhance the emulsification process, will locate mainly at the emulsion surface, as 
multilamellar liquid crystalline bilayers (Carey, 1988). As the lipolysis proceeds, the 
core of the emulsion droplet shrinks and parts of the surface coat pinch off as large 
liquid-crystalline structures (Hernell et al, 1990; Embleton et al, 1997). Postprandial' 
gall bladder emptying causes a transient elevation in total bile acid concentration to 
1 3 - 4 6 m M  (Carey et al, 1983). Continuous production of unsaturated BS will 
catalyse the formation of small unilamellar vesicles from multilamellar liposomes and 
a two-phase system of vesicles and mixed micelles. Unilamellar vesicles (single­
shelled liposomes) and micelles coexist in the aqueous-rich portion of duodenal 
contents and are readily dispersed in unsaturated BS into intestinal mixed micelles 
(Hernell et al, 1990; Embleton et al, 1997) (Figure 6.4). The structure of these large 
mixed micelles may be similar to, but larger than, that of the mixed disc model of BS- 
LC micelles (Carey et al, 1983). The intestinal absorption of FA, MG, Ch and other 
dietary and biliary lipids is probably in the form of micelles due to their large number 
and unexpectedly small size thereby giving more rapid diffusive access to the 
mucosal surface. However, absorption could take place from unilamellar and, 
perhaps, even multilamellar vesicles (Hernell et al, 1990). Therefore, saturation of 
mixed micelles by unilamellar vesicles produces the most favourable thermodynamic 
condition for maximizing lipid absorption rates from the upper small intestine; 
further; lipolytic products dispersed as uni-and multilamellar vesicles may explain the 
slow, but efficient, fat absorption that takes place from the entire small intestine in 
BS-deficiency cases. Lipid digestion products pass across the intestinal unstirred 
water layer. For LCT and cholesterol, passage across the unstirred water layer is rate 
limiting, whereas the brush border membrane limits passage of short-and medium
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Figure 6.4 Composite and simplified model of the physicochemical changes in 
duodenal content digestion. Postprandial duodenal contents exposed to lipase- 
colipase adsorb to the surface of crude emulsion particles entering the duodenum 
from the stomach. Lipolytic products in great excess on the emulsion surface lead to 
shrinking of the core of the oil and building up of FA, PL, and MG with enormous 
surface pressure. Surface pressures cause dissociation of multilayers of lamellae 
from the surface, which bud off as unilamellar vesicles. Subsequently they are 
solubilized by bile to form mixed micelles (Carey, 1983; Hernell et al, 1990, and 
Embleton et al, 1997).
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chain fatty acids. Within the unstirred layer, an acidic microclimate aids micellar 
dissociation so that protonated, and to a lesser extent, non-protonated monomers then 
pass across the intestinal brush-border membrane (Thomson et al, 1993).
6.5 Conclusion
The previous observations provide a fundamental framework for understanding the 
physical-chemical state of the fate of lipid excipients and/or SEDDS formulations in 
standard pH-stat solution under standard pH-stat conditions. The data obtained here 
has been correlated to the study on the upper intestinal contents reported by Staggers 
et al (1990) and agrees with their findings. However, a new viscous gel-like phase 
was identified; believed to comprise monoglycerides. This unexpected phase 
separation may have a considerable effect on the fate of drug dissolved in some 
formulations. The ability of lipid digestion products to keep the drug in solution is 
highly dependent on the physico-chemical properties of lipid themselves. Bile acid 
solubilization results in mixed micelles and liposomes, gel and liquid crystal phases.
Type III B can be a good solvent for both steroids and hydroxy benzoate derivatives 
after lipolysis because of the production of micellar phase (subphase). Therefore, the 
drug will be ready for absorption. The other SEDDS formulations they produced a 
precipitate after lipolysis which may entrapped a considerable amount as in case of 
hydroxy benzoate derivatives. The presence of bile salts was necessary in case of 
type I, II and S-F formulation to enable the formation of mixed micellar phase.
MCT lipolytic products are mainly subphase and precipitate. The fate of hydrophobic 
drugs in MCT could be absorption through the mixed micellar phase rather than 
precipitation as in case of hydroxy benzoate derivatives. However, in case of steroids 
the fate of the drug is uncertain because of their low solubility. The presence of gel­
like phase after the lipolysis of mixed mono-, di-, and tri-glycerides entrapped a 
significant amount of the hydrophobic drugs. The fate of the drug in gel-like phase 
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Figure 6.5 Determination the fate of butyl paraben in lipid excipients (LCT{Com
(8)oil}, MCT {Miglyol 812 }, and mixture of mono-, di-, and tri-glycerides {Imwitor 
988®}) phases after digestion for 30 min under standard pH-stat conditions (4 g of 
lipid excipients in the presence of 6 TBU / mg pancreatin enzyme in tris-maleate 
buffer (pH 7.0) in the presence of 15 mM NaTDC and 3.75 mM PL at 37°C). 
Samples were analysed using HPLC method after ultracentrifugation (104630 g). 
LCT (Corn oil) and MCT (Miglyol 812®) were repeated under the same standard pH- 
stat conditions in the absence of calcium (the error bars represent the standard 
deviation of three experiments).
• 5 min = samples were ultracentrifuged at 104630 g for 5 min at 37°C.
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Figure 6.6 Determination the fate of testosterone in lipid excipients (LCT{Com oil}, 
MCT (Miglyol 812®}, and mixture of mono-, di, and tri-glycerides (Imwitor 988®}) 
phases after digestion for 30 min under standard pH-stat conditions (4 g of lipid 
excipients in the presence of 6 TBU / mg pancreatin enzyme in tris-maleate buffer 
(pH 7.0) in the presence of 15 mM NaTDC and 3.75 mM PL at 37°C). Samples were 
analysed using HPLC method after ultracentrifugation (104630 g) for 30 min (the 
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Figure 6.7 Determination the fate of hydrocortisone in lipid excipients (LCT{Com
(S)oil}, MCT (Miglyol 812 }, and mixture of mono-, di-, and tri-glycerides (Imwitor 
988®}) phases after digestion for 30 min under standard pH-stat conditions (4g of 
lipid excipients in the presence of 6 TBU / mg pancreatin enzyme in tris-maleate 
buffer (pH 7.0) in the presence of 15mM NaTDC and 3.75 mM PL at 37°C). 
Samples were analysed using HPLC method after ultracentrifugation (104630 g) (the 
error bars represents the standard deviation of three experiments).
• 5 min = samples were ultracentrifuged at 104630 g for 5 min at 37°C.
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Figure 6.8 Determination the fate of methyl paraben in lipid excipients (LCT{Com
(5)oil}, MCT {Miglyol 812 }, and mixture of mono-, di, and tri-glycerides {Imwitor 
988®}) phases after digestion for 30 min under standard pH-stat conditions (4 g of 
lipid excipients in the presence of 6 TBU / mg pancreatin enzyme in tris-maleate 
buffer (pH 7.0) in the presence of 15 mM NaTDC and 3.75 mM PL at 37°C). 
Samples were analysed using HPLC method after ultracentrifugation (104630 g) for 
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Figure 6.9 Determination the fate of butyl paraben in mixtures of MCT (Miglyol 
812) and mixtures of mono-, di-, and tri-glycerides (Imwitor 988 ) (table 6.1) phases 
after digestion for 30 min under standard pH-stat conditions (4 g of lipid excipients in 
the presence of 6 TBU/mg pancreatin enzyme in tris-maleate buffer (pH 7.0) in the 
presence of 15mM NaTDC and 3.75 mM PL at 37°C). Samples were analysed using 
HPLC method after ultracentrifugation (104630 g) (the error bars represent the 
standard deviation of three experiments).
• 5 min = samples were ultracentrifuged at 104630 g for 5 min at 37°C.
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Figure 6.10 Determination the fate of testosterone in mixtures of MCT (Miglyol 
812®) and mixtures of mono-, di-, and tri-glycerides (Imwitor 988®) (table 6.1) 
phases after digestion for 30 min under standard pH-stat conditions (4 g of lipid 
excipients in the presence of 6 TBU / mg pancreatin enzyme in tris-maleate buffer 
(pH 7.0) in the presence of 15mM NaTDC and 3.75 mM PL at 37°C). Samples were 
analysed using HPLC method after ultracentrifugation (104630 g) for 30 min (the 
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turbid phase) phase) phase
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F igure 6.11 Determination the fate of hydrocortisone in mixtures of MCT (Miglyol 
812®) and mixtures of mono-, di-, and tri-glycerides (Imwitor 988®) (table 6.1) 
phases after digestion for 30 min under standard pH-stat conditions (4 g of lipid 
excipients in the presence of 6 TBU / mg pancreatin enzyme in tris-maleate buffer 
(pH 7.0) in the presence of 15mM NaTDC and 3.75 mM PL at 37°C). Samples were 
analysed using HPLC method after ultracentrifugation (104630 g) (the error bars 
represent the standard deviation of three experiments).
•  5 min = samples were ultracentrifiiged at 104630 g for 5 min at 37°C.
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Figure 6.12 Determination the fate of methyl paraben in mixtures of MCT (Miglyol 
812®) and mixtures of mono-, di-, and tri-glycerides (Imwitor 988®) (table 6.1) 
phases after digestion for 30 min under standard pH-stat conditions (4 g of lipid 
excipients in the presence of 6 TBU / mg pancreatin enzyme in tris-maleate buffer 
(pH 7.0) in the presence of 15mM NaTDC and 3.75 mM PL at 37°C). Samples were 
analysed using HPLC method after ultracentrifugation (104630 g) for 30 min (the 
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Figure 6.13 Determination the fate of butyl paraben in SEDDS formulations (table
6.1) phases after digestion for 30 inin under standard pH-stat conditions (4 g of lipid 
excipients in the presence of 6 TBU / mg pancreatin enzyme in tris-maleate buffer 
(pH 7.0) in the presence of 15mM NaTDC and 3.75 mM PL at 37°C). Samples were 
analysed using HPLC method after ultracentrifugation (104630 g) (the error bars 
represent the standard deviation of three experiments).
• 5 min = samples were ultracentrifuged at 104630 g for 5 min at 37°C.
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Figure 6.14 Determination the fate of testosterone in lipid excipients in SEDDS 
formulations (table 6.1) phases after digestion for 30 min under standard pH-stat 
conditions (4 g of lipid excipients in the presence of 6 TBU / mg pancreatin enzyme 
in tris-maleate buffer (pH 7.0) in the presence of 15mM NaTDC and 3.75 mM PL at 
37°C). Samples were analysed using HPLC method after ultracentrifugation 


















Oily phase Interface (slightly Subphase (micellar Pellet phase
turbid phase) phase)
Figure 6.15 Determination the fate of hydrocortisone in SEDDS formulations (table
6.1) phases after digestion for 30 min under standard pH-stat conditions (4 g of lipid 
excipients in the presence of 6 TBU / mg pancreatin enzyme in tris-maleate buffer 
(pH 7.0) in the presence of 15mM NaTDC and 3.75 mM PL at 37°C). Samples were 
analysed using HPLC method after ultracentrifugation (104630 g) (the error bars 
represents the standard deviation of three experiments).
• 5 min = samples were ultracentrifuged at 104630 g for 5 min at 37°C.
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Figure 6.16 Determination the fate of methyl paraben in SEDDS formulations (table
6.1) phases after digestion for 30 min under standard pH-stat conditions (4 g of lipid 
excipients in the presence of 6 TBU / mg pancreatin enzyme in tris-maleate buffer 
(pH 7.0) in the presence of 15mM NaTDC and 3.75 mM PL at 37°C). Samples were 
analysed using HPLC method after ultracentrifiigation (104630 g) for 30 min (the 
error bars represent the standard deviation of three experiments).
228
Chapter 7
General discussion and conclusions
The work performed in this thesis has provided new information regarding the use of 
lipid-based formulations for drugs which exhibit dissolution rate-limited absorption. 
In general, hydrophobic drugs with aqueous solubilities lower than 100 pg / ml often 
present dissolution limitations to absorption. The dose: solubility ratio of the drug 
provides an estimate of the volume of fluids required to dissolve an individual dose, 
and when this volume exceeds 11 litres, dissolution is often problematic (Dressman et 
al, 1986). When such a formulation is released into the lumen of the gut it disperses 
to form a fine emulsion, so that the drug remains in solution in the gut, avoiding the 
dissolution step which frequently limits the rate of absorption of hydrophobic drugs 
from the crystalline state. Generally, this can lead to improved bioavailability, and/or 
a more consistent temporal profile of absorption from the gut.
Steroids derivatives were used as models of hydrophobic drugs with log P between 1- 
4 and compared later with hydroxy benzoate derivatives in some studies. Hydroxy 
benzoate derivatives were used because of their low molecular weight and the 
expectation that they might exhibit better solubility than steroids in lipid excipients 
and formulations. The choice of model drugs for academic studies presents practical 
problems, and neither steroids or benzoates are ideal models. Neither is a good 
representation of the new chemical entities (NCEs) which are emerging as drug 
candidates in 2002. Choice of model drug was limited by cost and availability. A 
series of hydrophobic heterocyclic compounds with weakly basic amine groups 
would be better models of typical NCEs.
SEDDS formulations, consisting of emulsion pre-concentrates which produce fine 
oil- in- water or microemulsion when introduced an aqueous phase, are suitable for 
encapsulation thereby providing precise and convenient unit dose forms. However, 
constraints on solubility, potential interaction with excipients and physical stability
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limitations all impact on the utility of such formulation approach. Recently, three 
main criteria with which lipid formulations can be distinguished were described by 
Pouton (1999) to aid interpretation of comparative bioavailability (discussed earlier in 
chapter 1). Through my research, I have tried to verify these criteria’s and added to 
the classification with a new class of formulation described here as a Surfactant-Free 
(S-F) system.
Self-emulsifying formulations of new lipophilic benzodiazepine compounds which 
can be filled into hard or soft gelatin capsules for oral administration have been 
recently patented (Lievens et al, 1992). These formulations contain propylene glycol, 
polyglycolyzed glycerides, such as Labrafil M 2125 CS or M 1944 CS or Labrasol in 
combination with Tween 80 and are claimed to be useful for the treatment of pain and 
panic or anxiety (Constantinides, 1995). Improved dissolution and oral absorption of 
indomethacin in the rat from a self-microemulsifying drug delivery system 
incorporating polyglycolyzed glycerides as compared to an aqueous suspension of the 
drug has also been demonstrated (Farah et al, 1994).
Surfactants are known to increase the permeability by disrupting the cell membrane 
(Swenson et al, 1992). The main rate-limiting barrier for the drug absorption/ 
diffusion is the single layer of intestinal epithelial cells that covers the luminal surface 
of the intestinal wall. In addition, the pre-epithelial, unstirred aqueous layer presents 
a barrier hinder the poorly soluble drugs from reaching the absorption site 
(Arthursson et al, 1991). For the majority of drugs, absorption occurs via passive 
transcellular transport and the paracellular transport is limited due to tight junctions 
between the cells. Lindmark et al (1995) have used the medium chain fatty acids 
(e.g. sodium caprate) to enhance the absorption of hydrophilic drugs by modifying 
the tight junctions. It was reported that intestinal mucosa is frequently subjected to 
dietary induced damage (i.e. by bile salts, fatty acids and monoglycerides) and that 
mechanisms have evolved for rapid repair (Humberstone et al, 1997). Surfactants 
monomers are capable of partitioning into clear membrane where they can form polar 
defects in lipid bilayer. At high surfactant concentration in the cell membrane,
230
surfactant-surfactant occurs, and the membrane can be dissolved into surfactant- 
membrane mined micelle (Swenson et al, 1992).
With an increasing number of lipid excipients available for use, there is a need for 
more information to allow optimal choice of excipients. More knowledge is needed 
regarding surfactants in particular, of their toxicity and how important they are to the 
performance of the formulation. Due to these concerns of using surfactant for 
chronic administration, one motivation for the formulator is to find an alternative 
formulation using lipid excipients which have GRAS (generally regarded as a safe) 
status.
It is clear from the phase diagrams that the S-F formulations are clear, transparent, 
and thermodynamically stable. They are typically isotropic mixtures of medium 
chain oils < 40% (Miglyol 812®), mixture of mono-, di-, and tri-glycerides > 40% ( 
Imwitor 988®) and water soluble co-solvent < 30 % (Transcutol P®, PG, PEG 400). 
As can be seen, the area of mutual solubility produced by the S-F systems is extended 
over a wide range of compositions controlled by both the polarity of the cosolvent 
and the mono-, di-, and tri-glycerides content of the oil.
The processes by which lipid solubilized hydrophobic drug molecule eventually finds 
its way from its original bulk oil environment to the intestinal membrane, where it 
then diffuses across the mucosal bilayer to ultimately appear in the blood or the 
lymph, are extremely complex and likely to be critical components in determining 
bioavailability. Compared to these events, the chemical factors controlling drug 
solubility in a homogeneous lipid solvent seem an almost inconsequentially minute 
piece of the puzzle (Anderson, 1999). The essential first steps in a lipid-based 
strategy are to dissolve the drug in lipid excipients and/or SEDDS formulations 
(intrinsic solubility) in order to determine the solvent capacity of the formulation, and 
to determine whether the drug remains in solution on dispersion in aqueous solution.
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SEDDSs formulation and the individual excipients are viscous formulations; 
therefore, it is not easy to predict the length of time required reaching equilibrium. It 
was convenient to use gentle heating to speed up the dissolution process and it was 
important to make sure that the solubility measurements after re-equilibration at room 
temperature were true values of solubility rather than supersaturated systems.
Therefore, the protocol used for determining a single point of intrinsic solubility was 
to mix lipid excipients at elevated temperature in the presence of the drug for 2-3 
minute then left for equilibration for at least 48-96 hours before further analysis was 
undertaken.
A recent study reported by Nakervis et al (1996) used retinoids (isotretinoin log P ~ 
6.8, etretinate log P ~ 7.8 and temarotene log P ~ 8.7) as highly lipophilic molecules 
that are known to be transported in the intestinal lymph oral administration. Lipid 
solubility showed a general increase with increasing log P of the retinoids. The most 
lipophilic retinoid, temarotene, showed solubilites 109.5 mg/ml (linoleic acid) and 
170.6 mg/ml (Miglyol 812®), whereas the least lipophilic retinoid, isotretinoin 
showed much lower solubility between 5.1 (cottonseed oil) and 30.5 mg/ml (linoleic 
acid). Lymphatic uptake of temarotene was 4000-times and from etratinate 1000- 
times greater than isotretinoin. The rank order of increasing lymphatic uptake from 
each of the three oils shows an inverse relationship with solubility of the retinoid in 
each of the oils.
For lipid formulation it is necessary to understand how the intrinsic solubility will be 
affected by mixing various components, such as oils, cosolvents and surfactants, how 
solubility is related to choice of surfactants, and how solubility is related to molecular 
weight, melting point and log P of the drug. The ability to make predications from 
solubility studies in single excipients would allow the formulator to make an early 
choice between the types of lipid formulations.
The results revealed that the mixed glyceride excipients, Imwitor 988® and Capmul 
MCM®, were particularly good solvents for all of the cotricosteroids. There was a
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marked difference in solubility of steroids in MCT oil, and consequently it was 
considered that co-solvent might improve the solvent capacity of triglyceride-based 
systems. Surfactant-free formulation are typically composed of mixtures of 
Transcutol P®< 30 %, Imwitor 988® >50 % and Miglyol 812® >30 %. Surfactant-free 
(type IV) formulations were generally better solvents than SEDDS (type II) 
formulations but were generally more or less superior solvents to mixed glycerides of 
mono, di and tri-glycerides (Imwitor 988 ®) and (Capmul MCM®) alone. Type III 
SEDDS, which are hydrophilic, were also better solvents for most of the steroidal 
compounds than type II SEDDS. Although the homologous series of steroids span a 
considerable range of logP, their solubilities across a range of excipients and 
formulations were surprisingly similar, generally ranging from 0.2-2.1 g % w/v. 
Hydrocortisone acetate had the lowest solubility in most systems than the other 
steroids, and generally, progesterone had the highest solubility. Contrary to the 
observation with hydroxy benzoate derivatives, as Log P increased the solubility 
decreased in most systems.
Recently (Kommuru et al, 2001) reported a two fold increase in the bioavailability of 
CoQio (known as ubidecarenone used for treatment of cardiovascular disorder and as 
antioxidant) in SEDDS system compared to a powder formulation. They showed that 
the solubilities of CoQio in medium chain fatty acid glyceride and Myvacet® 9-45 
(diacetylated monoglycerides of Cig fatty acids) were higher than solubilities in long 
chain fatty acid glycerides.
The solubilities of hydrophobic drugs in aqueous dispersions of SEDDS formulations 
are poorly understood and documented. For hydrophobic drugs, the best strategy is 
to keep the drug in solution during its passage through the gut, to avoid the 
dissolution step. As well as presenting the drug in solution, the formulations would 
ideally be finely dispersed within the gut to ensure that drug can be made available 
for absorption from the lumen of the gut, partitioning from the reservoir of dissolved 
drug. Type I or type II lipid formulations are good candidates to avoid precipitation 
of hydrophobic drugs. However, these systems have limited solvent capacity for
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drugs such as cyclosporin A and steroids with high log P, which has encouraged the 
use of type III systems (Pouton, 1999). Type III systems upon dilution will form 
supersaturated solutions, but this need not necessarily lead to a rapid precipitation. 
The key issue is that if the drug precipitates on dilution of the formulation in the gut, 
then any advantage is likely to be lost.
The fate of each type of SEDDS formulations in the presence of the steroids 
derivatives upon dilution in water and/or tris-maleate buffer (pH 6.5) was determined. 
Self-emulsifying systems are expected to disperse rapidly within the contents of the 
stomach, which indicates that the formulation will empty into the intestine in a‘ 
manner similar to the emptying of aqueous solutions. Consequently, the rate of 
absorption from a type II and a type III system is likely to be rapid, particularly when 
administered to a fasted stomach. Hypnotics and analgesics are examples of drugs 
which may benefit from these formulations because they require rapid onset of action. 
On the contrary, these formulations may be disadvantageous for drugs with low 
therapeutic indexes. Type I formulations are likely to be dependent on digestion by 
lipolysis, is a process which takes place in the small intestine. The drug will be 
solubilized in mixed micelles of bile salts as long as the drug does not precipitate 
during digestion. Therefore, the drug will not have an unusually rapid onset of 
action. A major factor is the digestibility of the formulation. If the formulation is 
non-digestible then a colloidal state must be provided by self-emulsification, whereas 
if digestible oils are used, the colloidal state can be obtained by natural digestion. 
The overall bioavailability can then be equivalent to that achieved by type II or type 
III formulation (Pouton, 1999).
Steroids are non-electrolytes; their behavior in the small intestine can be compared 
with weak bases with a pK^ less than 7. Weak bases will not be highly soluble in the 
small intestine; they may dissolve in the stomach but may precipitate after gastric 
emptying. Therefore, weak bases may benefit from reformulation into lipid systems, 
which can give a reservoir of drug dissolved in either lipid or micellar solution.
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The key issue in relation to the use of type III A or B systems is the hydrophilic 
content (surfactant and co-solvent) that can keep the drug in solution. In practice, the 
presence of co-solvent and surfactant can improve the solvent capacity, but the instant 
they are diluted they can migrate to the aqueous phase solubilize leaving large 
amounts of the drug to precipitate. This effect is expected to be more pronounced in 
the presence of co-solvent, whereas a surfactant may be capable of forming a micellar 
solution. The results suggest that even in the presence of surfactant there can be a 
significant loss of the solvent capacity leading to precipitation of drug.
At one extreme, when a hydrophobic drug is formulated in an aqueous co-solvent 
(such as propylene glycol or PEG 400), there is usually a drastic loss of solvent 
capacity and consequent precipitation of drug. The amount of the drug which stays in 
aqueous solution of hydrophilic cosolvents can be estimated from the solubilization 
capacity (a). The solubilization capacity is relatively log P dependent. As log P 
increased the solubilization capacity increased and the increased was significantly 
noticed upon dilution in tris- maleate buffer (pH 6.5). Hydrocortisone acetate was the 
least affected by a co-solvent system which could be explained by its molecular 
structure. At the other extreme (lipophilic), if a drug is formulated in a triglyceride 
(TG) oil there will be no dissolution of TG, and no precipitation of drug because the 
MCT oil will still be present as a separate phase, though possibly in a partially 
emulsified state.
It can be anticipated that self-emulsifying formulations may also lead to a loss of 
solvent capacity, depending on the extent to which water-soluble components are 
used. Thus, type II SEDDS and S-F formulation should be less susceptible to 
precipitation than type III SEDDS. The inclusion of hydrophilic surfactants and co­
solvents could well lead to precipitation depending on the proportion of water- 
soluble components used. If the formulation contains a high proportion (Type III B) 
then precipitation is to be expected. Whether this becomes a problem will depend on 
the rate of crystallization in the gut.
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The amount of drug recovered after dispersion of steroids in aqueous solution of 
CRH 40® or T80® was more than expected due to the micellization effect. The 
micellization behaviour can be explained by the favourable entropy changes (Barry et 
al, 1976). Two opposing factors are involved. Insertion of solubilized molecules in 
micelles restricts molecular movement, i.e. a more ordered state, and provides a 
negative change in entropy. An opposing effect is that as relatively non-polar 
molecules leave the aqueous phase for the micelle, the configurational entropy of the 
water molecules increases due to the break up of iceberg structure surrounding non­
polar groups, i.e. a less ordered state produces a positive change in entropy.
For lipophilic steroids, the crowding effect predominates and hence a negative change 
in entropy occurs on solubilization. It is likely that more lipophilic steroids do not 
entirely lose their water structuring on entering the micelle because the region into 
which they are most likely to be incorporated, i.e. the outer layer of the 
polyoxyethylene shell, is heavily hydrated by water molecules physically trapped 
between the chains. Therefore, there would be little change in entropy, due to loss of 
water structure, but a decrease in entropy due to restriction of the solubilized 
molecules in the micelle. Relatively high log P (> 3) steroids, testosterone and 
progesterone, are solubilized in the less hydrated region of the polyoxyethylene shell, 
close to the hydrocarbon core, which is largely purely polyoxyethylene. When these 
steroids leave the aqueous phase, water structure breaks down and is not reformed in 
the micelle because there is little water at this site. Therefore solubilization of non­
polar steroids increases entropy, due to break up water structure, which is greater than 
loss in entropy due to restriction of steroids within the micelle an hence a net positive 
change in entropy occurs (Barry et al, 1976; Anderson, 1999).
The first estimation to make from the equilibrium solubilities is what happens in the 
expected worst case represented by formulation as a simple co-solvent solution. 
Since the steroids are only soluble at approximately 1.1% w/w in each formulation, 
then the maximum dose, which can be administered in solution, is approximately 
lOmg/ml, i.e. 1 lmg in a 1ml capsule. This means that a formulation of lg diluted to
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100ml must be able to dissolve the drug at 11 mg/100ml (0.011% w/w; 0.11 mg/ml). 
As a result 1 g of S-F formulations composed of 30 %< of mixed glycerides mono-, 
di-, and tri- glycerides, < 30 % medium chain oil with or without < 30 % hydrophilic 
surfactant could keep the drug into solution (20mg/ 100ml) because steroids are 
soluble at approximately 2.0% w/v in S-F formulations.
The presence of bile may improve the bioavailability of poorly water soluble drugs by 
enhancing the rate of dissolution and/or solubility. An increase in the rate of 
dissolution can occur via (i) a decrease in the interfacial energy barrier between solid 
drug and the dissolution medium (via enhanced wetting), leading to an effective 
increase in surface area, or (ii) an increase in solubility via micellar solubilization 
within the bile salt micelle i.e a decrease in the apparent diffusion coefficient of the 
drug. The changes in the dissolution rate of poorly soluble drugs due to wetting or 
solubilization is compound dependent due to the specificity of the interactions 
associated with these processes (Bakatselou et al, 1991).
In the small intestine, amphiphilic bile components such as bile salts, lecithin, lipid 
digestion products such as fatty acids and monooleins can enhance drug solubility. 
When these substances are present in concentration higher than their critical micellar 
concentration (CMC), micellar solubilization of the drug can occur (Aungst, 1993; 
Charman et al, 1997; Humberstone et al, 1997; Horter et al, 2001). Solubilization 
into simple bile salt micelles has been reported for many poorly soluble drugs 
including griseofulvin, glutethimide, digoxin, leucotriene-D antagonists and 
gemfibrozil (reviewed by Horter et al, 2001). The addition of physiological bile salt 
to aqueous media increased drug solubility up to 100- fold.
The addition of lecithin, monooleins, long chain fatty acids and/or triglycerides, in 
several cases, to bile salt solutions produced further enhanced in drug solubility. 
Addition of lecithin causes an increase in the molecular weight of micelles from 6000 
to 150000 Da (Shankland, 1970). In most cases, there is correlation between size and 
solubilization capacity of mixed micelles, but this dependent on the mechanism by
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which the drug is solubilized. The ratio of bile salt to lecithin may also influence the 
extent of solubilization. Rosoff et al, for example, showed that the greater the molar 
ratio of lecithin to bile salt, the higher the solubility of diazepam (Rosoff et al, 1980).
The effects of formulating drugs in SEDD formulations are far from predictable, 
although strong evidence exists in the literature of the potential usefulness of the 
approach. Charman et al (1992) examined the lipophilic antiviral compound WIN- 
54954 administered in a formulation containing a medium chain triglyceride and a 
nonionic surfactant. The SEDDS was compared to a PEG-600 formulation. No 
significant difference in mean bioavailability was seen between the two systems but 
greater reproducibility was noted for the SEDDS. In contrast, Shah et al (1994) 
examined the bioavailability of Ro-150778, a highly lipophilic naphthalene 
derivative, demonstrating a fourfold greater bioavailability for the SEDDS 
formulation than a PEG- 400 solution and a 20-fold greater bioavailability than from 
standard tablet. Gershanik and Benita (1998) have compared progesterone absorption 
in female rats from a range of formulations, including SEDDS, which form positively 
and negatively charged droplets. The positively charged systems, which include the 
cationic lipid oleylamine, showed the greatest bioavailability with a solution in PEG- 
300, although whether this reflection of the surface charge or surface composition is 
not clear (Craig et al, 2001).
As physiological lipid processing has been suggested to enhance bioavailability from 
a lipid-based formulation, the possible rate of digestion of lipid-based formulations in 
the duodenum was assessed in this study using an in vitro model of lipolysis. This 
model enabled examination of the rate at which a lipid substrate was digested by 
lipase, in the presence of non-ionic surfactants likely to be included within a lipid- 
based formulation.
An evaluation method of the hydrolysis of lipid formulations containing glycerides, 
for administration to the gastrointestinal tract, in the presence of pancreatic lipase, 
was established. A general method, which uses a pH-stat to determine liberation of
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free fatty acid, has been available for some time (MacGregor et al, 1997) but, given 
the complexity of the gut lumen, there is still much to learn about the use of in vitro 
models of lipolysis. This study aimed to investigate the variables which can affect 
lipolysis, and the significance of these variables on hydrolysis of long-chain 
triglycerides (LCT), medium-chain triglycerides (MCT), tributyrin (SCT) and mixed 
mono- and di-glycerides (MG). The activity of pancreatic lipase was expressed in 
terms of Tributyrin Units or TBUs. One TBU is the amount of enzyme that can 
liberate lpmole of fatty acid per minute from tributyrin at 25 °C and pH 8.5 in the 
presence of 5mM CaCL2.2H 20, 150mM NaCl. Normal human duodenal contents 
are reported to contain 1000 TBUs of colipase-saturated lipase per ml (Borgstrom et 
al, 1984). The optimum pH for lipase activity will depend upon conditions of the 
reaction medium such as the concentration of bile salts, ionic strength and the type of 
the substrate. A pH of 6 .5-7.0 was proposed for use with standard pH-stat assay on 
the basis it was typical of the fasting duodenal pH in healthy subjects. Pancreatin 
lipase activity was dependent, and was maximal at pH 7-7.5 for LCTs (Com oil®). 
The digestion of SCT (TB) and MCT (Miglyol 812®) and mixed glycerides (Imwitor 
988®) was less sensitive to change in pH, which may explained by the higher water 
solubility of C4 and Cg fatty acid in acidic conditions.
In general, pancreatic lipase-colipase catalyses the hydrolysis of tri- and diglycerides 
in the lumen of the small intestine. The enzyme has a preference for sn-1 and sn-3 
ester bonds, but displays no activity towards sn-2 linkages. The results are that 2- 
monoglycerides and fatty acids are the major products of intestinal lipolysis. 
However, 2- monoglycerides do undergo a slow and non-enzymatic isomerization at 
alkaline pHs to yield 1- monoglycerides, which are then available for hydrolysis by 
pancreatic lipase-colipase. The relative proportions of the different triglycerides 
breakdown products for a healthy humans are typically as follows: glycerol 2 2 %, 2 - 
monoglycerides 72 %, and 1-monoglyceride 6  % (Martin et al, 1983).
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The effect of increasing calcium concentration from 5mM to 40mM had a negligible 
impact on the rate of lipolysis of SCTs (TB), MCT (Miglyol 812®) and mixed 
glycerides (Imwitor 988® or Capmul MCM®). However, the calcium concentration 
had more pronounced effect on the rate of lipolysis of LCTs (Com oil®). The 
lipolysis of long chain triglycerides generated lipolytic products with little solubility 
(e.g. 10'6 and 10'3 M] for LC-FAs and MG respectively (Patton et al, 1985).
These monoglycerides and fatty acids therefore tend to accumulate at the interface 
between the digesting oil droplet and the aqueous phase (typically as liquid 
crystalline bilayers). The clearance of some fatty acid occurred (not MGs) from the 
surface of a digesting oil droplet through the formation of soaps between one divalent 
calcium ion and two fatty acids {i.e. Ca2+[FA~~]2 ).Bile salts and lecithin are the two 
major components in bile and the molar ratio is 2:1 to 5:1. Together they are 
essential to the formation of intestinal mixed micelles. As an amphiphilic compound, 
lecithin combines with bile salt to form highly solubilizing mixed micelles. The final 
effect on lipolysis depends on the ratio of lecithin to bile salt; low ratios enhance 
enzyme activity, whereas high ratios lead to inhibition (Lykidis et al, 1997). It is 
difficult to establish from the literature exactly what is the typical level of BS in the 
human small intestine. It has been reported that BS concentration ranges from 5.8- 
37mM (McGregor et al, 1997). The average value has been reported as 14.5mM ± 
8.8mM. The identity of BS had no appreciable impact on the rate of lipolysis; 
therefore, in this study inexpensive ox-bile was used instead of NaTDC to determine 
the effect of concentration of BS on the rate of lipolysis on different substrates.
LCTs (Com oil®) are dependent on the presence of bile salt micelles or mixed bile 
salt-lecithin micelles, which can solubilize long-chain fatty acid or monoglycerides. 
Bile salt concentration had significant effect on the rate of lipolysis of LCTs, but 
SCTs (TB) were insensitive to bile salt concentration, and MCTs (Miglyol 812®) 
were much less dependent than LCTs. Similar behaviour was observed for mixed 
glycerides (Imwitor 988®, Capmul MCM®). This indicates that medium-chain 
degradation products can be removed from the surface more easily, and did not
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require high concentrations of bile salts. Thus, the processing of lipid formulations in 
vivo may depend strongly on the alkyl chain length of TGs used.
A further aspect of SEDDS technology that is generating considerable interest is the 
role of the surfactant with regard to drug uptake from SEDDS, particularly in terms of 
the digestibility of the oil. ‘Self-microemulsifying’ systems which typically contain 
less oil and more hydrophilic components, such as CRH 40® as well as a co-solvent, 
may well resist lipolysis during their transit through the gut. The implication of this 
observation is that such type III formulations are not able to rely on lipolysis to 
disperse the oil and drug as a colloidal system. To enhance bioavailability they must 
emulsify efficiently in the stomach by a process independent of but not affected by 
the gut. Hydrophilic surfactants with hydrophile / lipophilic balance (HLB) values in 
the range of 13 to 15 were, in general, potent inhibitors of lipase activity towards 
medium chain triglyceride. Surfactants with dominant lipophilic character were also 
able to inhibit lipase activity although the inhibition was less severe, with limited 
lipolysis able to occur from the start of the assay. Non-ionic surfactant, typically 
trans-esterfication products of TGs and polyoxyethylene, are commonly used in self- 
emulsifying lipid formulations. Although these surfactants contain fatty acids esters, 
this study found that hydrolysis of materials in the presence of pancreatin was very 
limited. Mixtures of oils and hydrophilic surfactants can inhibit lipolysis of 
triglycerides. Surfactant with HLB > 11 (Cremophor RH 40® / BASF) inhibited 
lipolysis of TGs and mixed glycerides, if the concentration exceeds 40%w/w 
surfactant. Hydrophobic surfactant HLB < 10 (Labrafil Ml 944 Cs®/Gattefosse) did 
not inhibit lipolysis. Thus, the digestibility of dispersions formed by self-emulsifying 
systems depends on the surfactants used and the quantity of TG available for 
lipolysis. The mechanism by which the non-ionic surfactant (HLB >12) inhibit 
lipolysis that would be occurred once the oxyethylene mantle generated by the 
surfactant exceeds a critical thickness, which prevents binding of colipase-lipase 
complex to the surface of the oil droplet.
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In general, surfactants which are too hydrophobic to be water-soluble, are poor 
enhancers, whereas surfactants that are very hydrophilic cannot partition into the 
hydrophobic environment of the lipid bilayer (Swenson et al, 1992). In agreement 
with these observations, Crison and Amidon (1999) have reported a trend 
improvement of the bioavailability of nifedipine in dogs using a high HLB surfactant 
(Labrasol®, HLB 14) over that of a surfactant with low HLB value (Lauroglycol®, 
HLB 4), even though both formulations appeared to solubilize the drug to the same 
extent. In this study, a five fold increase in bioavailability with Labrasol® and a 
three-fold with Lauroglycol® were observed compared to powder formulation.
Solomon et al (1996) performed a study of the inhibition of MCT lipolysis by nonyl 
phenol ethoxylates, which enabled a more systematic study of the influence of HLB 
on inhibition. The rate of lipolysis was affected by the presence of nonyl phenol 
ethoxylates with HLB greater than 12, the effect being most pronounced within the 
HLB range 13-17. At very high HLB the inhibitory effect appeared to decline, an 
effect which may be explained by the weak surface activity of highly ethoxylated 
materials. When pure nonyl phenol or ethoxylates of very low HLB were used, the 
initial rate of hydrolysis was unaffected but the total hydrolysis of fatty acids from 
MCT oil was lower than expected. This effect could be explained by the phase 
separation of the oil and alkyl phenol on mixing with water into two populations of 
droplets (one rich in MCT oil and one in alkyl phenol), only one of which enables 
lipolysis to proceed (Solomon et al, 1996b; MacGregor et al, 1997)
Hydrophilic surfactants, orientated at the lipid/water interface may form a hydrophilic 
barrier around the substrate by means of their ethoxy chains. Initially this barrier 
would prevent access of colipase to the triglyceride interface, and thus inhibit lipase 
activity. However, eventually some colipase would be expected to bind followed by 
lipase, with the consequent production of lipolytic products. Accumulation of these 
products at the interface may act to promote partitioning of colipase into the substrate 
surface, with a resultant increase in lipase activity and reduction in the extent of 
inhibition from the surfactant molecules. Lipophilic surfactants when present in the
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system are suggested to speed this process up, either by containing lipolytic products 
as part of their composition or by providing an additional source of substrate for 
lipase.
Mono-, di-, and tri-glycerides (Imwitor 988®) and medium chain of fractionated 
coconut oil (Miglyol 812®) are rapidly digested to free fatty acids and 2- 
monoglycerides, and these products are solubilized to form a colloidal dispersion 
within bile salt-lecithin mixed micelles. The essential component of type II system, 
to promote emulsification of triglycerides or mixed glycerides, is a nonionic ester 
ethoxy late with intermediate HLB 10-12. These surfactants {e.g. polyoxyethylene 
(25)-glyceryl trioleate [Tagat TO®]) are water dispersible. They tend to form fine 
stable emulsion. Type II systems will be digestible unless the surfactant (Tagat TO®) 
concentration is too high. Surfactants themselves with HLB < 11 are very slowly 
digested and their presence at the oil-water interface can inhibit the digestion of 
glycerides.TGs present in ‘surfactant-free’ formulations consisting of oil, co­
surfactant and co-solvents were rapidly hydrolyzed. Co-solvents did not appear to 
influence lipolysis, once the formulation had dispersed. That is thought to be 
explained by phase separation of oil and co-solvent on dispersion of the formulation.
Porter and Charman (1997) reviewed the use of milk fat globule membrane (MFGM) 
as an emulsifying agent for the delivery of vitamins (D3 and A), epidermal growth 
factor, and insulin (Moriwaki et al, 1990). Earlier reports appear to suggest that this 
emulsifying agent may have some influence on lymphatic uptake, with the recent 
study suggesting an increase in the lymphatic uptake of vitamin D3 from emulsion 
stabilized with MFGM compared to those stabilized with polysorbate-80, although 
the increase was not statically significant (Liu et al, 1995).
The physico-chemical kinetic behaviour of lipid excipients and SEDDS formulations 
were studied in detail in the presence of the hydrophobic drugs (Chapter 6 ). The long 
chain lipid digests separated into an oily phase (containing undigested triglyceride 
and diglyceride), an aqueous phase (milky thick) (containing bile salt, fatty acid and
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monoglyceride) and a pellet phase (containing approximately 5 mm of fatty acid, 
presumably as an insoluble soap) after ultracentrifugation. Higher proportions of 
long chain fatty acid and monoglyceride were dispersed into the aqueous phase with 
increasing bile salt concentrations (Sek et al, 2002). In contrast, medium chain 
lipolytic products separated into a small volume of oily phase (4-6 ml), a precipitate 
and the rest of the solution, which was clear and/or slightly turbid. The precipitate 
was believed to be calcium soaps of fatty acids. A pellet fraction could be in a bile- 
salt-independent manner (Sek et al, 2002). On the contrary, the precipitate is calcium 
dependent-manner. The digestion of both the Cg/Cio and Ci8 monoglyceride / 
diglyceride lipid mixtures was more rapid than the corresponding triglyceride,- 
especially at early time points.
All formulations dispersed to form emulsions in a pure water but their behaviour in 
simulated intestinal pH-stat solution, was dependent on monoglycerides. When 
sufficient monoglycerides was present, >60% (Imwitor 988®) we observed 
demulsification and phase separation, which was dependent on the presence of 
phospholipid and resulted in sedimentation of what was believed to be a phase rich in 
monoglycerides swollen with water. The addition of medium chain triglycerides 
> 30 % (Miglyol 812®) stabilized the formation of mixed micelles, which remained in 
a finely dispersed state.The results indicate that the micellar hypothesis of fat 
absorption has been challenged but its general principles have not been changed, 
although the form in which was presented 20 years ago was an oversimplification.
The floating oil phase contained mostly unhydrolyzed triglycerides and diglycerides. 
The aqueous phase (micellar) was turbid contained mainly of monoglycerides and 
fatty acids with small amounts of triglycerides and diglycerides. The aqueous or 
‘micellar’ phase can contain at least two different aggregates: mixed disc-like 
micelles (multilamellar) saturated with lipolytic product and liposomes (unilamellar 
vesicles). Usually, in a static system these different phases in micellar phase are in 
equilibrium and interconvertible. In intestinal content, mixed lipids are formed by 
lipolysis at the same time as they are mixed with bile. The turbidity and
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heterogeneity of micellar phase was due to low total lipid concentration in relation to 
the bile salt concentration.
In the presence of insufficient bile salt (BL) and phospholipid, the micellar phase may 
contain liquid crystalline structures and optically isotropic L2 phase (inversed 
micelles in a lipid bilayer) containing fatty acids and monoglycerides. The presence 
of L2 is of interest because it consists of a continuous hydrocarbon chain matrix with 
surface properties resembling those of the oil phase. It may act to help disperse the 
oil phase, increasing the velocity of lipolysis. In the presence of calcium and 
insufficient amount of bile salts, ‘crusty’ crystalline phase (most likely comprising 
insoluble Ca -fatty acid soaps) may form a pellet (precipitate).
In our model system, the unexpected phase which sedimented was a viscous gel-like 
phase, believed to contain some of monoglycerides and fatty acids. This unexpected 
phase separation is likely to have a considerable effect on the fate of drug dissolved in 
such formulations. Mixed mono-, di-, and tri-glycerides are often good solvents for 
hydrophobic drugs, and are used to increase the solvent capacity of lipid 
formulations. Our results suggest that use of high concentrations of monoglycerides 
may be disadvantageous and could result in precipitation of drug. The ability of lipid 
digestion products to keep the drug in solution is highly dependent on the physico­
chemical properties of lipids themselves.
The analysis of hydrophobic drugs (hydrocortisone, testosterone, propyl paraben and 
methyl paraben) in lipid phases goes hand-on-hand with previous observations. 
Digestion of mixed mono- di-, and tri-glycerides in the presence of hydrophobic drug 
under standard pH-stat, suggested that the drug was entrapped in the viscous gel-like 
phase, thought to be rich in monoglycerides. In the presence of LCT (Com oil®), 
more than 65% w/v of the drug remained in the aqueous (micellar) phase. On the 
contrary, MCT (Miglyol 812®) was only capable of keeping less than 30 % w/v of the 
drug in solution (chapter 6).
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Type III B formulations upon digestion produced a clear aqueous solution which was 
capable of keeping the steroids in solution due to the presence of (> 40%) hydrophilic 
surfactant and water soluble co-solvent (> 40 %). In Type III A (<40 %, hydrophilic 
surfactant and <40 % mixed mono-, di-, and tri-glycerides), ~50 % of the drug was 
found in the viscous gel-like phase. In the case of surfactant-free formulations (> 50 
% mixed mono-, di-, and tri-glycerides, MCT >20% and water-soluble co-solvent < 
30%), almost ~ 80% of the drug was found in the subphase. In contrast, Type II 
formulations supported ~ 45 %w/v of the drug in the micellar phase (subphase) 
(chapter 6).
7.1 Future work
In general, the new formulation, surfactant-free system can be a promising 
formulation for lipophilic drugs with high log P >4. Unfortunately, steroids were not 
the good example used through the research to demonstrate the efficiency of these 
formulation in terms enhancing their solubility, although, they showed to certain 
extent an increase in the solubility with high log P >2. Simple solvents of mixtures of 
mono-, di-, and tri-glycerides can enhance the solubility of steroids better than 
SEDDS formulation. Because the amount of the steroids dissolved in SEDDS was 
small, it was difficult to make a clear estimate of the dose that can stay into solution 
upon dilution.
The validation method of in vitro studies of lipolysis using pH-stat method was a 
descriptive method for the fate of lipid excipients (SCT, MCT, LCT and mixed 
mono-, di-, and tri-glycerides). It was helpful to make assumption of the fate of 
SEDDS formulations in terms of how many monoglycerides and fatty acids 
produced. It was difficult in practice to calculate the MG and FA released from 
SEDDS formulations. The physical-chemical behaviour of lipid excipients and 
formulations was a challenge and in the same time difficult. Dealing with the phases 
in terms of extracting the phases and measuring the concentration of the drug was not 
an easy process. There could be some errors introduced by practical difficulties in
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separation of the phases, leading to error in the estimate of the concentration of the 
drug dissolved.
In conclusion, there is a need for chronic oral toxicity studies of most common 
surfactants containing formulation, preferably in gelatin capsule using a suitable 
animal model. Results from these studies would allow a therapeutically useful 
window to be identified between absorption enhancing and toxic dose of a particular 
surfactant. More attention needs to be paid to the characteristics of various lipid 
formulations available, so that guidelines and experimental methods can be 
established that allow identification of candidate at an early stage.
It is necessary to establish more methods for detecting the solubilization state of the 
drug in vivo, and there is a need for in vitro methods predicting the dynamic changes, 
which are expected to take place in the gut (i.e. in vitro / in vivo correlation methods).
The physical and chemical stability of drugs within lipid systems needs to investigate 
more and the physical phases formed during lipid digestion may need further studies. 
The priority for the future should be to conduct human bioavailability studies, and to 
accomplish more basic studies on the mechanisms of action of this fascinating and 
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Hydrocortisone 241.5* 242 445** 438.74 2.26
Hydrocortisone acetate 241.5* 241 390** 387.12 0.71
Progesterone 240** 240 314.47** 514.02 0.64
Testosterone 240* 240 288.43 ** 550.16 3.31
Testosterone acetate 241* 241 517.02 0.13
* from British Pharmacopoeia 
** from Merck index
1%
Table 1.1a Represents the parameters (A.max and E J  used for the calculation of solubility 










Practical CVHydroxy benzoate derivatives
Butyl paraben 2 9 5 * 2 5 2 * * 8 4 0 8 7 4 0 .9 2
Methyl paraben 2 6 1 * 2 3 1 * * 2 9 6 .1 8 0 .6 7
Ethyl paraben 2 9 5 * 2 3 5 * * 4 5 7 3 .4 4
Propyl paraben 2 9 6 * 2 6 6 * * 180 0 .6 7
* Merck index where diluted using alcohol 96 % v/v 
** The solvent used was Acetonitrile 99 % v/v
1 °/Table 1.1b Represents the parameters (tanax and Bcm) used for the calculation of 
solubility (g % w/v) of hydroxy benzoate derivatives in chapter 2 using the UV 
spectrophotometer method.
Hydrocortisone standard curve
A series of hydrocortisone solutions was prepared by dilution with ethanol 96 % v/v. 
Samples were produced which contained (0.432, 0.780,1.09,1.191 and 1.188) mg % of 
hydrocortisone. An analysis was performed as described in 2.2.22. A Beer-Lambert 
plot for concentration (% w/v) was determined using regression analysis.
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Progesterone standard curve
A series of progesterone solutions were prepared by dilution with ethanol 96 % v/v. 
Samples were produced which contained (0.431, 0.640, 0.821, 1.136, 1.145 and 1.180) 
mg % of hydrocortisone. An analysis was performed as described in 2.2.2.2. A Beer- 
Lambert plot for concentration (% w/v) was determined using regression analysis. 
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Testosterone standard curve
A series of testosterone solutions were prepared by dilution with ethanol 96 % v/v. 
Samples were produced which contained (0.412,0.860,0.920,0.999 and 1.09) mg % of 
testosterone. An analysis was performed as described in 2.2.2.2. A Beer-Lambert plot 
for concentration (% w/v) was determined using regression analysis.
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Testosterone acetate standard curve
A series of testosterone acetate solutions were prepared by dilution with methanol 96 % 
v/v. Samples were produced which contained (0.412, 0.830,1.1408,1.1456 and 1.168) 
mg % of testosterone acetate. An analysis was performed as described in 2.2.2.2. A 
Beer-Lambert plot for concentration (% w/v) was determined using regression analysis. 
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Hydrocortisone acetate standard curve
A series of hydrocortisone acetate solutions were prepared by dilution with methanol 96 
% v/v. Samples were produced which contained (0.467,0.623,1.050,1.300 and 1.426) 
mg % of hydrocortisone acetate. An analysis was performed as described in 2.2.2.2. A 
Beer-Lambert plot for concentration (% w/v) was determined using regression analysis. 
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Methyl paraben standard curve
A series of methyl paraben solutions were prepared by dilution with acetonitrile 96 % 
v/v. Samples were produced which contained (0.02912, 0.02184, 0.01450, 0.364 and 
0.0728 ) mg % of ethyl paraben. An analysis was performed as described in 2.2.2.2. A 
Beer-Lambert plot for concentration (% w/v) was determined using regression analysis. 
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IV
Ethyl paraben standard curve
A series of ethyl paraben solutions were prepared by dilution with acetonitrile 96 % v/v. 
Samples were produced which contained (0.014352, 0.01936, 0.04784, 0.02392 and 
0.09568) mg % ethyl paraben. An analysis was performed as described in 2.2.2.2. A 
Beer-Lambert plot for concentration (% w/v) was determined using regression analysis. 
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Propyl paraben standard curve
A series of propyl paraben solutions were prepared by dilution with acetonitrile 96 % 
v/v. Samples were produced which contained (0.01168,0.02393,0.03598, 0.04786 and 
0.05982) mg % propyl paraben. An analysis was performed as described in 2.2.2.2. A 
Beer-Lambert plot for concentration (% w/v) was determined using regression analysis. 
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Table 1.2a Percentage (w/v) solubility(Si) o f steroids in lipid excipients at 25 °C.
Imwitor 988® Capmul MCM® Miglyol 812® *Cremophor RH 40® Tagat TO®
Drug (Solubility % w/v) Mean SD RSD Mean SD RSD Mean SD RSD Mean SD RSD Mean SD RSD
(Si) (n=3) (n=3) %(n=3) (n=3) (n=3) %(n=3) (n=3) (n=3) %(n=3) (n=3) (n=3) %(n=3) (n=3) (n=3) %(n=3)
Hydrocortisone 1.55 0.04 1.85 1.002 0.034 3.344 0.100 0.003 3.054 0.73 0.007 0.955 0.1 0.006 5.864
Hydrocortisone acetate 0.22 0.007 3.24 0.122 0.07 5.27 0.386 0.008 2.156 0.15 0.004 2.98 0.025 0.002 8.221
Progesterone 1.60 0.03 2.83 1.2 0.019 1.58 1.147 0.024 2.064 1.21 0.033 2.734 0.83 0.034 7.203
Testosterone 0.82 0.004 0.449 0.79 0.015 1.93 0.847 0.033 3.849 0.97 0.068 7.011 0.301 0.013 4.381
Testosterone acetate 1.10 0.012 1.066 1.04 0.053 5.11 1.035 0.012 1.166 1.06 0.03 2.846 1.274 0.018 2.548
*Cremophor RH 40® solubility were determined at 30°C.
Table 1.2b Percentage (w/v) solubility (S) o f steroids in lipid excipients at 25 °C.
Propylene glycol PEG400 Transcutol P®




















Hydrocortisone 1.00 0.013 1.300 1.228 0.039 3.202 1.077 0.064 5.91
Hydrocortisone acetate 0.367 0.021 5.816 0.333 0.001 0.204 0.78 0.038 5.37
Progesterone 1.071 0.007 1.064 1.171 0.028 2.396 1.037 0.023 2.18
Testosterone 0.822 0.018 2.18 0.95 0.008 0.832 1.11 0.009 0.76
Testosterone acetate 0.876 0.019 5.303 0.92 0.019 2.055 1.142 0.008 0.71
vi
Table 1.3 Percentage ( w/v) solubility (Si) o f steroids in S-F formulations at 25 °C.




























H. 0.6331 0.019 0.926 0.614 0.006 0.963 1.203 0.018 1.927 0.747 0.0122 1.631
H.A 0.1144 0.002 1.4017 0.178 0.0018 1.054 0.1632 0.0024 1.4904 0.162 0.005 2.857
P. 2.376 0.019 0.959 2.598 0.009 0.756 2.215 0.0193 0.851 2.06 0.101 4.225
T. 1.5488 0.023 1.47 0.926 0.0125 1.345 2.576 0.0811 4.571 1.373 0.030 1.926
T.A 2.018 0.009 1.349 1.111 0.0141 1.27 2.06 0.0157 0.8513 1.850 0.024 1.422




% w /v  Sj
Testosterone 
% w /v  Sj
Testosterone Acetate 
% w /v  Sj
Hydrocortisone A cetate 
% w /v  Sj
Progesterone 































20: 80 0.418 0.008 1.980 0.504 0.023 4.464 0.459 0.032 6.950 0.01 0.001 2.410 1.057 0.117 1.104
30 :70 0.391 0.013 4.570 0.625 0.007 1.139 0.510 0.008 1.472 0.017 0.001 4.490 1.049 0.009 0.858
4 0 :6 0 0.290 0.016 5.470 0.674 0.027 2.937 0.562 0.029 3.510 0.029 0.001 1.540 1.00 0.004 0.265
5 0 :5 0 0.21 0.029 3.514 0.721 0.017 2.342 0.612 0.020 1.487 0.03 0.002 1.544 0.98 0.024 1.99
6 0 :4 0 0.176 0.002 1.366 0.772 0.027 2.303 0.636 0.015 0.822 0.048 0.001 4.770 0.89 0.030 2.406
7 0 :3 0 0.151 0.006 0.822 0.791 0.020 2.510 0.669 0.006 5.270 0.059 0.001 2.266 0.86 0.038 2.834
80 : 20 0.105 0.003 2.930 0.82 0.008 1.308 0.690 0.034 3.560 0.069 0.002 3.200 0.81 0.016 1.624
Table 1.5 Percentage (w/v) solubility (S) o f steroids in type III A at 25 °C.
Imwitor 988®+ Miglyol 812® + 
Cremophor RH 40®+ PEG400
Hydrocortisone 
g % w /v Sj
Hydrocortisone acetate 
g % w /v Sj
Progesterone 
g% w /v  Si
Testosterone 
g % w/v S;
































20%+ 30 %+ 30 %+ 20 % 0.705 0.003 0.350 0.194 0.001 0.006 1.266 0.031 2.590 0.956 0.025 2.620 1.037 0.206 1.980
20 %+ 30 %+25 %+25 % 0.763 0.005 0.666 0.206 0.004 1.716 1.312 0.002 0.170 0.928 0.012 1.240 1.080 0.053 4.860
15 %+35 %+ 30 %+ 20 % 0.713 0.005 0.675 0.173 0.006 0.369 1.263 0.033 2.810 0.850 0.025 2.880 0.904 0.003 0.272
35 %+ 15 %+ 25 %+25 % 0.777 0.010 1.240 0.193 0.002 1.237 1.163 0.010 0.827 0.910 0.015 1.637 1.044 0.009 0.184
25 %+25 %+30 %+20 % 0.739 0.028 3.735 0.193 0.009 4.890 1.364 0.006 0.422 1.034 0.022 2.140 1.104 0.020 1.800
Table 1.6 Percentage (w/v) solubility (S) o f steroids in type IIIB at 25 °C.
Imwitor 988®+Miglyol 812® + 
Cremophor RH 40®+PEG 400
Hydrocortisone 
g % w/v Sj
Hydrocortisone acetate g 
% w/v S;
Progesterone 
g % w/v S;
Testosterone 
g % w/v Si
Testosterone Acetate 































5 %+15 %+40 %+ 40 % 1.009 0.003 0.318 0.230 0.002 0.723 1.489 0.008 0.510 1.130 0.002 0.161 0.840 0.003 0.320
10 %+10 %+ 40 %+ 40 % 1.089 0.009 0.811 0.300 0.001 0.269 1.305 0.002 0.147 1.096 0.0004 0.035 0.798 0.003 0.403
Table 1.7 Percentage (w/v) solubility (Si) o f mixture o f mono-, di-, and tri-glycerides and medium chain fatty acids oil at 
2.5 °C.
Miglyol 812® : 
Imwitor 988®
Hydrocortisone
g % w/v Sj
Testosterone 
g % w/v S;
Testosterone Acetate 
g % w/v Si
Hydrocortisone Acetate g 
% w/v S
Progesterone 































30 :70 0.506 0.009 1.752 0.921 0.015 1.314 1.253 0.022 1.779 0.117 0.005 4.436 1.433 0.018 1.369
40 : 60 0.436 0.011 2.478 0.917 0.013 1.206 1.194 0.021 1.729 0.099 0.006 6.522 1.341 0.021 1.695
50:50 0.379 0.006 1.463 0.909 0.007 0.550 1.157 0.041 3.839 0.072 0.005 5.318 1.249 0.017 1.364
60 :40 0.325 0.015 4.690 0.90 0.033 2.900 1.02 0.004 0.404 0.062 0.0035 3.692 1.214 0.011 0.920
70 : 30 0.244 0.006 2.446 0.892 0.016 1.490 0.93 0.016 1.383 0.054 0.0052 0.001 1.176 0.052 3.593
80 : 20 0.152 0.006 3.988 0.838 0.013 1.416 0.84 0.022 0.279 0.042 0.001
3
0.005 1.049 0.011
Table 1.8 Percentage ( w/v) solubility (S) o f steroids in mixture o f mono-, di-, and tri-glycerides and propylene glycol as 
hydrophilic co-solvent at 25 °C.
I 988® : PG Hydrocortisone 
g % w/v Si
Testosterone 
g % w/v Sj
Testosterone Acetate 
g % w/v Sj
Hydrocortisone Acetate 
g % w/v Si
Progesterone 































30 :70 1.871 0.019 0.980 0.962 0.403 1.863 0.796 0.013 0.773 0.239 0.007 2.719 1.68 0.027 1.118
40 : 60 1.830 0.022 1.1830 1.98 0.063 3.500 0.718 0.054 3.139 0.241 0.003 1.162 1.52 0.024 0.928
50:50 1.759 0.020 1.092 2.35 0.132 3.002 0.838 0.030 3.730 0.251 0.005 1.780 1.39 0.003 0.118
60 :40 1.662 0.028 1.692 2.149 0.087 2.858 0.862 0.006 0.836 0.240 0.017 7.120 1.21 0.062 2.434
70 : 30 1.470 0.025 1.666 1.737 0.050 4.061 0.943 0.143 6.276 0.233 0.001 0.601 1.10 0.042 1.87
80 : 20 1.242 0.020 1.586 1.755 0.053 5.607 0.965 0.061 3.106 0.212 0.007 3.448 1.01 0.019 0.803
ix
Table 1.9 Percentage (  w/v) solubility (S) o f steroids in a mixture o f mono-, di-, and tri-glycerides and polyethylene glycol as
hydrophilic co-solvent at 25 °C.
Imwitor 988® : 
PEG 400
Hydrocortisone 
g % w/v Sj
Testosterone 
g % w/v S;
Testosterone Acetate 
g % w/v S;
Hydrocortisone Acetate 
g % w/v Sj
Progesterone 































30 :70 1.630 0.012 0.708 0.897 0.091 5.177 1.19 0.030 2.428 0.337 0.002 0.603 1.90 0.031 1.563
40: 60 1.587 0.009 0.521 0.884 0.064 3.559 1.1 0.011 0.731 0.329 0.001 0.315 1.81 0.047 2.440
50 :50 1.486 0.011 0.758 0.871 0.056 3.230 1.04 0.056 3.790 0.325 0.007 2.233 1.69 0.071 3.099
60 :40 1.367 0.039 2.837 0.859 0.090 2.658 1.0 0.005 0.353 0.321 0.005 1.945 1.57 0.118 5.239
70 : 30 1.264 0.0075 0.596 0.841 0.069 7.650 0.97 0.046 2.973 0.319 0.008 3.361 1.38 0.175 6.850
8 0 :2 0 1.148 0.040 3.470 0.834 0.026 3.061 0.93 0.047 2.744 0.316 0.007 3.099 1.21 0.115 4.425




S i% w/v Si % w/v Sj % w/v S; % w/v S; % W /V Sj % w/v Sj % w/v
25°C SD 30°C SD 40°C SD 50°C SD 60°C SD 70°C SD 80°C SD
0 1.046 0.0052 3.1440 0.0045 3.5060 0.0084 3.873 0.0067 5.2267 0.0027 3.9880 0.0847 4.7400 0.0100
6 2.240 0.0031 3.2650 0.0032 3.6100 0.0056 3.336 0.0053 4.5900 0.0063 4.1670 0.0092 4.1837 0.0095
12 2.349 0.0039 3.3850 0.0041 3.1200 0.0034 3.360 0.0028 3.5190 0.0073 3.6220 0.0094 3.8870 0.0043
24 2.450 0.0062 3.0600 0.0046 2.8710 0.0076 3.220 0.0027 3.3930 0.0039 3.3860 0.0052 3.5600 0.0093
36 2.56 0.0041 2.8370 0.0036 2.9190 0.0029 3.090 0.0082 3.2200 0.0024 3.3100 0.0024 3.3500 0.0089
48 2.591 0.0049 2.8370 0.0090 2.9000 0.0087 2.9170 0.0051 3.1700 0.0023 3.1100 0.0095 3.1200 0.0099
96 2.603 0.0036 2.7900 0.0041 2.8800 0.0032 2.8150 0.0037 2.8723 0.0012 3.0200 0.0024 2.9800 0.0076
x
Table 1.11 Effect o f temperature Vs time intervals on the solubility profile o f steroids in S-F formulations.
Hydrocortisone (St % w/v) Hydrocortisone acetate (St 
%w/v)
Testosterone acetate (Si % w/v)
Time (hour) 25C° SD Pre-heated 
at 50°C
SD 25C° SD Pre-heated 
at 50°C
SD 25C° SD Pre-heated 
at 50°C
SD
0 0.926 0.001 1.691 0.006 0.135 0.008 0.160 0.005 1.146 0.003 3.904 0.002
6 0.880 0.003 1.470 0.006 0.168 0.008 0.162 0.006 1.480 0.004 3.245 0.002
12 0.888 0.002 1.453 0.006 0.170 0.008 0.160 0.006 1.567 0.004 2.910 0.003
24 0.860 0.011 1.412 0.006 0.164 0.007 0.159 0.003 1.717 0.004 2.925 0.002
36 0.862 0.011 1.334 0.007 0.160 0.008 0.157 0.002 1.917 0.005 2.850 0.003
48 0.891 0.010 1.251 0.007 0.154 0.008 0.144 0.005 2.034 0.004 2.645 0.006
96 0.896 0.001 1.215 0.006 0.146 0.007 0.143 0.004 2.075 0.003 2.399 0.005
192 0.901 0.009 1.097 0.006 0.145 0.007 0.141 0.003 2.179 0.002 2.301 0.006
384 0.903 0.008 1.098 0.007 0.145 0.007 0.139 0.005 2.377 0.003 2.299 0.004
576 0.915 0.008 1.077 0.007 0.144 0.007 0.136 0.003 2.390 0.003 2.218 0.004
768 0.926 0.009 1.048 0.006 0.142 0.002 0.137 0.005 2.410 0.001 2.240 0.004
Testosterone (St % w/v) Progesterone (S°/o w/v)
Time (hrs) 25C° SD Pre-heated 
at 50°C
SD 25C° SD Pre-heated 
at 50°C
SD
0 1.046 0.005 3.873 0.007 1.825 0.005 3.261 0.004
6 2.240 0.003 3.336 0.005 2.089 0.004 2.907 0.006
12 2.349 0.004 3.360 0.003 2.11 0.002 2.694 0.004
24 2.450 0.006 3.220 0.003 2.345 0.004 2.583 0.004
36 2.56 0.004 3.090 0.008 2.648 0.003 2.467 0.003
48 2.591 0.005 2.917 0.005 2.681 0.008 2.375 0.004
96 2.603 0.004 2.815 0.004 2.744 0.005 2.298 0.006
192 2.610 0.003 2.70 0.002 2.727 0.002 2.230 0.006
384 2.651 0.004 2.635 0.004 2.710 0.008 2.235 0.008
576 2.721 0.005 2.601 0.002 2.715 0.004 2.211 0.005
768 2.742 0.006 2.591 0.004 2.710 0.005 2.143 0.008
Table 1.12 Solubility (%w/v) o f hydroxy benzoate derivatives in lipid excipients and/or SEDDS formulations at 25°C.

























Miglyol 812® 10.319 0.260 2.519 11.920 3.990 33.473 7.900 0.103 1.306 9.430 0.459 4.867
Imwitor 988® 26.870 0.960 3.573 15.740 4.070 25.858 9.320 0.667 7.157 24.160 1.670 6.912
Propylene glycol 31.840 0.545 1.712 12.480 0.622 4.984 11.990 0.370 3.085 29.570 4.077 13.788
* Surfactant-free 35.998 0.415 1.153 18.709 1.410 7.536 14.620 1.067 7.298 31.970 0.831 2.599
**Type II 25.270 1.800 7.123 14.335 0.838 5.846 9.270 0.388 4.186 20.920 2.030 9.704
***TypeIII A 19.419 0.506 2.606 19.198 0.306 1.595 9.990 0.429 4.294 24.938 1.936 7.763
****Type IIIB 50.976 1.450 2.844 21.152 0.376 1.778 12.610 2.230 17.684 30.557 2.230 7.298
*Type II Miglyol 812®+Tagat To®
40%:60%
**Surfactant-free Miglyol 812®+lmwitor 988®+PEG400
30%+50%+20%
***Type IIIA CRH 40®+lmwitor 988®+Miglyol 812®
35% + 35% + 30%




Hydrocortisone Hydrocortisone acetate Testosterone
Weight fraction 
o f cosolvent
%w/v So of 
PEG 400
SD %w/v So 
of PG
SD %w/v So ot 
PEG 400
SD %w/v So 
of PG
SD %w/v So of 
PEG 400
SD %w/v So 
of PG
SD
0.1 0.0O70 0.025 0.0088 0.0087 0.0007 0.0053 0.0006 0.0078 0.0013 0.0073 0.0010 0.0100
0.3 0.OO71 0.025 0.0091 0.0087 0.0067 0.0135 0.0025 0.0130 0.0048 0.0043 0.0098 0.0125
0.5 0.0073 0.007 0.0092 0.0093 0.0067 0.0158 0.0026 0.0173 0.0103 0.0035 0.0099 0.0100
0.7 0.0075 0.008 0.0009 0.0097 0.OO68 0.0058 0.0O29 0.0180 0.0153 0.0028 0.0090 0.0125
0.9 0.0086 0.008 0.0101 O.0098 O.O077 0.0105 0.0039 0.0148 0.0215 0.0103 0.0106 0.0125
1.0 0.0113 0.008 0.0103 O.0098 0.0086 0.0203 0.0045 0.0183 0.0328 0.0205 0.0113 0.0125
1.5 0.0168 0.010 0.0171 O.O1O0 0.0134 0.0008 0.0049 0.0220 0.0410 0.0138 0.0212 0.0100
2.0 0.0232 0.010 0.0235 0.0103 0.0183 0.0163 0.0064 0.0225 "0.0473- 0.0070 0.0312 0.0100
2.5 0.O319 o.oll 0.0353 0.0106 0.0233 0.0175 0.0076 O.0223 0.0533 0.0080 0.0738 0.0100
3.0 0.0382 0.011 0.0486 0.0113 0.0410 0.0133 0.0086 0.0245 0.0610 O.0048 0.0913 0.0125
3.5 0.O5O7 0.012 0.0612 0.0123 0.0510 0.0165 0.0095 0.0030 0.0663 0.0200 0.1286 0 .0 1 O0




%w/v So of 
PEG 400
SD %w/v So 
of PG
SD %w/v So of 
PEG 400
SD %w/v So 
of PG
SD
0.1 0.0053 0.0033 0.0054 0.0183 0.0011 0.0031 0.0014 0.0056
0.3 0.027O 0.0026 0.0133 0.0230 0.0071 0.0039 0.0057 0.0034
0.5 0.0570 0.0030 0.0413 0.0138 0.0091 0.0060 0.0058 0.0024
0.7 0.0825 0.0034 0.0713 0.0173 0.0116 0.0138 0.0058 0.0026
0.9 0.0950 0.0048 0.0917 0.0220 0.0133 0.0031 0.0062 0.0024
1.0 0.1075 0.0034 0.1090 0 .0 2 8 8 0.0141 0.0089 0.0063 0.0099
1.5 0.1350 0.0030 0.1324 0.0113 0.O2O8 0.0036 0.0145 0.0105
2.o 0.1633 0.0044 0.1548 0.0238 0.0332 O.0O26 0.0183 0.0046
2.5 0.1830 0.0030 0.1870 0.0230 0.0458 0.0041 0.0330 0.0036
3 .0 ' 0.2198 0.0034 0.2170 0.0288 0.0608 0.0056 O.O750 0.0029
3.5 0.2425 O.0O38 0.2350 0.0230 0.0709 0.0135 0.1120 0.0053
4.0 0.2684 O.0027 0.3274 0.0173 0.O87O 0.0031 0.1478 0.0083
Table 2.1 The solubility (% w/v) of steroids in aqueous solution of hydrophilic co-solvent (PG and/or PEG 400).
Hydrocortisone Hydrocortisone acetate Testosterone
Weight traction 
of cosolvent
%w/v So of 
PEG 400
SD %w/v So 
of PG
SD %w/v So of 
PEG 400
SD %w/v So 
of PG
SD %w/v So of 
PEG 400
SD %w/v So 
of PG
SD
" 0.1 0.OO77 0.0153 0.0089 0.0085 0.00077 O.Ol 13 ' o:ooos ~ m »028 0.0015 0.0026" "0.0013 0.0103
0.3 0.0096 0.0158 0.OO95 0.0135 0.0051 0.0165 0.OO23 0.0128 0.0092 0.0032 0.0175 0.0031
0.5 0.0098 0.0135 0.0098 0.0110 0.0065 0.0195 0.0025 0.0168 0.0110 0.0043 0.0350 0.0125
0.7 0.0101 0.0140 0.0133 0.0135 0.0081 0.0035 0.0028 0.0230 0.0225 0.0041 0.0525 O.0O83
0.9 0.0106 0.0158 0.0148 O.0O8O 0.0091 0.0160 0.0031 0.0195 0.0375 0.0039 0.0565 0.0036
1.0 — 0.0109 0.0143 0.O153 0.0088 0.0108 0.0058 0.0036 0.0195 0.0540 0.0053 0.0715 0.0117
1.5 0.0185 0.0128 0.0240 0.0053 0.O152 0.0123 0.0055 0.0113 1 0.0762 0.0056 0.0910 0.0138'
2.0 0.0246 0.0103 0.0423 0.0178 0.0233 0.0145 0.0069 0.0188 0.0973 0.0079 0:i035 " 0.0057
2.5 0.0363 0.0163 0.0505 0.0055 0.0346 0.0208 0.0080 0.0183 0.1250 0.0067” 0.1250 0.0084
3.0 0.0487 0.0178 0.0685 0.O08O 0.0461 0.0138 O.0091 0.0203 0.1672 0.0080 0.1469 0.0026
3.5 0.0637 0.0143 0.0800 0.0168 0.0671 0.0183 0.0101 0.O23O 0.2330 0.0103 0.1791 0.0028




%w/v So of 
PEG 400
SD %w/v So 
of PG
SD %w/v So of 
PEG 400
SD %w/v So 
of PG
SD
0.1 0.0050 0.0555 0.0052 0.0828 0.0010 ~inooj4" 0.O016 0.0335
0.3 0.0390 0.0200 0.0370 0.0280 0.00950 0.OO77 0.0115 0.0765
0.5 0.0635 0.02OO 0.036O 0.0570 0.0245 0.O055 0.0116 0.0548
0.7 0.1030 0.0225 0.0373 0.0343 0.0450 0.0103 0.0119 0.1028
0.9 0.0985 0.0300 0.0725 0.1055 0.0730 0.0128 0.0125 0.1280
1.0 0.1280 0.0400 0.0950 0.1280 0.0940 0.0028 0.0225 0.0278
1.5 0.1463 0.0573 0.1483 0.1505 0.1024 0.0041 0.0593 0.0413
2.0 0.1795 0.0685 0.1973 0.0520 0.1235 0.0048 0.1165 0.0483
to 0:1900 0.1530 0.2140 0.0258 0.1490 0.0071 0.1790 0.0710
3.0 0.2425 0.1255 0.2800 0.0910 0.1813 0.0083 0.2480 0.0833
3.5 0.3733 0.1158 0.4175 0.1778 0.2390 0.0026 0.3819 0.0263
4.0 0.4925 0.0263 0.5300 0.1303 0.3515 0.0074 0.6908 0.0738
Table 2.2 The solubility (% w/v) of steroids in tris-maleate buffer (pH 6.5)of hydrophilic co-solvent (PG and/or PEG 400).
x iv
Hydrocortisone Hydrocortisone acetate Testosterone
Weight fraction 
of surfactant
%w/v So o f  
CRH40
SD %w/v So of 
Tween 80
SD %w/v So of 
CRH40
SD %w/v So o f  
Tween 80
SD %w/v So of 
CRH40
SD %w/v So of 
Tween 80
SD
0.1 0.0050 0.0050 0.0228 0.0017 0.0209 0.0150 0.0104 0.0110 0.0225 0.0100 0.0223 0.0083
0.3 0.0950 0.0106 0.0300 0.0095 0.0218 0.0075 0.0143 0.0150 0.0475 0.0225 0.0305 0.0218
0.5 0.1075 0.0107 0.0577 0.0014 0.0245 0.0225 0.0236 0.0073 0.1025 0.0103 0.1218 0.0033
0.7 0.1358 0.0110 0.0753 0.0200 0.0688 0.0050 0.0258 0.0040 0.1525 0.0035 0.1635 0.0233
0.9 0.1625 0.0110 0.1046 0.0525 0.1108 0.0050 0.0373 0.0028 0.2150 0.0178 0.1808 0.0113
1.0 0.1871 0.0112 0.1320 0.0158 0.1282 0.0175 0.0393 0.0093 0.3275 0.0100 0.2213 0.0205
1.5 0.2054 0.0113 0.1566 0.0178 0.1725 0.0175 0.0595 0.0213 0.4100 0.0225 0.2428 0.0173
2.0 0.2321 0.0115 0.1825 0.0108 0.1973 0.0150 0.1065 0.0248 0.4725 0.0030 0.2600 0.0028
2.5 0.2685 0.0116 0.2055 0.0145 0.2310 0.0225 0.1580 0.0153 0.5325 0.0128 0.4025 0.0095
3.0 0.3233 0.0118 0.2280 0.0625 0.2757 0.0225 0.1943 0.0178 0.6100 0.0030 0.4625 0.0525
3.5 0.3626 0.0119 0.2631 0.0228 0.3600 0.0150 0.2335 0.0158 0.6625 0.0143 0.5800 0.1550




%w/v So of  
CRH40
SD %w/v So of 
Tween 80
SD %w/v So of 
CRH40
SD %w/v So of 
Tween 80
SD
0.1 0.0228 0.0023 0.0275 0.0058 0.0153 0.0030 0.0180 0.0030
0.3 0.0533 0.0030 0.0748 0.0083 0.0248 0.0023 0.0300 0.0085
0.5 0.1080 0.0078 0.1125 0.0030 0.0358 0.0030 0.0523 0.0210
0.7 0.1530 0.0105 0.1608 0.0210 0.0640 0.0003 0.0733 0.0203
0.9 0.2113 0.0128 0.2308 0.0068 0.0998 0.0021 0.0975 0.0220
1.0 0.3000 0.0105 0.3075 0.0095 0.1503 0.0137 0.1283 0.0223
1.5 0.3625 0.0213 0.3900 0.0113 0.1998 0.0073 0.1500 0.0198
2.0 0.4200 0.0059 0.4725 0.0090 0.2475 0.0187 0.2005 0.0203
2.5 0.4800 0.0103 0.5250 0.0045 0.3275 0.0145 0.2335 0.0203
3.0 0.5325 0.0248 0.6025 0.0035 0.4125 0.0059 0.2725 0.0120
3.5 0.5750 0.0050 0.6675 0.0040 0.4725 0.0015 0.4330 0.0225
4.0 0.6275 0.0058 0.7450 0.0045 0.5600 0.0019 0.5200 0.0048
Table 2.3 The solubility (%w/v) of steroids in aqueous solution of hydrophilic surfactant (Tween 80® or/ and CRH 40®)
at 25°C.
xv
Hydrocortisone Hydrocortisone acetate Testosterone
Weight fraction 
o f surfactant
%w/v So of  
CRH40
SD %w/v So of 
Tween 80
SD %w/v So of 
CRH40
SD %w/v So o f 
Tween 80
SD %w/v So of 
CRH40
SD %w/v So of 
Tween 80
SD
0.1 0.0173 0.0017 0.0190 0.0023 0.0613 0.0150 0.0803 0.0175 0.1030 0.0080 0.0240 0.0225
0.3 0.0600 0.0095 0.0325 0.0080 0.0855 0.0200 0.1143 0.0100 0.1788 0.0133 0.0330 0.0085
0.5 0.0860 0.0014 0.0718 0.0025 0.1063 0.0025 0.1498 0.0175 0.2275 0.0058 0.0885 0.0030
0.7 0.1220 0.0200 0.0878 0.0023 0.1499 0.0010 0.1608 0.0225 0.2486 0.0028 0.1948 0.0128
0.9 0.1464 0.0525 0.1225 0.0033 0.1780 0.0003 0.1973 0.0225 0.3223 0.0175 0.2488 0.0090
1.0 0.1695 0.0158 0.1400 0.0073 0.2000 0.0005 0.2110 0.0175 0.3425 0.0300 0.3781 0.0178
1.5 0.2550 0.0178 0.1600 0.0125 0.2478 0.0013 0.2488 0.0025 0.3775 0.1350 0.5825 0.0005
2.0 0.3412 0.0108 0.1780 0.0198 0.2973 0.0018 0.3235 0.0050 0.4850 0.1575 0.7050 0.0045
2.5 0.4035 0.0145 0.2085 0.0023 0.3535 0.0018 0.3998 0.0125 0.5525 0.0975 0.7825 0.0180
3.0 0.4890 0.0625 0.2303 0.0180 0.3975 0.0008 0.4550 0.0125 0.6750 0.1250 0.8550 0.0045
3.5 0.5100 0.0228 0.3000 0.0163 0.4450 0.0015 0.5348 0.0225 0.8000 0.0450 0.9275 0.0003




%w/v So o f  
CRH40
SD %w/v So of 
Tween 80
SD %w/v So of 
CRH40
SD %w/v So of 
Tween 80
SD
0.1 0.0275 0.0006 0.0325 0.0075 0.0178 0.0123 0.0208 0.0135
0.3 0.0575 0.0053 0.0725 0.0105 0.0358 0.0160 0.0380 0.0133
0.5 0.1223 0.0068 0.1078 0.0130 0.0495 0.0212 0.0695 0.0158
0.7 0.1530 0.0060 0.1780 0.0178 0.0985 0.0122 0.0808 0.0130
0.9 0.2225 0.0055 0.2328 0.0128 0.1408 0.0217 0.1530 0.0030
1.0 0.3075 0.0048 0.3375 0.0030 0.2085 0.0217 0.1778 0.0055
1.5 0.3800 0.0078 0.4500 0.0105 0.2750 0.0125 0.2418 0.0140
2.0 0.4950 0.0040 0.6025 0.0153 0.3575 0.0125 0.3075 0.0030
2.5 0.5850 0.0070 0.6825 0.0085 0.4358 0.0160 0.3825 0.0218
3.0 0.6525 0.0085 0.7475 0.0183 0.4825 0.0113 0.4725 0.0208
3.5 0.7450 0.0195 0.8100 0.0168 0.5800 0.0110 0.5625 0.0133
4.0 0.8300 0.0030 0.8950 0.0085 0.6625 0.0150 0.6950 0.0228
Table 2.4 The solubility (%w/v) of steroids in tris-maleate buffer (pH 6.5) of hydrophilic surfactant (Tween 80® and/or CRH
40®) at 25°C.
xvi





SD %w/v So of 
Type II
SD %w/v So 
of M 812
SD %w/v So of  
Type II
SD %w/v So 
of M 812
SD %w/v So of 
Type II
SD
0.1 0.00090 0.00003 0.00100 0.00001 0.00400 0.00775 0.00044 0.02200 0.00900 0.00900 0.00800 0.00230
0.3 0.00310 0.00013 0.00350 0.00010 0.01000 0.01300 0.00117 0.01900 0.02300 0.00720 0.01900 0.00173
0.5 0.00520 0.00004 0.00710 0.00011 0.02200 0.01725 0.00202 0.01350 0.04179 0.00720 0.03300 0.00345
0.7 0.00810 0.00005 0.00930 0.00014 0.02900 0.01800 0.00253 0.01900 0.05650 0.00900 0.05100 0.00288
0.9 0.00970 0.00006 0.01360 0.00016 0.03650 0.01475 0.00370 0.00925 0.06825 0.00720 0.06300 0.00173
1.0 0.01000 0.00006 0.01530 0.00019 0.03725 0.01825 0.00390 0.01625 0.07125 0.00900 0.06500 0.00230
1.5 0.01380 0.00007 0.01640 0.00021 0.05200 0.02200 0.00510 0.01650 0.09225 0.00900 0.09100 0.00173
2.0 0.01760 0.00008 0.01890 0.00023 0.08393 0.02250 0.00690 0.01275 0.13800 0.00900 0.13900 0.00173
2.5 0.01910 0.00008 0.02200 0.00027 0.10300 0.02225 0.00820 0.02275 0.19900 0.00900 0.18900 0.00127
3.0 0.02190 0.00008 0.02430 0.00032 0.13920 0.02450 0.01010 0.01475 0.27900 0.00720 0.22100 0.00230
3.5 0.02900 0.00009 0.02630 0.00036 0.18600 0.00300 0.01230 0.00250 0.31300 0.00720 0.26300 0.00288





o f M 812
SD %w/v So of 
Type II
SD %w/v So 
o f M 812
SD %w/v So of 
Type II
SD
0.1 0.0120 0.0050 0.0070 0.0058 0.0190 0.0035 0.0060 0.0083
0.3 0.0350 0.0080 0.0180 0.0105 0.0430 0.0120 0.0170 0.0133
0.5 0.0599 0.0053 0.0293 0.0030 0.0748 0.0105 0.0250 0.0095
0.7 0.0810 0.0128 0.0430 0.0103 0.0948 0.0010 0.0390 0.0105
0.9 0.1010 0.0053 0.0601 0.0155 0.1350 0.0145 0.0540 0.0038
1.0 0.1121 0.0055 0.0623 0.0030 0.1500 0.0009 0.0585 0.0045
1.5 0.1425 0.0003 0.0970 0.0028 0.1995 0.0122 0.0910 0.0028
2.0 0.2010 0.0230 0.1410 0.0035 0.3280 0.0113 0.1122 0.0093
2.5 0.2810 0.0035 0.1930 0.0130 0.3725 0.0223 0.1585 0.0058
3.0 0.3514 0.0045 0.2350 0.0073 0.4250 0.1225 0.1783 0.0065
3.5 0.4010 0.0058 0.2790 0.0128 0.5575 0.0203 0.2165 0.0045
4.0 0.4760 0.0105 0.3300 0.0155 0.6910 0.0113 0.2460 0.0060
Table 2.5 The solubility (w/v) of steroids in aqueous solution of type I (Miglyol 812®) and type II ( Miglyol 812® and Tagat
TO®)at 25°C.
XVll




o f M 812
SD %w/v So of 
Type II
SD %w/v So 
of M 812
SD %w/v So of 
Type II
SD %w/v So 
of M 812
SD %w/v So of 
Type II
SD
0.1 0.00785 0.00022 0.00090 0.1375 0.0038 0.0155 0.000500 0.0185 0.0085 0.0008 0.0079 0.000079
0.3 0.00210 0.00019 0.00320 0.1525 0.0090 0.0135 0.001275 0.0165 0.0210 0.0003 0.0170 0.000170
0.5 0.00450 0.00023 0.00630 0.0800 0.0130 0.0180 0.001675 0.0048 0.0387 0.0004 0.0291 0.000291
0.7 0.00730 0.00011 0.00860 0.1775 0.0190 0.0160 0.001950 0.0050 0.0501 0.0002 0.0410 0.000410
0.9 0.00870 0.00016 0.01340 0.1275 0.0251 0.0195 0.002225 0.0128 0.0623 0.0003 0.0520 0.000520
1.0 0.00910 0.00020 0.01420 0.2075 0.0261 0.0223 0.002950 0.0133 0.0641 0.0006 0.0541 0.000541
1.5 0.01090 0.00012 0.01610 0.1300 0.0340 0.0053 0.003550 0.0150 0.0890 0.0002 0.0820 0.000820
2.0 0.01410 0.00017 0.01810 0.1525 0.0470 0.0025 0.004825 0.0068 0.1100 0.0004 0.1100 0.001100
2.5 0.01870 0.00017 0.02010 0.1900 0.0580 0.0140 0.006438 0.0153 0.1510 0.0002 0.1530 0.001530
3.0 0.02120 0.00013 0.02310 0.1525 0.0710 0.0198 0.008147 0.0113 0.1990 0.0002 0.1810 0.001810
3.5 0.02510 0.00015 0.02710 0.0575 0.0870 0.0203 0.009800 0.0220 0.2310 0.0003 0.2310 0.002310






SD %w/v So of 
Type II
SD %w/v So 
o f M 812
SD %w/v So of 
Type II
SD
0.1 0.0110 0.0030 0.0065 0.0153 0.0170 0.0028 0.0057 0.0143
0.3 0.0310 0.0080 0.0161 0.0205 0.0320 0.0068 0.0150 0.0030
0.5 0.0570 0.0885 0.0250 0.0058 0.0610 0.0105 0.0230 0.0011
0.7 0.0740 0.0100 0.0410 0.0103 0.0870 0.0070 0.0320 0.0055
0.9 0.0910 0.0163 0.0580 0.0045 0.1100 0.0043 0.0490 0.1025
1.0 0.0931 0.0080 0.0600 0.0038 0.1200 0.0030 0.0510 0.0098
1.5 0.1290 0.0113 0.0890 0.0040 0.1800 0.0053 0.0830 0.0103
2.0 0.1890 0.0168 0.1210 0.0205 0.2200 0.0108 0.1010 0.0145
2.5 0.2310 0.0085 0.1890 0.0030 0.2780 0.0133 0.1400 0.0045
3.0 0.2910 0.0130 0.2310 0.0038 0.3010 0.0200 0.1710 0.0038
3.5 0.3410 0.0133 0.2760 0.0028 0.3530 0.0168 0.2110 0.0080
4.0 0.3810 0.0160 0.3010 0.0048 0.3990 0.0178 0.2420 0.0128
Table 2.6 The solubility (%w/v) of steroids in tris-maleate buffer (pH 6.5) of type I (Miglyol 812®) and type II 





%w/v So of 
Type III A
SD %w/v So of 
Type III B
SD %w/v So of 
S-F
SD %w/v So of 
Type III A
SD %w/v So of 
Type III B
SD %w/v So of 
S-F
SD
0.1 0.0090 0.0108 0.0080 0.0058 0.0120 0.000120 0.00190 0.0128 0.0011 0.0001 0.00150 0.0375
0.3 0.0190 0.0163 0.0120 0.0059 0.0371 0.000371 0.00540 0.0158 0.0033 0.0002 0.00580 0.0450
0.5 0.0310 0.0108 0.0230 0.0059 0.0750 0.000750 0.00890 0.0030 0.0050 0.0000 0.00910 0.1575
0.7 0.0046 0.0183 0.0390 0.0059 0.0930 0.000930 0.01200 0.0055 0.0086 0.0024 0.01200 0.1725
0.9 0.0630 0.0203 0.0500 0.0059 0.1239 0.001239 0.01970 0.0245 0.0141 0.0001 0.01610 0.2250
1.0 0.0647 0.0161 0.0510 0.0059 0.1250 0.001250 0.02100 0.0128 0.0150 0.0005 0.01640 0.0325
1.5 0.0830 0.0193 0.0720 0.0061 0.1741 0.001741 0.02730 0.0058 0.0190 0.0003 0.02100 0.2075
2.0 0.0920 0.0031 0.0910 0.0063 0.0210 0.000210 0.03010 0.0190 0.0252 0.0023 0.03000 0.1550
2.5 0.1100 0.0119 0.1100 0.0064 0.0281 0.000281 0.03520 0.0048 0.0291 0.0017 0.03620 0.1425
3.0 0.1620 0.0168 0.1490 0.0066 0.0350 0.000350 0.03910 0.0120 0.0351 0.0012 0.04410 0.1550
3.5 0.2100 0.0032 0.1960 0.0068 0.0411 0.000411 0.04420 0.0083 0.0381 0.0014 0.05340 0.1025




%w/v So of 
Type III A
SD %w/v So of 
Type III B
SD %w/v So of 
S-F
SD %w/v So o f 
Type III A
SD %w/v So o f 
Type III B
SD %w/v So of 
S-F
SD
0.1 0.0092 0.0015 0.0050 0.000050 0.0300 0.0125 0.0090 0.0030 0.0040 0.0030 0.0220 0.0025
0.3 0.0210 0.0050 0.0130 0.000130 0.0910 0.0300 0.0230 0.0550 0.0090 0.0058 0.0620 0.0075
0.5 0.0430 0.0025 0.0210 0.000210 0.1320 0.1125 0.0410 0.0028 0.0150 0.0105 0.1010 0.0100
0.7 0.0710 0.0058 0.0340 0.000340 0.1900 0.0030 0.0610 0.0038 0.0260 0.0031 0.1530 0.0050
0.9 0.0967 0.0175 0.0510 0.000510 0.2400 0.0058 0.0967 0.0030 0.0380 0.0131 0.2120 0.0223
1.0 0.0980 0.0025 0.0520 0.000520 0.2500 0.0085 0.0980 0.0035 0.0410 0.1050 0.2140 0.0058
1.5 0.1310 0.0075 0.0690 0.000690 0.4100 0.0108 0.1200 0.0045 0.0600 0.1050 0.3200 0.0113
2.0 0.1770 0.0125 0.0810 0.000810 0.5800 0.0135 0.1720 0.0030 0.0750 0.0141 0.4170 0.0070
2.5 0.2500 0.0075 0.0930 0.000930 0.7400 0.0085 0.2130 0.0035 0.0920 0.0185 0.5210 0.0040
3.0 0.2900 0.0150 0.0120 0.000120 0.9100 0.0025 0.2510 0.0048 0.1100 0.1550 0.6300 0.0035
3.5 0.3210 0.0110 0.0163 0.000163 1.0300 0.0058 0.2920 0.0023 0.1520 0.0035 0.7250 0.0040
4.0 0.3600 0.0025 0.0195 0.000195 1.2300 0.0080 0.3560 0.0033 0.1990 0.0128 0.8630 0.0030
Table 2.7 The solubility (%w/v) of steroids in aqueous solution of type IIIA (Miglyol 812®+ Imwitor 988® + CRH40®), 






%w/v So of  
Type III A
SD %w/v So of 
Type III B
SD %w/v So of 
S-F
SD %w/v So of 
Type III A
SD %w/v So of 
Type III B
SD %w/v So of 
S-F
SD
0.1 0.00870 0.0003 0.00770 0.00055 0.0110 0.0120 0.00170 0.0085 0.00110 0.000011 0.00149 0.000015
0.3 0.00172 0.0016 0.01300 0.00067 0.0330 0.0153 0.05210 0.0073 0.00325 0.000033 0.05200 0.000520
0.5 0.02900 0.0011 0.02200 0.00023 0.053 0.0208 0.00821 0.0245 0.00525 0.000053 0.00891 0.000089
0.7 0.04100 0.0020 0.03410 0.00076 0.0780 0.0215 0.00110 0.0135 0.09213 0.000921 0.01230 0.000123
0.9 0.05800 0.0020 0.04780 0.00093 0.0990 0.0128 0.01710 0.0080 0.01250 0.000125 0.01580 0.000158
1.0 0.05910 0.0021 0.04990 0.001 0.1090 0.0080 0.01930 0.0133 0.01380 0.000138 0.01600 0.000160
1.5 0.08800 0.0015 0.08600 0.00054 0.1600 0.0168 0.02430 0.0083 0.01690 0.000169 0.02210 0.000221
2.0 0.11200 0.0023 0.11000 0.0078 0.2210 0.0112 0.03010 0.0053 0.02090 0.000209 0.03110 0.000311
2.5 0.14900 0.0012 0.15000 0.0031 0.2800 0.0228 0.03910 0.0105 0.02510 0.000251 0.04230 0.000423
3.0 0.18700 0.0083 0.17200 0.0033 0.3340 0.0925 0.04810 0.0210 0.03410 0.000341 0.04780 0.000478
3.5 0.22100 0.0015 0.19900 0.0094 0.3910 0.0723 0.05770 0.0238 0.03890 0.000389 0.05120 0.000512




%w/v So of 
Type III A
SD %w/v So of 
Type III B
SD %w/v So of 
S-F
SD %w/v So of 
Type III A
SD %w/v So of 
Type III B
SD %w/v So of 
S-F
SD
0.1 0.00870 0.000087 0.00560 0.0025 0.0360 0.000360 0.0080 0.0025 0.00330 0.0085 0.0230 0.0030
0.3 0.02100 0.000210 0.01430 0.0075 0.0980 0.000980 0.0200 0.0133 0.00610 0.0056 0.0640 0.0105
0.5 0.04700 0.000470 0.02710 0.0050 0.1410 0.001410 0.0452 0.0158 0.01100 0.0133 0.0912 0.0155
0.7 0.06900 0.000690 0.03510 0.0105 0.2210 0.002210 0.0684 0.0158 0.02310 0.0160 0.1420 0.0208
0.9 0.08200 0.000820 0.04760 0.0163 0.3210 0.003210 0.0850 0.0223 0.03000 0.0153 0.2010 0.0230
1.0 0.08750 0.000875 0.05210 0.0053 0.3580 0.003580 0.0920 0.0030 0.03250 0.0110 0.2360 0.0183
1.5 0.11000 0.001100 0.07710 0.0129 0.4200 0.004200 0.1120 0.0213 0.04540 0.0168 0.3510 0.0123
2.0 0.15200 0.001520 0.09310 0.0183 0.5610 0.005610 0.1580 0.0223 0.06200 0.0172 0.5120 0.0203
2.5 0.18600 0.001860 0.12100 0.0140 0.6860 0.006860 0.1930 0.0030 0.08900 0.0230 0.5780 0.0180
3.0 0.21100 0.002110 0.15500 0.0030 0.7810 0.007810 0.2210 0.0113 0.12100 0.0450 0.6690 0.0156
3.5 0.24900 0.002490 0.18900 0.0203 0.8300 0.008300 0.2650 0.0188 0.15300 0.0130 0.7910 0.0108
4.0 0.27900 0.002790 0.22700 0.0230 0.9190 0.009190 0.2990 0.0183 0.18700 0.0025 0.9210 0.0178
Table 2.8 The solubility (% w/v)of steroids in tris-maleate buffer (pH 6.5) of type IIIA (Miglyol 812®+ Imwitor 988® + CRH40®),
type III B (Miglyol 812®+ Imwitor 988® + CRH40® + PG) and surfactant free formulation (Miglyol 812®+ Imwitor 988® + PG) at
25°C.
xx
Progesterone (H2O) Progesterone (tris-maleate)
%w/v So of 
Type III A
SD %w/v So of 
Type III B
SD %w/v So of 
S-F
SD %w/v So of 
Type III A
SD %w/v So of 
Type III B
SD %w/v So of 
S-F
SD
0.0110 0.0080 0.0065 0.0011 0.0210 0.0055 0.0130 0.0078 0.00650 0.0030 0.0230 0.0095
0.0467 0.0014 0.0120 0.0058 0.0630 0.0108 0.0331 0.0060 0.01020 0.0055 0.0674 0.0108
0.0690 0.0098 0.0270 0.0053 0.1010 0.0053 0.0612 0.0043 0.02830 0.0130 0.1100 0.0133
0.0843 0.0130 0.0510 0.0223 0.1530 0.0088 0.0930 0.0128 0.04140 0.0133 0.1720 0.0213
0.0998 0.0215 0.0750 0.0035 0.1920 0.0095 0.1120 0.0078 0.06210 0.0108 0.2030 0.0053
0.1020 0.0245 0.0770 0.0128 0.2210 0.0065 0.1340 0.0155 0.06600 0.0153 0.2410 0.0133
0.1620 0.0030 0.0930 0.0148 0.3130 0.0053 0.1930 0.0211 0.09210 0.0045 0.3490 0.0195
0.2100 0.0108 0.1230 0.0108 0.4000 0.0065 0.2610 0.0130 0.12700 0.0123 0.4820 0.0030
0.2730 0.0130 0.1780 0.0147 0.5120 0.0093 0.3160 0.0163 0.16900 0.0108 0.5620 0.0145
0.3310 0.0219 0.2220 0.0035 0.6200 0.0063 0.3520 0.0035 0.19500 0.0143 0.6730 0.0130
0.3860 0.0163 0.2580 0.0108 0.7230 0.0073 0.3800 0.0133 0.23700 0.0085 0.7990 0.0103
0.4250 0.0030 0.2890 0.0158 0.8470 0.0080 0.4310 0.0153 0.27890 0.0700 0.9170 0.0058
Table 2.9 The solubility (%w/v) of progesterone in aqueous solution or/ and tris-maleate buffer (pH 6.5) of type IIIA (Miglyo 
812®+ Imwitor 988® + CRH40®), type III B (Miglyol 812®+ Imwitor 988® + CRH40® + PG) and surfactant free formulatio 
(Miglyol 812®+ Imwitor 988® + PG) at 25°C.




A series of methyl paraben solutions was prepared by dilution with acetonitrile 
99%v/v. Samples were produced which contained (0.212, 0.5088, 0.848, 1.272, and 
1.696) mg % of methyl paraben. Hydrocortisone was added as an internal standard in 
concentration 0.653 mg%. An analysis was performed as described in 6.2.2.4. A 
Beer-Lambert plot for concentration (% w/v) was determined using regression 
analysis.




Methyl paraben concentration (% w/v)
0.0015 0.002 0.00250.0005
Testosterone
A series of testosterone solutions was prepared by dilution with methanol 99%v/v. 
Samples were produced which contained (0.468,0.976, 1.52, 1.952 and 2.92) mg % of 
methyl paraben. Dexamethasone was added as an internal standard in concentration 
1.332 mg %. An analysis was performed as described in 6.2.2.4. A Beer-Lambert 
plot for concentration (% w/v) was determined with following regression analysis. 
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Testosterone concentration (% w/v)
xxii
Hydrocortisone
A series of hydrocortisone solutions was prepared by dilution with methanol 99% 
v/v. Samples were produced which contained (0.122,0.917,1.528, 2.75,and 3.056) 
mg % hydrocortisone. Corticosteroids was added as an internal standard in 
concentration 0.682 mg %. An analysis was performed as described in 6.2.2.4. A 
Beer-Lambert plot for concentration (% w/v) was determined with following 
regression analysis.
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Butyl paraben
A series of butyl paraben solutions was prepared by dilution with acetonitrile 
99%v/v. Samples were produced which contained (0.6312, 1.26, 1.89, 2.52 and 
2.832) mg % of methyl paraben. Testosterone was added as an internal standard in 
concentration 5.364 mg %. An analysis was performed as described in 6.2.2.4. A 
Beer-Lambert plot for concentration (% w/v) was determined using regression 
analysis.
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30mincv CV CV CV CV
Oily phase 0.0895 0.514 0.079 1.44 0.060 2.217 0.104 0.646 0.093 2.311
Milky thick phase 0.0642 4.143 0.081 0.519 0.092 3.509
Clear slightly turbid phase 0.098 0.935 0.096 2.554
Pellet phase 0.030 6.126 0.039 0.642
Mass recovered 0.154 0.160 0.152 0.232 0.228
Mass balanced 0.156 0.171 0.173 0.237 0.238
% recovered 98.47 93.72 88.04 98.01 95.73
% digested 5.96 5.96 4.01 19.90 19.90
Miglyol oil Imwitor 988 Imwitor 988
without calcium CV 5 min CV 30 min CV
Oily phase 0.125 1.869 0.054 6.010 0.047 2.340
Clear slightly turbid phase 0.106 1.383 0.015 9.670 0.016 5.100
Viscous, gel-like phase 0.147 0.133 0.151 3.110
Pellet phase 0.030 2.762 0.117 2.120 0.109 4.210
Mass recovered 0.261 0.333 0.324
Mass balanced 0.212 0.322 0.322
% recovered 122.65 103.60 100.50
% digested 11-.30 24.76 24.76
Table 3.1 The amount (% w/v) of butyl paraben recovered of lipid excipients (LCT, MCT, mixed mono-, di-, and tri-glycerides) 
in standard pH-stat solution under standard pH-state conditions.
xxiv
Type II Type II Type IIIA Type IIIA Type III B Type III B
5 min CV 30min CV 5 min CV 30min CV 5 min CV 30min CV
oily phase 0.055 2.40 0.048 1.28
Interface (slightly turbid phase) 0.029 2.26 0.038 0.99 0.079 0.97 0.084 2.74
Subphase (micellar phase) 0.182 2.20 0.189 2.56 0.213 0.15 0.231 0.85 0.4520 4.40 0.4590 0.68
Pellet phase 0.046 2.07 0.049 3.48 0.091 1.85 0.101 1.58
Mass recovered 0.312 0.324 0.382 0.416 0.452 0.459
Mass balanced 0.325 0.378 0.443 0.466 0.463 0.460
% recovered 96.02 85.65 86.37 89.43 97.60 99.75
% digested 27.00 27.00 21.30 21.30 15.03 15.01
S-F S-F
5 min CV 30 min CV
Interface (slightly turbid phase) 0.112 1.07 0.123 3.00
Subphase (micellar phase) 0.248 0.43 0.240 1.84
Pellet phase 0.072 0.44 0.132 0.48
Mass recovered 0.432 0.495
Mass balanced 0.453 0.507
% recovered 95.22 97.63
% digested 33.09 33.09
Table 3.2 The amount (% w/v) of butyl paraben recovered of SEDDS formulations in standard pH-stat solution under standard 
pH-state conditions.
xxv





I 988: M812 
7:3 (5min)









CV CV CV CV CV CV
Interface (slightly turbid phase) 0.060 0.49 0.030 5.243 0.025 3.43 0.027 0.95 0.031 0.73 0.029 2.90
Subphase (micellar phase) 0.173 0.30 0.216 3.892 0.036 9.96 0.021 0.63
viscous, gel-like phase 0.150 0.69 0.160 0.82 0.232 3.30 0.215 3.21
Pellet phase 0.060 1.29 0.067 1.495 0.058 1.82 0.065 0.18 0.067 1.70 0.091 1.31
Mass recovered 0.293
CV
0.313 0.269 0.272 0.329 0.335
Mass balanced 0.298 0.299 0.279 0.272 0.317 0.341
% recovered 98.48 104.59 96.42 100.14 103.84 98.24
% digested 20.65 20.65 33.75 33.75 27.63 27.63
I 988: M812 
5:3 (5min)
I 988: M812 
5:3 (30min)
Interface (slightly turbid phase) 0.031 0.12 0.034 1.20
Subphase (micellar phase) 0.217 1.31 0.229 1.70
Pellet phase 0.064 1.31 0.065 1.70
Mass recovered 0.248 0.263
Mass balanced 0.278 0.281
% recovered 89.16 93.76
% digested 53.33 53.33
Table 3.3 The amount (% w/v) of butyl paraben recovered of mixtures of MCT and mixed mono-, di-, and tri-glycerides in 
standard pH-stat solution under standard pH-state conditions.
xxvi
Com oil Com oil Com oil without Miglyol 812
Miglyol
812
5 min CV 30 min CV calcium CV 5 min CV 30 min CV
Oily phase 0.0005 3.977 0.0008 0.875 0.0012 15.26 0.0009 0.548 0.0002 5.339
Milky turbid phase 0.0252 8.207 0.0261 20.627 0.0052 20.57
Subphase (micellar phase) 0.0097 5.386 0.0087 11.602
Pellet phase 0.0213 0.0237 3.259
Mass recovered 0.0257 0.0269 0.0064 0.3190 0.0325
Mass balanced 0.0292 0.0304 0.0068 0.3430 0.0343
% recovered 88.185 88.622 95.12 93.00 94.856
% digested 5.690 5.690 3.90 11.03 11.03
Imwitor 988 Imwitor 988 Imwitor 988
without
calcium CV 5 min CV 30 min CV
Oily phase 0.0002 5.339 0.0001 1.607 0.0001 1.607
Subphase (micellar phase) 0.0097 11.602 0.0075 3.353 0.0075 3.353
V iscous, gel-like phase 0.0193 3.259 0.0238 3.873 0.0238 3.873
Mass recovered 0.0292 0.0314 0.031
Mass balanced 93.818 0.0301 0.031
% recovered 0.0311 104.26 100.73
% digested 12.070 25.19 25.19
Table 3.4 The amount (% w/v) of hydrocortisone recovered of lipid excipients (LCT, MCT, mixed mono-, di-, and tri-glycerides) 
in standard pH-stat solution under standard pH-state conditions.
xxvii
Type II Type II Type IIIA Type IIIA Type III B Type III B
5min CV 30min CV 5 min CV 30min CV 5min CV 30min CV
Oily phase 0.00187 6.676 0.006 4.320
Interface (slightly turbid phase) 0.01447 9.559 0.0301 1.37 0.0033 6.361 0.0046 0.139
Subphase (micellar phase) 0.00957 2.510 0.0193 22.618 0.0153 1.101 0.0365 11.84 0.0372 9.2
Pellet phase
Mass recovered 0.0259 0.0362 0.0225 0.0199 0.0365 0.0372
Mass balanced 0.0355 0.0405 0.0191 0.0221 0.0361 0.0325
% recovered 73.06 89.45 117.92 90.10 101.35 114.34
% digested 8.24 8.24 29.78 29.78 21.23 21.23
S-F S-F
5min CV 30 min CV
Interface (slightly turbid phase) 0.0043 2.000 0.0001 3.230
Subphase (micellar phase) 0.0151 1.933 0.0194 2.456
Pellet phase 0.0034 2.135 0.0054 1.228
Mass recovered 0.0227 0.0249
Mass balanced 0.0239 0.0227
% recovered 95.27 109.84
% digested 25.43 25.43
Table 3.5 The amount (% w/v) of hydrocortisone recovered of SEDDS formulations in standard pH-stat solution under standard 
pH-state conditions.
xxviii
I 988: M812 I 988: M812 I 988: M812 I 988: M812 1 988: M812 1988: M812
3:7 (5min) CV 3:7 (30min) CV 7:3 (5min) CV 7:3 (30min) CV 5:5 (5min) CV 5:5 (30min) CV
Interface (slightly turbid phase) 0.0599 0.492 0.0295 17.324 0.0361 9.962 0.0211
Subphase (micellar phase) 0.0183 0.297 0.0216 12.818 0.0252 3.430 0.0265 31.270 0.0307 15.88 0.0287 15.758
Viscous, gel-like phase 0.1504 0.685 0.1597 9.407 0.2320 15.78 0.2150 7.829
Pellet phase 0.0603 1.290 0.0672 13.450 0.0576 1.822 0.0649 10.417 0.0667 11.23 0.0912 2.530
Mass recovered 0.138 0.118 0.269 0.272 0.329 0.335
Mass balanced 0.134 0.131 0.219 0.288 0.345 0.326
% recovered 103.23 90.34 122.75 94.52 95.41 102.61
% digested 14.93 14.93 39.28 39.28 26.47 26.47
I 988: M812 1 988: M812
5:3 (5min) CV 5:3 (30min) CV
Interface (slightly turbid phase) 0.0016 9.223 0.0021 2.427
Subphase (micellar phase) 0.0226 3.670 0.0231 14.248
Pellet phase 0.0044 1.420 0.0041 5.350
Mass recovered 0.0285 0.0293
Mass balanced 0.029 0.028
% recovered 100.13 100.13
% digested 35.32 35.32
Table 3.6 The amount (% w/v) of hydrocortisone recovered of mixtures of MCT and mixed mono-, di-, and tri-glycerides in 
standard pH-stat solution under standard pH-state conditions.
xxix
Com oil Miglyol 812 Imwitor 988
CV CV CV
Oily phase 0.0425 1.245 0.066 43.151 0.003 1.925
Milky thick turbid phase 0.0808 0.915 0.012 6.414 0.076 22.278
Viscous, gel-like phase 0.362 5.756
Pellet phase 0.088 2.969
Mass recovered 0.123 0.166 0.442
Mass balanced 0.125 0.169 0.475
% Recovered 98.94 98.09 93.13
% Digested 7.69 13.75 23.74
Table 3.7 The amount (% w/v) of methyl paraben recovered of mixtures of MCT and mixed mono-, di-, and tri-glycerides 
in standard pH-stat solution under standard pH-state conditions.
S-F Type IIIA Type III B Type II
CV CV CV CV
Oily phase 0.032 3.069
Interface (slightly turbid phase) 0.124 4.077 0.534 3.362 0.292 4.434
Subphase (micellar phase) 0.396 1.421 0.382 5.527
Pellet phase 0.042 4.014 0.083 4.359
Mass recovered 0.520 0.423 0.534 0.407
Mass balanced 0.572 0.456 0.556 0.433
% Recovered 90.92 92.74 96.04 93.97
% Digested 19.29 29.69 9.32 29.13
Table 3.9 The amount (% w/v) of methyl paraben recovered of SEDDS formulations in standard pH-stat solution under 
standard pH-state conditions.
XXX
1 988: M812 1 988: M812 I 988: M812 I 988: M812
3 : 2 CV 3 : 7 CV 5 :5 CV 7: 3 CV
Oily phase 0.073 9.102 0.025 1.117
Interface (slightly turbid phase) 0.037 4.315 0.316 7.742 0.016 8.525 0.071 1.246
Subphase (micellar phase) 0.037 0.607
Viscous, gel-like phase 0.377 0.391 0.302 2.638
Pellet phase 0.068 8.494 0.023 7.515
Mass recovered 0.075 0.384 0.393 0.396
Mass balanced 0.090 0.401 0.377 0.386
% Recovered 83.32 95.89 104.21 102.64
% Digested 36.14 24.21 21.98 20.67
Table 3.9 The amount (% w/v) of methyl paraben recovered of mixtures of MCT and mixed mono-, di-, and tri-glycerides 
in standard pH-stat solution under standard pH-state conditions.
Com oil Miglyo 1812 Imwitor 988
CV CV CV
Oily phase 0.004 2.145 0.006 12.656 0.00005 0.745
Milky thick turbid phase 0.0071 0.533 0.014 0.228
V iscous, gel-like phase 0.002 6.628
Pellet phase 0.0003 2.300 0.030 2.652
Mass recovered 0.0114 0.0201 0.033
Mass balanced 0.0123 0.0200 0.033
% recovered 92.60 100.68 100.11
% digested 7.04 14.39 22.65
Table 3.10 The amount (% w/v) of testosterone recovered of mixtures of MCT and mixed mono-, di-, and tri-glycerides 
in standard pH-stat solution under standard pH-state conditions.
xxxi
S-F CV Type IIIA CV Type III B CV Type II CV
Oily phase 0.0155 4.779
Interface (slightly turbid phase) 0.0147 1.253 0.0026 1.300
Subphase (micellar phase) 0.0420 0.647 0.0493 1.312 0.0527 1.425 0.02961 14.858
Pellet phase 0.0018 1.366 0.0027 0.373
Mass recovered 0.058 0.055 0.053 0.045
Mass balanced 0.058 0.058 0.051 0.049
% recovered 100.11 94.75 102.50 92.47
% digested 39.54 30.17 8.93 25.67
Table 3.11 The amount (% w/v) of testosterone recovered of SEDDS formulations in standard pH-stat solution under 
standard pH-state conditions._______  _________  _________
1988: M812 
3:2
I 988: M812 
7:3
I 988: M812 
5:5
I 988: M812 
3:7CV CV CV CV
Interface (slightly turbid phase) 0.0289 2.140 0.0026 2.221 0.0021 11.857 0.0062 1.503
Subphase (micellar phase) 0.0365 6.360 0.0233 9.161
Viscous, gel-like phase 0.0401 18.740 0.0235 3.872
Pellet phase 0.0075 10.718 0.0013 5.755 0.0016 10.970
Mass recovered 0.065 0.050 0.027 0.031
Mass balanced 0.070 0.055 0.033 0.036
% recovered ' 93.970 91.038 81.537 87.044
% digested 31.130 24.640 26.040 17.980
Table 3.12 The amount (% w/v) of testosterone recovered of mixtures of MCT and mixed mono-, di-, and tri-glycerides 
in standard pH-stat solution under standard pH-state conditions
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